Drug design and novel anti-cancer therapeutics : inhibitors of 17β [beta] hydroxysteroid dehydrogenase type 3 by Bailey, Helen Victoria
 1 
 
 
 
 
Drug Design and Novel Anti-Cancer Therapeutics: 
Inhibitors of 17β Hydroxysteroid Dehydrogenase Type 3 
 
 
Helen Victoria Bailey 
 
 
 
 
Volume 1 of 1 
A thesis submitted for the degree of Doctor of Philosophy 
University of Bath, Department of Pharmacy and Pharmacology 
 
November 2007 
 
 
 
 
 
COPYRIGHT 
 
Attention is drawn to the fact that copyright of this thesis rests with its author.  A copy 
of this thesis has been supplied on condition that anyone who consults it is understood 
to recognise that its copyright rests with the author and they must not copy it or use 
material from it except as permitted by law or with the consent of the author. 
 
This thesis may not be consulted, photocopied or lent to other libraries without the 
permission of the author for 3 years from the date of acceptance of the thesis. 
 
 
            
 
 2 
Abstract 
 
Herein, we describe the design and synthesis of novel inhibitors of 17β-hydroxysteroid 
dehydrogenase type 3 which converts androstenedione into testosterone, which is then 
converted into dihydrotestosterone (DHT).  This isozyme has been implicated in the 
growth of prostate cancer, which is stimulated by the presence of DHT. 
 
Using an in silico pharmacophore model based upon established activity, initial targets 
were planned, based around a diphenylether hydrophobic head linked to a 4-substituted 
piperidine ring.  Over 45 compounds were synthesised and many show significant 
biological activity when evaluated in a 17β-HSD Type 3 biological assay.  The most 
potent compound in this series is 1-(4-[2-(4-chloro-phenoxy)-phenylamino]-piperidin-
1-yl)-ethanone (101) with an IC50 of 700 nM.  The amine linked compounds are 
significantly more active than the amide equivalents. 
 
Synthesis of the amine-linked compounds was problematic and led to the development 
of a novel and general microwave assisted procedure for the reductive amination of 
anilines, enabling aromatic amine-linked compounds to be synthesised in excellent 
yields. 
 
A series of benzylamine linked inhibitors was also prepared.  Over 30 analogues were 
synthesised and several show very promising biological activity.  The most active 
compound is N-(2-([2-(4-chloro-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide 
(126), which exhibits an IC50 of 900 nM.  Effects of chirality were also explored.  The 
enantiomers of N-(2-(1-[2-(4-chloro-phenoxy)-phenylamino]-but-2-enyl)-phenyl)-
acetamide (172) were separated by chiral HPLC and X-ray crystallography was used to 
determine the absolute configuration.  These individual enantiomers and many other 
novel inhibitors are awaiting biological evaluation. 
 
The synthesis of compounds with a benzophenone linked hydrophobic head group led 
to an unexpected product.  X-ray crystallography was used to determine the structure, 
as a quinoline derivative.  This led to optimisation of a novel modification of the 
Friedländer synthesis of quinolines. 
 
The potent inhibitors synthesised are selective over 17β-HSD Types 1 and 2.  One 
inhibitor (165) also shows potentially interesting activity against the leukaemia cell line 
CCRF-CEM, in the NCI screening, with a GI50 of 10 nM. 
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10-Phenyl-3,4-dihydro-1H-pyrano[4,3-b]quinoline, 209 292 
9-Methyl-acridine, 210 293 
1-[8-Chloro-10-(2-fluoro-phenyl)-3,4-dihydro-1H-benzo[b][1,6] 
naphthyridin-2-yl]-ethanone, 211 293 
10-Phenyl-1,2,3,4-tetrahydro-benzo[b][1,6]naphthyridine, 212 294 
1-[4-(10-Phenyl-3,4-dihydro-1H-benzo[b][1,6]naphthyridine-2-carbonyl) -
cyclohexyl]-ethanone, 213 294 
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17β-HSD 17β Hydroxysteroid dehydrogenase 
Ac Acetyl 
ACN Acetonitrile 
AcOH Acetic Acid 
AKR Aldo-keto reductase 
Ar Aryl 
AR Androgen Receptor 
BID Dosed twice daily 
BINAP (±)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene 
BMS Bristol Myers Squibb 
Bn Benzyl 
br Broad (spectral) 
CNS Central nervous system 
d Doublet (spectral) 
DCE 1,2-Dichloroethane 
DCM Dichloromethane 
DELFIA®  
Dissociation Enhanced Lanthanide Fluorescence 
Immunoassay 
DHEA Dehydroepiandrosterone 
DHEA-S Dehydroepiandrosterone sulphate 
DHT Dihydrotestosterone 
DMA Dimetylacetamide 
DMAP Dimethylaminopyridine  
DMF N, N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DPP Diphenylphosphate 
EBNA Epstein-Barr virus nuclear antigen 
EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
eq. Equivalent 
ER Endoplasmic reticulum 
Et Ethyl 
EtOAc Ethyl acetate 
EtOH Ethanol 
FBS Foetal Bovine Serum 
G418 Geneticin® an aminoglycoside antibiotic 
GI50 Concentration causing 50% growth inhibition 
HDBC Hormone Dependent Breast Cancer 
HDPC Hormone Dependent Prostate Cancer 
HOBt 1-Hydroxybenzotriazole 
HSP Heat Shock Protein 
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HRMS High Resolution Mass Spectrometry 
Hz Hertz 
i.p. Intraperitoneally 
IC50 Concentration causing 50% inhibition 
IR Infrared 
J Coupling constant (spectral) 
Kg Kilogram(s) 
Ki Inhibition constant 
LC50 Lethal Concentration (Conc. required to cause 50% cell death) 
LCMS Liquid Chromatography Mass Spectrometry 
LH Luteinizing hormone 
LHRH Luteinizing hormone releasing hormone 
lit. Literature 
Lys Lysine 
m milli, multiplet (spectal) 
M Moles per litre, molecular ion (mass spectrometry) 
Me Methyl 
MeOH Methanol 
MHz MegaHertz 
MS Mass Spectrometry 
n Nano 
NADP(H) Nicotinamide adenine dinucleotide phosphate (reduced) 
nd Not determined 
NEAA Non-essential amino acid 
NMR Nuclear Magnetic Resonance 
PMS Phenazine methosulphate 
p.o Oral dosing 
ppm Parts per million 
p-TSA p-Toluenesulphonic acid 
q Quartet (spectral) 
QSAR Quantitative Structure Activity Relationship 
s Singlet (spectral) 
SAR Structure Activity Relationship 
SDR Short-chain dehydrogenase /reductase 
Ser Serine 
SPA Scintillation Proximity Assay  
t Triplet (spectral) 
T Testosterone 
tBoc tert-butyloxycarbonyl 
tBu tert-butyl 
TEA Triethylamine 
TFA Trifluoroacetic Acid 
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TGI Total Growth Inhibition 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
Tyr Tyrosine 
δ Delta (chemical shift) 
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Chapter 1: 
 
Introduction 
 
1.1 Hormone-Dependent Cancers 
 
Since the mid-nineteenth century, the average life expectancy in the UK has almost 
doubled.  Whilst this demonstrates positive medical advances and improvement in 
overall quality of life, it also means that more people are susceptible to cancer.  Indeed, 
cancer is a disease that affects mainly older people, with 64 % of cases occurring in 
those aged 65 and over.1  A further staggering statistic is that one in three people will be 
diagnosed with cancer during their lifetime.  In 2004, more than 280,000 new cases of 
cancer were diagnosed in the UK alone.1  There are over 200 different types of cancer 
but the four most common, lung, prostate, breast and large bowel (colorectal) account 
for over half of all cases diagnosed.1  Of all human cancers, 40 % are steroid hormone 
sensitive, (namely breast, prostate, ovarian and uterine cancers).1  The growth of breast 
tumours in postmenopausal women is often directly linked to the presence of oestradiol 
and so these tumours are classified as hormone-dependent breast cancers (HDBCs).  
Hormone-dependent prostate cancer growth, on the other hand, is stimulated by the 
presence of androgens, specifically dihydrotestosterone (DHT) which is synthesised 
from testosterone (T). 
 
1.2 Biosynthesis of Androgens in Adult Males 
 
The biosynthesis of androgens is controlled in the central nervous system (CNS) where 
luteinising hormone releasing hormone (LHRH) acts on the pituitary to increase 
luteinising hormone (LH) production.  In turn, luteinizing hormone acts on the testes 
which causes an increase in androgen synthesis.2  Androgens are synthesised from the 
inactive adrenal precursors; dehydroepiandrosterone (DHEA) and DHEA sulphate 
(DHEA-S).  DHEA-S levels in adult males are 100 - 500 times higher than the levels of 
testosterone, thus providing a large reservoir of substrate for conversion into androgens.  
The rate of formation of androgens is therefore dependent upon the level of expression 
of enzymes involved in the biosynthesis of active androgens (Scheme 1.1).3  Once 
synthesised these hormones can then act upon the appropriate receptors. 
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Scheme 1.1: Steroidogenic Pathway.4 
 
Active steroids are removed from circulation by metabolism in peripheral tissues to 
inactive molecules and subsequently into water soluble molecules for excretion from the 
body.  This is achieved by the formation of the sulphate or glucuronide derivatives on 
the hydroxyl groups of the steroids.  UDP-glucurosyltransferases inactivate testosterone, 
DHT and androsterone to their respective glucuronides.5 
 
1.3 The Androgen Receptor 
 
The androgen receptor (AR) is a member of the steroid and nuclear receptor 
superfamily, which has over 100 members.6  However, only 5 vertebrate steroid 
receptors (oestrogen, progesterone, androgen, glucocorticoid and mineralocorticoid) are 
known.  The AR is a soluble protein that functions as an intracellular transcription 
factor.6  It is mainly found in androgen target tissues, such as prostate tissue, skeletal 
tissue, muscle tissue, liver tissue and tissue in the central nervous system (CNS).6  The 
AR gene has been localised to the human X chromosome and to date only one AR gene 
has been identified.  This AR gene is more than 90 kb long, and codes for a protein of 
919 amino acids, which has three main domains; the N-terminal domain, the DNA-
binding domain and the ligand-binding domain.  The DNA binding domain is highly 
conserved between the vertebrate steroid receptors (sequence similarity 59-82 %) 
reflecting the common need to bind to DNA.  Sequence identity in the ligand-binding 
domain is lower (ranging from 22 to 55 %) showing the receptor selectivity for specific 
hormones.6  The crystal structures of the DNA-binding domain and the ligand-binding 
domain of the AR have been solved, but as yet, no crystal structure of the full receptor 
is available. 
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Unbound AR is found mainly in the cytoplasm and is associated with a complex of heat 
shock proteins (HSPs).6  Upon androgen binding, the AR goes through a series of 
conformational changes.  Firstly, the HSPs dissociate and the AR undergoes 
dimerisation, phosphorylation and translocation to the nucleus.6  The receptor can then 
bind to the androgen response element and initiate the recruitment of transcription co-
regulators which further ensure the amplification of AR regulated gene expression.  
This is the genomic pathway, but the AR can also be activated via a non-genomic 
pathway, either by rapid activation of kinase signalling cascades or modulation of 
intracellular calcium levels.  This non-genomic pathway of the AR has been reported in 
skeletal muscle cells, osteoblasts and prostate cancer cells.6  It has been proposed that 
specific ligands may cause the separation of genomic and non-genomic pathways and 
this might help to achieve tissue specificity.  However, the essential structural features 
for achieving this separation have not been determined.6  
 
1.4 Prostate Cancer 
 
Prostate cancer is the second most common cancer in males in western countries with 
679,000 new cases diagnosed each year (based upon 2002 data).7  In fact, it causes over 
~200,000 deaths per year worldwide.7  This represents a therapeutic area with a great 
unmet medical need.  Prostate cancer is often a very slow growing disease and watchful 
waiting is often the first stage of medical intervention.  If it is deemed that the prostate 
cancer is growing at a significant rate to affect the patient in terms of quality or 
longevitiy of life then further treatments are initiated.  Currently, a surgical procedure, 
radial prostatectomy, is one of the main treatments for prostate cancers.  This involves 
the removal of the prostate gland, seminal vesicles and nearby lymph nodes.  This is a 
major operation and therefore has associated risks.  The possible side effects include 
urinary incontinence, sterility and erectile dysfunction.  Radiotherapy is an alternative 
treatment, in which radiation is applied to the affected area to destroy the cancer cells.  
This can also cause undesirable side effects, including bladder irritation, erectile 
dysfunction and diarrhoea.8 
 
Androgens are necessary for the initiation of prostate cancer, the balance between 
androgen induced cell proliferation and apoptosis regulating growth.  A change in this 
balance can lead to excessive androgen influence and increased cell proliferation.  This 
dependency has been exploited for the treatment of prostate cancer since 1941.5  There 
are several methods of androgen deprivation in the clinical treatment of prostate cancer.  
Limitating the activity of androgens on prostate tissue reduces both cancerous and non-
cancerous prostate growth.  Castration is the frontline treatment, defined by a reduction 
in serum testosterone levels to <50 ng/ mL and this can be achieved surgically or 
 23 
medically.  Surgical castration results in a >90% decrease in serum testosterone, but 
only a 50% decrease in levels in the prostate, indicating that there is a significant local 
source of hormone synthesis.2  This will be discussed in detail later.  Medical castration 
can be achieved with 5α-steroid reductase inhibitors, gonadotropin-releasing hormone 
(GnRH) agonists, GnRH antagonists or oestrogen agonists.9  For example, finasteride 
(Figure 1.1, Proscar™, 1) limits DHT production by inhibiting the enzyme, 5α-steroid 
reductase type 2, which is responsible for the conversion of T into DHT.  This reduces 
DHT to 20-35% of baseline levels, thus helping to reduce the size of the prostate, often 
before surgery or radiation therapy.  Finasteride is a very potent inhibitor of 5α-steroid 
reductase with an IC50 value of 9.4 nM.
10  It does not however completely eradicate 
DHT. 
N
H
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Figure 1.1: Finasteride (Proscar™). 
 
GnRH agonists and antagonists can also be used to achieve medical castration.  GnRH 
is a small hormone, composed of 10 amino acids, which is secreted directly into the 
portal blood circulation.9  It interacts with high-affinity receptors in the anterior 
pituitary, stimulating the release of LH, which consequently leads to an increase in 
androgen production.  Continuous stimulation with high concentrations of GnRH results 
in receptor desensitisation and a reduction in LH release leading to a lower level of 
testosterone production in the testes.9  Endogenous GnRH has a very short half life due 
to peptidase degradation.  However, synthetically produced analogues, including 
goserelin, leuprorelin, buserelin and triptorelin, have been developed which have an 
increased resistance to peptidase degradation and therefore have a much longer half 
life.9  These are administered by subcutaneous injection every 1-3 months and ~ 95% of 
patients achieve significant testosterone suppression.  However, the initial increase in 
LH production, causing a corresponding increase in T and DHT levels, causes a tumour 
flare effect and, therefore, combination therapy with an anti-androgen is normally used 
for the first few weeks.9  GnRH antagonists can also be used as these cause a major and 
rapid reduction in serum T levels.  They also have the advantage that the tumour flare 
effect seen with GnRH agonists is avoided, and the more rapid decrease in serum T 
levels may increase the success of treatment.9  
 
Unfortunately, castration, whether medical or surgical, can cause a wide variety of 
detrimental side effects, known as the castration syndrome.  These side effects can 
include: loss of libido, erectile dysfunction, hot flushes, anaemia, obesity, fatigue, a 
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decrease in muscle strength, a decline in physical activity and vitality, mood changes, 
depression and osteoporosis.  These all affect the quality of life of the patient and, 
therefore, must be taken into account when considering castrative treatment for 
patients.9 
 
A treatment which avoids castration is the use of anti-androgens, such as bicalutamide 
(CasodexTM), flutamide (EulexinTM) and nilutamide (NilandronTM).  These compounds 
are all orally administered non-steroidal compounds (Figure 1.2), which inhibit the 
activity of androgens by competitively blocking the interaction of T and DHT with the 
androgen receptor.  They all offer many quality of life benefits in terms of sexual 
interest, physical capacity and preservation of bone mineral density.9  Bicalutamide 
(CasodexTM) was launched by AstraZeneca in 1995, as a combination therapy, with 
medical or surgical castration, for advanced stage prostate cancer.11  It has replaced 
flutamide and nilutamide as the anti-androgen of choice for prostate cancer treatment, as 
it has less hepatotoxicity and a longer half-life (6 days), which allows for once daily 
dosage.6  It was later licensed as a monotherapy for early stages of the disease.11  
However, in 2003 CasodexTM (150 mg) was withdrawn, after research showed an 
increase in mortality for CasodexTM versus placebo.12  Anti-androgens can also often 
trigger significant increases in LH release, which causes an increase in serum T levels.6   
Figure 1.4 shows the crystal structure of the ligand binding domain of the androgen 
receptor in complex with R-bicalutamide.13 
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Figure 1.2: (a) Bicalutamide (CasodexTM), (b) flutamide (EulexinTM), (c) nilutamide 
(NilandronTM). 
 
The widespread use of prostate-specific antigen (PSA) as a detection marker for prostate 
cancer has led to earlier diagnosis and detection of the disease.  Although this represents 
a major advance in prostate cancer diagnosis and treatment, it has caused a dramatic 
shift in the population of patients requiring treatment, as more cases are diagnosed in 
younger males.  Therefore, the systematic side effects of androgen deprivation and the 
effects on the quality of life have become more important.  At present, the strategies 
improve survival, but are not generally curative and also may lower the overall quality 
of life of the patient.  The main problem is that prostate cancer often advances to a 
“hormone refractory” state, in which the disease no longer responds to treatment with 
anti-androgens, or to castration therapies.  There is evidence to suggest that the AR is at 
the centre of this process.14  It has been reported that a 2 to 5 fold increase in the AR 
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mRNA is both necessary and sufficient for progression to the “hormone refractory” 
disease state.15  In the presence of elevated levels of AR in hormone refractory cancers, 
cells become highly sensitive to androgens.  This evidence provides a strong rationale 
for targeting the down regulation of AR to treat advanced prostate cancer.  Reducing the 
AR to a critical level would slow the growth and proliferation of prostate cancer.  
Several approaches are currently available, including small molecule approaches,16-18 
HSP-90 inhibitors19 and RNA interference. 
 
1.5 The 17β-Hydroxysteroid Dehydrogenase Enzymes 
 
The androgen biosynthetic pathway is continuing to be an interesting and challenging 
area of research for the discovery of new potential treatments for hormone dependent 
prostate cancer.  There are many different enzymes involved in the synthetic pathways 
from DHEA to T and DHT (Scheme 1.1).  These enzymes include: steroid sulphatase, 
3β-hydroxysteroid dehydrogenase (types 1 and 2), 5α-steroid reductase (types 1 and 2) 
and several members of the 17β-hydroxysteroid dehydrogenase family (Scheme 1.1).3 
 
The 17β-hydroxysteroid dehydrogenase enzymes (17β-HSDs, EC1.1.1.62, Table 1.1) 
catalyse the oxidoreduction of the hydroxyl/carbonyl groups on position 17 (see Figure 
1.3) of androgens and oestrogens (using NAD(P)(H) as a co-factor).  The 17β-HSDs 
therefore provide a pre-receptor control mechanism as 17β-hydroxylated forms have a 
significantly higher binding affinity with the appropriate receptors than the 17β-
carbonyl steroids, causing transactivation of the target genes.4 
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Figure 1.3: Androstenedione and the site of action of the 17β-HSD enzymes. 
 
Numbered in the order of discovery, there are, at present, 14 members of the 17β-HSD 
subfamily identified (Table 1.1), although the 17β-HSD type 13 isozyme has only 
recently been reported.20†  It is known that 12 of these isozymes exist in humans.  Those 
isozymes not found in humans are types 6 and 9 and they have been identified in rats 
and mice respectively.21  Six of the isozymes have been structurally characterised, 
namely, 1, 4, 5, 10, 11 and 14.  Although most of the isozymes are capable of catalysing 
                                                   
† The 17β-HSD type 13 isozyme was disclosed at a workshop on 11β- and 17β-HSDs: Role in Human Disease, 
Elmau Castle, Germany, 2005, and identified and previously classified as human retinal shortchain 
dehydrogenase/reductase 3, PDB code 1YDE. 
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both the oxidative and reductive reactions in vitro, in vivo they have preferred 
directionality and can therefore be classified into two categories: a) oxidative enzymes 
(17β-HSD types 2, 4, 6, 8, 9, 10, 11, 13 and 14), which catalyse the NAD(P)+-dependent 
oxidation in vivo and therefore the inactivation of steroids, and b) reductive enzymes 
(17β-HSD types 1, 3, 5 and 7), which catalyze the NAD(P)H dependent reduction of 
ligands in vivo forming active steroid hormones.20  All but one of the isozymes are 
members of the short-chain dehydrogenase/reductase (SDR) family.  The exception is 
17β-HSD type 5, which is an aldo-keto reductase (AKR).3  SDR enzymes constitute a 
large family of oxidoreductases.  To date 63 SDR members have been identified within 
the human genome.22  They are mainly oligomeric enzymes, with a typical chain length 
of 250-350 amino acid residues.  They share few distinct sequence motifs and contain a 
typical sequence identity of 15-30%.  However, SDR enzymes have a conserved α/β 
sandwich folding pattern (Rossmann-fold) and a highly conserved Tyr-X-X-X-Lys 
sequence in the active site, as a general acid/base catalyst.  This is facilitated by the 
lowering of the Tyr-OH pKa through a neighbouring lysine residue, and substrate 
carbonyl binding is aided through a conserved serine side chain.20  The SDR enzymes 
are mostly NAD(P)(H) dependent and act on a wide substrate spectrum, including 
steroids, retinols, prostaglandins, polyols and xenobiotics.   
 
High levels of 17β-HSD expression have been measured in prostate cancer cell lines, 
indicating that some of the 17β-HSDs are thought to be significant to hormone 
dependent prostate cancer.  Others are implicated in hormone-dependent breast cancer.  
The enzymes of interest are 17β-HSD types 1, 2, 3 and 5.  These therefore represent 
potential drug targets and will be discussed further. 
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Table 1.1: Summary of the 14 human isozymes of 17β-HSD.20, 21 
Human Protein Type Function 
PDB 
code 
Cofactor 
preference 
Substrates 
Subcellular 
localization 
Expression pattern Disease or Pathology 
17βHSD1 SDR E2 production 
1FDT, 
1EQU, 
1JTV 
NADP(H) oestrogens Soluble in cytosol 
widespread; gonads, 
breast, placenta, liver 
Breast and prostate cancer 
17βHSD2 SDR E2, T inactivation  NAD(H) 
oestrogens, 
androgens, progestins 
Membrane bound 
on ER 
widespread; prostate, 
liver, intestine 
Endometriosis, colon and prostate 
cancer, 
17βHSD3 SDR T production  NADP(H) androgens 
Membrane bound 
on ER 
mainly testis 
Pseudohermaphroditism and prostate 
cancer 
17βHSD4 SDR 
β-oxidation of FA, E2 
inactivation 
1ZBQ NAD(H) oestrogens, acyl CoAs peroxisomes widespread 
D-specific multifunctional protein 
deficiency, Stiff-man syndrome 
17βHSD5 AKR 
T production, 20αP 
activation, bile acid 
production and 
detoxification, 
1ZQ5 
2FGB 
NADP(H) 
androgens, 
eicosanoids 
Soluble in cytosol liver, prostate  
17βHSD7 SDR 
Cholesterol synthesis and E2 
production 
 NADP(H) 
oestrogens, 
cholesterol 
Membrane bound 
on ER 
  
17βHSD8 SDR 
E2 and androgen 
inactivaction 
 NAD(H) androgens  
widespread, liver, 
kidney 
 
17βHSD10 SDR 
Estrogen and androgen 
inactivation, β-oxidation of 
FA, bile acid isomerisation 
1SO8 
1UZT 
NAD(H) 
oestrogens, 
androgens,  
bile acids, 
progestions, 
branched/straight OH-
acyl CoAs 
mitochondria 
widespread, liver, 
CNS, kidney, testis 
Isoleucine degradation deficiency, 
Alzheimer disease 
17βHSD11 SDR 
Conversion of 5α-
androstane-3α,17β-diol to 
androsterone 
1YB1 NAD(H) androgens 
Membrane bound 
on ER 
steroidogenic tissues  
17βHSD12 SDR 
3-Ketoacyl-CoA reductase; 
FA synthesis 
 NADP(H) 
Steroids 
acyl CoAs 
   
17βHSD13 SDR Activity not known 1YDE      
17βHSD14 SDR 
E2, T inactivation; 
β-oxidation 
 NAD(H) 
oestrogens, 
androgens, fatty acyl 
CoAs 
Soluble in cytosol CNS, kidney  
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1.6 17β-Hydroxysteroid Dehydrogenase Type 1 
 
The 17β-HSD Type 1 (17β-HSD1) isozyme was the first 17β-HSD to be cloned and 
structurally characterised.  It is a soluble cytosolic protein which consists of 327 amino 
acids and has a molecular mass of 35 kDa.23  The protein has been crystallised, and this led 
to the first elucidation of the three-dimensional structure of a mammalian steroidogenic 
enzyme.  The core of the structure is a seven-stranded, parallel β-sheet, surrounded by 6 
parallel α-helices, three on each side of the β-sheet.  The binding site consists of a narrow 
hydrophobic tunnel, with Tyr155, Lys159 and Ser142 forming the catalytic triad of the 
enzyme.24  The crystal structure of 17β-HSD Type 1 complexed with oestradiol and 
NADP+ is shown in Figure 1.4.25 
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Figure 1.4: The crystal structure of 17β-HSD Type 1 complexed with estradiol and NADP+ 
(PDB code 1FDT).25 
 
The enzyme preferentially reduces estrone to oestradiol, and also to a more minor extent, 
reduces DHEA to 5-androstene-3β, 17β-diol.21  In humans, it is predominantly expressed in 
the ovaries, breast tissues, placenta and is expressed at a greater level in breast carcinoma.20  
Oestradiol exerts oestrogenic effects by binding with the oestrogen receptor which leads to 
a proliferative effect which accelerates tumour growth.10  Therefore, a specific 17β-HSD1 
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inhibitor would potentially lower the levels of estradiol and the proliferative effects 
exhibited in hormone dependent breast cancer.  Currently, there is a lot of interest in this 
area of research, with many reversible and irreversible 17β-HSD type 1 inhibitors having 
been reported.10  The structures of the inhibitors are very wide ranging.  Although most are 
based around a steroidal backbone, they are often analogues of the natural substrate, estrone 
(Scheme 1.1).26, 27  However, non-steroidal compounds have also been reported as 
inhibitors.  For example, fatty acids such as oleic acid have demonstrated moderate 
inhibitory activity.28  Research in this area is currently very active and the in vivo anti-
tumour efficacy of an agent against this target has been demonstrated.26, 29, 30 
 
1.7 17β-Hydroxysteroid Dehydrogenase Type 2 
 
The 17β-HSD type 2 (17β-HSD2) isozyme catalyses the NAD(H)-dependent conversion 
between estradiol, testosterone and 5α-dihydrotestosterone and the corresponding 17-oxo 
metabolites.  Due to its widespread tissue distribution it is thought that 17β-HSD Type 2 
acts to protect against damaging levels of active steroid hormone.20  It was cloned from a 
human prostate cDNA library and is thought to be localised on the endoplasmic reticulum 
(ER).31  However, the highly hydrophobic nature of the enzyme has prevented structure 
determination thus far.  The enzyme is a protein of 387 amino acids and has a molecular 
mass of ~ 42.8 KDa.31 
 
1.8 17β-Hydroxysteroid Dehydrogenase Type 3 
 
The 17β-HSD type 3 isozyme is an interesting drug target for limiting the biosynthesis of T 
and DHT.  Targetting this enzyme would lower the amount of active DHT available to 
stimulate an androgenic response in androgen-dependent diseases such as prostate cancer.  
17β-HSD3 is principally found in the Leydig cells of the testes so selective inhibitors may 
also have the potential to block spermatogenesis and function as a male anti-fertility 
agent.28, 32 
 
The 17β-HSD type 3 isozyme consists of 310 amino acids and has a molecular mass of 
~34.5 KDa.24  It is a microsomal enzyme, which is bound through an N-terminal 
transmembrane domain to the ER.20  It uses NADP(H) as a co-factor, and the equilibrium 
favours the reduction of androstenedione to testosterone, which is then converted by 5α-
steroid reductase to the most potent androgen, DHT (Scheme 1.2).  This reaction occurs in 
the Leydig cells of the testis under the control of the pituitary hormones.5 
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Scheme 1.2: The role of 17β-HSD Type 3 in androgen synthesis. 
 
Mutations in the 17β-HSD3 gene can result in the malfunctioning or lack of this enzyme.  
This leads to an accumulation of androstenedione and also gives rise to an autosomal 
recessive form of male undermasculinity: male pseudohermaphroditism.33  This is 
phenotypically characterised by the presence of testes and normally developed Wolffian 
duct derivatives.  However, patients show undervirilisation of the external genitalia.  These 
are often female in appearance.  Therefore, patients are most often raised as females.34, 35  In 
contrast 17β-HSD Type 3 deficiency in females is asymptomatic. 
 
1.9 17β-Hydroxysteroid Dehydrogenase Type 5 
 
The main biosynthesis of testosterone occurs in the testis, catalysed by 17β-HSD Type 3.  
However, conversion of androstenedione into testosterone also occurs to some extent in the 
prostate, this is catalysed by 17β-HSD Type 5.  The 17β-HSD type 5 (17β-HSD5) isozyme 
is highly expressed in the testes and extragonadal tissues such as basal cells of the prostate, 
adrenal glands and liver.20  It is the only 17β-HSD enzyme that belongs to the aldo-keto 
reductase (AKR) superfamily and has a much broader substrate specificity than 17β-HSD 
types 1-3.  It catalyses the NADPH dependent reduction of androstenedione to testosterone, 
as well as displaying many other activities, such as 3α-HSD, 20α-HSD and prostaglandin 
synthase activities.  Since 17β-HSD Type 3 is not expressed in the ovary, which is the 
location of androgen synthesis in women, it has therefore been suggested that 17β-HSD 
Type 5 is responsible for the biosynthesis of testosterone in females as this enzyme is found 
in the ovary.  It has been hypothesised that this enzyme is responsible for the rise in levels 
of testosterone at puberty in patients with a malfunctioning 17β-HSD3 enzyme (male 
pseudohermaphroditism).36  As 17β-HSD Type 5 is directly involved in the biosynthesis of 
androgens it is an emerging as an interesting therapeutic area for the treatment of prostate 
cancer, along with 17β-HSD Type 3.  The crystal structure has been determined both alone 
and in complex with different substrates and inhibitors, thus providing an excellent basis 
for inhibitor development.20   
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1.10 Inhibitors of 17β-HSD Type 3: Steroidal Inhibitors. 
 
The first study on inhibition of 17β-HSD Type 3 was reported in 1983, when Pittaway 
revealed that a steroid scaffold with a 17-keto group and non-aromatic A-ring were 
important factors for inhibition.37  They identified 4-estrene-3, 17-dione (2) and 5-
androstene-3, 17-dione (3) as inhibitors of 17β-HSD Type 3, with Ki values of 2.4 and 6.8 
µM respectively (Figure 1.5). 
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Figure 1.5: Early Identified Inhibitors of 17β-HSD3.37 
 
Since this initial research, many other steroid inhibitors have been synthesised and 
evaluated.  Recently, Poirer and co-workers published promising work concerning 
androsterone-3β-substituted derivatives as inhibitors of 17β-HSD3 (Table 1.2).32, 38 
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Activity over 17β-HSD Type 3 
IC50 (nM) 
Androsterone H H 330 
4 CH3(CH2)2 H 67 
5 CH3(CH2)5 H 100 
6 CH3CH2(CH3)CH H 73 
7 cyclohexyl-CH2-CH2 H 60 
8 phenyl H 81 
9 phenyl-CH2 H 57 
10 phenyl-CH2-CH2 H 99 
11 phenyl-CH2-CH2 CH3 73 
Table 1.2: Some of the androsterone derivatives tested for 17β-HSD3 inhibition.32 
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The inhibitors were tested for biological activity using a homogenised cell preparation, 
made from human embryonic kidney 293 (HEK-293) cells, which had been transfected 
with vectors encoding for 17β-HSD Type 3.  The inhibitors exhibited IC50 values ranging 
between 57 and 100 nM.32  Although they were less active in whole cells, 8 compounds (4-
11) exhibited >95 % inhibition at 10 µM.  Selectivity was also demonstrated.  The 
compounds did not show any inhibitory activity on isozymes 1, 2, 5 and only poor 
inhibition (13-38 %) on isozyme 7, at 10 µM, and thus, are selective inhibitors of 17β-HSD 
Type 3.  The binding affinities for androgen, estrogen, glucocorticoid and progestin 
receptors were also analysed.  None of the above compounds showed any significant 
binding affinity for these receptors.32  However, when the compounds were analysed for 
residual hormonal activity, by looking at proliferative activities on cells expressing the 
androgen receptor, some activity was observed.  Compounds 4, 5, 6, 7, 10 and 11 showed 
minimal effects, but compounds 8 and 9 showed a 72 % and 82 % enzyme inhibitory 
activity respectively at 1µM.  It can be assumed that there is a different mechanism for this 
activity as these effects are not achieved through androgen receptor mechanisms. 
Compounds 5, 7 and 10 emerged as interesting candidates for further investigation.32, 38  
 
The Poirier research group has also looked at the synthesis and 17β-HSD Type 3 inhibitory 
activity of androstenedione/adenosine hybrid compounds, (Figure 1.6).39  These 
compounds were thought to possess bisubstrate inhibition properties, by blocking both the 
cofactor binding site and the substrate binding site simultaneously.  It was hypothesised 
that the phosphorylated compound (13) would be a better inhibitor than the non-
phosphorylated compound (12), as the enzyme has a higher affinity for NADPH than 
NADH and thus that the enzyme would also have a higher affinity for a NADPH mimic 
than a NADH minic.40  However, once the compounds had been tested for 17β-HSD Type 
3 activity the results were actually contrary to the hypothesis, with the phosphorylated 
compound (13) proving to be a slightly less potent inhibitor of 17β-HSD Type 3, when 
compared to the non-phosphorylated compound (12), with IC50 values of 1.66 and 0.62 µM 
respectively.  The reasons for this lower activity were investigated and it was suggested that 
the cofactor NADPH, which is present in a much higher concentration than the inhibitor, 
would bind first to the enzyme, so that the cofactor binding site would be occupied and thus 
the potential inhibitor can only interact with the substrate-binding site.  This would result in 
lower activity than if the compounds were true bisubstrate inhibitors.40 
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Figure 1.6: Androstenedione/adenosine hybrid compounds as 17β-HSD3 inhibitors. 
 
1.11 Inhibitors of 17β-HSD Type 3: Non-Steroidal Inhibitors 
 
The steroid based structures of the inhibitors discussed so far may preclude them from 
further development due to undesirable pharmacological properties, or other undesirable 
features such as intrinsic androgenic activities.  For this reason the design and synthesis of 
non-steroidal inhibitors has been receiving considerable interest over the past few years.28  
Many different classes of non-steroidal compounds have been identified as inhibitors of 
17β-HSD3, these include p-benzoquinones, flavones, iso-flavones, coumarins and 
triphenylethene derivatives.28  However, many of these were shown to be non-selective 
and/or had various levels of androgenic or oestrogenic activity.  The coumarins proved to 
be an interesting family of compounds, in particular umbelliferone (14) and 4-
methylumbelliferone (15), with IC50 values of 1.4 and 0.9 µM respectively, (Figure 1.7).
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Figure 1.7: Coumarin inhibitors of 17β-HSD3 
 
Novel tetralone, benzopyranone and benzofuranone derivatives with general structures 16 
and 17, were the focus of a patent filed in 1998 as preventative and/or curative treatments 
for various hormone sensitive diseases (Figure 1.8).42  
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Where R1-7 can include H, Cl, Br, F, Me amongst others  
Figure 1.8: Novel 17β-HSD3 inhibitors 
 
Lota et al recently reported a study where they looked into the possible transition states of 
the enzyme catalysed reduction reaction in order to design novel inhibitors.43, 44  They 
established the importance of a steroid backbone mimic region and a carbonyl moiety in the 
correct orientation.  For this reason a series of 4-hydroxyphenyl ketones were tested for 
their inhibitory potential, a selection is shown in Table 1.3.  From the biological data, 
obtained from an enzymatic assay (from rat testicular microsomes), it can be seen that the 
inhibitory activity increases with increasing alkyl chain length, up to a maximum of C8.  
After this point an increase in chain length leads to a reduction in activity.   
 
HO
R
O
 
Compound Number R IC50 (µM) 
18 CH3 1709 
19 C4H9 61 
20 C8H17 2.9 
21 C11H23 7.6 
Table 1.3: A selection of the inhibitors reported by Lota et al43 
 
By utilising a molecular modelling study, it was hypothesised that the octyl chain is the 
optimum length which directly mimics the steroid backbone and the longer chains 
introduce unfavourable steric interactions in the active site.  It is also hypothesised that the 
4-hydroxyphenyl moiety is able to undergo hydrogen bonding with the active site.  This has 
been validated by the evaluation of various inhibitors (not reported) which lacked this 
hydrogen bond forming ability.  These compounds were either weak or did not inhibit the 
enzyme. 
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A high-throughput screening programme of >200,000 compounds by Bristol-Myers Squibb 
revealed that anthranilamide based compounds showed some 17β-HSD Type 3 activity.2  A 
limited amount of Structure-Activity Relationship (SAR) data is available (Table 1.4). It 
can be seen that substitution on the 4-position (R2) of the anthranoyl moiety is very 
beneficial to activity (compounds 25 vs. 23) and the introduction of differing groups on the 
2-position (R1) can help to improve the activity of the inhibitors.  However, it appears that 
as the enzymatic inhibitory activity increases the cellular potency decreases, perhaps 
indicating a problem with cell permeability and solubility of the compounds within the 
series (compounds 22-24).  It is anticipated that this series can be effectively modified to 
have more favourable drug-like properties.2 
 
Cl
HO
H
N
O
O
H
N
R1
R2 
Compound no R1 R2 Enzyme IC50 (nM) Cellular IC50 (nM) 
22 OMe
 
OPh 60 300 
23 Cl
 
OPh 40 710 
24 
 
OPh 1 1200 
25 Cl
 
H 170 1600 
Table 1.4: Novel series of anthranilamide based inhibitors.2 
 
Bristol-Myers Squibb have also reported a series of tetrahydrodibenzazocines that are 
potent inhibitors of 17β-HSD Type 3.45  They also identified these initial lead structures 
following high-throughput screening using an enzymatic scintillation proximity assay 
(SPA).  Following this, the cellular effects were also examined before the lead compounds 
were identified.  The dibenzothiazocine, compound 26 (Table 1.5), was identified as an 
attractive starting point for the Bristol-Myers Squib medicinal chemistry programme.  This 
compound is discussed in more detail in Chapter 2. 
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 Enzyme IC50 (µM) Cellular IC50 (µM) 
N
S
O
26 
0.40 0.32 
Table 1.5: Compound 26 and the inhibitory activity reported.45 
 
Modification of this scaffold led to increases in potency, as shown in Table 1.6.  The best 
compound reported (31) had an additional methyl benzoate group.  This extra substitution 
led to a substantial increase in activity.  It is hypothesised that this group lies near to the 
nicotinamide ring within the active site, suggesting a ring-ring interaction, possibly π 
stacking. 
N
X
O
Cl
Y
 
Compound 
no. 
X Y 
Enzyme 
IC50 (nM) 
Cellular 
IC50 (nM) 
27 S H 100 160 
28 CH2 H 70 63 
29 CH2 -Ph(o-OMe) 2 5 
30 CH2 -Ph 4 18 
31 CH2 -Ph(o-CO2Me) 0.002 0.5 
Table 1.6: Improvements in potency from compound 26. 
 
These compounds are some of the most active that have been reported in the literature so 
far, although no information is yet available regarding their in vivo activity or 
pharmacological properties. 
 
High throughput screening has been also used by a number of other research groups and 
companies to identify lead compounds.  Another significant example of this is compound 
32, which was identified by the Schering-Plough Corporation as an inhibitor of 17β-HSD3, 
which when its activity was tested upon the human 17β-HSD3 enzyme, it exhibited an IC50 
value of 2.5 nM (Figure 1.9).46 
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Figure 1.9: Lead compound identified by the Schering-Plough Corporation. 
 
This led to the synthesis of a large number of compounds in this and related series, which 
subsequently resulted in a number of patents in 2003/2004.47-50  The patents cover a wide 
range of modifications to the initial lead, some of which are shown in Table 1.7. 
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Compound 
no. 
R
1
 R
2
 R
3
 IC50 (nM) 
32 
(Initial Lead) N
Br Cl
 
CH2CH2OCH3 NH2 2.5 
33 
N
 
CH2CH2OCH3 NH2 2600 
34 
Cl Cl
 
CH2CH2OCH3 NH2 1.1 
35 
Cl Cl
 
(CH3)3 NH2 0.01 
36 
(SCH-451659) 
Cl Cl
 
(CH3)3 CH3 0.005 
Table 1.7: Some of the modifications to the original lead compound.46 
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Modifications of the aryl substituent, R1 led to the inclusion of a more flexible dichloro 
substituted diaryl group, which caused an improvement in potency (compounds 32 and 34).  
These halogen substitutions were shown to be beneficial for activity, 34.46  Further 
investigations led to the introduction of an (S)-lipophilic t-butyl substitution at the 2 
position of the piperazine ring, which also improved potency, 35.  This potency was further 
improved by the introduction of acetyl group on the piperidine moiety.  This led to SCH-
451659 (Figure 1.8, 36), which has now become a potential clinical candidate, although its 
formal clinical development status, if any, has not been disclosed.  This compound (36, 
SCH-451659) is also detailed in Chapter 2.   
 
Efficacy studies, using compound 36, in cynomologus monkeys showed promising results, 
leading to a 50% reduction in serum testosterone levels, an 85% decrease in testes 
testosterone levels and a 20% decrease in prostate weight after 4 weeks dosing at 15 mg/kg, 
BID, p.o.51  Similar studies on a related compound (SCH-391, 37, Figure 1.10), showed 
that the inhibition of 17β-HSD3 led to the inhibition of androgen-dependent Shionogi 
tumour growth in nude mice (75 mg/kg, BID, i.p.).52  These results illustrate the proof of 
concept in higher mammals, showing that inhibition of 17β-HSD3 is a valid target for 
prostate cancer. 
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Figure 1.10: Compounds tested for efficacy: SCH-451659 (36) and SCH-391 (37). 
 
It can be seen that there is a great deal of interest in the design and synthesis of potent 
inhibitors of 17β-HSD Type 3 from both academic and industrial researchers.  Much more 
work is required before a 17β-HSD Type 3 inhibitor will be seen in clinical trials or 
eventually as a potential treatment of choice in the clinic for prostate cancer. 
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1.12 Aims of This Thesis 
 
The aims of this project are to design and synthesise novel 17β-HSD Type 3 inhibitors.  It 
is anticipated that inhibitors of 17β-HSD Type 3 would block the biosynthesis of 
testosterone and therefore be an effective treatment for prostate cancer and other androgen 
dependent diseases.  It is hoped that this project will produce compounds which are potent 
inhibitors and are selective over other isozymes in the 17β-HSD enzyme family, 
particularly 17β-HSD Types 1 and 2.   
 
This project will utilise many modern medicinal chemistry techniques.  The first step is that 
a lead series of compounds needs to be identified.  In order to do this most effectively, a 
survey of competitor compounds will be undertaken and from this a pharmacophore can be 
established.  It is hoped that this will provide an effective starting point for synthesis.   
 
The project will also use modern computational chemistry techniques to assess the potential 
success of compounds and to establish areas of space that warrant further investigation.  A 
crystal structure of 17β-HSD Type 3 is not currently available so a homology model will be 
constructed from the available crystal structure of a closely related enzyme.  This will 
enable potentially significant interactions between the enzyme and inhibitors to be 
identified. 
 
During this project the main focus will be the development of an effective SAR between 
potential inhibitors and the 17β-HSD Type 3 enzyme.  The compounds synthesised will be 
assessed for their biological potency using a whole cell assay developed by colleagues at 
Imperial College.  As biological results are obtained a QSAR should be constructed, thus 
aiding project progression further.   
 
This project aims to design and synthesise compounds that would be suitable drug 
candidates.  Therefore the inhibitors must have suitable molecular weights, lipophilicity 
and other properties.  Only non-steroidal templates will be explored as this should help to 
limit any possible androgenic activity of the compounds.   
 
Initially it is planned that the compounds synthesised will not contain a chiral centre.  This 
will also negate the need for the use of asymmetric chemistry.  As the project progresses 
chirality is likely to become an important issue that will need to be investigated using chiral 
separation or asymmetric chemistry as required. 
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Overall, the aim of this project is to produce novel inhibitors of 17β-HSD Type 3 which 
exhibit an IC50 below 100 nM and which could ultimately be applied to an unmet medical 
need. 
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Chapter 2 
 
Selection and Synthesis of Compounds 26 and 36 as Positive Control Compounds 
 
2.1 Selection of Positive Control Compounds 
 
During the development and validation of the biological assay used in this project it was 
necessary for a positive control compound to be available.  A positive control compound is 
required to cause a known effect in the biological assay so, in this case, compounds that 
were known to exhibit inhibitory activity on 17β-HSD Type 3 were needed.  It has been 
previously stated that there are many 17β-HSD3 inhibitors reported in the chemical 
literature,28, 46 and a selection of suitable compounds were identified for further 
investigation, including compound 36, a compound detailed by Schering Plough,47 and 
compound 26, which is a compound designed by Bristol-Myers-Squibb, (Figure 2.1).45 
 
Cl
N
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S
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36 26  
Figure 2.1: Positive control compounds, 3647 and 26.53 
 
2.2 Identification and Synthesis of Compound 36 
 
As previously mentioned, Schering-Plough have published a number of patents and 
publications over the past few years regarding novel non-steroidal 17β-HSD Type 3 
inhibitors.46-52  A large number of compounds has been synthesised during their medicinal 
chemistry programme; one of the most potent is SCH-451659, (36, Figure 1.8).46  This 
compound is a potential clinical candidate and has showed promising proof of concept 
results in animal models, for more details see Chapter 1.51  As one of the most potent 
inhibitors detailed in the chemical literature, compound 36 was the logical choice for an 
initial biological control compound.   
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The experimental procedure for the synthesis of this compound was detailed in a patent 
from Schering-Plough.47  This synthetic route was repeated by Dr G. M. Allen and 
compound 36 was subsequently used as the positive control in the biological assay 
development and screening.   
 
However, during the course of the project it was found that compound 36 had an inhibitory 
activity that was several orders of magnitude more potent than the novel compounds 
synthesised as part of this project.  The highly potent nature of compound 36 meant that a 
consistently low IC50 was obtained (approx 2-6 nM), and this was not in a similar range to 
the in-house compounds, meaning any possible assay inconsistencies may have been 
masked by this highly potent activity, so an alternative positive control compound was 
required. 
 
2.3 Identification and Synthesis of Compound 26 
 
It was desired that a positive control could be identified, which exhibited activities in the 
same range as the best of the novel, in-house compounds, which had approximate IC50 
values of between 300 and 900 nM (see Chapters 6-10).  This means that any changes 
exhibited by the standard between assay runs, would show up inconsistencies within the 
biological assay. 
 
A search of the chemical literature exposed a recent paper by Fink et al45 detailing a novel 
series of 17β-HSD type 3 inhibitors based around the tetrahydrodibenzazocine core.  They 
identified compound 26 (Figure 2.2 and Table 1.5) as a compound in the series with 
moderate activity.  This was discussed in more detail in Chapter 1. 
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Figure 2.2: Compound 26 
 
Based on the activities reported by Fink et al,45 it was decided that compound 26 would be 
a good choice for a new positive control for use in the biological assay.  This was because 
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the reported activity (cellular IC50 = 0.32 µM) is in the region displayed by our novel in-
house compounds and also in view of the facile two step synthesis that was possible from 
commercially available starting materials.54, 55 
 
The synthesis of compound 26, was first reported by Yale et al in 1972.54  This paper 
looked at the synthesis of novel polycyclic heterocyles, but did not examine any potential 
biological activity the compounds may possess.   
 
Following the original synthetic strategy (Scheme 2.2)54 a mixture of 2-aminothiophenol 
and α,α΄-dibromo-o-xylene was added to a solution of DMF at 100 °C.  This was heated for 
30 minutes, before being cooled and evaporated to dryness.  Following an extraction 
between NaHCO3 and diethyl ether a brown oil was isolated (38).  By treatment with HCl 
in diethyl ether, this was converted into the HCl salt, which was isolated by filtration.  The 
salt was dissolved in water and KOH was added.  This was heated to 100 °C for 3 h, cooled 
and extracted with EtOAc to yield the free amine.  The free amine was then reacted with 
acetyl chloride to yield the desired product, (Scheme 2.1).  However, this initial synthetic 
strategy only led to 11 % yield overall.  When compared with the original paper, which 
reported an overall yield of approximately 60 %, this shows that a significant improvement 
in the synthesis was required. 
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Scheme 2.1: Initial synthesis of compound 26. Overall Yield: 11 % 
 
It was felt that the formation of the HCl salt and the following release of the amine were 
unnecessary steps, which could be replaced by simple column chromatography after the 
first step.  This increased the overall yield to 32 %.  However, a vast improvement in yield 
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was obtained when this purification step was removed entirely and the acetylation was 
carried out on the crude product from the first step, 38.  This, and reducing the reaction 
time in the first step to just 10 minutes, led to an increase in yield to 73 % overall, (Scheme 
2.2).  This meant that this positive control could be easily and rapidly synthesised in 
relatively large quantities to be used continuously in the biological assay.   
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Scheme 2.2: Improved synthetic route to compound 26.  Best overall yield: 73 % 
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Chapter 3 
 
Biological Evaluation 
 
3.1 Introduction 
 
The compounds synthesised needed to be assessed for their inhibitory activity upon 17β-
HSD Type 3, in order for a successful Structure Activity Relationship (SAR) to be 
developed and thus allow the project to progress and more active compounds to be 
designed and synthesised.  Initially, all the compounds were assessed for 17β-HSD3 
inhibitory activity by analysis in a whole cell assay.  It measured and compared the amount 
of testosterone produced by the cells in the presence and absence of potential inhibitors, 
and therefore allowed a comparison of enzymatic activity with those cells that were not 
exposed to any potential inhibitors. 
 
There are many ways of assessing testosterone formation, including direct and indirect 
methods.  During the course of this project two different assay formats have been utilised: 
direct measurement of testosterone using a Thin Layer Chromatography (TLC) based assay 
and an indirect DELFIA® assay (Dissociation Enhanced Lanthanide Fluorescence 
Immunoassay). 
 
3.2 Thin-Layer Chromatography (TLC) Whole Cell Assay 
 
This assay was developed and carried out by colleagues at St Mary’s Hospital Medical 
School (Imperial College, London). 
 
This assay is a whole cell assay, using a transfected 293-EBNA cell line (derived from 
embryonic kidney cells) with stable expression of human 17β-HSD Type 3 (293-
EBNA[HSD3]).  Non-transfected cells had negligible 17β-HSD3 activity, but when 
transfected with 17β-HSD Type 3 cDNA in pCEP4, the transfected cells exhibit a huge 
over-expression of 17β-HSD3 (Figure 2.1).  The over-expression of 17β-HSD3 results in a 
correspondingly large increase in 17β-HSD3 activity, the production of testosterone from 
androstenedione (Figure 2.1).  This activity was dramatically reduced when the cells were 
incubated with 10 µM of compound 36, showing the positive control compound to exert the 
effects expected (Figure 2.1). 
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Figure 2.1: A bar chart to show the increase in 17β-HSD3 activity in the transfected cells 
and the inhibition of activity caused by compound 36. 
 
The 293-EBNA[HSD3] cells were plated at ~50,000 cells/well in 24 well plates, in 
complete growth medium (including 10% FBS, but without G418 or Hygromycin B).  After 
48 hours 2-3 nM 3H-androstenedione was added, in the presence or absence of the potential 
inhibitor (initially at 10 µM concentration), and the cells were incubated at 37 °C.  The 
samples were subjected to extraction with diethylether, spotted onto silica TLC plates and 
androstenedione and testosterone were separated using a 4:1 DCM: EtOAc mobile phase 
(Figure 2.2).  Good separation is achieved using this solvent system, with an Rf of 0.72 for 
androstenedione compared to 0.48 for testosterone.  After drying, the testosterone spots 
were identified, isolated, removed and placed into a scintillation vial.  Methanol and 
scintillation fluid were added and the samples were subjected to scintillation counting.  
 
17β-HSD 
Transfected Cells 
With Compound 36 
(at 10 µM) 
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Figure 2.2: Layout of the TLC plate used for the assay, (using 4:1 DCM: EtOAc solvent 
system). 
 
The inhibitory activities (measured as the percentage inhibition at 10 µM) of the test 
compounds were assessed by comparison with the control (where no test compound was 
added).  The same assay was used to measure the IC50 of selected compounds.  Compounds 
were applied to the cells at a range of concentrations (commonly 6 different concentrations 
between 0.001µM and 10µM) and data analysis allowed the IC50 for each test compound to 
be calculated. 
 
The TLC assay was validated using compound 36, the initial positive control compound.  
The results obtained using compound 36 were excellent.  It exhibited a low IC50 of between 
2nM and 7nM.  Schering-Plough reported compound 36 to exhibit an IC50 of 0.005nM, 
which is considerably lower than the results obtained in this assay.  However, the assay 
used by Schering-Plough is an enzymatic assay and therefore it would not be expected to 
produce the same results as the whole cell TLC assay.  The whole cell assay results will be 
influenced by the ease of which the test compound can pass through the cellular membrane 
and the compound can also be subject to metabolism or excretion from the cell.  All of 
these factors can cause a lower apparent activity.  Most importantly, in the TLC assay the 
Solvent front
Relative front for 
Androstenedione 
Rf = 0.72 
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Direction of 
movement 
Sample 
spots 
Relative front for 
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results obtained for compound 36 were consistent, and thus showed the assay to be reliable 
and reproducible. 
 
The TLC assay was the original assay to be developed for the project, and it produced 
consistent, reliable results.  However, the main disadvantage with this assay is the time and 
manpower required.  This assay is laborious and therefore cannot be transferred to a high-
throughput assay format.  Some aspects of this assay can be automated, for example 
automated TLC spotters can be used, however, even with this automation the TLC assay is 
low throughput.  For these reasons investigations were carried out into the development of 
a new high-throughput assay format.  These developments led to the introduction of the 
DELFIA® assay. 
 
3.3 DELFIA
®
 Assay 
 
The DELFIA® assay used for this project is the Perkin Elmer DELFIA® Testosterone 
Assay, which was originally designed for the quantitative determination of low level 
testosterone in human serum samples.56 
 
The DELFIA® Testosterone assay is a fluoroimmunoassay, based upon the competition 
between europium labelled testosterone and free testosterone within the sample for 
polyclonal anti-testosterone antibodies (Figure 2.3).  The testosterone contained within 
standard solutions, control solutions and serum samples inhibit the binding of labelled 
testosterone to the antibodies to varying extents, dependent upon concentration.  A second 
antibody, which binds to the anti-testosterone antibody, is attached to the solid phase of the 
96 well plate, thus meaning separation of bound and unbound antigen is experimentally 
straightforward.  Enhancement solution is finally added to the wells, which dissociates 
europium ions from the labelled testosterone, these then form highly fluorescent chelates 
with components of the enhancement solution.  This fluorescence is measured and is 
inversely proportional to the concentration of testosterone in the original sample or 
standard.57-59  A calibration curve is constructed from the standards supplied with the test 
kit; this is used to obtain testosterone concentrations, from which the percentage inhibition 
can be obtained. 
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Figure 2.3: Principle of DELFIA® Assay.8 
 
The main advantage of this kit is that it is a high-throughput assay.  The 96-well plate 
format means that at one concentration up to 40 different compounds can be analysed to 
obtain a percentage inhibition result in one assay, thus meaning that results are obtained 
rapidly and project progression should be swift. 
 
3.3.1 Development and Validation of DELFIA
®
 Assay 
 
The DELFIA® assay was developed by Argenta Discovery Ltd,60 using the 293-
EBNA[HSD3] cell line derived at St Mary’s, London.  Further development and results 
were obtained by colleagues at IPSEN Ltd, Paris. 
 
Argenta Discovery were supplied with three compounds to use for assay validation; these 
compounds were compound 36, the Schering-Plough compound,47 and compounds 100 and 
101 (see Chapter 7), which were, at the time, the best novel, in-house compounds we had 
synthesised (see Chapter 7).18  These three compounds were analysed by Argenta 
Discovery Ltd in both the newly developed DELFIA® Assay and in the original TLC assay, 
(Table 2.1).  The IC50 values obtained for compound 36 are comparable in both assay 
formats; however the results for compounds 100 and 101 were less promising, as both 
showed a clear difference in IC50 values in the two assay formats.  It appeared that the two 
compounds are five to tenfold less potent in the DELFIA® assay, when compared with the 
TLC assay.  It was not possible to obtain the sensitivity shown in the TLC assay using the 
DELFIA® assay format. 
 
Incubation  
and washing 
+ + 
Eu 
Eu + 
Eu 
Eu 
Eu 
+ + Eu 
Solid phase  
anti-rabbit IgG 
Fluorescence 
Testosterone  
in sample 
 
Anti-testosterone-
IgG 
Enhancement  
solution 
Eu Labelled 
Testosterone  
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Compound TLC (IC50) DELFIA
®
 (IC50) 
36 1 nM 6 nM 
100 7 µM ~ 80 µM 
101 3 µM ~ 37 µM 
Table 2.1: IC50 values for positive control compounds during assay validation by Argenta. 
(Note: 50 nM substrate used). 
 
Many possible explanations for the differences in sensitivity between the two assay formats 
have been hypothesised and explored, including substrate concentration, cell density, the 
presence of antibiotics, solvent choice and DMSO concentration.  None of the 
investigations carried out has been able to identify the cause of the disparity.   
 
The assay underwent transfer from Argenta Discovery to IPSEN, where further 
optimisation and validation took place.  Many of the test compounds were then subjected to 
routine primary screening to establish the percentage inhibition exhibited by the 
compounds.  However, problems were still encountered regarding the sensitivity of the 
DELFIA® assay, as the vast majority of the compounds tested were found to be inactive.  
Some of the compounds that were shown to be inactive in this assay had previously been 
shown to be active in the TLC assay (Table 2.2 and individual Chapters 6-8).  For example, 
compound 165 (see Chapter 8) showed a highly promising percentage inhibition of 91% (at 
10µM) in the TLC assay, with a moderate IC50 of 3.9 µM, but when the compound was 
tested in the DELFIA® assay, no activity was observed and a percentage inhibition result of 
-51% (at 10µM) was obtained.   
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Percentage Inhibition  
(%, at 10µM) 
IC50 (µM) Compound 
no. 
DELFIA
®
  TLC DELFIA
®
 TLC 
36 99 99 0.015 0.0024 
63 -52 51 a a 
101 -23 89 37 0.7 
123 94 94 3 0.383 
126 -10 87 a 0.9 
131 -33 86 a a 
162 -10 55 a a 
165 -51 91 a 3.9 
Table 2.2: Selected biological data, to illustrate discrepancies between the sensitivity of the 
DELFIA® assay and the TLC assay. (a Not determined) 
 
To assess the reliability of a biological assay, a positive control compound is used, as any 
change in the results would highlight discrepancies in that assay.  Up to this point 
compound 36 had been used as the biological control.  However, as mentioned previously 
(Chapter 2), it is a highly potent compound and because of this, small alterations in assay 
format may not affect the overall result.  It is desirable to have a positive control compound 
which has similar activity to the compounds that are being analysed.  This led to the 
introduction of compound 26 as the new biological control (see Chapter 2).  When 
compound 26 was tested, the clear difference in activity observed with the TLC and the 
DELFIA® assay remained.  In the TLC assay compound 26 exhibited an IC50 of 590 nM, 
compared to an IC50 of 1000 nM in the DELFIA
® assay.  The causes of these differences 
remain unknown. 
 
It seemed that although the DELFIA® assay was able to produce reliable results for the 
highly potent Schering-Plough positive control (36), the assay was unable to produce 
satisfactory results for the in-house inhibitors, as the potency of these is lower as the lead 
series is developed.  Once the project has progressed to a stage where the potency of the 
novel compounds approaches the activity of compound 36, the DELFIA® assay may 
become suitable for this project.  However, it was decided that at the current stage of the 
project, the DELFIA® assay was not suitable, so attention was diverted back to the TLC 
assay, and the results obtained from this assay.  All results quoted in further Chapters were 
obtained from the TLC assay run at St Mary’s Hospital. 
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Unfortunately, due to time restrictions no further progress has been made in the 
development of a suitable assay.  This means that the biological evaluation of many 
completed targets has not yet been carried out, delaying effective project progression.  
These compounds will be evaluated after submission of this thesis. 
 
Where biological results have been received these will be discussed in the individual 
Chapters 6-10. 
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Chapter 4 
 
Computational Modelling 
 
4.1 Introduction  
 
A detailed knowledge of a target binding site would significantly aid the design of potential 
inhibitors.  In cases where enzymes have been crystallised it is possible to determine the 
structure of the protein and the nature of the binding of ligands by X-ray crystallography.  
However, in the case of 17β-HSD Type 3 an X-ray crystal structure is not available, as the 
enzyme is membrane bound and crystallisation is therefore difficult.  The amino acid 
sequence of 17β-HSD Type 3 is known (Swiss-Prot identifier P37058, entry name DHB3-
Human) and this allows a homology model to be constructed.34  This procedure develops a 
three-dimensional model from a protein sequence based on the structures of homologous 
proteins.  Please note this work was carried out by Dr A Smith and Dr M Trusselle. 
 
4.2 Construction of the 17β-HSD Type 3 Homology Model 
 
The structure of an analogous protein was required for use as the template for a homology 
model of 17β-HSD Type 3.  In order to choose the correct template it is necessary to look at 
the evolutionary path of the protein of interest, enabling the most closely related protein 
structure to be used.  A phylogenetic tree reported by Breitling et al was used and this is 
shown in Figure 4.1.61  Those enzymes with an available X-ray structure are represented by 
their PDB code.62, 63  From the phylogenetic tree it can be seen that the 17β-HSD family is 
split into two distinct branches.  The first branch contains types 1, 2, 6, 7 and 9, the second 
branch contains types 3, 4, 8 and 10 and so this is the branch of interest.  There are no 
crystal structures currently available for types 4, 8 or 10 and so the closest available crystal 
structure is that of 1FMC (7α-hydroxysteroid dehydrogenase from Escherichia coli).64  The 
use of 1FMC as a template allowed a homology model to be constructed (Figure 4.2). 
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Figure 4.1: Phylogenetic Tree for the 17β-HSD family. 
 
 
Figure 4.2: Constructed Homology Model.  (Template shown in yellow, Homology model 
shown in blue). 
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4.3 Use of the 17β-HSD Type 3 Homology Model. 
 
Androstenedione, the natural enzyme substrate, and NADP(H), the co-factor, are shown 
docked into the homology model (Figure 4.3).  It can be seen that the C17 carbonyl group 
on androstenedione is orientated towards the nicotinamide ring of the co-factor in the 
catalytic region.   
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Figure 4.3: The 17β-HSD Type 3 homology model with androstenedione and NADPH 
docked.  The enzyme surface colours indicate lipophilic (green) to hydrophilic (red). 
 
It can be seen from Figure 4.4 that compound 36, a potent 17β-HSD Type 3 inhibitor from 
Schering-Plough,47 appears to bind tightly with the active site of the homology model.  An 
association can be observed between the co-factor and the acetamide at the base of 
compound 36.  The t-butyl group occupies a lipophilic pocket formed by Ile-187, Phe-190, 
Tyr-198 and Leu-303.  It can also be seen that the diphenylmethylene headgroup interacts 
effectively with a hydrophobic pocket of the enzyme. 
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Figure 4.4: Key interactions between compound 36 and amino acid residues in the active 
site of 17β-HSD Type 3, identified from the docking calculations 
 
Once the homology model had been constructed and optimised it was then suitable for use 
in the design of novel 17β-HSD Type 3 inhibitors.  Structures of interest were examined 
using the homology model and the docking of potential inhibitors enabled important 
interactions to be estimated and regions of space to be identified. 
 
It was hoped that this information could be used to predict or explain differences in 
biological activity.  It should be noted though, that a homology model can only be used as a 
guide.  Although every care was taken to ensure the accuracy of its design, it cannot be 
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assumed to be conclusive.  It is possible that the shape of the active site may not be 
accurately represented by a homology model and the fluctuations that occur in enzyme 
active sites are not fully accounted for by the docking program.  An X-ray crystal structure 
would be more reliable; however, as this is not currently available the homology model was 
used as a tool in structure based drug design. 
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Chapter 5: 
 
Development of Initial Lead Series 
 
It has been hard to gather detailed information concerning the Schering-Plough non-
steroidal 17β-HSD Type 3 inhibitors, as the patents contain no specific biological data.47-50  
From the patents it was possible to identify a selection of compounds which were thought 
to be the most promising.  From this selection, SCH-451659 (36) was selected as a positive 
control (see Chapter 2).  This compound was synthesised and subjected to biological 
evaluation (see Chapter 3), which showed SCH-451659 (36) to be a highly potent 17β-HSD 
Type 3 inhibitor.  The activity of this series of compounds was therefore confirmed.  More 
information was subsequently published by Schering-Plough regarding SCH-451659, (36) 
and other similar compounds,46, 51, 52 thus providing further evidence that the series of 
compounds identified from the patent show potent 17β-HSD Type 3 inhibitory activity.  
Much information about other novel, potential inhibitors could be gained from these 
structures. 
 
5.1 Inhibitor Design 
 
The structures from the Schering-Plough patents were examined and then were analysed to 
give a representation of a general pharmacophore required for 17β-HSD Type 3 activity 
(Figure 5.1a).  This pharmacophore showed four distinct regions which were subject to 
little variation between the many compounds (Figure 5.1b).  The four main regions were: 
(i) a hydrophobic head group, with varying structure and substitution, (ii) the lipophilic 
alkyl group on position two of the piperazine, (iii) a linking group and (iv) a hydrogen bond 
acceptor, most commonly a carbonyl group at the other end of the molecule to the 
hydrophobic head (Figure 5.1b). 
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Figure 5.1: (a) The pharmacophore established from Schering-Plough compounds,47-50  
(b) SCH-451659 (36) showing the common regions in Schering-Plough 
compounds. 
 
This pharmacophore information was used to identify suitable compounds from available 
commercial databases.  One compound, 39 (Figure 5.2) was identified from the Maybridge 
database as fitting the desired pharmacophore hypothesis.  The compound had the main 
desired regions from the pharmacophore; the hydrophobic head group was, in this case, a 
substituted diphenylether moiety. 
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Figure 5.2: The diphenylether compound identified from the Maybridge database 
(RFJ01724, 39). 
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This compound was subjected to biological testing in the 17β-HSD Type 3 TLC assay.  
Although only weakly active (17 % inhibiton at 10 µM) this compound was used to gain 
ideas and suggestions for a novel series of 17β-HSD Type 3 inhibitors.  This diphenylether 
moiety is a suitable novel hydrophobic head group for the design of a novel class of 
compounds as potential inhibitors of 17β-HSD Type 3. 
 
The pharmacophore obtained from the overlaid Schering-Plough compounds has a 
hydrogen bond acceptor.  This is most commonly a carbonyl group, but can also be other 
groups that act as a carbonyl mimic.  It was hypothesised that the orientation of this 
carbonyl is important for the inhibition of 17β-HSD Type 3, as this is within the catalytic 
region of the active site, and there may be beneficial interactions between the 
substrate/inhibitors and the NADPH cofactor. 
 
5.2 Initial Targets 
 
The information obtained from the pharmacophore and the lead compound identified from 
the Maybridge database (39) led to the proposal of an initial compound design strategy 
(Figure 5.3). 
 
O
Y
N R
O
X
X= Various Substituents
Y= Linking Group
R= Various alkyl and aryl 
substituents
Diphenylether Hydrophobic 
Head Group
Linker
Section
Carbonyl H-bond acceptor  
Figure 5.3: Initial compound design. 
 
This general structure allowed for the initial design of two novel series of targets: the amide 
and amine linked compounds (Figure 5.4).  Various derivatives were analysed in silico 
using the 17β-HSD3 homology model and the amide and amine linked compounds were 
shown to have good docking scores.  This will be discussed in more detail in Chapters 6 
and 7. 
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Figure 5.4: Amine and amide linked initial targets. 
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Chapter 6: 
 
Synthesis and Biological Evaluation of the Amide Linked Series of Inhibitors 
 
6.1  Synthesis of Initial Targets 
 
The synthesis of a novel series of amide linked target compounds was initiated (Scheme 
6.1).  It was hoped that this series of compounds would help to provide valuable knowledge 
about the size and shape of the active site and ultimately the tolerability of the enzyme to 
inhibitors.  The use of an amide linking group determines not only the size, but also the 
geometry, polarity and electronics of the compounds.  This series was also used to examine 
the effects of differing hydrophobic head group substituents and R groups in the hydrogen 
bond accepting region of the template (Figure 6.1).  Using information regarding 
biologically active inhibitors from the Schering-Plough patents,47-50 five different 
hydrophobic head substitution patterns were selected.  These were 4-chloro, 2,4-dichloro, 
3,5-dichloro, 4-trifluoromethyl and 4-trifluoromethoxy (Figure 6.1). 
 
Cl
O
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O O
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F3C
O
F3CO
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(a) (b) (c)
(d) (e)  
Figure 6.1: Selected diphenylether substitution patterns. (a) 4-chloro, (b) 2,4-dichloro, (c) 
3,5-dichloro, (d) 4-trifluoromethyl, (e) 4-trifluoromethoxy. 
 
To explore the SAR of the R group on the carbonyl mimic section of the compounds, six 
different alkyl groups of different sizes and electronics were selected to probe the steric 
constraints in this region.  These were methyl, phenyl, cyclohexane, cyclopentane, iso-butyl 
and iso-valeryl.  The t-Boc protected intermediates were also submitted for biological 
testing, to investigate the effects of the t-Boc moiety. 
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The synthesis of the amide linked targets is outlined in Scheme 6.1 and exhibited moderate 
to good yields. 
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Fe, NH4Cl,
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 o
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40a: X = 2,4-dichloro, 97 %
    b: X = 3,5-dichloro, 98 %
    c: X = 4-chloro, 83 % (MW)
    d: X = 4-CF3, 90 %
     e: X = 4-OCF3, 99 %
41a: X = 2,4-dichloro, 90 %
    b: X = 3,5-dichloro, 89 %
    c: X = 4-chloro, 82 %
    d: X = 4-CF3, 82 %
     e: X = 4-OCF3, 95 %
43: X = 2,4-dichloro, 84 %
44: X = 3,5-dichloro, 60 %
45: X = 4-chloro, 65 %
46: X = 4-CF3, 72 %
47: X = 4-OCF3, 57 %
48a: X = 2,4-dichloro, 98 %
    b: X = 3,5-dichloro, 21 %
    c: X = 4-chloro, 75 %
    d: X = 4-CF3, 89 %
     e: X = 4-OCF3, 87 %
EDC, DMAP, 
TEA, DCM,
r.t. 2-7 days
r.t. 1-2 h DCM, TEA,
r.t. 1-2 h
X = 2,4-dichloro,  3,5-dichloro, 
      4-chloro, X = 4-CF3 or 
      X = 4-OCF3,
Compounds 49-74
Yields: 47-97 %
42
 
Scheme 6.1: Synthesis of amide linked target compounds (40-74). 
 
The first step in the synthetic route was the diphenylether formation (40a-e), which 
involved the coupling of the appropriate substituted phenol (e.g. 2,4-dichlorophenol) and 2-
fluoro-1-nitrobenzene, in the presence of potassium carbonate.  The mixtures were heated 
at reflux in DMF for between 16 and 20 hours.65  This proved to be a very successful 
method with excellent yields obtained for many varying substitutions.  However, the 
reaction time is very long, so a new method utilising microwave (MW) assisted synthesis 
was developed.  The reaction between 4-chlorophenol and 2-fluoro-nitrobenzene, with 
potassium carbonate in DMF was heated using a CEM Discover® instrument,66 for various 
times and at various temperatures.  The results are shown in Table 6.1. 
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Time Temperature (°C) Conversion (%)
a, b 
10 160 75 
20 180 77 
30 180 91 
a Measured by HPLC 
b Reaction conditions: 4-chlorophenol (2.25 mmol), 2-fluoronnitrobenzene (1.5 mmol), 
K2CO3 (2.7 mmol) in DMF (3 mL), were heated in a CEM Discover
® instrument. 
Table 6.1: Conversion results for varying times and temperatures. 
 
It was found that the reaction had not reached completion when heated at 160 °C or 180 °C 
for 10 or 20 min.  Completion was approached when the reaction time was increased to 30 
min.  The correct product was isolated in an 83 % yield using this MW technique.  This is 
comparable to the original method, but with a reaction time greatly reduced from 18 h to 30 
min. 
 
The nitro group on the synthesised intermediates was reduced using iron powder and 
ammonium chloride in a mixture of ethanol and water at reflux to form the diphenylether 
aniline template (41a-e).65  An amide coupling was now required and, although slow 
(reaction time 2-7 days), this step has allowed for the successful synthesis of 30 compounds 
in this series.  Following the amide coupling, the compounds required the removal of the t-
Boc protecting group by TFA, followed by the final synthetic step in this route; the amide 
formation with the appropriate acid chloride.  Figure 6.2 shows an illustrative example of a 
HPLC trace for 2 compounds synthesised in this series, 52 and 67. 
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Figure 6.2: Illustrative examples of HPLC traces for compounds 52 and 67, (solvent 
system: 90 % Acetonitrile in water at 1.0 mL/min). 
 
The final step in this synthetic route could either be carried out using standard laboratory or 
parallel synthesis techniques.  The initial methyl and phenyl derivatives were prepared 
using standard laboratory techniques, and the cyclohexane, cyclopentane, iso-butyl and iso-
valeryl compounds were all prepared using parallel synthesis techniques.  There was no 
significant change in yields when parallel synthesis techniques were used.  However, they 
allow many more compounds to be made in a shorter time.  This is essential in medicinal 
chemistry research, where many similar compounds need to be synthesised in order to 
successfully and rapidly establish an SAR between the compounds and the enzyme in 
question. 
 
6.2  Biological Results and Discussion: Amide Linked Series. 
 
Thirty amide linked target compounds were synthesised, Table 6.2 shows all the 
compounds synthesised.  All the amine linked target compounds have been submitted for 
biological testing. Table 6.2 also shows the available biological data obtained from the TLC 
assay. 
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Compound 
Number 
X R 
% Inhibition (at 10 
µM).
a 
43 2,4-dichloro t-butyl b 
49 2,4-dichloro Methyl 66 
50 2,4-dichloro Phenyl 45 
51 2,4-dichloro Cyclohexyl b 
52 2,4-dichloro Cyclopentyl b 
53 2,4-dichloro Isobutyl b 
54 2,4-dichloro Isovaleryl b 
44 3,5-dichloro t-butyl b 
55 3,5-dichloro Methyl 30 
56 3,5-dichloro Phenyl 27 
57 3,5-dichloro Cyclohexane b 
58 3,5-dichloro Cyclopentane b 
59 3,5-dichloro Isobutyl b 
60 3,5-dichloro Isovaleryl b 
45 4-chloro t-butyl b 
61 4-chloro Methyl 31 
62 4-chloro Phenyl 13 
45 4-trifluoromethyl t-butyl b 
63 4-trifluoromethyl Methyl 50 
64 4-trifluoromethyl Phenyl 38 
65 4-trifluoromethyl Cyclohexane b 
66 4-trifluoromethyl Cyclopentane b 
67 4-trifluoromethyl Isobutyl b 
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68 4-trifluoromethyl Isovaleryl b 
47 4-trifluoromethoxy t-butyl b 
69 4-trifluoromethoxy Methyl 44 
70 4-trifluoromethoxy Phenyl 34 
71 4-trifluoromethoxy Cyclohexane b 
72 4-trifluoromethoxy Cyclopentane b 
73 4-trifluoromethoxy Isobutyl b 
74 4-trifluoromethoxy Isovaleryl b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %,  
b Not determined. 
Table 6.2: Full range of novel amide linked target compounds synthesised and available 
enzyme inhibition data. 
 
The limited biological data available on these compounds allow for some rudimentary 
conclusions regarding the effects of different substitutions on the diphenylether 
hydrophobic headgroup.  Five different substitution patterns were tested and no dramatic 
differences between them were observed.  All are viable substitution patterns for future 
investigations.  It can be concluded, however, that the 2,4-diCl is preferred over 3,5-diCl 
substitution pattern, as the percentage inhibitions were obtained as 66 % and 27 % for the 
phenyl substituted compounds respectively (49 and 56).  This is not conclusive as not all 
the compounds have been tested and the IC50 values have not been obtained.  In addition a 
4 substituent is tolerated and 4-chloro, 4-CF3 and 4-OCF3 show moderate inhibition at 10 
µM.  It is hoped that further biological data will give more detailed information regarding 
the effects of the substituents on the diphenylether hydrophobic headgroup. 
 
There is one main pattern visible in this series, with the better inhibitory activities generally 
being shown by those compounds with a methyl group, rather than a phenyl group, in the 
hydrogen bond acceptor region of the template.  The introduction of cyclohexane, 
cyclopentane, t-butyl, isobutyl and isovaleryl will help to explore the SAR surrounding the 
size and electronics in this region.   
 
The difference between the methyl and phenyl substituted compounds may be simply due 
to the size difference between the two groups affecting the ability of the inhibitor to fit 
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effectively into the active site of the protein.  Alternatively it may be due to electronic 
interactions or an induced change in the geometry/shape of the molecule.  In-silico studies 
were able to propose an explanation for these differences. 
 
6.3 Docking Studies of the Amide Linked Series 
 
All the compounds in Table 6.2 were docked into the 17β-HSD Type 3 homology model 
discussed in Chapter 4 by Dr A Smith and Dr M Trusselle.  This presented some interesting 
observations that may help to explain the biological results.  For example, compound 61 
and compound 62 differ only in the R group in the hydrogen bond accepting region of the 
compound.  Compound 62 has a phenyl ring, whereas compound 61 has the much smaller 
methyl group.  Both have a 4-Cl substituted hydrophobic head group, linked via an amide 
bond to the piperidine ring.  Figures 6.3 and 6.3 shows these 2 molecules docked into the 
17β-HSD Type 3 homology model. 
 
It can be seen that the two compounds sit very differently within the active site of the 
homology model.  Compound 61 fits into the active site with the N-acetyl group towards 
the cofactor, possibly due to an interaction between the N-acetyl and the co-factor itself.  
This interaction seems to be absent in compound 62 and therefore the molecule is 
positioned completely differently.  It is hard to know the exact reason for this, but it is 
possible that the phenyl ring is simply too large to allow the interaction between the amide 
and the co-factor to occur, thus indicating that the molecule can be attracted into a different 
region of the active site. 
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Figure 6.3: Compound 61 docked into the 17β-HSD Type 3 homology model. 
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Figure 6.4: Compound 62 docked into the 17β-HSD Type 3 homology model. 
 
It is hypothesized that the active site of 17β-HSD Type 3 is spacious as there are many 
large reported inhibitors of the enzyme.28, 46  This is supported by the docking studies, as 
space can be seen either above 61 or below 62.  It had been envisaged that the hydrophobic 
head group would fit into the large hydrophobic pocket of the active site, as can be seen 
with 61. However, in 62 the molecule is not sitting in this region, as the distance between 
the headgroup and the N-acetyl group is too short.  This may be the reason why the 
Schering-Plough positive control47 (Chapter 2, 36) exhibits a much higher potency than the 
compounds synthesised in this series so far.  Compound 36 is much longer in length and 
therefore may be able to occupy both the hydrophobic pocket and interact with the cofactor 
simultaneously (Figure 6.5).  It can be seen that there is a clear difference in size and length 
between compound 36 and the amide linked compound synthesised (49).  For these reasons 
the synthesis of a new series of extended amide linked compounds was initiated. 
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Figure 6.5: Comparison between 36 (Green) and 49 (White). 
 
6.4 Synthesis of Extended Amide Linked Compounds 
 
The synthetic route to the extended amide linked compounds is shown in Scheme 6.2.  The 
three compounds synthesised in this series, 76, 77 and 78, were all synthesised from the 
same intermediate (75) used to make the amide linked compounds described previously 
(Scheme 6.1).  The synthetic route to the extended compounds is shown in Scheme 6.2.  
The piperidine amine 75 was reacted with 1-acetylpiperidine-4-carbonyl chloride, to form 
another amide bond linking the extra piperidine ring to the compound.  Excellent yields of 
86 % and 84 % were obtained for compound 76 and 77 respectively.  The same piperidine 
amine 75 was also subjected to an amide coupling reaction with (1-acetyl-piperidin-4-yl)-
acetic acid and although the yield of this reaction was low at just 17 %, the compound was 
synthesised successfully and submitted for biological testing. 
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Scheme 6.2: Synthesis of extended amine linked compounds 76, 77 and 78. 
 
However, these compounds have not been subjected to biological testing so far, so no 
definite conclusions can be drawn from this series as yet.  These compounds were docked 
into the 17β-HSD Type 3 homology model and this produced some interesting results.   
 
The docking of the extended compounds 76 and 78 are shown in Figures 6.6 and 6.7.  It can 
be seen from these docking studies that 76 and 78 both lie in a similar conformation within 
the active site of the homology model.  The diphenylether headgroup of the molecules can 
be seen to be positioned deep within the large hydrophobic pocket of the active sites.  This 
should help to increase the binding efficiency of the compounds and therefore the 
inhibitory activity.  At the same time the increased length of these compounds may allow 
the N-acetyl group to interact with the cofactor, thus hopefully increasing the binding 
strength.  It would appear that the presence of the extra CH2 in 78 compared to 76 has little 
impact upon the way the compound is positioned within the active site. 
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The methyl group in the hydrogen bond accepting region of the two compounds is directed 
slightly differently.  In 78 it is sitting in a small pocket within the active site, whereas in 78 
this is not observed.  This may or may not be significant to the activity.  No firm 
conclusions can be reached until biological data has been obtained.  From these docking 
studies it is anticipated that the three compounds in this series will exhibit enhanced 
inhibitory activity compared to the original, shorter amide linked compounds (43 to 74). 
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Figure 6.6: Compound 76 docked into the 17β-HSD Type 3 homology model. 
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Figure 6.7: Compound 78 docked into the 17β-HSD Type 3 homology model. 
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6.5 Table of Compounds Synthesised within Chapter 6 
 
Compound  
no.  
Structure 
% Inhibition (at 
10 µM).
a
 
43 
Cl
Cl
O
HN
O
N
O
O
 
b 
49 
Cl
Cl
O
HN
O
N
O
 
66 
50 
Cl
Cl
O
HN
O
N
O
Ph
 
45 
51 
Cl
Cl
O
HN
O
N
O
 
b 
52 
Cl
Cl
O
HN
O
N
O
 
b 
53 
Cl
Cl
O
HN
O
N
O
 
b 
54 
Cl
Cl
O
HN
O
N
O
 
b 
 77 
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O
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Cl
 
b 
55 O
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O
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O
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Cl
 
30 
56 O
HN
O
N
O
Cl
Cl
 
27 
57 O
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O
N
O
Cl
Cl
 
b 
58 O
HN
O
N
O
Cl
Cl
 
b 
59 O
HN
O
N
O
Cl
Cl
 
b 
60 O
HN
O
N
O
Cl
Cl
 
b 
45 
Cl
O
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O
N
O
O
 
b 
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61 
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31 
62 O
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O
N
O
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13 
45 O
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O
N
O
O
F3C
 
b 
63 O
HN
O
N
O
F3C
 
50 
64 O
HN
O
N
O
F3C
 
38 
65 O
HN
O
N
O
F3C
 
b 
66 O
HN
O
N
O
F3C
 
b 
67 O
HN
O
N
O
F3C
 
b 
68 O
HN
O
N
O
F3C
 
b 
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47 O
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O
N
O
O
F3CO
 
b 
69 O
HN
O
N
O
F3CO
 
44 
70 O
HN
O
N
O
F3CO
 
34 
71 O
HN
O
N
O
F3CO
 
b 
72 O
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O
N
O
F3CO
 
b 
73 O
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O
N
O
F3CO
 
b 
74 O
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O
N
O
F3CO
 
b 
76 
O
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O
N
O
N
O
Cl
 
b 
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77 
O
HN
F3C
O
N
O
N
O  
b 
78 
O
HN
Cl
O
N
O
N
O
 
b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %,  
b Not determined. 
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Chapter 7 
 
Synthesis and Biological Evaluation of an Amine Linked Series of Inhibitors 
 
In the initial stages of the project both amide and amine linked compounds were identified 
as potential inhibitors (Figure 5.4).  The amide linked compounds were synthesised and 
showed some inhibitory activity.  However, a large amount of investigation was still 
required to reach the potency level exhibited by our competitor compounds.46, 51, 52  A series 
of novel amine linked compounds was therefore synthesised.   
 
7.1 Synthesis of Initial Targets 
 
The initial amine linked target molecules were analysed retrosynthetically and their 
synthesis was planned and initiated (Scheme 7.1).  The first two synthetic steps are 
common with the synthesis of the amide linked compounds.  These common, diphenylether 
aniline intermediates were made in large batches and kept in stock for use in all series.  The 
diphenylether aniline headgroup then required a reductive amination with t-butyl-4-oxo-1-
piperidine carboxylate to form the amine bond.  This reaction proved to be highly 
problematic. 
 
X
O
NH2
NBocO
NH
O
HN
X
X
O
HN
NBoc
R Cl
O X
O
HN
N
O
R
DCM, TFA
Reductive 
Amination
 
Scheme 7.1: Proposed route to amine linked compounds. 
 
The lower reactivity of anilines was considered before experimental procedures were 
initiated, and successful literature procedures were found, which detailed many similar 
reactions, using various different anilines and cyclohexanones.50, 67-71  Many reductive 
amination methods were attempted (Table 7.1).  These included direct reactions, where the 
piperidone and the amine were mixed with the reducing agent, without prior formation of 
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the imine (Table 7.1, Entries 2, 4, 5 and 6).  Some methods were indirect/stepwise 
reactions, where the imine was preformed and was reduced in a second stage (Table 7.1, 
Entries 1 and 3).  Overall, these attempted reductive amination methods met with limited 
success and a different method was required. 
 
NH2
O
Cl
Cl
NBocO
O
NBoc
HN
Cl
Cl
41b
 
Entry Reagents Conditions Yield (%) 
1 
p-TSA, 4 Å MS, toluene, 
Then NaBH4.
71 
Reflux 18 h 
r.t., 2 h 
25 
2 AcOH, THF, NaBH(OAc)3.
50 r.t., 66 h a 
3 
TiOiPr, 
Then EtOH and NaCNBH3.
67 
r.t., 2 h 
r.t., 60 h 
a 
4 NiCl2
.6H2O, MeOH, NaBH4.
68 50 °C, 5 h a 
5 Activated Zn dust, AcOH, H2O.
70 70 °C, 5h 9 
6 Activated SiO2, HCOOK, (CH3COO)2Pd, DMF.
69 r.t., 18 h, 
40 °C, 26 h 
a 
a No product isolated. 
Table 7.1: Attempted Procedures for the Reductive Amination. 
 
7.2 Development and Optimisation of a Novel Microwave Reductive Amination 
Procedure 
 
Anilines are weakly basic amines, (pKa of 4.6, cf. 10.7 for cyclohexylamine72).  This is 
partly due to a negative inductive effect from the nitrogen atom being attached to an sp2 
carbon but, more influentially it is caused by the partial delocalisation of the nitrogen lone 
pair into the aromatic ring.  This reduced pKa means that anilines are less reactive than 
other primary amines.73  This slows the initial attack on the carbonyl carbon and leads to a 
slower overall reaction rate.   
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Traditionally, sodium cyanoborohydride has been the reducing agent of choice in direct 
reactions.74, 75  However, the reagent and its by-products are highly toxic, which is 
undesirable.  Since then, sodium triacetoxyborohydride has been identified as a mild, 
selective and efficient alternative.76  Imines are much more basic than ketones or aldehydes 
and thus are preferentially reduced by sodium triacetoxyborohydride. 
 
Due to the reactivity issues with anilines, Abdel-Magid’s group demonstrated the use of 
several different sets of reaction conditions for the direct reductive amination of anilines 
using sodium triacetoxyborohydride.77-79  Although their overall approach was successful, 
because of the numerous protocols reported, it seemed difficult to easily select optimal 
reaction conditions.  It would therefore be useful if a more general, user-friendly protocol 
could be developed, thus allowing for the rapid synthesis of aromatic amines.  It was also 
interesting to investigate whether the use of modern microwave technology could enhance 
the reaction rate and overall efficiency of the reductive amination process.   
 
Since the pioneering work of Gedye80 and Giguere,81 the use of microwaves (MWs) in 
organic chemistry has become a quickly growing area of interest within synthetic organic 
chemistry.82-84  Since the 1980s microwaves have been used in synthetic organic chemistry.  
However, it was not until the mid 1990s that the number of MW publications started to 
increase dramatically.  The main reason for this was the availability of specialised 
commercial MW equipment intended for organic chemistry, which allowed for safer and 
more reliable, reproducible reactions.   
 
Traditionally, most organic reactions are heated using heat transfer equipment, such as oil 
baths or heating mantles.  However, these techniques can be rather slow and a temperature 
gradient can occur, which can lead to localised overheating, and the potential for 
decomposition or the formation of by-products.  In contrast, MW radiation passes through 
the walls of the vessel and through dielectric heating, heats only the reactants and solvents.  
This helps to keep the temperature uniform throughout the vessel, which can lead to fewer 
by-products and/or decomposition and, therefore, often results in increased yields.84  In 
pressurised systems, such as microwave reaction vessels, it is possible to heat solvents to a 
point far above the boiling point of the solvent, thus introducing a higher amount of energy 
to the reaction.  New MW technologies are allowing investigations into large scale 
synthesis, batch processes, high-throughput library synthesis and flow processes.  This 
could have a dramatic effect upon research and process chemistry.82-84 
 84 
The principal advantage of the use of microwaves in organic chemistry is the dramatically 
reduced reaction times.  As previously mentioned in Chapter 6, the formation of the 
diphenylether hydrophobic headgroup required heating at reflux for ~18 h, but this could be 
reduced to 30 min by utilising MW technology, without the yields being detrimentally 
affected.  It was hoped that similar improvements could be made by using MW technology 
for the reductive amination of anilines. 
 
At the outset of the study, and in order to develop and optimise a suitable microwave-
assisted direct reductive amination process, the general method described by Abdel-Magid 
and co-workers was used as a basis.77-79  A standard reaction between aniline and 
cyclohexanone was initially selected to carry out an initial time and temperature study 
(Scheme 7.2).85  The reaction was carried out in sealed microwave tubes containing a 
solution of aniline (1 mmol), cyclohexanone (2 mmol), sodium triacetoxyborohydride (2.5 
mmol) and acetic acid (3 mmol) in toluene (2 mL) which was then heated for various times 
and temperatures using a CEM Discover® instrument.66 
 
NH2
O
+
N
H
NaBH(OAc)3, AcOH
Toluene
79  
Scheme 7.2: The reductive amination of cyclohexanone with aniline. 
 
The results of the initial time and temperature study are shown in Table 7.2.  Pleasingly, it 
was found that a smooth and successful reaction could be achieved at 100 °C in only 10 
minutes (Entry 1).  Moreover, it was discovered that the yields of desired product could be 
enhanced to a 87 % by increasing the temperature to 140 °C (Entry 3).  Interestingly, 
heating beyond this temperature proved to be detrimental to the product yields (Entries 4 
and 5).  Furthermore, a 10 minute reaction time seemed to be optimal, as heating for a 
longer time period showed no significant benefits (Entries 6 and 7).  Therefore, all further 
reactions were heated at 140 °C for 10 minutes. 
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Entry Time (min) Temperature (°C) Yield (%)
a 
1 10 100 70 
2 10 120 81 
3 10 140 87 
4 10 160 81 
5 10 180 77 
6 15 120 84 
7 15 140 86 
a Yield of isolated product. 
Table 7.2: The effects of time and temperature on the reductive amination of 
cyclohexanone with aniline. 
 
In order to further optimise the reductive amination process it was crucial to investigate an 
array of solvents that possess different microwave properties (Table 7.3).83, 86  Whilst all 
solvents performed well, the yield of 94 % that was obtained with 1,2-dichloroethane was 
particularly impressive (Entry 2). It was therefore decided that all further reactions would 
be carried out using DCE as the solvent.  Nevertheless, the result of 91 % obtained with 
acetonitrile (Entry 4) is comparable and, if required, this solvent could be used as an 
alternative. 
 
Entry Solvent Yield (%)
a 
1 Toluene 87 
2 THF 79 
3 DCM 81 
4 Acetonitrile 91 
5 1,2-DCE 94 
a Yield of isolated product. 
Table 7.3. The effects of solvents used in reductive amination of cyclohexanone with 
aniline. 
 
Investigations were also made to see whether the reducing agent or the acid could be 
sucessfully substituted for alternative reagents (Table 7.4).  First, it was found that the use 
of both sodium cyanoborohydride and resin-bound MP-triacetoxyborohydride87 resulted in 
inferior yields (Entries 1 and 2).  However, the yield of ~70 % obtained with the use of the 
reducing agent MP-sodium triacetoxyborohydride (Entry 2) is still synthetically useful, as 
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this reagent offers the benefit of a simple filtration rather than an aqueous work-up.  The 
role of the acetic acid is clearly very important; it is thought to protonate the intermediate 
imine, therefore assissting in the reduction.  All attempts to substitute this for other acid 
derivatives resulted in lower yields (Entries 3-5).   
 
Entry Acid Reducing agent Yield (%)
a
 
1 AcOH NaCNBH4 56 
2 AcOH MP-BH(OAc)3
87 69 
3 p-TSA NaBH(OAc)3 45 
4 Amberlite IRC50-H NaBH(OAc)3 64 
5 MP-TsOH NaBH(OAc)3 35 
a Yield of isolated product. 
Table 7.4. Alternative reagents for the reductive amination of cyclohexanone with aniline. 
 
Now that optimised microwave conditions had been established,85 reductive amination 
reactions were attempted with a range of electronically different anilines and ketones of 
varying reactivity (Table 7.5).  Cyclopentanone and hexan-2-one reacted extremely readily 
with aniline to provide excellent yields of 88 % and 92 % respectively (Entries 2 and 3).  
Indeed, even the much less reactive cyclooctanone provided a very good yield of 68 % in 
only 10 minutes (Entry 4).  In almost every instance the use of microwave irradiation to 
facilitate the reductive amination of various anilines was highly successful, with reactions 
reaching completion in just 10 minutes.  Moreover, both p-methoxyaniline and o-toluidine 
performed extremely well with all the ketones used (Entries 5-11).  However, and perhaps 
not surprisingly due to their lower reactivity, reactions involving the electron poor o-
bromoaniline and p-nitroaniline gave lower yields (Entries 12-15).  It should be noted that 
in these cases it was possible to observe some of the starting aniline by TLC.  Nevertheless, 
this protocol still allowed for the swift formation of synthetically useful building blocks, 
albeit in moderate yields.85 
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Entry Aniline Ketone Product 
Yield 
(%)
a
 
1 NH2 
(a) 
O
 
N
H
79  
94 
2 (a) 
O
 
N
H
80  
88 
3 (a) 
O
 
N
H
81  
92 
4 (a) 
O
 
N
H
82  
68 
5 NH2
MeO
 
(b) 
O
 
N
H
MeO
83  
77 
6 (b) 
O
 
N
H
MeO
84  
64 
7 (b) 
O
 
N
H
MeO
85  
87 
8 (b) 
O
 
N
H
MeO
86  
64 
9 NH2
Me
 
(c) 
O
 
N
H
Me
87  
95 
10 (c) 
O
 
N
H
Me
88  
81 
 88 
11 (c) 
O
 N
H
Me
89  
92 
12 NH2
Br
 
(d) 
O
 
N
H
Br
90  
56 
13 (d) 
O
 
Br
N
H 91  
40 
14 NH2
O2N
 
(e) 
O
 
N
H
O2N
92  
34 
15 (e) 
O
 
N
H
O2N
93  
26 
a Yield of isolated product. 
Table 7.5. Microwave-assisted reductive amination between anilines (a-e) and ketones. 
 
To fully explore the scope of these newly developed reductive amination conditions, the 
reaction between various anilines and an aldehyde, cyclohexanaldehyde, was examined 
(Table 7.6).  However, due to the increased reactivity of aldehydes, when using the 
established protocol, the di-alkylated compound was found to be the major product.  This 
problem was easily overcome by utilizing the aldehyde as the limiting reagent (2 mmol 
aniline with 1 mmol of aldehyde).  Indeed, the desired mono-alkylated products were then 
obtained successfully in excellent yields of up to 91 %.  Even the very un-reactive o-
bromoaniline and p-nitroaniline provided the desired products in high yields of 75 % and 
61 % respectively (Entries 4 and 5).85 
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Entry Aniline Product Yield (%)
a
 
1 
NH2 
N
H
94  
91 
2 
NH2
MeO
 
N
H
MeO
95  
83 
3 
NH2
Me
 
N
H
Me
96  
88 
4 
NH2
Br
 
N
H
Br
97  
75 
5 
NH2
O2N
 
N
H
O2N
98  
61 
a Yield of isolated product. 
Table 7.6. Microwave-assisted reductive amination between anilines and 
cyclohexanaldehyde. 
 
Having established this novel microwave protocol, it was interesting to investigate whether 
acid labile groups were tolerated by the technique.  To investigate this, 1,4-
cyclohexanedione monoethylene acetal, which contains an acid labile acetal protecting 
group, was chosen to undergo a reductive amination with aniline (Scheme 7.3).  
Gratifyingly, using this general protocol the reaction proceeded extremely smoothly 
without cleavage of the acetal group, to afford the desired product with an excellent yield of 
82 %. 
 
OO
O
NH2
O
N
H
O
+
82%
NaBH(OAc)3, AcOH, DCE
10 min, 140 oC
99
 
Scheme 7.3: Microwave-assisted reductive amination with an acid sensitive substrate. 
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This novel microwave-assisted direct reductive amination procedure offers many 
advantages over more traditional methods.  The most beneficial is the rapid reaction time, 
with the vast majority of reactions producing excellent yields after merely 10 minutes.  
Additionally, the reaction conditions are mild and simple; sodium triacetoxyborohydride is 
much less toxic than the alternative sodium cyanoborohydride and acid sensitive 
functionality can be tolerated by this system.  A further advantage of this procedure is that 
inert conditions are not necessary.  This, coupled with only minimal work-up and 
straightforward flash chromatography, means that the reactions are operationally very 
simple.85 
 
7.3 Application of Novel Microwave Method 
 
When applied to the original amine linked 17β-HSD Type 3 target compounds, this new 
procedure led to greatly increased yields and much cleaner reactions (Scheme 7.4).  It was 
also found that 1-acetyl-piperidin-4-one and 1-benzoyl-piperidin-4-one were commercially 
available; thus the initial synthetic route to methyl or phenyl substituted amides could be 
shortened by 2 steps, as the N-t-Boc deprotection and following acylation was no longer 
required.  This revised route allowed for the successful synthesis of two of the final amine 
linked targets, compounds 100 and 101 (Scheme 7.4).   
 
O
NH2
Cl
X
NO
O
R
O
HN
N
O
R
Cl
X
NaBH(OAc)3, AcOH, DCE,
MW, 100 
o
C, 15 min
 X= Cl, R= Me, 99 %, 100
 X= H,  R= Me, 98 %, 101
X=Cl, 41a
   =H, 41c
 
Scheme 7.4: Novel reductive amination procedure85 to afford amine linked compounds 100 
and 101. 
 
It should be noted that although the optimised conditions for reductive aminations with 
anilines were found to be 140 °C for 10 minutes, these are a guideline and excellent results 
can be obtained with alternative conditions.  This means that the reaction can be 
successfully altered depending upon the substrates involved, for example compounds that 
are sensitive to high temperatures. 
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7.4 Biological Results and Discussion: Amine Linked Series 
 
The methyl and phenyl derivatives of the amine linked target compounds were synthesised.  
These are detailed in Table 7.7.  The IC50 curves are shown in Figure 7.1. 
 
O
HN
N
O
R
Cl
X
 
Compound 
no. 
X R 
% Inhibition at 
10 µM
a
. 
IC50 
(µM) 
100 Cl Me 84 2.7 
102 Cl Ph 64 b 
101 H Me 87 0.7 
103 H Ph 42 b 
104 H tBu 43 b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ± 5 %, b Not determined. 
Table 7.7: Biological results obtained for initial amine linked compounds. 
 
 
Figure 7.1: Curves to show the inhibition of 17β-HSD Type 3 by compounds 100 and 101 
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It can be seen that those compounds containing a smaller R group, i.e. the methyl group in 
compounds 100 and 101, show better inhibitiory activity than those with the larger phenyl 
group, duplicating the pattern observed with the amide linked compounds. A t-Boc 
protected compound (104) was also submitted for biological testing and it can be seen that 
the t-Boc group is detrimental to activity (compound 104 compared to compound 101).  It 
can be observed that the presence/absence of chlorine at the 2-position of the diphenylether 
hydrophobic headgroup has only a small impact on the inhibitory activity of the 
compounds.  The IC50 values for compounds 100 and 101 have been measured.  They are 
2.7 and 0.7 µM respectively.  This shows that the amine linked compounds are a valid lead 
series and an excellent starting point for lead optimisation.  A great deal of further 
investigation is required to fully develop the SAR of this series, surrounding both the 
diphenylether substituents and the size and electronics of the R group. 
 
7.5 Docking Studies of the Amine Linked Compounds 
 
Figure 7.2 shows compound 107 docked into the 17β-HSD Type 3 homology model.  It can 
be seen that this compound is positioned in a similar way to the previously mentioned 
amide linked compounds (Figures 6.2 and 6.3).  The N-acetyl group of compound 107 is 
positioned towards the cofactor, with the diphenylether hydrophobic headgroup positioned 
towards a hydrophobic pocket.  However, as with the original amide linked series, it 
appears that the compound is too short to be able to interact with both the cofactor and the 
hydrophobic region simultaneously.  For this reason the design and synthesis of extended 
amine linked compounds may require attention at a later stage, dependent upon the 
inhibitory activity exhibited by the extended amide linked compounds.  
 
Cl
Cl
O
HN
N
O  
Figure 7.2: Compound 100 docked into the 17β-HSD Type 3 homology model. 
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7.6 Comparison of the Amide and Amine Linked Series of Compounds 
 
Even from the limited amount of biological data available, it is possible to determine a 
distinct pattern emerging in comparison of the two main series so far.  The amide linked 
compounds show reduced activity in comparison with the corresponding amine linked 
derivatives previously described.  For example, 100 and 50 (Figure 7.3) have percentage 
inhibitions of 84 % and 44 % respectively. 
 
O
HN
N
O
Cl
Cl
O
HN
Cl
Cl
O
N
O
100
% inhibition at 10 uM = 84%
50
% inhibition at 10 uM = 44%  
Figure 7.3: Comparison between amine (100) and amide (50) linked target compounds. 
 
There are no clear cut differences in activity between the various hydrophobic head group 
substitutions tested in the series so far, indicating they are all valid templates, as implied by 
the Schering-Plough patents,47-50 although 4-chloro and 2,4-dichloro do show a slight 
improvement in activity over the other substitutions.  From all the biological results 
obtained so far, it can be concluded that the most promising compounds are those that have 
a 4-substituted hydrophobic head group and an amine linking group.   
 
For the next areas of investigation, the 2,4-dichloro head group and amine linker were kept 
constant, to allow effective comparisons between compounds during the SAR exploration. 
 
7.7 Synthesis of Alternative, Flexible Extended Amine Linked Compounds 
 
New reagents and synthetic building blocks are constantly being developed and launched 
by the various chemical suppliers.  During the course of the project, a new product was 
launched by SigmaAldrich: N-Boc-4-piperidine acetylaldehyde 105 (Figure 7.4a).88  This 
could be used to make a novel alternative extended amine linked series of compounds, 
(Figure 7.4b). 
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Figure 7.4: (a) N-Boc-4-piperidine acetylaldehyde (105), (b) Initial targets in this series. 
 
These compounds would be an extension of the original amine linked targets, which appear 
to be too short for optimal activity.  It is hoped that the introduction of this novel two-
carbon amine linking group may help to make the compounds more active, as the length 
may be more optimal.  This linking group is also highly flexible, which may help the 
compound form a favourable conformation within the enzyme.   
 
The synthesis of the target was initiated (Scheme 7.5).  However, a mistake was made in 
the first step synthetic step.  In this reductive amination procedure, two equivalents of the 
aldehyde were used and due to the increased reactivity of aldehydes compared to ketones, 
the reaction produced the di-substituted compound (106).  This was deprotected and 
acetylated as normal, to produce 2 compounds in this series (106 and 108).  It is not known 
whether these compounds exhibit any inhibitory activity over 17β-HSD Type 3.  However, 
as previously mentioned the active site of 17β-HSD Type 3 is very large and these 
compounds will be useful to investigate the size tolerability of the enzyme. 
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Scheme 7.5: Synthesis of alternative di-substituted extended amine linked compounds, 106 
and 108. 
 
The synthetic route was repeated using the correct ratio of starting materials.  This led to 
the desired intermediate (109, Scheme 7.6).  This was deprotected successfully using the 
standard conditions, leaving just the acetylation required to lead to the correct product.  
Using the standard acetylation conditions (3 eq. acetyl chloride, 3 eq. TEA, 0 °C to r.t. 1 h), 
the desired product was not obtained, but an alternative 111 was formed, where the 
piperidine nitrogen and the aniline nitrogen were both acetylated.  This constitutes an 
interesting compound in itself, as it may help to understand the effects of the NH moiety 
upon activity.  Alteration of the acetylation conditions (1 eq, acetyl chloride, 1 eq TEA, -10 
°C for 20 min) led to the desired product (112) in 55 % yield. 
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Scheme 7.6: Synthesis of alternative extended amine linked compounds 109, 111 and 112. 
 
In summary, five compounds have been synthesised in this series, (including the t-Boc 
protected intermediates): two di-substituted compounds (106 and 102), and three mono-
substituted compounds (109, 111 and 112).  These five compounds have been submitted for 
biological testing, and the results should give much information regarding size, shape and 
electronics of the active site. 
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7.8 Introduction of Heterocyclic and Adamantyl Groups on to the Piperidine Ring 
 
To further investigate the SAR of the R group substitution in the hydrogen bond acceptor 
region of the template, it was decided that heterocycles and large hydrophobic cyclic 
structures should be introduced.  These are much larger groups, which have differing 
electronics to those compounds already made.  The new R groups were to be incorporated 
into one of the most successful series so far, the 2, 4-dichloro substituted diphenylether 
head with an amine linking group.  The planned cyclic moieties included thiophene, furan, 
adamantyl and pyridine groups. 
 
The first to be synthesised was the furan derivative 114 (Scheme 7.7).  The first synthetic 
step was the amide coupling of 2-furoic acid with piperidin-4-one.  Piperidin-4-one was 
only available as the hydrochloride salt, and the free amine was required before amide 
coupling could occur.  The free amine was released using a resin bound equivalent of 
triethylammonium carbonate (MP-carbonate resin).87, 89  To ensure that the amine was free 
to react with the desired activated carboxylic acid, the resin remained in the reaction 
throughout the reaction duration.  A standard amide coupling method, using EDC to 
activate the carboxylic acid, afforded compound 113 with an excellent yield of 86 %.  The 
use of HOBt is known to decrease racemization but, more importantly in this case, speed up 
amide couplings.73  However, no significant reduction in reaction time was observed when 
HOBt was utilised in this system.  The piperidone 113 was then reacted with the 
diphenylether aniline, 41a.  Initially, the reductive amination was attempted using the 
previously established microwave procedure.85  In this case, the conditions led to the 
decomposition of starting materials, and no product was obtained.  This may be due to the 
promotion of side reactions.  For example, a Diels-Alder reaction with the furan ring.  The 
reductive amination was then attempted at room temperature and, although a greatly 
increased reaction time was used (~ 4 days), compound 114 was synthesised in just 15 % 
yield (Scheme 7.7).  This synthetic procedure is far from optimised and further exploration 
of the conditions would be required before a large series of further compounds could be 
synthesised. 
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Scheme 7.7: The synthetic route to 114 
 
Once this general route had been initially developed, it was applied to the synthesis of the 
other desired cyclic structures, 3-furan, adamanatyl and thiophene (Scheme 7.8).  The 
piperidin-4-one hydrochloride was reacted with the desired acid in an amide coupling 
reaction.  The reactions took ~18 h and gave the desired products in moderate yields of 
between 43-63 %.  As with the synthesis of the 2-furan substituted compound, extensive 
reaction times and low yields (between 22 % and 50 %) were observed for the reductive 
amination.   
O
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+
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12041a 119  
Scheme 7.8: Preparation of further compounds with cyclic R groups. 
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Unfortunately, the reductive amination proved to be unsuccessful in the attempted synthesis 
of the pyridine analogue, 4-[2-(2,4-dichloro-phenoxy)-phenylamino]-piperidin-1-yl-
pyridin-3-yl-methanone, and only the starting aniline was recovered.  This may be due to 
the basic nitrogen in the pyridyl group interfering with the desired reaction.   
 
In conclusion, 4 compounds in this series have been synthesised (114, 116, 118 and 120), 
purified to >95 % purity and fully characterised.  These compounds have been submitted 
for biological evaluation, but have not undergone testing yet. 
 
These compounds have been docked into the 17β-HSD Type 3 homology model.  Figure 
7.5 shows compound 120, the 3-furan substituted compound.  It can be seen that this 
compound is positioned in a similar manner to 100, with the carbonyl at the base of the 
molecule interacting with the cofactor, and the hydrophobic head group directed towards 
the hydrophobic pocket of the active site.  It is also possible that the oxygen in the furan 
ring may interact with the cofactor, but it is not known whether this will be beneficial or 
otherwise to the binding and inhibitory activity of the compound.  Until biological results 
are obtained it cannot be deduced how the introduction of the furan ring, and the other 
heterocycles and large hydrophobic cyclic substitutions will affect the inhibitory activity of 
the compounds. 
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Figure 7.5: Compound 120 docked into the 17β-HSD Type 3 homology model. 
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7.9 Table of Compounds Synthesised within Chapter 7 
 
Compound  
no. 
Structure 
% Inhibition (at 
10 µM).
a
 
100 
Cl
Cl
O
HN
N
O  
84 
101 
Cl
O
HN
N
O  
87 
102 
Cl
O
HN
N
O
Cl
 
64 
103 
Cl
O
HN
N
O  
42 
104 
Cl
O
HN
N O
O  
43 
106 
Cl
O
N
BocN NBoc
 
b 
 102 
108 
Cl
O
N
N N
O O  
b 
109 
Cl
O
HN
NBoc  
b 
111 
Cl
O
N
N
O
O
 
b 
112 
Cl
O
HN
N
O  
b 
114 
Cl
O
HN
N
O
O
Cl
 
b 
116 
Cl
O
HN
N
O
S
Cl
 
b 
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118 
Cl
O
HN
N
O
Cl
 
b 
120 
Cl
O
HN
N
O
Cl O
 
b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %,  
b Not determined. 
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Chapter 8 
 
Design and Synthesis of Benzylamine Linked 17β-HSD3 Inhibitors 
 
8.1 Introduction 
 
So far the best activity in this project has been exhibited by 101 (Table 7.7), with an IC50 of 
0.7 µM.  This represents an excellent lead compound, but there is still great scope for 
improvement.  The homology model of 17β-HSD Type 3 has been very useful to the 
project.  It has enabled some conclusions to be made about the size and shape of the active 
site.  The active site is large and therefore it is anticipated that the enzyme will tolerate 
compounds that are much larger, either in length or bulk (see Chapters 6 and 7).   It can be 
seen from the docking of 101 (Figure 8.1), that there is much unoccupied space around the 
inhibitor, especially around the central piperidine ring and the hydrophobic head group.  
Therefore, there is scope for further substitution and alternative flexible linkers to hopefully 
facilitate additional interactions in the active site. 
 
 
Figure 8.1: Compound 101 docked into the 17β-HSD Type 3 Homology Model. 
 
Increasing the length of the molecule (see Chapters 6 and 7) may help to realign the 
compound, so that it can interact with other hydrophobic regions and the cofactor, but this 
still appears to leave a large amount of space around the central piperidine ring.  The 
Schering-Plough competitor compounds, such as compound 36 (see Chapter 5) also help to 
illustrate the importance of this region.  A key feature of the Schering-Plough compounds is 
the large hydrophobic region (e.g. t-butyl) on the central piperidine ring.  The importance 
of this region was demonstrated (Figure 8.2), the activity greatly increases with the 
Cl
O
HN
N
O
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incorporation of this hydrophobic group, with the IC50 being reduced from 3.3 nM to just 5 
pM, a greater than 600 fold potency increase.46 
 
Cl Cl
N
N
O
N
O
R
R=H, IC50=3.3 nM, 121
R=C(CH3)3, IC50= 5 pM, 36
 
Figure 8.2: Improvements shown following the inclusion of a t-butyl group in the 
Schering-Plough competitor compounds.46 
 
It was, therefore, very important that this region of the molecule was investigated further.  
The synthesis of compounds 122 and 123 was carried out by Dr C Sharland.  Initially, this 
region was explored by introducing a large aromatic substituent (Figure 8.3) which actually 
led to a reduction in inhibitory activity, with an IC50 for compound (122, Figure 8.3) of 28 
µM.  Although a reduction in activity was observed, some level of activity remained, thus 
showing that enlargements are tolerated, and that there is therefore potential around this 
region.  When a seven-membered ring was introduced (123, Figures 8.3 and 8.4), the 
activity of this series was dramatically improved with an IC50 of 383 nM.   
 
O
HN
N
O
Cl
N
HN
O
Cl
O
122 123  
Figure 8.3: Benzofused N-acetyl piperidine (122) and azopine linked (123) compounds. 
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Figure 8.4: Inhibition of 17β-HSD Type 3 by compound 123 
 
This implies that there are spatial restrictions in this region of the active site, and that 
exploiting this space is likely to be very beneficial for activity, although it is possible that 
some restrictions will lead to lower activities.  These need to be fully explored. 
 
In order to further explore this region of the molecule, the next step was the introduction of 
a more flexible central region of the molecule, where the restrictive 7-membered piperidine 
ring has been removed.  This introduces a benzylamine template, whilst keeping the overall 
shape of the molecule similar to that of compounds 122 and 123.  This led to the design of 
a series of benzylamine linked targets (Figure 8.5).   
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Figure 8.5: Novel benzylamine linked targets. 
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8.2 Synthesis of Initial Targets and Biological Data Obtained 
 
The synthesis of the first target was initiated (Scheme 8.1).  The commercially available 2-
nitrobenzaldehyde was reduced to the corresponding primary amine using iron powder.  
This intermediate can decompose due to reactions between the amine and the aldehyde 
functional groups, so must either be stored in the freezer or quickly used in the next step.  
This step acetylated the nitrogen, which also stabilises the intermediate.  The aldehyde can 
then be reacted with the desired headgroup aniline using the standard reductive amination 
conditions,85 to produce the desired final compounds.   
 
NO2
O
O
NH2
X Y
NH2
O
O
HN
H
N
O
X Y
N
H
O
OFe, NH4Cl, EtOH/H2O
Reflux, 1-3 h, 99 %
Acetyl  Chloride, 
TEA, DCM
0 oC to r.t. 1 h, 71 %
NaBH(OAc)3, AcOH, DCE, 
MW 140 oC, 10 min
X= Cl, Y=H:         126, 38 %
X= OCF3, Y=H,   127, 55 %
X= Cl, Y=F,          128, 27 %
124 125
 
 
Scheme 8.1: Synthesis of benzylamine linked targets 126, 127 and 128. 
 
These were the first targets synthesised in this novel series and so, ideally the inhibitory 
activity of these compounds needed to be established before further compounds were 
synthesised.  Unfortunately, only compound 126 has been subjected to biological testing so 
far.  It showed good inhibitory activity, with an IC50 value of 0.9 µM (Figure 8.6), which is 
very similar to the lead compound (101, IC50 = 0.7 µM), thus showing compound 126 to be 
a very promising lead compound and an excellent starting point for further medicinal 
chemistry investigations. 
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Figure 8.6: Inhibition of 17β-HSD Type 3 activity by compound 126, (IC50 = 0.9 µM) 
 
8.3 In-Silico Analysis of the Initial Targets 
 
Figure 8.7 shows compound 126 docked into the 17β-HSD Type 3 homology model.  It can 
be seen that the compound is aligned within the active site very differently from the amide 
and amine linked compounds discussed in Chapters 6 and 7 respectively.  The 
diphenylether hydrophobic headgroup can be seen to lie further within the hydrophobic 
pocket of the active site, thus, the alignment of the molecule is such that the central 
aromatic ring lies towards the cofactor at the base of the active site.  In the other previously 
discussed compounds (Chapters 6 and 7), it has been observed that the carbonyl in the 
acetyl group is usually orientated towards the cofactor.  However, in this case the acetyl 
group is aligned differently.  It can be seen that this molecule appears to fit the active site 
well, but that there is a significant amount of space surrounding the molecule that can be 
investigated and exploited to improve the activity of the compounds.  Although the docking 
is only a guideline, it is useful to generate hypotheses in early lead optimisation. 
Inhibition of 17ß-HSD Type 3 Activity in 293-
EBNA[HSD3] Cells by STX2232.
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
0.001 0.01 0.1 1 10 100
Concentration (µM)
M
e
a
n
 %
 I
n
h
ib
it
io
n
STX2232
0.9 µM
Inhibition of 17β-HSD3 activity in 293-EBNA[HSD3] cells by 
compound 126 
126 
 109 
 
 
Figure 8.7: Compound 126 docked in the 17β-HSD Type 3 Homology Model 
 
8.4 Modifications to the Benzylamine Template 
 
The lead compound in this series, compound 126, showed good inhibitory activity (IC50 = 
0.9 µM), and was the starting point for a novel series of compounds.  The regions of 126 
that required explanation are shown in Figure 8.8.  Many of these areas of exploitation were 
regions of space that could be observed around the molecule in the docking study shown in 
Figure 8.7.  Full investigations into these modifications will allow a very detailed SAR to 
be acquired.  It should also be possible for a QSAR study to be carried out based upon the 
results from these compounds. 
 
Substitution
Substitution
Amide
Substitutions,  
inc. Me, Et, etc..Differing 
substitutions
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Extensions
Reduction
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N
O
Differing 
substitutions
 
Figure 8.8: Compound 126 and the regions modified to prepare a wide range of analogues. 
 
Substitution around the hydrophobic headgroup has already been explored with the 
preparation of compounds 127 and 128 (Scheme 8.1).  The results of the biological 
Cl
O
HN
H
N
O
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evaluation of these compounds are eagerly awaited.  The rest of this Chapter will look at 
the design and synthesis of other analogues of compound 126. 
 
8.4.1 Modifications to the Benzylamine Template: Substitutions on the Central 
Aromatic Ring 
 
The docking of 126 in the 17β-HSD Type 3 homology model is shown in Figure 8.8.  In 
this figure it can be seen that there is a large amount of space surrounding the central 
aromatic ring.  This region also lies towards the cofactor, and therefore there may be scope 
for potential interactions in this region.  At this stage it was unknown what type of 
substitutions would be beneficial to activity so the synthesis of a wide range of 
substitutions was planned, including halogens, heterocycles, naphthyl, alkyl and alkoxy 
groups. 
 
Initially, the synthesis of these compounds was attempted using the same synthetic route as 
the synthesis of 126, (Scheme 8.2a and b).  In the case of the methylenedioxy substitution, 
this synthetic route was successful and compound 131 was synthesised effectively (Scheme 
8.2a).  It should be noted that the final step in the route, the reductive amination, was now 
carried out at room temperature as the use of the MW led to the decomposition of starting 
materials and/or products.  However, when the same route was applied to the naphthyl 
analogue (Scheme 8.2b), it was unsuccessful, as the intermediate 132 was unstable.  Even 
when used immediately or stored in the freezer, it decomposed before acetylation could 
occur.  For this reason a new route was required. 
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Scheme 8.2: (a) Synthesis of 131, (b) Attempted synthesis of the naphthyl analogue 
 
Investigations were initiated to find a synthetic route that was suitable for a wide range of 
substituents.  The availability of starting materials meant that the methylenedioxy 
substituent was used in these investigations.  In the new route (Scheme 8.3) reductive 
amination would be the first step and the nitro group would then be reduced and acetylated, 
thus avoiding the previously problematic intermediate.  However, the reduction of the nitro 
group was unsuccessful and the desired product was not isolated.  The iron reduction 
conditions caused the amine bond in the molecule to break, and only the diphenylether 
hydrophobic headgroup aniline was isolated.  This occurs as the intermediate contains a 
benzyl protected amine type moiety, thus indicating that the amine bond might be highly 
sensitive to benzyl deprotection conditions, such as hydrogenation, or in this case iron 
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reduction.  It is possible that this step could be controlled in order to isolate the desired 
product, but at this stage a more robust, universal route was required. 
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Scheme 8.3: Second attempted synthetic route to analogues with a substituted central 
aromatic ring 
 
Another route was initiated.  The new route proceeds via the preparation (or purchase) of 
the nitro benzylalcohol.  The presence of the alcohol means that when the primary amine 
functional group is present the compound is more stable to decomposition than the 
corresponding aldehyde.  Therefore, this was a much more successful synthetic route 
(Scheme 8.4). 
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Scheme 8.4: New synthetic route to compounds with a substituted central aromatic ring. 
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Before this route was used to prepare a range of compounds with varying substitution 
patterns around the central aromatic ring, a certain amount of optimisation was required.  
The reduction of the aldehyde to the alcohol was carried out using NaBH4, with quantative 
yields achieved in 2 h.  The reduction of the nitro group and the subsequent acetylation 
were also carried out successfully using the standard iron reduction conditions.65  The 
oxidation of the alcohol to the aldehyde required more detailed investigations.  There are 
many available reagents for this oxidation, and some of these were tested to find the most 
suitable for this application (Table 8.1). 
 
A literature study revealed a new method by Luca et al90 in which trichloroisocyanuric acid 
(Scheme 8.5) was used to activate TEMPO for the mild and chemoselective oxidation of 
alcohols (Table 8.1, Entry 1).  However, for this particular application it is not a suitable 
reagent as it also caused a substitution reaction with a chlorine atom, which led to the 
formation of an alternative product (Scheme 8.5).  Although, 5-chloro substitution is one of 
the targets in this series, this is not a desired method as only the one analogue can be 
prepared in this way.  This is a very interesting reaction and has a possible use as a 
chlorination procedure, which could potentially be used to introduce chloro substitutions 
into intermediates, as an alternative to using chlorinated starting materials. 
 
It was hoped that the trichloroisocyanuric acid could be removed from this reaction, and 
TEMPO could act alone.  However, after 3 days, only the starting alcohol was isolated, 
(Table 8.1, Entry 2). 
OH
NH
O
O
NH
O
H
133 125  
Entry Reagent/Conditions Yield (%) 
a
 
1 Trichloroisocyanuric Acid, TEMPO, 0°C to r.t. 10 min90 c 
2 TEMPO, DCM, 3 days b 
3 SWERN, (oxallyl chloride, DMSO, -50°C, 2 h)91 53 
4 Mp-Tso-TEMPO,87 acetonitrile, 4h 66 
5 Dess Martin Periodinane (DMP),92, 93 DCM, 10 min 67 
6 MnO2, DCM, 18 h 71 
a Isolated Yield.  b Only starting material isolated.  c Incorrect product isolated, mono-chloro 
substitution occurred. 
Table 8.1: Oxidation conditions investigated. 
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Scheme 8.5: Formation of alternative chloro substituted product. 
 
Four successful methods for this oxidation were discovered (Entries 3-6), all producing the 
correct product in similar yields.  The least successful method was the SWERN oxidation,91 
as only a 53 % yield was obtained.  As other, more facile options are available, the SWERN 
reaction is not the method of choice.  All the other three successful methods, resin bound 
MP-TsO-TEMPO,87 Dess Martin Periodinane (DMP)92, 93 and MnO2, would be a suitable 
choice for this reaction.  DMP (Figure 8.9) was chosen as the method of choice,92, 93 
because in these initial investigations it gave the most reproducible results, did not require 
anhydrous conditions and the reagent is easy to remove at the end of the reaction, through a 
simple aqueous work up and standard flash chromatography. 
 
O
I
O
OAc
OAc
AcO
 
Figure 8.9: Dess-Martin Periodinane 
 
DMP was used to oxidise the alcohol in the synthesis of all targets in this series, (Scheme 
8.6).  Unfortunately, the reliable results observed in the test reactions were not conserved, 
and the yields varied from 25-77 %.  If it is required to repeat the synthesis of any of these 
compounds or more compounds in this series are required, it is recommended that MnO2 is 
investigated further as a more reproducible reagent for the oxidation.  This may produce 
better results or the results of the oxidation may be substrate dependent. 
 
There are many different suitable starting materials with differing substitution patterns that 
are commercially available, either as the 2-nitrobenzaldehyde, the 2-nitrobenzylalcohol or 
the 2-aminobenzylalcohol.  The availability of the commercial starting materials dictated at 
which step in the route synthesis began.  For example, the 4,5-dimethoxy substitution 
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pattern was only available as the 2-nitroaldehyde, so the full 5 step synthesis was required.  
In contrast, the 5-chloro substitution was available as the 2-aminobenzylalcohol, so only the 
final 3 steps were required. 
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135a X = 4,5-diOMe, 93 %
       b X = Naphthyl, 86 %
       c X = 5-Me, 79 %
          X = 5-Cl, Commercially available
136a X = 4,5-diOMe, 59  %
       b X = Naphthyl, 82 %
       c X = 5-Me, 79 %
       d X = 5-Cl, 89 %
137a X = 4,5-diOMe, 50 %
        b X = Naphthyl, 77 %
        c X = 5-Me, 25 %,
        d X = 5-Cl, 70 %,
Y Y
138 X = 4,5-diOMe, Y = 4-Cl, 11 %
139 X = 4,5-diOMe, Y = 2,4-diCl, 38 %
140 X = Naphthyl,   Y = 4-Cl, 24  %
141 X = 5-Me,          Y = 4-Cl, 47 %,
142 X = 5-Cl,            Y = 4-Cl, 26 %,
143 X = 5-Cl,            Y = 2,4-diCl, 60 %,
144 X = 5-Cl,            Y = 4-OCF3, 30 %
41
Scheme 8.6: Synthetic route for the synthesis of analogues with various substitutions 
around the central aromatic ring 
 
This synthetic route has led to a wide range of 126 analogues with various substitutions 
around the central aromatic ring.  Eight novel compounds were prepared in this series.  
These are listed in Table 8.2.  They have all been submitted for biological evaluation.  
However, only some results have so far been obtained. These are shown in Table 8.2. 
 
It can be seen from the few available biological results that substitutions around the central 
aromatic ring are well tolerated, as even the dioxyl substitution on 131 does not have a 
substantially detrimental affect upon the activity.  Although the functionalities are tolerated, 
they do not seem to lead to the desired increase in activity, as 126 is still the most active 
compound in this series so far.  This may, of course, change once full biological data is 
obtained for all compounds in this series. 
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Compound 
No. 
X Y 
% Inhibition  
(at 10 µM).
a 
138 4,5-diOMe 4-Cl b 
139 4,5-diOMe 2,4-diCl b 
140 naphthyl 4-Cl b 
141 5-Me 4-Cl b 
142 5-Cl 4-Cl 
97  
(IC50 = 1.9 µM) 
143 5-Cl 2,4-diCl b 
144 5-Cl 4-OCF3 
b 
131 Dioxylc 4-Cl 86 
126 Hd 4-Cl 
87  
(IC50 = 0.9 µM) 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %.  b Not determined.  c Synthesised using a different route, see Scheme 8.2a.  d 
Synthesised using a different route, see Scheme 8.1. 
 
Table 8.2: Full compound list and biological data obtained for 126 analogues with 
substitutions around the central aromatic ring. 
 
Some interesting observations can be made from the docking studies of these compounds, 
(Figures 8.10 and 8.11).  Some substitutions, such as the chloro substitution in compound 
142 (Figure 8.10) do not seem to affect the overall position of the molecule within the 
active site, when compared to 126.  This might explain why little difference in inhibitory 
activity is observed. 
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Figure 8.10: Compound 142 docked into the 17β-HSD Type 3 homology model. 
 
However, a considerable change in alignment is observed in the docking study of the dioxyl 
substituted compound 131 (Figure 8.10), as the compound no longer is aligned in the same 
way as 126 (Figure 8.7).  It appears that the dioxyl is interacting strongly with the cofactor 
within the active site.  This interaction is strong enough to realign the molecule, as the 
hydrophobic headgroup is no longer in a hydrophobic pocket of the enzyme.  It could be 
assumed that this change in alignment would greatly alter the biological activity.  However, 
the result of compound 131 is not substantially different to 126 and both have a percentage 
inhibition of approximately 86 %.  Unfortunately the IC50 of compound 131 has not been 
established so far, so a more definite conclusion cannot be made. 
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Figure 8.11: Compound 131 docked into the 17β-HSD Type 3 homology model. 
 
Once the full biological data have been obtained, a much clearer SAR will be gained for 
this region.  So far it can be established that substitutions around the central aromatic ring 
are not detrimental to activity, although the substitutions tested so far have not shown 
beneficial inhibitory effects.  This means that this region may require further investigation. 
 
8.4.2 Modifications to the Benzylamine Template: Synthesis of Benzamide 
Analogues 
 
As shown in Chapter 5, amide linked compounds were one of the initial targets for this 
project.  Therefore, the preparation of amide linked analogues of compound 126 would 
allow SAR comparisons to be made with the amide linked compounds discussed in Chapter 
6.  This would investigate whether the aromatic linker is beneficial to activity compared 
with a piperidine linker.  The synthesis of these analogues was initiated (Scheme 8.7).  The 
aniline headgroup (41a) was reacted with 2-nitrobenzoylchloride to form the desired amide 
bond.  Reduction of the nitro group afforded the primary amine to react with the desired 
acid chloride.  This primary amine intermediate (146) was split into two batches and 
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reacted with 2 different acid chlorides (acetyl chloride and benzoyl chloride) to form a 
small series comprising two final compounds, 154 and 155.  These compounds have been 
submitted for biological testing, but the results have not yet been obtained. 
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Scheme 8.7: Synthesis of benzamide linked compounds 147 and 148. 
 
8.4.3 Modifications to the Benzylamine Template: Substitutions on the Nitrogen 
Atoms 
 
In any medicinal chemistry programme it is important to investigate any potential hydrogen 
bond interactions that may be occurring between the molecule and the active site of the 
enzyme.  Hydrogen bonds most commonly occur between functional groups containing 
nitrogen or oxygen atoms, which can undergo hydrogen bond donor-acceptor interactions.  
In this series, the main potential hydrogen bond regions are the nitrogen atoms in the amine 
and the amine bond and also the oxygen atoms in the diphenylether headgroup and the 
amide bond.  The introduction of a non H-bonding substitution on to either/both nitrogen 
atoms will help to determine if either NH plays an important part in enzyme-inhibitor 
interactions as a hydrogen bond donor.  The synthesis of a series of N-methylated 
compounds was initiated to remove the hydrogen donating ability of the NH.  In order to 
methylate the amide nitrogen alone, it was thought necessary to carry out the methylation 
on the N-(2-formyl-phenyl)-acetamide intermediate (125), before the reductive amination 
with the headgroup.  This methylation was successful and the methylated intermediate was 
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isolated in 56 % yield.  This was then reacted with the desired headgroup to produce 150 in 
44 % yield (Scheme 8.8). 
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(i) DMF, NaH, 1 h
(ii) MeI, 3 days
56 %
NaBH(OAc)3, AcOH, DCE
r.t. 2 h, 44 %
150
125 149  
Scheme 8.8: Synthesis of compound 150. 
 
Another method of methylation was investigated as a possible way to synthesise the desired 
compounds directly from 126.  By using different ratios of sodium hydride and methyl 
iodide it was hoped that the three desired methylated analogues could be synthesised.  
However, it was not straightforward, as the desired product was not always obtained as 
predicted.  Methylation of both the amine and the amide nitrogen simultaneously was 
possible via this route (23 %, 151, Figure 8.12), even though the major product of the 
reaction was actually the mono-methylated product previously synthesised, (43 %, 150, 
Scheme 8.8).  Compound 151 has no hydrogen bond donors available for enzyme-inhibitor 
interactions, so the biological activity will show whether these are important interactions 
for inhibitory activity.  The attempted synthesis of the mono-methylated amine analogue 
was carried out.  Unfortunately, this did not produce the desired product and only the 
mono-methylated amide product previously synthesised (150) was formed.  An alternative 
route was therefore required for this analogue.   
 
Cl
O
N
N
O
151
 
Figure 8.12: Di-methylated product, 151. 
 
Methylation of the amine nitrogen alone was possible via a different method, directly from 
compound 126 (Scheme 8.9).  The compound was reacted with paraformaldehye to give the 
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N-formyl product in-situ which was then reduced with NaBH4/TFA to form the desired 
product (152) in a 62 % yield.94 
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NaBH4 (5 eq), TFA,
DMF, 0 oC to r.t. 18 h, 62 %
126 152
 
Scheme 8.9: Synthesis of compound 152 
 
The possible effects of the introduction of an acetyl group were also investigated by the 
synthesis of 153 (Scheme 8.10).  It was a one step procedure to the product (153), which 
was obtained in a 48 % yield. 
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Acetyl chloride, TEA, DCM
0 oC to r.t. 1 h, 48 %
 
 
Scheme 8.10: Synthesis of compound 153 
 
There are now 4 compounds in this series, all of which have been submitted for biological 
testing.  However, the results have not yet been obtained.  It is hoped that the biological 
results will allow for a direct comparison with the parent template, 126, and will give a 
good indication of the SAR surrounding the nitrogen atoms in the molecule and the 
potential for hydrogen bond donor interactions. 
 
8.4.4 Modifications to the Benzylamine Template: 2, 3 and 4 N-Acetamide 
Analogues 
 
This benzylamine series of compounds aimed to be a more flexible version of 122 and 123 
(Figure 8.3) by removing the restriction caused by the piperidine ring.  However, the 
docking of the original target 126 (Figure 8.8) showed that the alignment of the compound 
was different to that which had been expected.  Activity may be improved by redesigning 
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the compound to allow it to take up an alignment more similar to the original amide or 
amine linked compounds (Figures 6.2 and 7.2).  It was hypothesised that this may be 
achieved by migrating the N-acetamide around the central aromatic ring, from the original 
2-position of 126 to the 3 or 4 position (Figure 8.13). 
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Figure 8.13: New targets with a migrated N-acetamide 
 
Compound 126 is the 2-substituted compound, so therefore there were two further 
compounds that required synthesis in this series for an SAR to be established.  The 
synthesis of these two analogues was initiated (Scheme 8.11).  For the 4-substituted 
analogue, the 4-N-acetylated aldehyde was commercially available, thus meaning that the 
final compound, 154, could be synthesised in one step by reductive amination with the 4-
chloro diphenylether aniline and isolated in 78 % yield.  The 2,4-dichloro analogue was 
also synthesised, 155 (isolated yield 69 %).  For the 3-substituted analogue, the 3-N-
acetylated aldehyde required synthesis from the commercially available 3-nitroaldehyde.  
In this particular case it was possible to reduce the nitro group with the aldehyde present 
and then acetylate the primary amine.  This is not the ideal synthetic route as it is low 
yielding due to the decomposition of the 3-aminoaldehyde intermediate.  However, the 
desired product was obtained, which was then reacted with the 4-chloro headgroup aniline 
to produce compound 158 in a 63 % yield. 
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Scheme 8.11: Synthesis of 154, 155 and 158.  
 
These 3 compounds have been submitted for biological testing, and the available results are 
shown in Table 8.3.  The results show that, contrary to the hypothesis, the migration of the 
N-acetyl group does not lead to increased inhibitory activity and in this series the 2-acetyl 
substitution remains the most active inhibitor. 
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Compound  
no 
2/3/4 X 
% Inhibition  
(at 10 µM).
a 
126 2 H 87 
158 3 H 53 
154 4 H 29 
155 4 Cl b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %.  b Not determined. 
 
Table 8.3: The available biological data for compounds with a migrated N-acetamide 
group. 
 
These compounds have been analysed in-silico and the docking studies with the 17β-HSD 
Type 3 homology model are shown in Figures 8.15 and 8.16.  It can be seen that the 
migration of the N-acetamido group to both the 3- and 4- positions causes the compounds 
to be pulled towards the cofactor, thus meaning that the hydrophobic headgroup is no 
longer orientated in the hydrophobic pocket of the enzyme.  In the case of the 3-substituted 
compound, (158, Figure 8.14), the N-acetamide is drawn towards the cofactor, and the 
hydrophobic head group is aligned into a different pocket of the enzyme.  In the 4-
substituted compound (154, Figure 8.15), the same phenomenon seems to have occurred, 
except that this has also changed the alignment of the headgroup.  These changes in 
alignment may explain the reasons for the lower activity observed with these compounds 
compared to the 2-substituted compounds.   
 
The lack of activity suggests that this series does not command further investigation.  It 
should be noted that a change in another part of the template may improve activity for these 
compounds so, at a later date, this series may be worth exploring again. 
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Figure 8.14: Compound 158 docked into the 17β-HSD Type 3 homology model. 
 
 
Figure 8.15: Compound 154 docked into the 17β-HSD Type 3 homology model. 
 
8.4.5 Modifications to the Benzylamine Template: Extended Analogues 
 
Many different regions of this template have been explored and so far, with the available 
biological results no improvement in activity over the original compound 126 have been 
observed.  In previous series, (see Chapters 6 and 7), it was hypothesised that increasing the 
length of the potential inhibitors might help to fill the space in the active site and allow the 
inhibitors to interact with both the hydrophobic head group and the cofactor 
simultaneously.  In the case of this benzylamine series, it is not as clear from the docking 
studies whether this extension will help, as the compound is aligned differently.  It is 
possible that the extension of this series will cause the molecule to be realigned within the 
active site, and this may increase the activity.  For these reasons, the synthesis of extended 
benzylamine linked analogues was initiated (Scheme 8.12). 
 
The synthetic route was different to those already used within this series of compounds.  
Since the point of diversification is desired to be the final step in the synthesis common 
intermediates are used for the majority of the synthetic route.  Hence, the first step was the 
O
HN
Cl
HN
O
 126 
reductive amination between the headgroup aniline and 2-nitrobenzaldehyde.  This was 
carried out using the standard MW conditions,85 and the product was isolated in an 
excellent 77 % yield.  At this point, it was thought that the aniline nitrogen required some 
kind of protection to ensure that it did not interfere with any reactions at the primary amine 
at a later stage in the synthetic route.  The first choice for this protection was an N-Boc 
protecting group.  However, only starting material was isolated from the reaction with di-t-
butyl-dicarbonate so another method was required.  The use of a small acetyl group was 
chosen, meaning that the formation of the protected amine was successful (45 % yield).  
Deprotection would, however, be more problematic, although compounds with an acetyl 
group present are still potential inhibitors.  The reductive amination with 1-acetyl-4-
piperidone produced the desired compound, 162 in an excellent yield (77 %). 
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Scheme 8.12: Synthetic route to the extended analogue 162. 
 
It was then decided to investigate whether this N-acetyl protection was required, or whether 
the steric constraints and decreased reactivity of the aniline NH were enough to stop these 
potential side reactions occurring.  Therefore, the synthetic route was initiated again 
(Scheme 8.13).  It turned out that when the reductive amination was carried out with 1-
acetyl-4-piperidone the reaction occurred successfully, albeit with a low yield, to produce 
the desired compound, 164.  There was no sign that the aniline nitrogen had been involved 
in the reaction.   
 
Previously extended compounds in the original amine and amide linked series had been 
extended using an amide bond and therefore this would be an interesting modification to 
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include in this series.  The same primary amine intermediate (163) was therefore reacted 
with 1-acetyl-piperidine-4-carbonyl chloride to produce compound 165, a compound 
extended via an amide bond (Scheme 8.13). 
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Scheme 8.13: Synthesis of compounds 164 and 165. 
 
It was also decided to synthesise an extended compound which has had the N-acetamide 
group migrated around the ring to the 3-position (Scheme 8.14).  This final compound 
could be synthesised in a manner similar to the normal length analogues in the extended 
analogue series, except at the acetylation step, 1-acetyl-piperidine-4-carbonyl chloride was 
used as the acid chloride.  This synthetic route gave the desired product 167. 
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Scheme 8.14: Synthesis of compound 167. 
 
The extended analogues were submitted for biological testing and the whole series has been 
tested for inhibitory biological activity.  The results are shown in Table 8.4, and show some 
interesting patterns.  The extension of this series via an amine bond (162 and 164) is 
detrimental to activity, reducing the percentage inhibition to 55 and 36 % respectively.  
Extension of this series via an amide bond (165 and 167) was much more promising, with 
percentage inhibitions of 91 and 97 % respectively.  The IC50 values for these two 
compounds were also established, and are shown in Table 8.4.  They both show a reduction 
in activity compared to comopund 126 (IC50= 0.9 µM), but in the case of compound 167 it 
is only a small reduction.  The activity is highly comparable to that of 126. 
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Compound 
no. 
R X 2/3 
% Inhibition  
(at 10µM).
a
 
IC50 
(µM) 
162 Ac NH 2 55 b 
164 H NH 2 36 b 
165 H NHCO 2 91 3.9 
167 H NHCO 3 97 1.1 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %.  b Not determined. 
Table 8.4: Biological results obtained for the extended analogues. 
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The extended compounds were analysed in-silico and the docking of compounds 162 and 
167 is shown in Figures 8.16 and 8.17.  These show that both these compounds are aligned 
very differently to the shorter compounds, such as compound 126 (Figure 8.7).  In both 
cases, the extra length of the compounds means that the hydrophobic head groups lies 
within the hydrophobic pocket.  From these docking figures alone, it is hard to see why 
there is such a difference in activity between the two compounds in this series.  Both have a 
similar alignment and are similar in length.  It can be hypothesised that the difference is due 
to a favourable interaction between the carbonyl of the central amide in 167, whereas this is 
absent in 162.  This slight increase in length may also mean that the carbonyl of the N-
acetamide group can form a better interaction with the cofactor at the base of the active site.  
The 3-substituted compound 167 is more linear than the corresponding 2-substituted 
compound 165.  This difference in linearity may explain the difference in activity between 
them.  The active site has a narrower region in the centre.  Therefore, the more linear 
compounds may fit better within this channel unaffected by unfavourable steric constraints. 
 
 
Figure 8.16: Compound 162 docked into the 17β-HSD Type 3 homology model. 
 
 
Figure 8.17: Compound 167 docked into the 17β-HSD Type 3 homology model. 
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Extension of the compounds may also have the added advantage that if the compounds are 
a more restricted fit within the 17β-HSD Type 3 active site, they may be more selective 
over other 17β-HSD isozymes.  However, there is no evidence that this is relevant to this 
series of compounds. 
 
Once this benzylamine template has been fully explored, the biological results will enable a 
satisfactory SAR to be developed.  The extension of the compounds via an amide bond to a 
piperidine ring is a feature of the series that should be retained, and if applicable, combined 
with other favourable features to see if there are additive effects on potency.  The 
combination of successful features from the SAR exploration should lead to more active 
compounds will be synthesised in the future. 
 
8.4.6 Modifications to the Benzylamine Template:  Substitution on to the CH2 of the 
Benzylamine Bond. 
 
8.4.6.1 Introduction  
 
As discussed at the beginning of this Chapter, a favourable feature of the Schering-Plough 
Competitor compounds is the (S)- lypophilic t-butyl group on the piperidine ring.  It has 
been demonstrated that this region leads to a very favourable increase in inhibitory 
activity.46 It is therefore likely to be beneficial to incorporate a hydrophobic group that can 
mimic this region into the design of novel inhibitors.  Within this series of benzylamine 
targets there are a few regions which may be able to mimic this group, including the central 
aromatic ring itself and also substitutions around the central aromatic ring.  This region has 
been previously investigated and biological data are eagerly awaited.  It is also possible that 
the inclusion of alkyl groups on to the CH2 of the amine bond may have favourable 
hydrophobic interactions.  Therefore, a novel range of targets with substitutions in this 
region was designed (Figure 8.18). 
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Where R= Me, Et, Pr, Ph, allyl, vinyl, amongst others. 
 
Figure 8.18: Novel range of substituted targets. 
 
8.4.6.2 Route A: Attempted Reductive Amination with Ketone. 
 
The introduction of a methyl substituent was the initial target.  The synthesis was started 
from the commercially available starting material, 2-aminoacetophenone.  This was 
acetylated and then subjected to a reductive amination with the diphenylether aniline.  
However, this reaction did not proceed as expected because the standard reductive 
amination conditions discussed in Chapter 7 were unsuccessful (Table 8.5),85 even when an 
extended reaction time was used (Entry 1).  The same lack of reactivity was observed when 
traditional Dean-Stark conditions were used (Entry 2).  Many different sets of conditions 
for an indirect reductive amination were then attempted (Entries 3-6).  Using TiCl(OiPr)3 as 
the Lewis acid, it was attempted to form the imine, which could then be reduced in-situ to 
form the desired product.  Unfortunately, none of the sets of conditions attempted led to the 
desired product.  In some cases, an interesting phenomenon was observed.  The use of 
sodium borohydride as the reducing agent (Entry 3) led to the formation of an alternative 
product (169, Scheme 8.15), where the two starting materials have undergone a reductive 
amination as intended.  However, the N-acetyl amide bond has also been reduced to an 
ethyl group.  Attempts to control this reaction, by using shorter reaction times or cooler 
reaction conditions were not successful, as only starting materials were isolated.  The 
synthesis of compound 169 may be beneficial as it will help to investigate the effects of the 
amide bond upon enzyme binding.  Compound 167 was then acetylated to produce 170 
(Scheme 8.15), where the standard N-acetyl group is now present, but the NH of the amide 
is substituted with an ethyl group.  This will give further SAR around this nitrogen atom, as 
previously discussed. 
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Entry Conditions Result 
1 Standard MW conditions85, 140 °C, 30 min SM only 
2 p-TSA, 4Å MS, Dean-Stark reflux 18 h SM only 
3 
TiCl(OiPr)3, r.t. 18 h, then cooled to -78 °C and NaBH4 
added, 0 °C, 5h.95 
Not desired 
product, 169 
4 
TiCl(OiPr)3, r.t. 2 days, then NaBH4 (2 eq.) and succinic 
acid (2 eq.) added, r.t. 3 h. 
No Product 
5 
TiCl(OiPr)3, r.t. 2 days, then 1M borane (2 eq.) and 
succinic acid (2 eq.) added, r.t. 3 h.96 
As Entry 3 
6 TiCl(OiPr)3, r.t. 10 min, then NaBH(OAc)3, r.t. 6 h
95 
Not desired 
product, 169 
7 TiCl(OiPr)3, DCM, r.t. 18 h. 
No imine 
formation. 
Table 8.5: Attempted Reductive Amination Conditions. 
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Scheme 8.15: Synthesis of 170 from 169 
 
So far it had not been possible to determine whether the problem with this reaction lay with 
the formation or reduction of the imine.  It was therefore attempted to form and identify or, 
if possible, even isolate the intermediate imine.  However, this was unsuccessful as no 
imine was formed.  This proved that the problem lay with the formation of the imine, 
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probably due to the low reactivity of the ketone.  This meant that a new synthetic route was 
required. 
 
8.4.6.3 Route B: Use of Organometallic Reagents. 
 
It has been previously shown (Scheme 8.1) that the diphenylether aniline reacts 
successfully with the aldehyde, N-(2-formyl-phenyl)-acetamide, in a reductive amination to 
form compound 126.  It was hypothesised that if the intermediate imine (171) could be 
formed,95 then organometallic chemistry techniques could be used to insert the desired 
alkyl groups into the imine bond, thus forming the products.  The proposed synthetic route 
is shown in Scheme 8.16.  The imine is formed and isolated, before being reacted with a 
Grignard reagent which will attack the imine and add the desired alkyl group.  This route is 
ideal for this series of targets as the intermediates remain common until the last step, 
allowing for efficient diversification. 
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Scheme 8.16: Second proposed synthetic route to substituted targets 
 
The formation of the imine intermediate (171) could be achieved using two different sets of 
conditions: either by stirring in DCM with 10 eq. of anhydrous MgSO4 for 18 h, or by 
stirring in DCM with 2 eq. TiCl(OiPr)3 for 4 h.
95  Both sets of conditions were effective, but 
the second procedure was chosen as the procedure of choice as it showed better 
reproducibility and exhibited a shorter reaction time.  The conversion of aldehyde (125) to 
imine (171) was easily be detected by proton NMR (Figures 8.19 and 8.20), as there was a 
distinct difference in the chemical shift between the aldehyde proton at 9.90 ppm (Figure 
8.19) in the starting material and the imine proton at 8.60 ppm (Figure 8.20). 
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Figure 8.19: 1H NMR specrum for the aldehyde starting material 125 
 
Figure 8.20: 1H NMR spectrum for the imine intermediate 171. 
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Once the imine had been formed, the DCM was removed under vacuum and replaced with 
THF.  The Grignard reactions were carried out immediately, thus minimising any chance of 
degradation of the imine.  BF3.OEt2 has been shown to enhance the reaction and so this was 
used in the procedures.  Many different Grignard reagents were tested (Table 8.6).  
However, the majority of these met with little success.  The procedures where phenyl, 
isopropyl, cyclopropyl, vinyl or methyl magnesium Grignard were used all exhibited a lack 
of reactivity, as in all cases a significant proportion of the starting imine was isolated, even 
following an aqueous work-up and flash column purification.  It was attempted to 
overcome this lack of reactivity using heat.  The reaction with MeMgBr was heated under 
both conventional reflux conditions (Entry 7) and microwave conditions (Entry 6).97  In 
both cases, the heating caused a decomposition of the starting imine, without producing any 
of the desired product.  Instead the diphenylether aniline was the only compound isolated. 
 
Some success was observed with the Grignard procedures as the reactions between the 
preformed imine and both allylmagnesium bromide and benzylmagnesium bromide were 
moderately successful (Entries 8 and 9).  These were carried out under the same conditions 
as previously with BF3.OEt2 added, and as previously, the reactions were stirred for 18 h at 
room temperature.  The allyl substituted product was isolated in 57 % yield (172), and the 
benzyl substituted product in 8 % yield (173). 
 
Entry Grignard Conditions Result 
1 PhMgBr BF3OEt2, r.t.18 h Imine isolated 
2 IsopropylMgCl BF3OEt2, r.t.18 h Imine isolated 
3 CyclopropylMgBr BF3OEt2, r.t.18 h Imine isolated 
4 VinylMgBr BF3OEt2, r.t.18 h Imine isolated 
5 MeMgBr BF3OEt2, r.t.18h Imine isolated 
6 MeMgBr BF3OEt2, MW 100°C, 10min Aniline SM isolated 
7 MeMgBr BF3OEt2, Reflux, 6h Aniline SM isolated 
8 AllylMgBr BF3OEt2, r.t.18h 
57 % isolated yield 
(172) 
9 BnMgBr BF3OEt2, r.t.18h 
8 % isolated yield 
(173) 
Table 8.6: Grignard Additions into Imine Intermediate. 
 
It appears that there is a distinct difference between the reactivity of the allyl and benzyl 
Grignard reagents and the other Grignard reagents used.  It is thought that this difference is 
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due to the basicity of the reagents.  Organometallic reagents are strong bases and in this 
case it is possible that the reagents could therefore deprotonate the imine proton (pKa ~22-
24) as well as the amide NH.98  This would inactivate the Grignard, forming the 
corresponding alkane, though this can be compensated for by the usage of an excess of 
reagent (in this case 3 equivalents were used).  However, the problem remains that the 
deprotonation of the imine means that it is no longer open to attack by the nucleophilic 
Grignard reagent.  The imine stays in this deprotonated state until it is subjected to the 
aqueous work-up at the end of the reaction period, where the imine is reprotonated, 
regenerated and in some cases isolated.  The allyl and benzyl Grignard reagents are much 
weaker bases so they are less likely to deprotonate the imine and therefore the imine is 
available to react with the nucleophilic Grignard reagent.  The two products (allyl and 
benzyl) were only obtained in moderate yields.  This may be due to the decomposition of 
the imine or due to some deprotonation still occurring, especially in the case of the benzyl 
Grignard. 
 
The allyl substituted product is a useful intermediate, which could be successfully reduced 
to produce the propyl substituted compound (174, Scheme 8.17).  This was achieved using 
palladium on carbon as the catalyst, in an atmosphere of hydrogen (atmospheric pressure).  
It was a fast reaction, reaching completion in just 15 min to produce compound 174. 
 
Cl
O
HN
H
N
O
Cl
O
HN
H
N
O
Pd/C, H2, EtOAc
r.t. 15 min, 88 %
172 174
Cl
O
NH2
O
NH
O
+
Cl
O
N
H
N
O
AllylMgBr, BF3.OEt2
THF, r.t. 18 h, 57 %
TiCl(OiPr)3, DCM
r.t. 3 h
125
171
41c
Scheme 8.17: Synthesis of compound 172 and its reduction to form compound 174 
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At this stage there were three compounds in this series, the allyl, benzyl and propyl 
substituted compounds.  However, a general route to a series of compounds had not been 
identified.  For this reason, further investigations were made into the organometallic 
addition reactions (Table 8.7). 
 
A review of recent literature revealed some possibly useful alterations to the Grignard 
reaction, with various other reagents added to alter the properties and reactivity of the 
reagents.99-104  Unfortunately, the use of zinc chloride (Entry 1), copper iodide (Entry 2), 
scandium triflate (Entry 3) and the N-heterocyclic carbene, 1,3-bis(2,4,6-trimethylphenyl)-
imidazolinium chloride (Entry 4) were unsuccessful and in most cases the imine was 
isolated. 
 
The reagents used all attempt to alter the reactivity of the reaction in some way.  For 
example, the use of copper iodide means that the copper will transmetallate the Grignard to 
give an organocopper reagent, which is softer in nature than the Grignard reagent.73  This 
aimed to match the reactivity of the reagent to the imine bond, however it was not 
successful.   
 
When cerium chloride was used as an additive, success was obtained (Entry 5) and the 
desired methyl substituted product was synthesised (175, Figure 8.21).  It was hypothesised 
that the success observed using cerium chloride was due to the cerium chloride increasing 
the reactivity of the Grignard by decreasing the basicity and improving nucleophilicity.  
This further helps to further explain that the problem with this reaction, as mentioned 
previously, maybe due to the Grignard reagent acting as a base, deprotonating the imine 
and therefore stopping the desired reaction. 
 
Entry Conditions Result 
1 
Isopropyl MgCl, ZnCl2, r.t. 1 h, then imine added, r.t. 
18 h99 
Imine Isolated 
2 Isopropyl MgCl, CuI, BF3OEt2, r.t. 18 h
100 Imine Isolated 
3 Sc(OTf)3, Methyl MgBr, r.t. 18 h
101 Imine Isolated 
4 
1,3-Bis(2,4,6-trimethylphenyl)-imidazolinium 
chloride, BuMgCl, r.t. 1 h, then imine, r.t. 3 days102 
No Product 
5 
CeCl3,MeMgBr, r.t. 2 h, then imine added, then r.t. 
18 h103, 104 
Correct Product 
isolated, 175, 8%. 
Table 8.7: Investigations into possible alternatives to the Grignard procedure 
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Figure 8.21: Compound 175 
 
However, the yield for the successful reaction was extremely low: just 8% isolated yield.  
For this reason, the reaction was repeated under the same conditions.  However, the success 
could not be repeated and although the reaction was attempted many times no further 
product was isolated.  The cerium chloride was purchased from Sigma-Aldrich as cerium 
chloride hexahydrate (CeCl3.7H2O) which requires dehydration to cerium chloride (CeCl3) 
before use.  The original batch of cerium chloride hexahydrate had been dried in an oven 
before use, but this was not successful when repeated, so a few alternative methods were 
attempted.  The cerium chloride was heated under vacuum for 5h, before use in the 
reaction, but with no success.  In another attempt the cerium chloride was heated under 
vacuum as previously, and then left in an oven for 24h.  None of the subsequent reactions 
showed any sign of product and unfortunately no explanation for this phenomenon was 
found so this reagent was abandoned.  There was a sufficient amount of compound 175 
synthesised to enable biological evaluation, but unfortunately the results have not been 
obtained as yet. 
 
An alternative option to a Grignard reagent is to use an alkyl lithium reagent.  The 
attempted procedures are shown in Table 8.8.  However, similar problems with reactivity 
were encountered with the use of methyl lithium as with the methyl Grignard and only the 
starting imine could be isolated.  A review of the chemical literature revealed that 
dimethylcopper lithium could be used as an alternative.105  This was made in-situ using 
methyl lithium and copper iodide.  However, this was also unsuccessful. 
 
Entry Conditions Result 
1 MeLi, -80 °C, 18h, r.t. 5 h106 Imine Isolated 
2 
Me2CuLi formed in-situ.  CuI, MeLi, -40 °C, 1 h, 
then imine added, -40 °C to r.t. 18 h 105 
Imine Isolated 
Table 8.8: Attempted procedures using organolithium reagents. 
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It was therefore decided that this route, reacting the intermediate imine with an 
organometallic reagent, was not a suitable route to this series of targets, as only the allyl 
substituted compound (172) could be synthesised successfully in moderate yields.  A new 
route was required to enable a diverse range of these targets to be made successfully and, 
most importantly, reliably. 
 
8.4.6.4 Route C: Buchwald-Hartwig Amination. 
 
Due to the lack of success so far, a whole new approach to this series of targets was 
required; a new way of forming the amine bond in the centre of the molecule was needed.  
One possible option was to use a Buchwald-Hartwig amination to couple the diphenylether 
headgroup to the rest of the molecule (Scheme 8.18). 
 
Cl
O
Br
R
NH2
NHR
Cl
O
HN
NHR
R
+
Buchwald-Hartwig Coupling
 
Scheme 8.18: Third proposed route to the substituted targets 
 
The synthesis of the diphenylether bromo intermediate has been previously reported.  Nie et 
al
107 and Ricardson et al108 both report the synthesis of a series of similar intermediates.  
The two methods vary in their choice of base (TEA and pyridine), but the yields are 
comparable.  A comparison of these methods is shown in Table 8.9.  It can be seen that the 
two methods both produce the desired products in moderate yields.  In the case of the 
unsubstituted boronic acid the best yield of 47 % was obtained using TEA as the base107, 
after stirring at room temperature for 18h (Entry 1), and the yield did not increase with 
extended reaction times (Entry 2).  Although, these yields were not ideal, the simplicity of 
the reaction and its purification allowed the chloro substituted bromo intermediate to be 
synthesised in the quantities required (Entry 4). 
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B(OH)2 HO
Br
O
Br
+
X X
 
Entry 
Compound 
no 
Base used Reaction time X Yield 
a
 
1 176 TEA107 18 h H 47 
2 176 TEA107 3 days H 47 
3 176 Pyridine108 3 days H 36 
4 177 TEA107 18 h Cl 59 
a Isolated yield.   
Table 8.9: Comparison of methods for the synthesis of 1-bromo-2-phenoxy-benzene 
 
The synthesis of the other intermediate required for this route, N-[2-(1-amino-ethyl)-
phenyl]-acetamide, was more problematic.  It was initially attempted to convert the 
previously synthesised ketone N-(2-acetyl-phenyl)-acetamide into the desired primary 
amine (Scheme 8.19).  Miriyala et al109 reported a procedure for the conversion of carbonyl 
compounds to primary and secondary amines, using ammonia in ethanol solution and 
titanium isopropoxide to form the imine which was subsequently reduced by sodium 
borohydride.  Unfortunately, the procedure was very problematic and showed only minimal 
success, although the product was at one stage isolated in a 14 % yield, this could not be 
repeated and no further product could be isolated.  An alternative method using ammonium 
acetate110 was attempted, but this was also unsuccessful.  
 
O
NH
O
NH2
NH
O
Ti[OiPr]4, NH3 in EtOH, r.t. 4 h
NaBH4, r.t. 18 h, 14 %
168
 
Scheme 8.19: Synthesis of N-[2-(1-amino-ethyl)-phenyl]-acetamide. 
 
In case the N-acetyl group is able to interfere with this reaction in some way, the same 
procedure was attempted using 2-nitroacetophenone.109  However, no product was isolated 
from the reaction, thus meaning a new approach to the synthesis of the primary amine 
intermediate was required. 
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A review of the chemical literature revealed an alternative method in which Salerno et al 
used an oxime as the intermediate in the synthesis of 1-(2-nitro-phenyl)-ethylamine 178.111  
The oxime intermediate is more stable than other imines, because the methoxy group can 
participate in delocalisation of the imine double bond due to the alpha effect.73  When this 
procedure was carried out it led to the successful synthesis of the desired product in 
moderate yields (Scheme 8.20).  It should be noted that the primary amine is very hard to 
isolate, possibly due to instability to decomposition.  For this reason, the amine was 
converted directly into the hydrochloride salt 179, which could be isolated in a stable form.  
Although the overall yield for the synthesis of this product is poor, it is reproducible.  It 
should also be noted that only a moderate yield of 50 % was reported by Salerno et al.111 
 
O
NO2
N
NO2
O
NH2
NO2
.HCl
MeONH2.HCl, Pyridine, 
EtOH, 4 A MS
Reflux, 3 h, 87 %
(i) Borane/THF, Reflux 6 h,
(ii) H2O, KOH, relux 2 h,
(iii)DCM, conc. HCl, filtered.
17 %
178 179  
Scheme 8.20: Synthesis of 1-(2-nitro-phenyl)-ethylamine 
 
The next step in the synthetic procedure was the Buchwald-Hartwig amination with the 
previously synthesised bromo diphenylether headgroup.  There are many different 
conditions for these types of reactions reported in the chemical literature.112  In this 
particular case, the reaction conditions were investigated using the commercially available 
1-phenylethylamine with the previously synthesised diphenylether bromo headgroup (Table 
8.10).  The first set of conditions (Entry 1) was unsuccessful and no product was obtained.  
The next set of conditions attempted was based on a paper by Harris et al,113 detailing 
different conditions for the coupling of both primary and secondary amines and proved to 
be successful with the desired products obtained in modest yields (Entries 2 and 3).   
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NH2
O
Br
+
O
HN
X
X
 
Compound 
no 
Entry X 
Conditions 
Yield 
a 
180 
1 H 
Amine, Cs2CO3, Pd2(dba)3, BINAP, 
dioxane, sonicated 40 min. Bromo 
added, reflux 18 h. 
No Product 
180 
2 H 
Pd(OAc)2, BINAP, starting materials, 
toluene, r.t. 10 min. Then NaOtBu 
added, reflux 18 h.113  
49% 
181 
3 Cl 
Pd(OAc)2, BINAP, starting materials, 
toluene, r.t. 10 min. Then NaOtBu 
added, reflux 3 h.113  
41% 
a Isolated Yield. 
Table 8.10: Development of conditions for the Buchwald-Hartwig amination. 
 
These conditions were then successfully applied to the desired targets, thus allowing the 
methyl substituted target in this series to be successfully and reliably synthesised.  The 
Buchwald amination proceeded smoothly and gave the desired product in a moderate yield 
(48 %).  From here it was just 2 further steps to the final product (Scheme 8.21).  The nitro 
group in this intermediate was reduced using the standard conditions and then the primary 
amine was subsequently acetylated to produce the desired compound.  Importantly, this 
route has been proved to be reproducible.  Overall, the yields in this synthetic route are 
moderate, although it should be possible for all the yields to be improved with further 
optimisation.   
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O
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Cl
H
N
O
+
Pd(OAc)2, BINAP, toluene, 
r.t. 10 min. 
NaOtBu added, reflux 3 h.
48 %
Fe, NH4Cl, EtOH/H2O
Reflux 10 min, 25 %
Acetyl Chloride, 
TEA, DCM
0 oC, 10 min, 96 %
175
182
183
177
 
Scheme 8.21: Successful synthesis of compound 175 
 
Currently this route has only been used to prepare the methyl substituted compound.  
However, this route is likely to be applicable to many other alkyl groups.  If the ketone can 
be purchased or synthesised then it should be possible to convert it into the desired final 
target using this route. 
 
In summary, six compounds have been synthesised in this series, the allyl, benzyl, propyl 
and methyl substituted compounds.  These six compounds have been submitted for 
biological evaluation, but the results have not been obtained as yet.  Once these results have 
been obtained a decision can then be made as to whether this series is worth pursuing.  If 
the biological results are favourable and functionality around this region is beneficial to 
activity, then the synthesis of many more compounds will be required to extend the SAR in 
this series.  With the potential for further optimisation the developed synthetic route 
(Scheme 8.21) will allow a wide range of targets to be prepared. 
 
8.4.6.5 Investigations into the Effects of Chirality on Enzyme Inhibition 
 
The majority of the compounds prepared in this project so far have been achiral.  This 
simplifies the SAR development process, as chirality can have a huge impact upon activity.  
So in order to get a good SAR each chiral form of a compound needs to be subjected to 
biological evaluation separately to establish if one or both enantiomers are active.  Those 
compounds discussed in this Chapter, which are substituted on the amine CH2 bond, are 
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chiral compounds.  They have one chiral centre in the molecule, therefore there are two 
possible enantiomers.  It was therefore vital to look at the effects of chirality in this series, 
to assess the effects on the inhibitory activity of the compounds. 
 
The most successful synthesis in this series so far was the synthesis of compound 172, the 
allyl substituted compound (Scheme 8.17), which was prepared via an imine formation 
between the headgroup aniline and the corresponding aldehyde, which was then reacted 
with allylmagnesium bromide to form the desired product in a 57 % yield.  This allowed a 
suitable amount of the compound (~ 200 mg) to be prepared.  The product from this route is 
produced as a racemic mixture, with equal amounts of each enantiomer formed.  
Investigations were then conducted into how to separate the chiral forms of the compound.  
Preparative chiral HPLC can be a suitable option for separation of compounds on a small, 
laboratory scale.  When compound 172 was subjected to separation using an analytical 
scale Chiralcel AD-H chiral HPLC column (Figure 8.22), it showed that the mixture 
contained, as expected, a 1:1 mixture of enantiomers.  It was also clear that separation of 
the enantiomers was possible as the separation observed was good, with enantiomer A 
(184) having a retention time of 9.0 min and enantiomer B (185) 11.5 min.   
 
 
Figure 8.22: Chiral Separation of compound 172 using Chiralcel AD-H chiral HPLC 
Column (80 % methanol and 20 % water at 1.0 mL/min). 
 
The compound was then subjected to separation on a preparative scale using the same 
column specification as before.  This allowed ~ 70 mg of each compound to be isolated and 
analysed.  It can be seen from Figures 8.23 and 8.24 that, once separated, enantiomers A 
and B were shown to be enantiomerically pure by the use of a Chiralcel column for the 
LCMS analysis. 
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Figure 8.23: LCMS trace of Enantiomer A (184) of compound 172 using Chiralcel AD-H 
chiral column (80 % methanol, 20 % water at 1.2 mL/min). 
 
 
Figure 8.24: LCMS trace of Enantiomer B (185) of compound 172 using Chiralcel AD-H 
chiral column (80 % methanol, 20 % water at 1.2 mL/min). 
 
In order to identify the absolute stereochemistry of the enantiomers it was necessary to use 
X-ray crystallography.  Both enantiomers were crystallised (from hexane/DCM) and 
enantiomer A was analysed by X-ray crystallography (Figures 8.25 and 8.26, see also 
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Appendix 3).  This allowed enantiomer A to be conclusively identified as the R-enantiomer, 
meaning that enantiomer B is therefore the S-enantiomer. 
 
Figure 8.25: X-Ray crystal structre of enantiomer A (184, (R)-). 
 
It can be seen from Figure 8.26 that hydrogen bonds form between the hydrogen (grey, H2) 
on the acetamide nitrogen (blue, N2) and the carbonyl (red, O2) of a neighbouring 
molecule. 
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Figure 8.26: The packing structure of Enantiomer A (184, (R)-). 
 
The optical rotation of the compounds was also measured.  The results are shown in Figure 
8.27.  The optical rotations (measured as [α]D) were directly opposite for the two 
compounds of a similar magnitude.  Therefore enantiomer A is R-(-)- and B is S-(+)-. 
 
O
HN
Cl
H
N
O
 
O
HN
Cl
H
N
O
 
Enantiomer A  Enantiomer B  
R-(-)- S-(+)- 
184 185 
[α]D= -155.7 (in DCM at 20 °C) [α]D= +158.0 (in DCM at 20 °C) 
Figure 8.27: Enantiomers from compound 172. 
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Once these two compounds had been separated and the absolute configurations had been 
determined they were both submitted for biological testing.  The results are awaited. 
 
Both the racemic mixture and the two enantiomers will be evaluated, thus giving very 
important information about the active site.  Biological systems show a degree of chirality, 
so it is possible that one enantiomer of compound 172 may be less active while the other 
more active than the racemic mixture.  Whichever is the more active enantiomer is likely to 
be the active enantiomer across this substituted series of compounds.   
 
Both enantiomers were docked into the 17β-HSD Type 3 homology model as shown in 
Figures 8.28 and 8.29.  Both compounds docked into the model in multiple modes due to 
the high degree of flexibility from the high number of rotatable bonds (only the one mode is 
shown in Figures 8.28 and 8.29).  Enantiomer A (184) has a predicted hydrogen bond 
between the carbonyl oxygen and Tyr198 side chain.  In enantiomer B (185) a hydrogen 
bond is predicted between the diphenylether oxygen and a nitrogen atom in Val221 side 
chain.   
 
Overall, the protein-ligand van der Waals interactions are highest for enantiomer A (184), 
indicating that this compound is a better fit into the active site.  Therefore, it is anticipated 
that enantiomer A (184), the R-(-)- enantiomer, is likely to be the more effective inhibitor.  
This can only be proved when biological testing has taken place. 
 
O
HN
Cl
H
N
O  
Figure 8.28: Enantiomer A (184, R-(-)-) docked into the 17β-HSD Type 3 homology 
model. 
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Figure 8.29: Enantiomer B (185, S-(+)-) docked into the 17β-HSD Type 3 homology 
model. 
 
Compound 173 was also synthesised as a racemic mixture and has so far not undergone 
chiral separation.  Each enantiomer of this compound was docked into the 17β-HSD Type 3 
homology model to see if the same differences in docking between the enantiomers was 
repeated.  Figure 8.30 shows the docking of the R-enantiomer into the homology model.  
As previously, due to the high number of rotatable bonds the compound docked with 
multiple modes, but in this case no potential hydrogen bonds were observed.  Comparing 
the two enantiomers, the equivalent rings are placed in similar positions and there is 
possible π-π stacking interaction between the compounds and the cofactor, although this is 
more optimal for the R- enantiomer.  The protein–ligand van der Waals interactions are 
considerably higher for the R- enantiomer indicating that it is a better fit in the active site.  
Thus, as with the enantiomers of 172 the R- enantiomer is again predicted to be the more 
effective inhibitor. 
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Figure 8.30: R-Enantiomer of compound 173 docked into the 17β-HSD Type 3 homology 
model. 
 
It is anticipated that, if the two enantiomers do show differing activity that all the 
biologically significant analogues prepared in this series would need to be separated into 
the corresponding enantiomers and subjected to further biological testing.  When they are 
received the biological results will be very useful to the progression of the project.  It is 
hoped that an asymmetric synthetic route could be developed for the synthesis of these 
compounds if one enantiomer is shown to be significantly more active than the other. 
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8.5 Table of Compounds Synthesised within Chapter 8 
 
Compound  
no.  
Structure 
% Inhibition  
(at 10 µM).
a
 
126 
Cl
O
HN
H
N
O
 
87 
IC50 = 0.9 µM 
127 
O
O
HN
F
F
F
H
N
O
 
b 
128 
Cl
O
HN
H
N
O
F
 
b 
131 
Cl
O
HN
H
N
O
O
O  
86 
 152 
138 
Cl
O
HN
H
N
O
O
O
 
b 
139 
Cl
O
HN
H
N
O
O
O
Cl
 
b 
140 
Cl
O
HN
H
N
O
 
b 
141 
Cl
O
HN
H
N
O
 
b 
142 
Cl
O
HN
H
N
O
Cl  
97 
IC50 = 1.9 µM 
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143 
Cl
O
HN
H
N
O
Cl
Cl  
b 
144 
O
O
HN
H
N
O
F
F
F
Cl  
b 
147 
Cl
O
HN
H
N
O
O
 
b 
148 
Cl
O
HN
H
N
O
O
 
b 
150 
Cl
O
HN
N
O
 
b 
 154 
151 
O
N
Cl
N
O
 
b 
152 
O
N
Cl
H
N
O
 
b 
153 
O
N
Cl
H
N
O
O
 
b 
154 
Cl
O
HN
HN
O  
29 
155 
Cl
Cl
O
HN
HN
O  
b 
 155 
158 
Cl
O
HN
N
H
O
 
53 
162 
Cl
O
N
H
N
N
O
O
 
55 
164 
Cl
O
HN
H
N
N
O  
36 
165 
Cl
O
HN
H
N
O
N
O
 
91 
IC50 = 3.9 µM 
167 
Cl
O
HN
N
H
O
N
O  
97 
IC50 = 1.1 µM 
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169 
Cl
O
HN
H
N
 
b 
170 
Cl
O
HN
N
O
 
b 
172 
O
NH
Cl
H
N
O
 
b 
173 
O
NH
Cl
H
N
O
 
b 
174 
O
NH
Cl
H
N
O
 
b 
 157 
175 
Cl
O
HN
H
N
O
 
b 
184 
Cl
O
HN
H
N
O
R-(-)- 
b 
185 
Cl
O
HN
H
N
O
S-(+)- 
b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %, b Not determined. 
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Chapter 9 
 
Design and Synthesis of Compounds with an Amide Linked Hydrophobic Headgroup 
 
9.1 Synthesis of Initial Targets 
 
All the compounds discussed so far have had the same diphenylether headgroup, albeit with 
differing substituents.  Other areas of the target compounds have been varied greatly to 
explore the SAR with the 17β-HSD Type 3 enzyme, so it would be interesting now to 
introduce alternatives to the diphenylether hydrophobic headgroup in order to further probe 
the SAR. 
 
One variation that may prove to be interesting is the incorporation of an amide linking 
group between the two aryl groups of the hydrophobic head unit.  It would be an interesting 
change in the size, geometry and electronic properties of the molecule, and therefore useful 
to the development of the SAR.   
 
During the planning stages of this series, it was found that 2-aminobenzanilide was 
commercially available, meaning that the synthesis of compounds with an amide linked 
hydrophobic headgroup was possible in just one synthetic step (Scheme 9.1).  The 
compounds were synthesised in one step from commercial starting materials using the 
standard reductive amination conditions discussed in Chapter 7.85  The compounds (186 
and 187) were obtained in moderate yields and have both been submitted for biological 
testing. 
 
H
N
O NH2
NaBH(OAc)3, AcOH
DCE, MW 140 oC, 10 min
NO
R
O
N
H
O HN
N R
O
R = Me, 47%, 186
R = Ph, 21%, 187  
Scheme 9.1: Synthesis of compounds with an amide linked hydrophobic headgroup 186 
and 187. 
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Figure 9.1 shows compound 187 docked into the 17β-HSD Type 3 homology model.  It can 
be seen from this docking that the compound lies in a similar alignment to previous 
compounds, with the hydrophobic headgroup interacting with Phe-214 (See Chapter 6) and 
the N-acetyl carbonyl group is positioned towards the cofactor.  Until biological data has 
been obtained it is unknown if this similarity in alignment will be important to inhibitory 
activity. 
 
N
H
O HN
N
O
 
Figure 9.1: Compound 187 docked into the 17β-HSD Type 3 homology model. 
 
Within this series of compounds with an amide linked hydrophobic headgroup it is possible 
for the amide to be in two different forms, the original form (shown in Scheme 9.1) and the 
reversed formation, where the CONH are reversed.  There was no in-silico docking 
information or biological data to suggest that either form may be more active than the other, 
so both forms required synthesis and biological testing. 
 
The route to the compounds with a reversed amide linked hydrophobic head group was 
initiated.  There was not a suitable starting material commercially available, so in this case 
a different synthetic route was required.  This new route was to utilise a Buchwald-Hartwig 
amination112, 114, 115 to couple the bromo substituted amine linked headgroup with a primary 
amine on the piperidine (Scheme 9.2).  Two analogues of the hydrophobic headgroup were 
synthesised using benzoyl chloride and 2,4-dichlorobenzoyl chloride (Scheme 9.2).  The 
first step, a coupling of 2-aminobromobenzene with the desired benzoyl chloride, was 
successful and compounds 188 and 189 were synthesised in excellent yields.  The final step 
to the desired targets was planned to be a palladium catalysed Buchwald-Hartwig 
amination, with 4-amino-piperidine-1-carboxylic acid tert-butyl ester 190, to afford the 
final amide linked hydrophobic headgroup target compounds.  However, the preparation of 
4-amino-piperidine-1-carboxylic acid tert-butyl ester, 190, was not straightforward. 
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188: X = H, 100 %
189: X = 2,4-dichloro, 89 %
Where X = H, 
            X = 2,4-dichloro,
 
Scheme 9.2: Synthetic route to amide linked hydrophobic head group. 
 
The synthesis of 4-amino-piperidine-1-carboxylic acid tert-butyl ester 190 was attempted 
using the method by Miriyala et al, previously mentioned in Chapter 8 (Scheme 9.3).109  
Firstly, the imine is formed using ammonia in ethanol solution with titanium iso-propoxide 
as the Lewis acid.  This is subsequently reduced using sodium borohydride to form the 
desired primary amine.  However, this reaction was very variable and unreliable.  Some 
success was shown initially, but this success could not be repeated and, unfortunately 
therefore, this was not a viable route to the desired targets.  
 
N
Boc
O
N
Boc
NH2
(i) TiO
i
Pr, NH3 (2 M in EtOH), r.t. 18 h
(ii) NaBH4, r.t. 3 h
87 % 190
 
 
Scheme 9.3: Synthesis of 4-amino-piperidine-1-carboxylic acid tert-butyl ester. 
 
The lack of synthetic success led to the planning and initiation of an alternative route to 
amine linked hydrophobic headgroup target compounds (Scheme 9.4).  Formation of the 
amide bond in the headgroup was achieved, as previously, via an acid coupling, in this 
instance between a benzoyl chloride and 2-nitroaniline.  This was achieved with excellent 
yields.  The consequent reduction of the nitro group was also successful leading to the 
desired amide linked diphenyl aniline headgroup precursor (193 and 194).  This was then 
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subjected to the normal reductive amination conditions described in Chapter 7.85  In the 
case of the 2,4-dichloro substituted target, the reductive amination was successful and the 
first reversed amide linked hydrophobic headgroup target compound, 195, was isolated in 
42 % yield.  This compound has been submitted for biological testing, but the results have 
not yet been obtained.  However, in the case of the unsubstituted hydrophobic headgroup 
this route did not produce the desired compound, an alternative product was formed 
instead. 
 
Cl
O
+
H2N
NO2
H
N
O
NO2
H
N
O
NH2
H
N
O
HN
N
O
X = 2,4-diCl, 83 %, 193
X = H, 75 %, 194
X = 2,4-diCl, 73 %, 191
X = H, 99 %, 192
Fe, NH4Cl,
EtOH, H2O
Reflux, 2 h
TEA,DCM
Reflux, 18 h
X = H,  (see below)
X = 2,4-Cl, 42 %, 195
NaBH(OAc)3, 
AcOH, DCE, 
MW 140
 o
C, 10 min
X
X
X
X
NO
O
 
Scheme 9.4: The second and successful route to the amide linked hydrophobic headgroup. 
 
9.2 The Formation of an Alternative Product  
 
The products from the amide formation and nitro reduction were obtained in good yields 
using unsubstituted benzoyl chloride as the starting material, but the reductive amination 
did not produce the expected compound.  The yield of the reaction was 72 %, a very good 
yield, thus proving that the compound identified was the main product from the reaction.  
Proton NMR, carbon NMR and LCMS data were used to try to identify the product.  
However, these were inconclusive, as although it could be proved that the product isolated 
was not as expected, it was not possible to categorically determine the structure of the 
product obtained.  Crystalline material was obtained and thus X-ray crystallography was 
used to conclusively solve the structure.  This is shown in Figure 9.2, (for full details see 
Appendix 3). 
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N
N
N
O
196
 
Figure 9.2: X-ray crystal structure of compound 196 and the confirmed structure 
 
The X-ray crystal structure proved that, as hypothesised the reductive amination reaction 
between 1-acetyl-4-piperidone and N-(2-amino-phenyl)-benzamide did not produce the 
expected product, but an alternative benzimidazole product (196).  Although compound 
196 was not the desired compound, it still constitutes an interesting and novel hydrophobic 
head group within the project.   
 
 163 
Figure 9.5 shows a proposed mechanism for the formation of compound 196.  Firstly, the 
starting materials undergo a reductive amination method, as expected, to form the desired 
product.  However, at this stage the newly formed secondary amine undergoes an 
intramolecular reaction with the carbonyl group of the amide bond.  This is an unexpected 
reaction, as the amide was assumed to be unreactive under these conditions.  Following this 
attack and subsequent proton transfer, the imine is formed by electron transfer from the NH 
of the amide.  The double bond is not reduced, so remains in the molecule, thus forming the 
final benzimidazole based compound.  This reaction is driven by the intramolecular 
reactions leading to the formation of a stable aromatic product in the last step which is 
therefore irreversible.  The use of MW irradiation is also presumably an influencing factor, 
as the energy available to the reactants is very high, thus assisting the reaction.   
 
The presence of the 2,4-dichloro substitution is sufficient to inhibit this alternative reaction.  
The ortho-chlorine is likely to affect the electronic stability of the compounds and, in 
particular, the amide bond.  The chloro substitutions may also affect the geometry of the 
compound, changing from the favourable geometry seemingly found in the unsubstituted 
intermediate to an unfavoured conformation, meaning that this alternative mechanism 
cannot occur. 
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Scheme 9.5: Proposed mechanism for the formation of compound 196. 
 
9.3 Synthesis of Extended Analogues 
 
Using the information from the docking studies in Chapter 6 and 7, it is known that the 
active site of 17β-HSD Type 3 is very large.  It would therefore be interesting to test the 
tolerability of the active site to large compounds.  The synthesis of an extended analogue of 
196 was therefore initiated (Scheme 9.6).  The reductive amination between N-(2-amino-
phenyl)-benzamide and 1-Boc-4-piperidine proceeded as previously in this series, with the 
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alternative benzimidazole based product forming (197).  This compound was submitted for 
testing, as the t-Boc group is an alternative R group in this region of the molecule.  The N-
Boc deprotection of this compound proceeded smoothly under standard conditions, and the 
free amine (198) was isolated in 87 % yield.  This was then reacted with the desired acid 
chloride to produce the extended analogue, 199, with an extra piperidine unit at the base of 
the molecule.  If these compounds show biological significance, this route could be used to 
prepare a series of benzimidazole based compounds. 
 
N
H
O
NH2
N
Boc
O
N
N
N
H
N
O
O Cl
N
N
N
Boc
N
N
N
O N
O
+
197NaBH(OAc)3, AcOH
DCE, MW 10 min, 140 oC
57 %
TFA, DCM, 0 oC, 30 min
87 %
TEA, DCM, r.t. 4 h,
9 %
199
194
198
Scheme 9.6: Synthesis of the extended analogue, 199. 
 
9.4 Biological Results Obtained 
 
The three compounds in this series were submitted for biological testing.  However, only 
the result for the original compound, 196, has been received so far (Table 9.1).  
Unfortunately, the biological results showed 196 to be essentially inactive.  Investigations 
were also conducted to see if 196 had any other significant biological effects.  The 
compound was tested in the 17β-HSD Type 1 TLC assay, where it also showed no activity.  
Compound 196 was also submitted to the National Cancer Institute for testing in the 60 
different cancer cell lines (see Chapter 11 for more details).  However, no significant 
activity was exhibited by this compound.  Until the full biological data for the whole series 
has been received it is not possible to draw conclusive results.  However, it seems that 
inclusion of this novel benzimidazole based headgroup is greatly detrimental to inhibitory 
activity in 17β-HSD Type 3.  Unless the biological data received for compounds 197 and 
198 are more promising, this series of compounds will not be further explored. 
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Compound 
no 
% Inhibition of 17β-HSD 
Type 3 (at 10 µM).
a
 
196 13 
197 
b 
199 
b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %,  
b Not determined. 
Table 9.1: Biological results obtained for the compounds 196, 197 and 199. 
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9.5 Table of Compounds Synthesised within Chapter 9 
 
Compound  
no.  
Structure 
% Inhibition (at 
10 µM).
a
 
186 
N
H
O HN
N
O
 
b 
187 
N
H
O HN
N
O
 
b 
195 
Cl
Cl
H
N
O
HN
N
O
 
b 
196 
N
N
N
O  
13 
197 
N
N
N
OO
 
b 
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199 
N
N
N
O
N O
 
b 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %,  
b Not determined. 
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Chapter 10 
 
Design and Synthesis of Compounds with a Benzophenone Linked Headgroup 
 
10.1 Synthesis of Initial Targets 
 
Another variation of the diphenylether hydrophobic headgroup that may prove interesting is 
the inclusion of a benzophenone headgroup (Figure 10.1).  Although the compounds with a 
hydrophobic headgroup linked via an amine bond have, so far in the project, exhibited 
better inhibitory properties than the corresponding amide, it is possible that a change in 
another part of the molecule may alter this pattern. For this reason, synthesis of the 
benzophenone linked headgroup targets were planned in both the amide and amine linked 
series. 
 
X
O HN
O
N
O
X
O HN
N
O
(a) (b)  
Figure 10.1: Initial targets in the benzophenone linked hydrophobic headgroup series. 
 
The unsubstituted 2-aminobenzophenone and the halogen substituted 2-amino-5-chloro-2΄-
fluorobenzophenone were commercially available,88 making the synthesis of these target 
compounds feasible in just one step. 
 
10.1.1 Amide Linked Targets  
 
The synthesis of the amide linked targets in this series is shown in Scheme 10.1.  Only one 
step was required from the 2-aminobenzophenone starting material to the final product.  
However, there was a problem encountered with the reactivity in this series.  An amide 
coupling reaction was attempted, with 1-acetyl-piperidine-4-carboxylic acid, using EDC as 
the activating reagent.  However, this was unsuccessful.  Next it was attempted to form the 
amide bond using a standard reaction with the corresponding acid chloride.  However, the 
same reactivity problem was encountered and only starting materials were isolated.  A 
study of the chemical literature revealed two articles that used different, more forcing, 
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conditions to those already attempted.  Park et al 116 heated the starting materials in DCM 
with 6 eq. pyridine for 6 h and Kettlera et al 117 used a very similar method, heating the 
reaction in toluene for 6 h.  These two sets of conditions were combined and the desired 
reaction was heated in toluene with 6 eq. pyridine for 6 h.  This produced the correct 
products in yields of 46 and 48 % respectively.  The two compounds synthesised (200 and 
201) have been submitted for biological evaluation, but the results have not yet been 
obtained. 
 
O HN
O
N
O
O NH2
N
O
Cl O
TEA, DCM, 0 oC to r.t. 18 h
X
N
O
HO O
EDC, DMAP, TEA, 
DCM, 10 days
X
O HN
O
N
O
X
Y
X
Y
X
Y
O HN
O
N
O
N
O
Cl O
Toluene, 6 eq. pyridine, 
reflux 5 h,
X
Y
When X = Y = H, 200, 48 %
         X = F, Y = Cl, 201, 46 %  
Scheme 10.1: Synthesis of amide linked compounds (200 and 201) with a benzophenone 
linked headgroup. 
 
10.1.2 Amine Linked Targets and the Formation of Alternative Products 
 
The synthesis of the amine linked compounds in this series was carried out using the 
standard MW reductive amination method detailed in Chapter 7 (Scheme 10.2).85  
Disappointingly, the yield was low at only 36 %, but this did mean that a sufficient amount 
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of compound 202 was synthesised for biological evaluation, but the result has not been 
obtained.  
 
O HN
N
O
O NH2
+
N
O
O
NaBH(OAc)3, AcOH, DCE
MW, 140 oC, 10 min, 36 %
202
 
Scheme 10.2: Synthesis of amine linked compound 202, with a benzophenone linked 
headgroup. 
 
It was hoped that the yield of the above reaction (Scheme 10.2) could be improved from 36 
%, so the reaction was repeated.  However, a different product was obtained, in 60 % yield.  
Proton NMR, carbon NMR and LCMS data were used to try to identify the unexpected 
product.  Crystalline material was obtained and X-ray crystallography was employed to 
confirm the structure of the product 203, (Figures 10.2 and 10.3 and Appendix 3).  It was 
found that the difference between the two reactions was the supply of NaBH(OAc)3 used.  
The NaBH(OAc)3 used in the second attempt was found to have degraded, and the 
alternative product had been formed in the absence of active NaBH(OAc)3.  Thus, by 
accident an interesting, novel modification of the Friedländer Synthesis of Quinolines has 
been discovered.118  
 
O NH2
+
N
O
O
NaBH(OAc)3, (inactive)
MW, 140 oC, 10 min, 60 %
N
N
O
AcOH, DCE
203
 
Scheme 10.3: Formation of the alternative product 203. 
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Figure 10.2: Friedländer product formed from the reductive amination of 1-acetyl-
piperidin-4-one with 2-aminobenzophenone, 203. 
 
Figure 10.3 shows the packing structure of compound 203.  It can be seen that the 
compound has formed hydrogen bonds with water molecules.  The H bonds are formed 
between the water hydrogens and both the nitrogen of the quinoline ring (blue, N2) and the 
carbonyl oxygen (red, O1), thus forming bonds between the neighbouring molecules in the 
crystal. 
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Figure 10.3: The packing structure of compound 203 
 
10.2 Optimisation of the Friedländer Synthesis of Quinolines. 
 
Synthesis of the quinoline ring system is very important to the synthetic organic chemist, as 
it appears in many natural products and pharmaceutical entities, notably Quinine and 
Streptonigrin, an antibiotic.  The structural core of quinolines can be made by many 
different methods,119 including the Friedländer synthesis.  The Friedländer synthesis of 
quinolones was originally published in 1882.118  It is traditionally thought of as a reaction 
in which an o-aminobenzaldehyde is cyclised by reaction with a α-methyleneketone in the 
presence of a base.120  It has been shown that the Friedländer synthesis can be acid or base 
catalysed or it can even proceed without catalysis although uncatalysed Friedländer 
synthesis requires very high temperatures, up to 220 °C.119  In many cases, it has been 
found that acid catalysis is more effective than basis catalysis.121  Catalysts used for this 
reaction include hydrochloric acid,121 sulfamic acid,122 CuCl2,
123 p-toluenesulphonic acid,124 
chlorotrimethylsilane,125 and diphenylphosphate (DPP)126 amongst others.119  There has also 
been a recent flurry of MW enhanced procedures,121, 124-126 which demonstrates the 
advantages that MW assisted synthesis have upon this reaction, in both speeding up the 
reaction and improving yields.127  In summary, the Friedländer synthesis is a versatile and 
reliable reaction, with many different options depending on the substrates available.   
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A suggested mechanism of this reaction is shown in Scheme 10.4.119  It is generally 
accepted that the reaction proceeds via the initial formation of a Schiff base, followed by an 
internal aldol condensation (Scheme 10.4).119   
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Scheme 10.4: Suggested mechanism for the formation of compound 203.119 
 
Many of the reactions in the literature show almost quantitative yields.  This is an 
improvement over the 60 % yield exhibited so far under the conditions shown in Scheme 
10.3, thus meaning that the yields of the reaction may be improved by optimisation.  After 
the initial discovery of this alternative reaction, many investigations were made into the 
optimum conditions for this reaction.  The reaction was repeated as previously (Scheme 
10.3) except without the inclusion of NaBH(OAc)3, and the yield remained similar at 70 %.   
 
The reaction between 2-aminobenzophenone and cyclohexanone was used to optimise the 
conditions.  A study into the effects of time and temperature was initiated.  The results are 
shown in Table 10.1.  A solution of 2-aminobenzophenone (1 mmol), cyclohexanone (2 
mmol) in DCE (2 mL) with AcOH (3 mmol) was heated as stated in Table 10.1.  At room 
temperature the reaction does proceed, but incredibly slowly, with only an 18 % yield 
isolated after 3 days under standard conditions (r.t.).  The yield was dramatically increased 
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by the use of MW technology (See Chapter 7 and Entries 1-6).  It can be seen that an 
increased temperature leads to an increase in yields.  However, above 200 °C there is no 
longer a significant increase observed (Entry 6) and higher temperatures could lead to 
degradation of starting materials or products.  For this reason, 180 °C was the maximum 
temperature investigated from here onwards.  It can also be stated that the optimum 
reaction time is a maximum of 20 minutes, as completion was not reached after 10 minutes 
and greater reaction times lead to reduced yields (Entry 2). 
 
O NH2
+
O
 3eq. AcOH, 
DCE, MW N 204
 
 
Entry Temperature  
(MW heating, °C) 
Time (min) Yield (%) 
a
 
1 140 20 70 
2 140 40 15 
3 160 20 71 
4 180 20 78 
5 200 20 86 
6 220 20 85 
a Isolated yield. 
 
Table 10.1: The effects of time and temperature on the Friedländer synthesis of quinolines, 
with 2-amino benzophenone and cyclohexanone. 
 
As with the original MW reductive amination optimisation (Chapter 7), it was crucial to 
investigate an array of solvents that possess different microwave properties (Table 10.2).83, 
86  It can be seen that the use of acetonitrile does not greatly affect the yields, compared to 
DCE (Entries 2 and 3), whereas the use of toluene increases the yield from 78 % to 89 % 
(Entries 1 and 5). 
 176 
 
Entry Solvent 
Temperature  
(MW heating, °C) 
Time 
(min) 
Yield  
(%) 
a
 
1 DCE 180 20 78 
2 acetonitrile  180 20 71 
3 Toluene 140 20 78 
4 Toluene 160 20 83 
5 Toluene 180 20 89 
6 Toluene 180 10 72 
a Isolated yield. 
 
Table 10.2: The effects of solvent on the Friedländer synthesis of quinolones, with 2-amino 
benzophenone and cyclohexanone. 
 
At this point, investigations were undertaken to attempt to drive the reaction fully to 
completion, by assisting with the dehydration (Scheme 10.4).  It was hoped that the 
removal of water would help to encourage the forward equilibrium and therefore increase 
the yield of the reaction.  Dehydrated magnesium sulphate (3 eq.) and 4 Å molecular sieves 
were tested, but reduced the isolated yield to 76 and 54 % respectively. 
 
Investigations were also made to see whether the acetic acid used so far could be 
successfully substituted for alternative reagents (Table 10.3).  These results show that, as 
expected, acid catalysis is required for protonation and dehydration, because without an 
acid present the yield is reduced to just 17 %, (Entry 1).  Solid phase Amberlite ICR50 H-
form is not a suitable alternative reagent, as this reduces the yield to just 7 %, (Entry 2).  
Conversely, it was found that, as reported in the chemical literature, p-TSA is a very 
successful alternative reagent,128 and even when utilised in catalytic amounts it leads to 
excellent yields of 84 %, (Entries 3-5).  However, the best conditions identified from this 
study were the use of AcOH as the solvent, as operationally this is facile and excellent 
yields are obtained (Entry 6). 
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Entry Solvent Acid Yield (%) 
a
 
1 Toluene - 17 
2 Toluene Amberlite ICR50 H-form 7 
3 Toluene 3eq. p-TSA 86 
4 Toluene 1eq. p-TSA 84 
5 Toluene Cat. p-TSA 84 
6 - AcOH as solvent 87 
a Isolated yield. 
 
Table 10.3: The effects of solvent on the Friedländer synthesis of quinolines, using 2-
amino benzophenone and cyclohexanone. 
 
The use of AcOH as solvent and acid catalyst is highly advantageous to this reaction in 
terms of results and operational simplicity.  The new procedure was simply to heat 2-
aminobenzophenone (1 mmol) and cyclohexanone (2 mmol) in AcOH (2 mL) in a MW 
tube.  The use of this procedure has led to higher yields and shorter reaction times (Table 
10.4).  This system is now so efficient that the reaction proceeds efficiently, even at room 
temperature, (89 % after 24 h).  The best yields are obtained with just a five or ten minute 
heating period at 160 °C (Entries 2 and 3), with almost optimal yields obtained.  Longer 
heating periods lead to a decrease in isolated yield (Entry 4) 
 
Entry 
Temperature  
(MW heating, °C) 
Time (min) Yield (%) 
a
 
1 100 5 79 
2 160 5 94 
3 160 10 94 
4 160 20 87 
a Isolated yield. 
 
Table 10.4: The effects of time and temperature on the Friedländer synthesis of quinolones 
when AcOH is used as the solvent. 
 
Following the identification of the optimal Friedländer conditions, using AcOH as the 
solvent and heating in a MW for just 5 minutes at 160 °C, further investigations were 
undertaken to examine the potential of this application.  A larger scale reaction was carried 
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out using 500 mg of 2-aminobenzophenone (2.5 mmol) in the same volume of AcOH (2 
mL), thus more than doubling the concentration of starting materials.  A yield of 95 % was 
obtained.  This shows no difference due to scale, thus showing this reaction has a high 
potential for large scale reactions, where minimal solvent use is desired.   
 
Investigations were also carried out to explore the effect, if any, of reducing the relative 
amount of ketone used (Table 10.5).  There was little difference in yields observed when 
using 1, 1.5 or 2 equivalents of cyclohexanone.  For this reason, the amount of ketone used 
in all subsequent reactions has been reduced to 1.5 equivalents.  An excess was used to 
ensure complete consumption of the aniline.  This ratio could be reduced if required by a 
particular application. 
 
Entry Equivalents of cyclohexanone used Yield (%) 
a
 
1 2 94 
2 1.5 92 
3 1 87 
a Isolated yield. 
 
Table 10.5: The use of differing amounts of ketone on the Friedländer synthesis of 
quinolines, with 2-aminobenzophenone and cyclohexanone. 
 
Now the conditions have been optimised, the new procedure for the Friedländer synthesis 
of quinolones was used on a range of different starting materials (Table 10.6).  Excellent 
yields were obtained in all cases.  The reaction with 2-hexanone showed some degree of 
regioselectivity as the two possible products were obtained in a 1: 1.9 ratio (Entry 4). 
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Entry Starting Material Ketone Product 
Yield 
(%)
a
 
1 
O NH2  
O
 
N
204
 
94 
2 
O NH2  
O
 
N
205
 
93 
3 
O NH2  
O
 
N
206
 
99 
N
207
 
23b 
4 
O NH2  
O
 
N
208
 
43b 
5 
O NH2  
O
O
 
N
O
209
 
99 
 180 
6 
O NH2  
O
 
N
210
 
91 
a Isolated yield. 
b Regioisomers obtained, 1:1.9, overall yield 66 %. 
 
Table 10.6: Microwave assisted Friedländer Synthesis of quinolones. 
 
Application of this new procedure was applied to the original target compounds (Scheme 
10.5) affording the expected compounds in excellent yields of 68 and 70 %.  However, 
when 1-acetyl-4-piperidone is used as the ketone, there is an additional problem concerning 
the removal of the excess starting ketone.  The product and the ketone co-elute so cannot be 
separated by flash chromatography.  Although this problem had been reduced by using only 
1.5 equivalents of ketone, it was still significant.  Luckily, it was easily solved by stirring 
the crude product with a scavenger resin, PS-TsNHNH2,
87 in DCM for 1 hour.  The resin is 
then simply removed by filtration and the final compound purified by flash 
chromatography.  This extra purification may be part of the reason why these yields are 
lower than with other compounds (Table 10.6) because the overall yield for this step did not 
actually show any improvement following the optimisation process.  The new conditions 
are, however, faster and more operationally simple. 
 
O NH2
X
Y
N
O
O
AcOH
N
N
O
X
Y
+
MW, 160 oC, 5 min
When X = H, Y = H, 203, 68 %
         X = F, Y = Cl, 211, 70 %  
Scheme 10.5: Synthesis of quinoline based potential inhibitors, 203 and 211. 
 
Although compounds 203 and 211 were not the original targets, they do display certain 
aspects of the original pharmacophore required for activity discussed in Chapter 5.  There is 
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a large hydrophobic head group, with a linking unit attached to a hydrogen bond acceptor.  
This suggests that these compounds may exhibit some activity.  There is, of course, no 
guarantee that these compounds will have any activity as, although they do have similar 
regions to the designed compounds, the tricyclic system means that the compounds are 
more planar and are consequently occupy a very different spatial geometry than the 
designed target compounds.  In order to answer this hypothesis compounds 203 and 211 
were submitted for biological evaluation, but no results have yet been obtained.  
Compounds 203 and 211 have also been submitted for screening in the NCI cancer cell 
lines (for more details see Chapter 11) these results are also awaited. 
 
Figure 10.4 shows compound 203 docked into the 17β-HSD Type 3 homology model.  
From this docking some potentially important docking interactions were identified.  There 
is a potential hydrogen bond formed between the aromatic nitrogen of the compound and a 
Ser185 side chain.   
 
N
N
O  
Figure 10.4: Compound 203 docked into the 17β-HSD Type 3 homology model.   
 
10.3 Synthesis of Extended Analogues  
 
As with the other series mentioned in Chapters 6 and 7, it was likely that these quinoline 
based compounds (203 and 211) would be too short for optimal inhibitory activity, so 
extended analogues were synthesised (Scheme 10.6).  The initial step between 2-
aminobenzophenone and 1-Boc-4-piperidone did not proceed as expected.  The reaction, 
did not produce the t-Boc protected intermediate. The reaction led to the deprotected free 
amine intermediate.  Although this was not as planned, it means that the synthetic route is 
actually one step shorter, as the Friedländer synthesis and deprotection occur in one step, in 
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a good yield of 65 %.  This does, however, show that acid labile groups are not tolerated by 
this optimized Friedländer synthesis.  The free amine was then reacted with 1-acetyl-
piperidine-4-carbonyl chlorideusing the standard conditions.  The final product (213) was 
isolated in 21 % yield.  This compound has been submitted for biological evaluation, but 
the results have not been obtained yet. 
 
O NH2
N
Boc
O
AcOH
N
O
OCl
O
N
O
N
N
N
HN
+
MW, 160 oC, 5 min, 65 %
TEA, DCM, r.t., 2 days, 21 %
213
212
 
Scheme 10.6: Synthesis of an extended quinoline based potential inhibitor, 213. 
 
10.4 Future Work in these Series 
 
There is one potential drawback to this series of compounds: the removal of the substitution 
on the phenyl rings of the hydrophobic headgroup, when compared to all other series 
mentioned in previous chapters.  It is possible that the halogen, trifluoromethyl or 
trifluoromethoxy substitutions may affect the activity of the compounds, either 
detrimentally or beneficially.  When the biological results are obtained these two series of 
compounds, the benzophenone linked headgroup and the quinoline based compounds will 
be assessed to determine whether further investigations are needed.  If some activity is 
shown, then the synthesis of direct hydrophobic headgroup analogues (i.e. 4-chloro, 2,4-
dichloro etc.) will be required.  Although the desired substitution patterns are not 
commercially available as 2-aminobenzophenones, they can be easily synthesised from 
isatoic anhydride (Scheme 10.7).129  Fyre et al report that 2-amino-4΄-chloro-benzophenone 
can be synthesised using this method, with the second step proceeding with a 55 % yield 
(Scheme 10.7). 
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Scheme 10.7: Literature Synthesis of substituted benzophenones.129 
 
This substituted 2-aminobenzophenone could then be subjected to the synthetic procedures 
established in this Chapter to produce the substituted analogues of compounds previously 
synthesised (Scheme 10.8). 
 
O NH2
Cl
AcOH
N
Cl
N
O
O HN
Cl
N
O
O HN
Cl
O
N
O
NaBH(OAc)3, AcOH
DCE, MW, 140 oC, 10 min
Toluene, Pyridine,
6 h, reflux
MW, 160 oC, 5 min
Cl Cl
Cl
Cl
 
Scheme 10.8: Future synthesis of potential inhibitors with a substituted hydrophobic 
headgroup. 
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10.5 Table of Compounds Synthesised within Chapter 10 
 
Compound  
no.  
Structure 
% Inhibition (at 
10 µM).
a
 
200 
O HN
O
N
O
 
b 
201 
O HN
O
N
O
F
Cl
 
b 
202 O HN
N
O  
b 
203 N
N
O  
b 
211 
N
N
O
F
Cl
 
b 
213 
O
N
O
N
N
 
 
a Results obtained from the TLC assay.  Mean of at least 2 measurements with typically a 
SD of ±5 %, b Not determined. 
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Chapter 11 
 
Results of Other Biological Tests 
 
11.1 Selectivity 
 
It is anticipated that any drug that is selective for the desired target will have lowered 
toxicity or side effects compared to a less specific compound.  It is essential that any 17β-
HSD Type 3 inhibitor is selective over the other 17β-HSD isozymes, particularly Type 1 
and 2.  17β-HSD Type 1 is involved in the biosynthesis of oestrogens and 17β-HSD Type 2 
catalyses the inactivation of active androgens and oestrogens.  Inhibition of 17β-HSD Type 
2 may lead to the accumulation of active steroids which may cause toxicity problems and 
other side effects.  For this reason the 17β-HSD Type 3 inhibitors were assessed for their 
inhibitory activity on 17β-HSD Types 1 and 2 in order to establish selectivity. 
 
11.1.1 Selectivity over 17β-HSD Type 1 
 
Table 11.1 shows the inhibitory activity data obtained when the active 17β-HSD Type 3 
inhibitors were tested in the 17β-HSD Type 1 assay.  The assay is of a similar format to the 
17β-HSD Type 3 TLC assay.  T-47D breast cancer cells, which express a high ratio of 17β-
HSD Type 1 to 17β-HSD Type 2, were used to test the conversion of labelled oestrone to 
oestradiol in the presence and absence of the potential inhibitors.  The cells were incubated 
with 3H-oestrone at a concentration of 2 nM, in the absence or presence of the inhibitors 
(10 µM).  After incubation of the culture for 3 h at 37 °C, the products were isolated and 
separated by TLC using DCM/ EtOAc (4:1).  The amount of oestradiol formed was 
measured and compared to the control cells where no inhibitor was present.130  Each assay 
was carried out in the presence of a positive control (214,131 see Figure 11.1), to ensure 
reproducible results were being obtained.  A selection of those compounds which exhibited 
significant 17β-HSD Type 3 inhibition were submitted for testing.  The results show that 
the compounds tested are essentially inactive against 17β-HSD Type 1.  This is an excellent 
result and therefore does not preclude these compounds and related series from further 
investigations. 
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Compound  
no. 
Inhibition of 
17β-HSD Type 3 
(IC50, nM) 
Inhibition of  
17β-HSD Type 1 
(%, at 1 µM
a
 or 10 µM
b
) 
Inhibition of 
17β-HSD Type 2 
(%, at 10 µM) 
36 
(Positive Control) 
5 19.6 b 18.4 
101 700 12.7 a 10.9 
123 200 nd 20.3 
126 900 1.3 a 15.9 
165 3900 -2.3 b - 
a Tested at 1 µM, b Tested at 10 µM. 
 
Table 11.1: Selectivity of 17β-HSD Type 3 inhibitors of 17β-HSD Type 1 and Type 2. 
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Figure 11.1: Compound 214, the 17β-HSD1 positive control, (IC50 = 27 nM).
131 
 
11.1.2 Selectivity over 17β-HSD Type 2 
 
The activity of a selection of 17β-HSD Type 3 inhibitors on 17β-HSD Type 2 was assessed.  
The results are shown in Table 11.1.  The 17β-HSD Type 2 assay uses the same TLC 
format as the 17β-HSD Type 3 assay.  In this case, the assay analyses the conversion of 
oestradiol to oestrone.  MDA-MB-231 human breast cancer cells were incubated with 3H-
oestradiol at a concentration of 2 nM, in the absence or presence of the inhibitor (10 µM).  
After incubation of the culture for 3 h at 37 °C, the products were isolated and separated by 
TLC using DCM/ EtOAc (4:1).  The amount of oestrone formed was measured and 
compared to the control cells where no inhibitor was present.130  Compound 215 (Figure 
11.2) is used as a positive control in this assay to ensure reproducible results are being 
obtained.132  The results in Table 11.1 show that the compounds tested are only weakly 
active against 17β-HSD Type 2.  This is an excellent result and therefore does not preclude 
the compounds and related series from further investigations. 
 
 187 
HO
H H
H
OH
N
 
Figure 11.2: Compound 215, the 17β-HSD2 positive control, (IC50 = 5.4 µM).
132 
 
11.2  National Cancer Institute Screening Programme 
 
The drug discovery and development arm of the National Cancer Institute (NCI), the 
Developmental Therapeutics Program (DTP) plans, conducts and facilitates the 
development of therapeutic agents for cancer.133  An important part of this programme is 
the in vitro and in vivo anti-cancer compound screening program, which aims to identify 
and evaluate novel chemical leads and biological mechanisms of action.  Once compounds 
have been accepted by the NCI programme, they are subjected to the In Vitro Cell Line 
Screening Project (IVCLSP).  This project screens up to 3,000 compounds a year for any 
potential anticancer activity.  It utilizes 60 different human tumour cell lines, representing 
leukaemia, melanoma and cancers of the lung, colon, brain, ovary, breast, prostate, and 
kidney.  The screening begins with the evaluation of all compounds against the 60 cell lines 
at a single dose of 10 µM.  Compounds which exhibit growth inhibition are evaluated 
against the 60 cell line panel at five concentration levels.  Other available testing includes 
the in vivo hollow fibre assay and relevant human tumour xenograft and rodent tumour 
models. 
 
Selected compounds were submitted to the NCI for screening.  As previously mentioned in 
Chapter 9, compound 196 was analysed, but showed no significant activities in any cell 
line.  The other compounds accepted for testing were: 
• Compound 100 exhibited an average GI50 of 15 µM.  The compound did not show 
any significant activity on any of the 60 cell lines. 
• Compound 126 also exhibited an average GI50 of 15 µM.  The compound did not 
show any significant activity on any of the 60 cell lines. 
• Compound 165 (Figure 11.3) exhibited an average GI50 of 18.6 µM.  However, this 
compound showed a much higher activity in one leukaemia cell line, CCRF-CEM.  
This is a T lymphoblastoid line obtained from the peripheral blood of a 4 year old 
Caucasian female with acute lymphoblastoid leukaemia.134  Compound 172 
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exhibited a GI50 of 10 nM, a Total Growth Inhibition (TGI) of 235 nM and an LC50 
of 5 µM.  The full data is shown in Figure 11.4.  These results are worthy of further 
investigation, this is in progress. 
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Figure 11.3: Compound 165, tested for activity in the NCI screen. 
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Figure 11.4: Results received from the NCI for compound 165
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11.3 LNCaP Model used for Efficacy Evaluation 
 
An in vitro model was developed by colleagues at St Mary’s Hospital (Imperial 
College, London) using an LNCaP cell, an androgen receptor positive prostate cancer 
cell line.  It can be seen from Figure 11.5 that the growth of the wild type LNCaP cells 
could be stimulated (~ 4 fold) with DHT, but was only mildly stimulated (~ 2 fold) in 
the presence of androstenedione (A4).  
 
Proliferation of LNCaP Cells in the Presence of Androstenedione and DHT 
for 13 days.
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Figure 11.5: Stimulation of wild type LNCaP cells by androstenedione (A4) and DHT. 
 
The stimulatory effects of the androgens was studied in a cell line derived from 
LNCaPs, LNCaP[HSD3], which had been transfected to have stable expression of 17β-
HSD Type 3.  These cells were equally stimulated by androstenedione, T or DHT, due 
to the increased 17β-HSD Type 3 activity (Table 11.2). 
 
Treatment Growth 
0.1 % FBS  100 % (Control) 
10 nM Androstenedione 300 % 
10 nM Testosterone 309 % 
10 nM DHT 312 % 
 
Table 11.2: Androgenic stimulation of LNCaP[HSD3] cell. 
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This assay was then used to evaluate the in-vitro efficacy of some of the most potent 
compounds in this project so far (Figure 11.6).  Those compounds tested were: 
• Compound 36, the Schering-Plough positive control, IC50 = 1-5 nM,
47 
• Compound 26, the BMS positive control, IC50 = 200 nM,
45 
• Compound 123, a potent in-house compound, IC50 = 300 nM, 
• Compound 216, see Figure 11.6, IC50 = 300 nM. 
 
Initially, the compounds were assessed at 5 µM.  At this concentration, compounds 36 
and 123 surprisingly led to substantial toxic effects.  In contrast compound 26 was not 
as toxic, but it did not show any efficacy in this model.  Compound 216 (Figure 11.7) a 
novel in-house inhibitor, showed low toxicity and good efficacy in this model.  When 
the cells were incubated with 10 nM of androstenedione and 5 µM of compound 216, 
the inhibitor effectively reduced the androstenedione-stimulated proliferation of LNCaP 
cells, to just 34 % compared to the control cells. 
 
Stimulation of the Growth of LNCaP[HSD3] Cells in the Presence of 
Androstenedione and 17ß-HSD Type 3 Inhibitors (at 5 µM) over 16 days.
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Figure 11.6: Growth stimulation by androstenedione (A at 10 nM) and the effects of 17β-
HSD Type 3 inhibitors (at 5 µM) upon this growth. 
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Figure 11.7: Compound 216 and the ChiralPak HPLC trace obtained during the 
separation of the diastereomers. 
 
The experiment was repeated using the inhibitors at a concentration of 500 nM.  At this 
concentration, compounds 36 and 123 no longer showed the toxicity previously 
observed at the higher concentration.  Therefore, as expected compound 36 showed 
excellent inhibitory activity of 93 %.  Compound 123 also showed excellent activity, 
causing 74 % inhibition of stimulation.  When compound 216 was evaluated at this 
lower concentration it exhibited a percentage inhibition of 52 %.  This show that 
currently compound 123 is the most efficacious compound synthesised and tested in-
house so far. 
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Stimulation of the Growth of LNCaP[HSD3] Cells in the Presence of 
Androstenedione and 17ß-HSD Type 3 Inhibitors (at 500 nM) over 16 days.
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Figure 11.8: Growth stimulation by androstenedione (A at 10 nM) and the effects of 17β-
HSD Type 3 inhibitors (at 500 nM) upon this growth. 
 
The results of these preliminary studies showed that the competitor compound 26 has 
significant problems with efficacy.  Therefore, this compound is not suitable for use in 
the development of a 17β-HSD Type 3 in vivo assay.  However, compounds 36, 123 and 
216 (Figure 11.7) show good potency and good efficacy in this model.  This means that 
these compounds are promising candidates for the development of a 17β-HSD Type 3 in 
vivo assay and investigations are on-going. 
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Chapter 12: 
 
Summary, Structure Activity Relationships and Conclusions 
 
12.1 Introduction 
 
Prostate cancer represents a massive unmet medical need and remains a great challenge 
to doctors, patients and researchers.  It is known that prostate cancer growth is often 
stimulated by the presence of androgens and that growth of androgen dependent prostate 
cancer can be reduced with androgen depletion.  The enzyme 17β-HSD Type 3 is 
involved in the biosynthesis of androgens.  It catalyses the synthesis of androstenedione 
into testosterone, which is in turn converted to DHT, the most active androgen.  
Inhibition of 17β-HSD Type 3 would lead to a lower level of testosterone and therefore 
DHT.  It is anticipated that a reduction in androgen levels would reduce the growth of 
prostate cancer.  Proof of concept has been demonstrated by Schering-Plough with their 
potent inhibitors.  This was discussed in detail in Chapter 1.51, 52  The compounds 
reported by Schering-Plough are just some of the 17β-HSD Type 3 inhibitors reported 
in the scientific literature.  These compounds show excellent potency but, as yet, none is 
clinically significant. 
 
One of these potent compounds, 36 was chosen as a positive control compound for use 
in development of the in-house biological assays.  However, due to the exceptional 
potency of this compound in comparison to the current in-house synthesised 
compounds, problems with sensitivity were experienced.  An alternative compound 26 
was then selected as a new positive control.  This compound has been successful as a 
positive control and is now used as such in all assay development and testing. 
 
During the course of this project the biggest challenge has been the development of a 
successful and efficient biological assay.  The original TLC assay was undertaken using 
a transfected 293-EBNA cell line with stable human 17β-HSD Type 3 expression.  This 
was a successful assay which gave reliable results.  However, it was desired to change 
the format of the assay to a high-throughput assay, using the DELFIA format.  This was 
highly problematic and it has been decided that attention will revert back to using the 
TLC assay, until a later stage in the project where the DELFIA assay may be more 
suitable for use with hopefully more potent compounds.  These problems have 
unfortunately led to a significant delay in obtaining biological results in the project.  
This means that much of the biological activity information has not been obtained so far 
and thus a lot of potentially useful SAR information from this thesis is unavailable.  
These results will be obtained at a later date. 
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12.2 Amide and amine linked targets 
 
The initial targets in this project were established by the use of pharmacophore 
modelling which identified 4 main regions that were likely to be important to activity.  
This was discussed in more detail in Chapter 5.  A series of compounds based around a 
diphenylether hydrophobic headgroup and a piperidine ring was designed (Figure 12.1). 
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Figure 12.1: Amine and amide linked initial targets. 
 
A range of compounds in both series were synthesised (see Chapters 6 and 7) and the 
biological data for some compounds have been obtained.  From the data currently 
available some SAR information for these series can nevertheless be established.  These 
are shown in Figure 12.2. 
 
O
Y
N
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X
4- or 2, 4- substitution
 best
Substitution 
tolerated
Amine bond more 
active than amide
Small groups 
more active than 
larger groups
t-Boc group 
detrimental to activity  
Figure 12.2: SAR diagram of the original amide and amine linked target compounds. 
 
The first potent compounds of the project were synthesised in the amine linked series.  
The most potent compound was 101 (Figure 12.3).  This compound has an IC50 of 700 
nM and has been subjected to selectivity testing for 17β-HSD Types 1 and 2.  No 
significant activity was observed in either assay, thus showing 101 to be an active, 
selective 17β-HSD Type 3 inhibitor. 
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Figure 12.3: Compound 101, the most potent compound in the amine or amide linked 
series. 
 
There is much biological information about these series of compounds still to be 
obtained.  Figure 12.4 shows some of the SAR information that should be established 
once full biological results have been obtained.  This includes the effects upon activity 
when the compounds are extended with a further piperidine ring.  The docking studies 
of these compounds have indicated that they should show enhanced activity over the 
shorter, original targets. 
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Figure 12.4: Areas of the original amide and amine linked target compounds where 
biological activity information is still to be established from the compounds awaiting 
biological testing. 
 
12.3 Benzylamine Linked Series 
 
Throughout the course of the project a 17β-HSD Type 3 homology model was used to 
aid structure based drug design.  The docking studies using compounds from the amide 
and amine linked series showed an area of space around the central piperidine region.  
Attempts to utilise this space have been successful, including compound 123 (Figure 
12.5) and the benzylamine linked series of compounds (Chapter 8).  The initial target, 
compound 126 was synthesised and showed excellent inhibitory activity, with an IC50 of 
900 nM. 
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Figure 12.5: Compound 123 (IC50 = 300 nM) and 126 (IC50 = 900 nM). 
 
Extensive modifications of this template were then undertaken.  However, in this series, 
only limited biological data has been obtained.  From the data obtained some SAR 
conclusions can be drawn, these are shown in Figure 12.6. 
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Figure 12.6: SAR diagram of the benzylamine linked targets. 
 
The best compounds tested so far are the original target 126 (IC50 = 0.9 µM) and 
compounds 142 (IC50 = 1.9 µM) and 167 (IC50 = 1.1 µM).  The structures are shown in 
Figure 12.7.  Compound 126 has been tested for selectivity against 17β-HSD Types 1 
and 2.  No significant activity was observed, thus showing 126 to be a potent, selective 
17β-HSD Type 3 inhibitor. 
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Figure 12.7: The most active inhibitors in the benzylamine series. 
 
There are many compounds synthesised in this series (>30), most of which have yet to 
undergo biological testing.  Once obtained, this information will help to establish a 
robust SAR for this series.  Figure 12.8 shows some of the SAR information that should 
be established once full biological results have been obtained. 
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Figure 12.8: Areas of the benzylamine based target compounds where biological 
activity information is still to be established from the compounds awaiting biological 
evaluation. 
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An important area of investigation in this series was the effects of chirality on the 
biological activity, as the introduction of substitutions onto the CH2 of compound 126 
leads to the formation of a chiral centre.  The potential importance of this was 
investigated using racemic compound 172 as an example.  The two enantiomers (184 
and 185) were separated by chiral HPLC and X-ray crystallography was used to 
determine the absolute configuration.  The optical rotations were also measured and 
found to be directly opposing for the two enantiomers.  This confirmed enantiomer A 
(184) to be the R-(-)- enantiomer and compound 185 to be the S-(+)- enantiomer 
(Figure 12.9). 
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Enantiomer A  Enantiomer B  
R-(-)- S-(+)- 
184 185 
[α]D= -155.7 (in DCM at 20 °C) [α]D= +158.0 (in DCM at 20 °C) 
 
Figure 12.9: Enantiomers from racemic compound 172. 
 
The two separate enantiomers and the racemic mixture are now awaiting biological 
evaluation.  It is hoped that the results received will establish whether inhibitory 
activity is affected by the chirality of the compound within this series and therefore will 
give vital information regarding the size and shape of the enzyme active site.   
 
Within this benzylamine linked series, many alternations to the original template are 
possible and many compounds have been synthesised to investigate how these 
modifications affect the inhibitory activity of the compounds.  However, none of the 
modifications has shown an improvement in potency when compared to the original 
target, 126.  It is hoped that some of the compounds awaiting evaluation will exhibit an 
improvement in potency.  Once all the information has been obtained it is also possible 
that there may be additive effects and the combination of successful modifications 
would be a possible way to see an enhancement in potency. 
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12.4 Microwave Assisted Synthesis and Novel Methodology  
 
Throughout the course of this project there has been an emphasis upon investigating 
novel methodology and technology as the need arose.  During the synthesis of the 
original amide and amine linked compounds (Chapters 6 and 7) it was found that the 
synthesis of the aromatic amine bond was highly problematic.  This was most likely due 
to the low reactivity of the anilines being used.  The introduction of MW assisted 
synthesis greatly increased the yields and reliability of the reaction, whilst ensuring fast 
reaction times.  This methodology proved itself to be a highly valuable asset, and it can 
be applied to reactions with a wide range of ketones, aldehydes and anilines.85  This 
reaction has proved to be highly useful and was used extensively within the project.  
When a reaction between an aniline and an aldehyde was desired, it was found that the 
reaction proceeded effectively at room temperature, the use of MW technology was no 
longer required.  This methodology, either using the MW or at room temperature led to 
the synthesis of all the amine linked compounds and the majority of the benzylamine 
linked compounds. 
 
This project also led to the development of an operationally simple, efficient, fast and 
reproducible modification of the Friedländer synthesis of quinolines.  The new MW 
methodology allows the reaction between 2-aminophenylketones and cyclic ketones to 
proceed to form the desired quinoline scaffold in just 5 minutes in almost quantitative 
yields.  This has great advantages over the high temperatures or strong acids required in 
previously reported methods (for more details see Chapter 10). 
 
12.5 Conclusions  
 
This project set out to explore the inhibitory potential of compounds against 17β-HSD 
Type 3, with the aim to develop clinically significant treatments for androgen dependent 
prostate cancer.  Although this aim is likely to be many years away, this project has 
identified some potentially significant series of compounds, which will require further 
optimisation.  Full biological activity data is still awaited for many of the compounds 
synthesised but, once obtained, a much clearer picture of the hoped for success of these 
series will be attained.  This will help to construct an SAR, which could then be 
developed into an effective QSAR to aid in-silico predictions of compound activity.  
This will all help to bring the project closer to the ultimate aim of a safe, effective, 
clinically successful treatment for prostate cancer and other androgen dependent 
diseases and disorders. 
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Chapter 13 
 
Biological Experimental Details: Thin Layer Chromatography (TLC) Assay. 
 
17β-Hydroxysteroid Dehydrogenase Type 3 Activity in the Presence or Absence of 
Regulatory Agents. 
 
(Based upon STERIX S.O.P. No. : 20041007v1.0) 
 
1.0 Purpose 
 
To determine in vitro 17β-hydroxysteroid dehydrogenase Type 3 activity in the stable 
17β -HSD3-transfected 293-EBNA cell line, 293-EBNA[17β-HSD3], in the presence or 
absence of inhibitor compounds. 
 
2.0 Assay Procedure for 17β-Hydroxysteroid Dehydrogenase 3. 
 
2.1 Plating of cells 
Plate cells at 50,000 / well in 24 well plates in complete growth medium (10 % FBS) 
without G418 or Hygromycin B 48 hours before assay.  Leave 3 wells empty. 
 
2.2 Assay medium 
When ready to assay, prepare the assay medium:  To 500 mL MEME medium add 5 mL 
100 x Pen/Strep, 5mL 100 x L-Glutamine, 5 mL 100 x NEAA and 5 mL 7.5 % sodium 
bicarbonate solution. 
 
2.3 Substrate medium 
Prepare 50 mL 2-3 nM 3H-Androstenedione substrate medium per 24 well plate to be 
assayed.  Evaporate the volume of 3H-A required to achieve a final concentration of 2-3 
nM to near dryness in a glass test tube before adding to 50 mL assay medium.  Vortex 
to ensure substrate solution is well mixed. 
 
2.4 Inhibitor dilution 
Prepare inhibitors at required dilutions each in 6mL substrate solution in 30 mL sterilin 
tubes.  Aliquot 12 mL to use for triplicate Blank and Control wells. 
 
2.5 Cell treatment 
Add 1.5 mL substrate medium +/- inhibitor (I) per well to triplicate wells, ensuring all 
controls are present as follows: 
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Wells 1-3: No cells: Blank: 1.5 mL substrate medium / well. 
Wells 3-6: Cells: Control: 1.5 mL substrate medium / well. 
Wells 7-21: Cells: Assay:  1.5 mL substrate medium +/- I / well. 
Wells 21-24: Cells: Count  1.5 mL complete growth medium / well. 
 
2.6 Incubation 
Return to cell culture incubator for 2 hours. 
 
2.7 Extraction 
After 2 hours take 1 mL medium from each well (except wells 21-24) and place in 125 
x16 mm glass test tubes containing 25 µl of recovery solution (containing approx. 5000 
cpm 14C-T and 25 µg unlabelled T).  Mix and add 4 mL of diethylether before vortexing 
on the multi-tube vortexer for 2 x 30 sec, starting on speed setting 4 and gradually 
increasing to 8.  Allow the samples to settle into two phases then freeze the aqueous 
phase of the sample mixture by placing the tubes in a mixture of dry ice and methanol.  
When the aqueous phase is frozen (~ 3 min), the upper organic phase should be 
decanted into labeled 75 x 12 mm tubes and evaporated to dryness under an airstream 
using the sample concentrator set at 40 oC. 
 
2.8 Preparation of TLC plate 
While the ether is evaporating, the TLC plate is prepared as in Figure 1. 
 
Solvent front
Relative front for 
Androstenedione
Rf = 0.716
Sample 
spots Origin
Relative front for 
Testosterone
Rf = 0.476
Direction of 
movement
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Figure 1. Diagram illustrating the thin layer chromatography plate. 
• Origin = 2 cm from the bottom of the plate (marked by pencil). 
• Side edge = 1 cm (marked by scoring). 
• Each lane = 1.5 cm wide (marked by scoring). 
• The lane edges are scored to prevent crossing over of samples between lanes (a mask 
should be worn to prevent inhalation of silica dust). 
 
2.9 Loading the TLC plate 
Remove the evaporated samples from the concentrator after approximately 30 minutes. 
Add 8 drops of ether to Tube 1 to dissolve the residue, vortex for 20 s, and add the 
sample drop-wise to the center of the origin in Lane 1 allowing the spot to dry between 
each drop.  Add another 3 drops of ether to Tube 1, vortex for 10 s, and add drop-wise 
to the spot on Lane 1 of the TLC plate.  Repeat the spotting process with each sample 
on a new lane. 
 
2.10 TLC 
When all samples have been loaded onto the plate, leave it to dry completely and 
prepare the mobile (solvent) phase for the TLC.  The mobile phase consists of 4:1 v/v 
DCM: EtOAc.  Therefore mix 80 mL DCM and 20 mL EtOAc gently in a measuring 
cylinder and pour into a clean TLC tank.  Replace and weigh down the lid of the tank. 
When the solvent has saturated the tank (around 30 minutes) the TLC plate (or plates) 
should be carefully placed into the tank so that the base of the plate (but not the origin) 
is immersed in the solvent.  The tank should then be closed and weighted, and the plate 
left in the tank for about 90 minutes to enable the mobile phase (solvent front) to move 
to within one or two cm from the top of the plate.  Remove the plate and leave to dry 
flat for approximately 5 minutes before observing the plate under a UV lamp, and 
locating and marking the major spots (denoting testosterone) in pencil (at high 
concentrations inhibitor spots may also become visible by UV). 
 
2.11 Elution and radioactivity determination 
The spots circled on the TLC plate should be cut out as a square with a gap around the 
spot to allow for any of the silica that might fall away.  These should then be placed in 
individual scintillation vials containing 0.5 mL methanol.  These are then shaken lightly 
and left for 15 min to elute the radioactivity.  The vials are then shaken again before 
adding 10 mL of EcoScint A (scintillation fluid) to each tube along with 0.5 mL assay 
medium. 
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Before the counting the samples, prepare three “total 3H” vials, each containing 0.5 mL 
Substrate medium, 0.5 mL methanol, and 10 mL of EcoScint A; and three “total 14C” 
vials, containing 25 µl of recovery solution, 0.5 mL Assay medium, 0.5 mL methanol 
and 10 mL EcoScint A.  The “total radioactivity” vials are needed to determine the 
original level of 3H-A and 14C-T added at the start of the assay in order to make the final 
activity calculations. 
 
The vials are lidded, labelled, and shaken, and then checked to ensure that all the TLC 
pieces are lying horizontally on the bottom of the vial so as not to affect the count.  The 
samples are placed in a rack in the scintillation spectrometer and counted using the 
program for dual [3H/14C] isotopes. 
 
2.12 Cell count 
The medium should be removed from the remaining 3 wells (wells 22-24) and the no. of 
cells / well counted. 
 
3.0 Calculation 
To determine the enzyme activity and percentage inhibition. 
 
3.1 Corrections to the raw data. 
Overall there are 4 corrections that need to be applied to the raw data: 
3.1.1. Crossover correction: to correct for the percentage crossover of 14C into 
the 3H channel (usually 12-14 %). 
3.1.2 Recovery correction: to correct for the proportion of product recovered 
from the assay (i.e. to account for procedural losses). 
3.1.3 Blank correction: to correct for any non-enzymatic degradation of 
substrate to product. 
3.1.4. Dilution correction: to correct for any dilution that was made prior to 
eluting the activity. 
 
3.2 Data input and calculation. 
First, put the raw data into a spreadsheet program (e.g. MS Excel): 
• Enter the 3H count data in column A, and the 14C count data in column B. 
• 12% of B (14C) should be calculated in column C (cross-over). 
• Column D = A - C (this corrects the 12 % cross-over factor). 
• Column E = B ÷ mean “total 14C” (the proportional recovery). 
• Column F = D ÷ E (this corrects the recovery). 
• Column G = F – mean Blank (from column F). 
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• Activity (fmol/2hr/well) = Column H = G x Constant (see below): 
• Constant = (1.5 mL/ 1.0 mL) ÷ (1.5 mL/ 0.5mL x total 3H cpm) x 
fmol 
3
H-A per well. 
• ≈ (1.5 ÷ total 3H-A cpm in 1.5 mL (e.g.~ 150,000)) x ~ 3000 ≈ 0.03 fmol. 
• It accounts for the different volumes used in the sample and the “total 
3H” vial counts, and the specific activity of the 3H-A. 
• Activity (fmol/2hr/million cells) = Column I = H ÷ (mean no. cells per well 
(millions). 
• Activity (% of control) = Column J = 100 x (Sample I ÷ mean Control I). 
• Column K = sample name 
• Column L = mean activity of triplicate 
• Column M = (100 – L) = mean % inhibition of triplicate 
• Column N = standard deviation of triplicate (%) 
 
4.0 Other notes 
The substrate and inhibitors are not stable at RT or 37oC (they must be kept on ice until 
required).  3H-Androstenedione and 14C-testosterone are checked for purity every 6 
months, and purified when necessary using the TLC system described. 
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Chapter 14 
 
Biological Experimental Details: DELFIA® Assay. 
 
17β-Hydroxysteroid Dehydrogenase Type 3 Activity in the Presence or Absence of 
Regulatory Agents. 
 
1. Maintenance of 293-EBNA cells 
293-EBNA [17β-HSD3] cells are maintained in Biocoat (poly-D-lysine coated) T75 
flasks (Becton Dickinson 356537) in 20 mL of Dulbecco’s Modified Eagles Medium 
(DMEM, Sigma D6171) supplemented with 10 % foetal bovine serum (FBS), 1 mM L-
glutamine and 250 µg/mL G418 and 250 µg/mL Hygromycin B in a humidified 5 % 
CO2 incubator at 37 
oC. 
 
Cells are passaged, twice a week (Tuesdays and Fridays), 1 in 10 split.  Assays can be 
performed three times each week; cells are plated on Friday (for assay Monday), 
Monday (for assay Thursday) and Tuesday (for assay Friday). 
 
2. 17βHSD3 Assay Methods 
2.1 Plating of cells 
Cells are plated at a density of 15,000 cells per well in 200µl of DMEM supplemented 
with 10 % FCS and 1mM L-Glutamine in Biocoat (poly-D-lysine coated) 96 well tissue 
culture plates (Becton Dickinson 356461), 72 hours before use in assays (i.e. Mondays, 
Tuesdays and Fridays).   
 
Outer wells are filled with 200 µl of media and only the inner 60 wells are plated with 
cells, as there is significant evaporation over the 72 hours prior to the assay.  This 
causes assay drift.  Alternatively, it may be possible to seed the cells at a higher density 
and used 24 hours after plating to reduce the evaporation effect. 
 
2.2 Assay Medium 
Assay medium is prepared immediately prior to the assay: (DMEM supplemented with 
1x pen/strep (Invitrogen 15070-063), 1x L-glutamine (Invitrogen 25030-024), 1x 
NEAA (Invitrogen 11140-035) and 0.075 % sodium bicarbonate (Sigma S-8761). 
 
2.3 Compound Dilution 
Prepare 10 mM stock solutions of the compounds in 100% DMSO.  Dilute stock 
solutions to 100 times the required concentration in DMSO, add 5 µl of the DMSO 
stock solution to 245 µl of assay medium.  
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2.4 Androstenedione Dilution 
Prepare a 100nM androstenedione solution in 0.001 % DMSO: assay medium from the 
10 mM androstenedione stock in DMSO. Add 25 µl of the substrate to 25 µl of pre-
incubated compounds. 
 
2.5 Compound and substrate addition 
Remove 200 µl of growth medium 
Add 25 µl of compound in assay medium 
Incubate for 30 minutes in the humidified CO2 incubator 
Add 25 µl of 100 nM androstenedione 
Incubate for 120 minutes in the humidified CO2 incubator 
Collect cell supernatant (this can be stored at 4oC until ready for testing if necessary) 
 
3. 17β-HSD3 DELFIA Assay Method 
Refer to DELFIA instruction manual 
 
3.1 The protocol is summarised below. 
Pre-warm the required number of microtitration strips, DELFIA assay and wash buffer, 
Testosterone-Eu tracer, Testosterone antiserum, Testosterone standards and 
Enhancement solution. 
Wash the microtitration strips with 1x 300 µl DELFIA wash buffer, 
Add 25 µl of testosterone standards or 25 µl of cell supernatant, 
Add 100 µl of 1 in 10 dilution of Testosterone-Eu tracer in DELFIA assay buffer, 
Add 100 µl of 1 in 10 dilution of Testosterone antiserum in DELFIA assay buffer, 
Seal plate and incubate at room temperature for 2 hours, shaking slowly, 
Remove well contents and wash with 4x 300 µl DELFIA wash buffer, 
Add 200 µl of Enhancement solution, 
Seal plate and incubate at room temperature for 5minutes, shaking slowly, 
Read on Victor V using Europium protocol, 
Note:-It may be necessary to dilute the cell supernatant with media buffer prior to 
testing, to ensure that the levels of testosterone falls within the linear region of the 
Testosterone standard curve. 
Testosterone standards are reconstituted in 1 mL media buffer rather than 1 mL distilled 
water. 
 
3.2 Cell number estimation 
Following the removal of cell supernatant, after compound / substrate addition, replace 
with 100 µl of assay buffer 
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Add 20 µl of 1 in 20 dilution of PMS (phenazine methosulphate) solution, incubate for 
60 minutes in the humidified CO2 incubator.  Read absorbance at 492 nm on a 
spectrophotometer (MultiSkan MCC/340) 
 
3.3 Calculation of results 
All measurements were performed in duplicate, testosterone concentrations produced by 
the cells are determined from testosterone standard curves which are plotted using a 
Spline/Lowess equation in Graphpad PRISM®. 
 
The level of testosterone is corrected for cell number, using the absorbance values.  
Levels of testosterone in the presence of antagonist were expressed as percent inhibition 
of the total testosterone produced. 
 
To determine enzyme activity and percentage inhibition: 
First, put the raw data into a spreadsheet program (MS Excel), 
Calculate the B/Bmax for each testosterone concentration for the standard curve, 
(B/Bmax = RFU value of sample/RFU value of standard A (0 nM testosterone), 
Calculate the B/Bmax for all the unknown samples, 
 
In Graphpad Prism: 
Plot the B/Bmax for the standards on the y-axis against the concentration of the 
standards against the x-axis, 
Type in the B/Bmax of the unknown samples in the y-axis column, the data was 
analysed with a cubic spline curve fit and the x-value (testosterone level) of the 
unknown samples was calculated from the B/Bmax. 
 
Copy the testosterone levels back into the spreadsheet program and, if samples have 
been diluted, the concentration determined from the standard curve must be multiplied 
by the dilution factor.  Divide the corrected testosterone levels by the corresponding 
absorbance values at 492nm for the MTS assay to correct for cell number, calculate the 
percentage inhibition according to the formula: 
 
100-((TestosteroneSample-TestosteroneBlank/TestosteroneControl-TestosteroneBlank) x 100) 
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Chapter 15 
 
Experimental Details: Chemistry 
 
All chemicals were purchased from Aldrich Chemical Co. (Gillingham, UK) or 
Lancaster Synthesis (Morecambe, U.K.).  All organic solvents were supplied by Fisher 
Scientific (Loughborough, U.K.). Reactions using anhydrous solvents were carried out 
under nitrogen. 
 
Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC 
aluminium sheets silica gel 60 F254).  Product(s) and starting material(s) were detected 
by either viewing under UV light and/or treating with a suitable staining system, for 
example vanillin, followed by heating.  Flash column chromatography was performed 
on silica gel (Sorbsil/Matrex C60) or using Argonaut prepacked columns with a 
FlashmasterTM.  IR spectra were recorded on a Perkin-Elmer Spectrum RXI FT-IR in 
DCM solution cells and peak positions are expressed in cm-1.  1H NMR (270 MHz or 
400 MHz) and DEPT-edited 13C NMR (68 MHz or 101 MHz) spectra were recorded 
with a Jeol Delta 270 or a Varian Mercury VX 400 NMR spectrometer and chemical 
shifts are reported in parts per million (ppm).  HPLC analyses were performed on a 
Waters Millenium 32 instrument equipped with a Waters 996 PDA detector.  A Waters 
Radialpack C18 reversed phase column (8×100 mm) was eluted with the solvent system 
specified at 1 mL/min.  FAB low and high resolution mass spectra were recorded at the 
Mass Spectrometry Service Centre, University of Bath, using m-nitrobenzyl alcohol 
(NBA) as the matrix.  ES and APCI low resolution mass spectra were obtained on a 
Waters Micromass ZQ.  Elemental analyses were performed by the Microanalysis 
Service, University of Bath.  Melting points were determined using a Reichert-Jung 
Thermo Galen Kofler block and are uncorrected. 
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Experimental Details: Chapter 2: Synthesis of Compound 26 as Positive Control 
 
6, 11-Dihydro-12H-dibenzo[b,f]1,4]thiazocine, 38, C14H13NS, MW 227.32, 
S
NH
 
The above compound was synthesised by a modification of the method described by 
Yale et al.54  To a solution of α,α’-dibromo-o-xylene (250 mg, 0.95 mmol) in DMF (5 
mL) at 100 °C was added 2-aminothiophenol (0.1 mL, 0.95 mmol) in DMF (5 mL) and 
the resulting solution stirred at 100 °C for 10 min.  The DMF was removed in-vacuo, 
then NaHCO3 (20 mL) and DCM (2 x 20 mL) were added and the product extracted, 
evaporated to dryness and isolated as a yellow oil, 435 mg (>>100 %).  This was used 
crude in following steps.  R.f. 0.45 (Hexane: DCM, 1:1), LCMS: tr = 2.46 min (80 % 
MeOH in water), m/z M+H 227.9, HPLC: tr = 2.3 min (90 % acetonitrile in water), ~60 
%, 1H NMR (CDCl3, 270 MHz,): δ 3.92 (1H, br.s, NH), 4.40 (2H, s, CH2), 4.85 (2H, s, 
CH2), 6.75-6.88 (2H, m, ArH), 7.10-7.45 (6H, m, ArH).  
13C NMR (CDCl3, 68 MHz): 
36.6, 49.5 (CH2), 120.3, 120.5 (ArCH), 124.3 (ArC), 127.5, 127.6, 128.1, 129.0, 129.7, 
133.4 (ArCH), 137.1, 139.6, 148.0 (ArC). 
 
12-Acetyl-6,11-dihydro-12H-dibenzo[b,f][1,4]thiazocine, 26, C16H15NOS, MW 
269.36, 
N
S
O
 
The above compound was synthesised by considerable modification of the procedure 
described by Yale et al.54  6,11-Dihydro-12H-dibenzo[b,f]1,4]thiazocine (215 mg, 0.95 
mmol) in DCM (5 mL) was cooled to 0 °C and to this was added acetyl chloride (0.3 
mL, 2 mmol) and TEA (0.15 mL, 2 mmol).  The resulting solution was stirred at r.t. for 
1 h.  Saturated NaHCO3 solution (20 mL) was added and this was extracted with DCM 
(2 x 20mL) and dried (MgSO4).  The crude product was purified by flash 
chromatography (0-100 % DCM in hexane), 185 mg, 73% yield (over 2 steps).  R.f. 
0.35 (DCM:Hexane), m.p. 123-125 °C, (lit. 124-126 °C),54 LCMS: tr = 1.01min (95 % 
MeOH in water), m/z M+H 270.02, HPLC: tr = 1.83 min (90 % acetonitrile in water), 96 
%, 1H NMR (CDCl3, 270 MHz,): δ 1.87 (3H, s, CH3), 3.67 (1H, d, J=12.4, ½CH2), 4.02 
(1H, d, J = 15.1 Hz, ½CH2), 4.45 (1H, d, J = 12.4 Hz, ½CH2), 6.66 (1H, d, J = 15.1 Hz, 
½CH2), 6.90-7.25 (8H, m, ArH).  
13C NMR (CDCl3, 68 MHz): 22.9 (CH3), 34.7, 51.1 
(CH2), 127.6, 128.2, 128.7, 128.8, 129.4, 130.2, 132.4 (ArCH), 134.7, 135.1, 135.7, 
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140.9 (ArC), 170.6 (CO).  HRMS: Calcd for C16H15NOS (M+H)
+ 292.075 (+Na), found 
(M+H)+ 292.0767 (+Na). 
 
Experimental Details: Chapter 6: Synthesis and Biological Evaluation of the 
Amide Linked Series of Inhibitors 
 
General Procedure for the 2-Nitro-diphenylether Formation 
O
NO2
X
 
This procedure is modified from that described by Matsuo et al.65  A mixture of 2-
fluoro-1-nitrobenzene (1 eq.), substituted phenol (1.5 eq.) and potassium carbonate (1.5 
eq.) in DMF (5 mmol/mL) was stirred at reflux for 3 to 19 h.  The solvent was removed 
in vacuo and the residue was dissolved in diethylether and washed with sodium 
hydroxide (5 %).  The organic layers were combined, dried (MgSO4), filtered and 
evaporated in vacuo to afford the desired 2-nitro-diphenylether.  Flash column 
chromatography was carried out if required. 
 
General Procedure for the Reduction of the Nitro Group 
O
NH2
X
 
This procedure is modified from that described by Matsuo et al.65  To a mixture of iron 
(5.5 eq.) and ammonium chloride (0.7 eq.) in a 10:1 mixture of EtOH: H2O, the 2-nitro-
diphenylether (1 eq.) was added.  This reaction mixture was stirred at reflux for 30 min-
4 h.  The reaction was monitored by TLC, until complete consumption of the starting 
material was observed.  It was allowed to cool and the solvent removed in vacuo.  The 
residue was re-dissolved in DCM and washed with sat. NaHCO3.  The organic layers 
were combined, dried (MgSO4), filtered and evaporated in vacuo to afford the desired 
diphenylether aniline.  Flash column chromatography was carried out if required. 
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Synthesis of Diphenylether Anilines 
 
1-(2, 4-Dichlorophenoxy)-2-nitrobenzene, 40a, C12H7Cl2NO3, MW 284.09, 
Cl
Cl
O
NO2  
Using the general procedure for the 2-nitro-diphenylether formation the desired 
compound was obtained as a light yellow solid, 3.4 g, 97 % yield.  R.f: 0.73 (DCM), 
m.p. 54-55 °C. HPLC tr = 2.39 min (90% acetonitrile in H2O) 99 %, LCMS m/z M-H 
283.06, 285.07,  1H NMR (CDCl3, 270 MHz): δ 6.85 (1H, dd, J = 8.4, 1.2 Hz, ArH), 
6.97 (1H, d, J = 8.9 Hz, ArH), 7.23 (2H, m, ArH), 7.48 (1H, d, J = 2.5 Hz, ArH), 7.51 
(1H, m, ArH) and 7.98 (1H, dd, J = 8.2, 1.7 Hz, ArH). 
 
2-(2, 4-Dichlorophenoxy)phenylamine, 41a, C12H9Cl2NO, MW 254.11, 
Cl
Cl
O
NH2  
Using the general procedure for the reduction of the nitro group the desired product was 
obtained as an oil, 2.01 g, 90 % yield.  R.f: 0.56 (DCM), HPLC tr = 2.51 min (90% 
acetonitrile in H2O) 93 %, LCMS m/z M+H 254.27, 256.29, 
1H NMR (CDCl3, 400 
MHz) δ 3.85 (2H, br s, NH2), 6.75 (1H, m, ArH), 6.84 (1H, d, J = 8.8 Hz, ArH), 6.84 
(1H, dd, ArH), 6.87 (1H, dd, J = 7.6, 1.6 Hz, ArH), 7.04 (1H, m, ArH), 7.17 (1H, dd, J 
= 8.8, 2.4 Hz, ArH) and 7.49 (1H, d, J = 2.4 Hz, ArH). 
 
1,3-Dichloro-5-(2-nitro-phenoxy)benzene, 40b, C12H7Cl2NO3, MW 284.10, 
Cl
Cl O
NO2 
Using the general procedure for the 2-nitro-diphenylether formation the desired product 
was obtained as a light yellow solid, 0.57 g, 33 % yield.  m.p. 78-80 °C, (lit. 77-79 °C)65 
1H NMR (270 MHz, CDCl3)δ 6.88 (2H, d, J = 1.7 Hz, ArH, ArH), 7.12 (1H, t, J = 1.7 
Hz, ArH), 7.12 (1H, dd, J = 1.2, 8.2 Hz, ArH), 7.32 (1H, td, J = 7.4, 1.2 Hz, ArH), 7.6 
(1H, td, J = 7.4, 1.7 Hz, ArH), 8.00 (1H, dd, J = 8.2, 1.7 Hz, ArH). 
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2-(3,5-Dichloro-phenoxy)phenylamine, 41b, C12H9Cl2NO, MW 254.11, 
O
Cl
Cl
NH2 
Using the general procedure for the reduction of the nitro group the desired compound 
was obtained as a brown oil, 1.45 g, 89 % yield.  R.f 0.6 (DCM); LCMS: tr = 3.01 min 
(90 % MeOH in water), m/z M+H 254.1, 256.2, 1H NMR (CDCl3, 270 MHz): δ 3.67 
(2H, s, NH2), 6.68 (1H, td, J = 7.4, 1.5 Hz, ArH), 6.77 (1H, dd, J = 7.9, 1.5 Hz, ArH), 
6.77 (2H, d, J = 2.0 Hz, ArH, ArH), 6.84 (1H, dd, J = 7.9, 1.5 Hz, ArH), 6.97 (1H, t, J = 
2.0 Hz, ArH), 6.98 (1H, td, J = 7.4, 1.5 Hz, ArH).  HRMS: Calcd for C12H9Cl2NO 
(M+H)+ 254.0134, found (M+H)+ 254.0124.  Compound has been previously 
synthesised using a the same method by Matsuo et al.65 
 
2-(4-Chloro-phenoxy)nitrobenzene, 40c, C12H8ClNO3, MW 249.65.
135  (Alternative 
MW Method), 
Cl
O
NO2  
4-Chlorophenol (2.9 g, 22.5 mmol) and 2-fluoronitrobenzene (1.6 mL, 15 mmol) was 
dissolved in toluene (30 mL) and then placed into 10 separate MW tubes (3 mL 
solution/tube).  To each tube was then added K2CO3 (373 mg, 2.7 mmol).  Each tube 
was then subjected to MW heating at 180 °C for 30 min.  All tubes were combined, the 
solvent was removed in vacuo and the residue was dissolved in diethylether (100 mL) 
and washed with sodium hydroxide (5 %, 50 mL).  The organic layers were combined, 
dried (MgSO4), filtered, and evaporated in vacuo to afford the desired product as a wax.  
Purification was not carried out so the product was used crude in the next step.  A small 
sample was purified to allow for characterisation.  HPLC tr = 5.4 min (90 % acetonitrile 
in H2O) 95 %, LCMS m/z M-H 248.11, 
1H NMR (CDCl3, 270 MHz,): δ 6.92-6.97 (2H, 
m, ArH), 7.00 (1H, dd, J = 1.2, 8.4 Hz, ArH), 7.19-7.25 (1H, m, ArH), 7.28-7.33 (2H, 
m, ArH), 7.48-7.55 (1H, m, ArH), 7.93 (1H, dd, J = 1.5, 8.2 Hz, ArH). 
 
2-(4-Chloro-phenoxy)phenylamine, 41c, C12H10ClNO, MW 219.67, 
Cl
O
NH2  
Using the general procedure for the reduction of the nitro group and subsequent 
purification (0-50 % DCM in hexane) the desired product was obtained as a light yellow 
oil, 2.7 g (82 % yield over 2 steps).  R.f. 0.55 (EtOAc), LCMS: tr = 4.87 min (90 % 
 214 
MeOH in water), m/z M+H 219.9, HPLC: tr = 2.12 min (90 % acetonitrile in water), 94 
%, 1H NMR (CDCl3, 270 MHz,): δ 3.78 (2H, br.s, NH), 6.67-6.76 (1H, m, ArH), 6.81-
6.92 (4H, m, ArH), 6.97-7.03 (1H, m, ArH), 7.22-7.27 (2H, m, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 116.8, 118.4, 119.1, 120.4, 125.4 (ArCH), 127.7 (ArC), 129.7 
(ArCH), 138.71, 142.8, 156.2 (ArC).  HRMS: Calcd for C12H10ClNO (M+H)
+ 
220.0524, found (M+H)+ 220.0531, 222.0487. 
 
4-Trifluoromethyl-5-(2-nitro-phenoxy)benzene, 40d, C13H8F3NO3, MW 283.21, 
O
NO2
F3C
 
 
Using the general procedure for the 2-nitro-diphenylether formation the desired 
compound was obtained as a brown oil, 1.24 g, 68 % yield.  R.f. 0.6 (1:1, DCM: Petrol), 
1H NMR (CDCl3, 400 MHz)δ 7.11 (2H, d, J = 8.4 Hz, ArH), 7.17 (1H, dd, J = 8.4, 0.8 
Hz, ArH), 7.36 (1H, td, J = 7.2, 1.2 Hz, ArH), 7.62-7.67 (1H, m, ArH), 7.65 (2H, d, J= 
9.6 Hz, ArH), 8.04 (1H, dd, J = 1.6, 8.0 Hz, ArH).  HRMS: Calcd for C13H8F3NO3 
(M+H)+ 284.0529, found (M+H)+ 284.0524. 
 
2-(4-Trifluoromethyl-phenoxy)phenylamine, 41d, C13H10F3NO, MW 253.23,  
O
NH2
F3C
 
 
Using the general procedure for the reduction of the nitro group the desired compound 
was obtained as a light yellow oil, 0.97 g, 82 % yield.  R.f 0.45 (DCM: hexane, 1:1); 
LCMS: tr = 2.11 min (90 % MeOH in water), m/z M+H 254.2, 
1H NMR (CDCl3, 400 
MHz): δ 3.84 (2H, s, NH2), 6.84 (1H, td, J = 7.2, 1.2 Hz, ArH), 6.91 (1H, dd, J = 1.6, 
8.0 Hz, ArH), 7.01 (1H, dd, J = 0.8, 7.6 Hz, ArH), 7.10 (2H, d, J = 9.2 Hz, ArH), 7.13 
(1H, td, J = 4.0, 7.2 Hz, ArH), 7.63 (2H, d, J = 8.4 Hz, ArH).  HRMS: Calcd for 
C13H10F3NO (M+H)
+ 254.0787, found (M+H)+ 254.0776.  This compound has been 
previously synthesised using a different methods by Golinske et al.136 
 
1-Trifluoromethoxy-4-(2-nitro-phenoxy)benzene, 40e, C13H8F3NO4, MW 299.21, 
O
F3CO
NO2 
Using the general procedure for the 2-nitro-diphenylether formation the desired 
compound was obtained as a yellow oil, 2.34 g, >100 % yield.  R.f: 0.72 (DCM), 1H 
NMR (CDCl3, 270 MHz): δ 7.01-7.06 (3H, m, ArH), 7.20 (2H, dd, J = 0.9, 10.1 Hz, 
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ArH), 7.21-7.27 (1H, m, ArH), 7.51-7.54 (1H, m, ArH), 7.97 (1H, dd, J = 1.5, 8.2 Hz, 
ArH).  This compound was previously synthesised using a different method, by 
McEvoy et al.137 
 
2-(4-Trifluoromethoxy-phenoxy)phenylamine, 41e, C13H10F3NO2, MW 269.22,
137 
O
F3CO
NH2 
Using the general procedure for the reduction of the nitro group the desired compound 
was obtained as a brown oil, 1.57 g, 95 % yield.  R.f: 0.6 (DCM), 1H NMR (CDCl3, 270 
MHz): δ 3.81 (2H, s, NH2), 6.76 (1H, td, J = 1.5, 8.2 Hz, ArH), 6.84 (1H, dd, J = 1.2, 
7.9 Hz, ArH), 6.91 (1H, dd, J = 1.0, 7.9 Hz, ArH), 6.98 (2H, d, J = 9.1 Hz, ArH), 7.01-
7.07 (1H, m, ArH), 7.18 (2H, d, J = 8.7 Hz, ArH).  This compound was previously 
synthesised using a different method, byMcEvoy et al.137 
 
N-Boc-piperidine-4-carboxylic acid, 42, C11H19NO4, MW 229.28, 
N
O OH
O O  
To a solution of isonipecotic acid (2.0 g, 16 mmol) in 1,4-dioxane (50 mL) and water 
(50 mL) was added di-t-butyl dicarbonate (3.4 g, 16 mmol) and sodium hydroxide (6.2 
g, 155 mmol).  The reaction mixture was stirred at room temperature for 21 h.  The 
solvent was removed in vacuo and the residue was re-dissolved in EtOAc and acidified 
to pH 3-4 using hydrochloric acid (1M).  The mixture was then extracted with further 
EtOAc (100 mL) and washed with water (50 mL).  The organic layers were dried 
(MgSO4), filtered and evaporated in vacuo to afford the title compound as a white solid, 
2.2 g, 61 % yield.  m.p. 151-153 °C, (Lit. 148-153 °C),138 R.f: 0.72 (10 % MeOH in 
DCM), LCMS: tr = 2.13 min (90 % MeOH in water), m/z M+Na 252.2, 
1H NMR (270 
MHz, CDCl3): δ 1.4 (9H, s, CH3), 1.55-1.69 (2H, m, CH2), 1.89 (2H, dd, J = 3.0, 13.4 
Hz, CH2), 2.42-2.53 (1H, m, CH), 2.83 (2H, t, J = 11.1 Hz, N-CH2), 4.03 (2H, d, J = 
12.0 Hz, N-CH2).  HRMS: Calcd for C11H19NO4 (M+Na)
+ 252.1206, found (M+Na)+ 
252.1199. 
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General Procedure for the Formation of the Amide Linker between the 
Diphenylether Aniline and Piperidine Units 
O
HN
O
N O
O
X
 
This method is adapted from a method by Vicker et al.139  To a solution of N-Boc-
piperidine-4-carboxylic acid (1 eq.) in anhydrous DCM (0.15 mmol/mL), was added 
DMAP (cat.), EDC (3.5 eq.) and TEA (0.15 mL/mmol).  The reaction mixture was 
stirred under nitrogen at room temperature for 30 min.  The diphenylether aniline (1.2 
eq.) was then added and the mixture was stirred under nitrogen for a further 18-96 h.  It 
was then diluted with DCM and washed with hydrochloric acid (1M,), NaHCO3 and 
finally, brine.  The organic layers were combined, dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography to 
afford the desired product. 
 
General Procedure for the Removal of the N-Boc Protecting Group 
O
HN
O
NH
X
 
To a solution of the desired t-Boc-protected amine (1 eq.) in anhydrous DCM (10 mL/1 
mmol) at 0 °C was added TFA (5 mL/1 mmol).  The reaction mixture was stirred under 
nitrogen for 1-2 h, poured onto solid K2CO3 (12 g/mmol) and water was added.  The 
resulting solution was extracted with DCM and the organic layers were dried (MgSO4), 
filtered and evaporated in vacuo to afford the desired amine.   
 
General Procedure for the Acylation of the Piperidine Nitrogen 
O
HN
O
N R
O
X
 
To a solution of the desired amine (1 eq.) in DCM (5 mL/2 mmol) at 0 °C, was added 
acid chloride (2 eq.) and TEA (5 eq.).  The reaction mixture was allowed to warm to 
room temperature and stirred for 1 h.  The reaction was then quenched with sodium 
bicarbonate and extracted with DCM.  The organic portions were washed with 1M HCl 
and finally, brine.  The organic layers were dried (MgSO4) and evaporated in vacuo.  
The crude mixture was purified using flash chromatography to afford the desired 
acetylated product.   
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4-[2-(2,4-Dichlorophenoxy)phenylcarbamoyl]piperidine-1-carboxylic acid tert-
butyl ester, 43, C23H26Cl2N2O4, MW 465.37, 
N
HN
O
O
Cl
Cl
O
O
 
Using the general procedure for the formation of the amide linker, the desired 
compound was obtained as a white solid, which was used in the next step without 
further purification, 754 mg, 84 % yield.  A small sample was purified for 
characterisation.  m.p. 120-121 ºC (from hexane), R.f: 0.31 (Hexane/EtOAc 7:3), 
LC/MS tr = 1.39 min, m/z M-H 464.96, 
1H NMR (270 MHz, CDCl3) δ 1.44 (9H, s, 
3CH3), 1.65-1.76 (2H, m, CH2), 1.84-1.86 (2H, br d, CH2), 2.40 (1H, tt, CH), 2.77 (2 H, 
br t, CH2), 4.14 (2H, br d, CH2), 6.71 (1H, dd, J = 8.2, 1.7 Hz, ArH), 6.94 (1H, d, J = 
8.9 Hz, ArH), 7.01 (1H, td, J = 8.2, 1.5, ArH), 7.12 (1H, td, J = 8.2, 1.5 Hz, ArH), 7.21 
(1H, dd, J = 8.9, 2.5 Hz, ArH), 7.48 (1H, d, J = 2.5 Hz, ArH), 7.76 (1H, br s, NH) and 
8.40 (1H, dd, J = 7.9, 1.5 Hz, ArH).  HRMS: Calcd for C23H26Cl2N2O4 (M+H)
+ 
465.1342, found (M+H)+ 465.1333. 
 
Piperidine-4-carboxylic acid [2-(2,4-dichlorophenoxy)phenyl]amide, 40a, 
C18H18Cl2N2O2, MW 365.25, 
NH
O
HN
O
Cl
Cl
 
Using the general procedure for the removal of the N-Boc protecting group the desired 
compound was obtained as an oil which was used in the next step without further 
purification, 61 mg, 90 % yield.   R.f: 0.175 (DCM/methanol 4:1 plus 3 drops of TEA), 
1H NMR (270 MHz, CDCl3) δ 1.65-1.80 (2H, m, CH2), 1.87-1.91 (2H, m, CH2), 2.24 
(1H, br s, NH), 2.40 (1H, m, CH), 2.66 (2H, td, CH2), 3.15 (2H, br d, J = 12.6 Hz, CH2), 
6.72 (1H, dd, J = 8.2, 1.5 Hz, ArH), 6.93 (1H, d, J = 8.6 Hz, ArH), 6.99 (1H, td, J = 7.9, 
1.5 Hz, ArH), 7.12 (1H, td, J = 7.9, 1.2 Hz, ArH), 7.20 (1H, dd, J = 8.9, 2.5 Hz, ArH), 
7.47 (1H, d, J = 2.5 Hz, ArH) and 8.41 (1H, dd, J = 7.9, 1.2 Hz, ArH). 
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1-Acetylpiperidine-4-carboxylic acid [2-(2,4-dichlorophenoxy) phenyl]amide, 49, 
C20H20Cl2N2O3, MW 407.29, 
N
O
HN
O
Cl
Cl
O
 
To an ice cooled solution of piperidine-4-carboxylic acid [2-(2,4-
dichlorophenoxy)phenyl]-amide (61 mg, 0.167 mmol) in dry DCM (6 mL) were added 
TEA (0.23 mL, 1.67 mmol) and acetyl chloride (0.024 mL, 0.334 mmol).  The reaction 
mixture was stirred at room temperature until completion by TLC (30 min), and 
quenched with saturated NaHCO3 (20 mL).  The resulting solution was extracted with 
DCM (3 x 20 mL) and the combined organic layers were washed with water, 1M HCl (3 
x 20 mL) and brine, dried (MgSO4), filtered and evaporated to dryness.  Flash 
chromatography of the crude product (hexane to EtOAc) gave the desired product as a 
white solid, 51 mg, 75 % yield.  mp 194-196 ºC, R.f: 0.15 (EtOAc), LC/MS (APCI) tr = 
2.45 min, m/z M+H 409.31, HPLC tr = 2.594 min (99 %), 1H NMR (270 MHz, CDCl3) 
δ 1.65-1.76 (2H, m, CH2), 1.89-1.92 (2H, m, CH2), 2.09 (3H, s CH3), 2.51 (1H, m, CH), 
2.67 (1H, m, ½CH2), 3.11 (1H, m, ½CH2), 3,87 (1H, m, ½CH2), 4.59 (1H, m, ½ CH2), 
6.72 (1H, dd, J = 8.0, 1.5 Hz, ArH), 6.94 (1H, d, J = 8.9 Hz, ArH), 7.00 (1H, td, ArH), 
7.12 (1H, td, ArH), 7.22 (1H, dd, J = 8.7, 2.5 Hz, ArH), 7.48 (1H, d, J = 2.5 Hz, ArH), 
7.79 (1H, br s, NH) and 8.38 (1H, br d, J = 8.2 Hz, ArH).  HRMS: Calcd for 
C20H20Cl2N2O3 (M+H)
+ 407.0924, found (M+H)+ 407.0924. 
 
1-Benzoylpiperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)phenyl] amide, 50, 
C25H22Cl2N2O3, MW 469.36, 
N
O
HN
O
Cl
Cl
O
 
To an ice cooled solution of piperidine-4-carboxylic acid [2-(2,4-
dichlorophenoxy)phenyl]-amide (100 mg, 0.274 mmol) in dry DCM (10 mL) were 
added pyridine (0.044 mL, 0.548 mmol) and benzoyl chloride (0.047 mL, 0.411 mmol).  
The reaction mixture was stirred at room temperature until TLC showed consumption of 
starting material (1 h), then quenched with saturated NaHCO3 (15 mL).  The resulting 
solution was extracted with DCM (3 x 20 mL) and the combined organic layers were 
washed with water, 1M HCl (3 x 20 mL) and brine (20 mL), dried (MgSO4), filtered 
and evaporated.  Flash chromatography of the crude product (hexane to EtOAc) gave 
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the desired product as a white solid, 98 mg, 76 % yield.  mp 176-177 ºC, R.f: 0.17 
(hexane/EtOAc 1:1), LC/MS (APCI) tr = 1.10 min, m/z M+H 471.26, HPLC tr = 2.88 
min (99 %), 1H NMR (270 MHz, CDCl3) δ 1.85 (4H, m, 2CH2), 2.55 (1H, tt, CH), 3.01 
(2H, m, CH2), 3.89 (1H, m, ½CH2), 4.74 (1H, m, ½CH2), 6.72 (1H, dd, J = 8.2, 1.5 Hz, 
ArH), 6.95 (1H, d, J = 8.6 Hz, ArH), 7.01 (1H, td, ArH), 7.14 (1H, td, ArH), 7.22 (1H, 
dd, J = 8.6, 2.5 Hz, ArH), 7.39 (5H, s, ArH), 7.49 (1H, d, J = 2.5 Hz, ArH), 7.78 (1H, br 
s, NH) and 8.38 (1H, br d, J = 8.2, ArH).  Anal. Calcd. for C25H22Cl2N2O3: C 63.97, H 
4.72, N 5.97. Found: C 64.10, H 4.83, N 5.88 %. 
 
1-Cyclohexanecarbonyl-piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-
phenyl]-amide, 51, C25H25Cl2N2O3, MW 475.41 
O
NH
O
N
Cl
Cl
O
 
To a solution of piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-amide 
(0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and cycloheane 
carbonyl chloride (0.072 mL, 0.54 mmol).  The reaction mixture was allowed to warm 
to room temperature and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-5 
% methanol in DCM), to afford a white solid, 120 mg, 95 % yield.  m.p. 46-48 °C, R.f. 
0.65 (EtOAc), LCMS: tr= 5.42 min (50 % MeOH in water at 0.5 mL/min), m/z M+H 
475.16, HPLC: tr= 4.24 min (80 % acetonitrile in water at 1.0 mL/min), 97 %, 
1H NMR 
(CDCl3, 270 MHz): δ 1.14-1.89 (14H, m, 7CH2), 2.23-2.32 (1H, m, CH), 2.33-2.49 (1H, 
m, CH), 2.61 (1H, t, J = 10.0 Hz, CH2), 3.02 (1H, t, J = 9.5 Hz, CH2), 3.92 (1H, d, J = 
11.3 Hz, CH2), 4.57 (1H, d, J = 11.9 Hz, CH2), 6.67 (1H, dd, J = 7.3, 1.4 Hz, ArH), 6.89 
(1H, d, J = 7.8 Hz, ArH), 6.95 (1H, td, J = 7.0, 1.4 Hz, ArH), 7.07 (1H, td, J = 1.4,7.6 
Hz, ArH), 7.16 (1H, dd, J = 2.4, 8.1 Hz, ArH), 7.43 (1H, d, J = 2.2 Hz, ArH), 7.69 (1H, 
s ,NH), 8.34 (1H, d, J = 7.02 Hz, ArH).   13C NMR (CDCl3, 101 MHz): δ 25.8, 25.9, 
29.3, 29.5 (CH2), 40.5 (CH), 41.0 (CH2), 44.4 (CH), 44.7 (CH2), 116.5, 121.4, 121.5, 
124.2, 124.6 (ArCH), 126.4 (ArC), 128.4 (ArCH), 128.9, 130.1 (ArC), 126.4 (ArC), 
128.4 (ArCH), 128.9, 130.1 (ArC), 130.7 (ArCH), 145.2, 150.3 (ArC), 172.2, 174.6 
(CO).  HRMS: Calcd for C25H25Cl2N2O3 (M+H)
+ 475.1550, found (M+H)+ 475.1552,   
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1-Cyclopentanecarbonyl-piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-
phenyl]-amide, 52, C24H26Cl2N2O3, MW 461.38 
O
NH
O
N
Cl
Cl
O
 
To a solution of piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-amide 
(0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and cyclopentane 
carbonyl chloride (0.066 mL, 0.54 mmol).  The reaction mixture was allowed to warm 
to room temperature and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-
100 % DCM in hexane).  The desired product was recrystallised from diethyl 
ether/hexane as a white solid, 46 mg, 37 % yield.  m.p. 135-137 °C, R.f. 0.67 (EtOAc), 
LCMS: tr = 5.29 min (50 % MeOH in water at 0.5 mL/min), m/z M+H 461.32, HPLC: tr 
= 3.96 min (80 % acetonitrile in water at 1.0 mL/min), 98 %, 1H NMR (CDCl3, 270 
MHz): δ 1.54-1.97 (12H, m, 6CH2) 2.46-2.57 (1H, m, CH), 2.63-2.73 (1H, m, CH2), 
2.82-2.93 (1H, m, CH), 3.03-3.08 (1H, m, CH2), 4.03 (1H, d, J = 13.8 Hz, CH2), 4.63 
(1H, d, J = 13.1 Hz, CH2), 6.72 (1H, dd, J = 8.15, 1.46 Hz, ArH), 6.95 (1H, d, J = 8.7 
Hz, ArH), 7.00 (1H, td, J = 7.6, 1.73 Hz, ArH), 7.13 (1H, td, J = 7.91, 1.2 Hz, ArH), 
7.22 (1H, dd, J = 8.64, 2.48 Hz, ArH), 7.49 (1H, d, J = 2.5 Hz, ArH), 7.76 (1H, s, NH), 
8.4 (1H, dd, J = 8.15 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 26.0, 28.6, 29.1, 29.9, 
30.2 (CH2), 41.1 (CH), 41.2 (CH2), 44.4 (CH), 44.8 (CH2), 116.5, 121.4, 121.4, 124.2, 
124.6 (ArCH), 126.31 (ArC), 128.3 (ArCH), 128.8, 130.1 (ArC), 130.6 (ArCH), 145.1, 
150.3 (ArC), 172.3, 174.4 (CO).  HRMS: Calcd for C24H26Cl2N2O3 (M+H)
+ 461.1393, 
found (M+H)+ 461.1385.  Anal. Calcd for C24H26Cl2N2O3: C 62.48, H 5.68, N 6.07 %. 
Found C 62.5, H 5.63, N 5.96 %. 
 
1-Isobutyryl-piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-
amide, 53, C22H24Cl2N2O3, MW 435.34, 
O
NH
O
N
Cl
Cl
O
 
To a solution of piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-amide 
(0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and isobutyryl 
chloride (0.057 mL, 0.54 mmol).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 (15 
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mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-10 % methanol 
in DCM).  The title compound was recrystallised from diethylether/hexane as a white 
solid, 89 mg, 75 % yield.  m.p. 50-52 °C, R.f. 0.65 (EtOAc), LCMS: tr = 5.0 min (50 % 
MeOH in water at 1.0 mL/min), m/z M+H 435.31, HPLC: tr = 2.58 min (90 % 
acetonitrile in water at 1.0 mL/min), 97 %, 1H NMR (CDCl3, 270 MHz): δ 1.05-1.06 
(6H, m, CH3), 1.61-1.70 (2H, m, CH2), 1.88 (2H, s, CH2), 2.41-2.56 (1H, m, CH), 2.59-
2.69 (1H, m, CH2), 2.71-2.78 (1H, m, CH), 3.04 (1H, t, J = 11.1 Hz, CH2), 3.94 (1H, d, 
J = 12.2 Hz, CH2), 4.58 (1H, d, J = 11.6 Hz, CH2), 6.67 (1H, td, J = 6.2, 1.4 Hz, ArH), 
6.89 (1H, d, J = 8.1 Hz, ArH), 6.95 (1H, td, J = 6.8 Hz, ArH), 7.07 (1H, td, J = 7.29, 1.1 
Hz, ArH), 7.16 (1H, dd, J = 7.83, 2.16 Hz, ArH), 7.43 (1H, d, J = 2.2 Hz, ArH), 7.71 
(1H, s, NH), 8.30 (1H, dd, J = 7.29, 1.1 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 
19.3, 19.6 (CH3), 28.6, 29.1 (CH2), 30.10 (CH), 41.1 (CH2), 44.30 (CH), 44.7 (CH2), 
116.4, 121.3, 121.42, 124.2, 124.6, 126.34, 128.40, 128.81, 130.20, 130.70, 145.11, 
150.30 (ArC), 172.2, 175.30 (C=O).  HRMS: Calcd for C22H24Cl2N2O3 (M+H)
+ 
435.1237, found (M+H)+ 435.1233.  Anal. Calcd for C22H24Cl2N2O3: C 60.70, H 5.56, 
N 6.43 %. Found C 61.0, H 5.71, N 6.38 %. 
 
1-(3-Methyl-butyryl)-piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-
phenyl]-amide, 54, C23H26Cl2N2O3, MW 449.37 
O
NH
O
N
Cl
Cl
O
 
To a solution of piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-amide 
(0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and isovaleryl 
chloride (0.057 mL, 0.54 mmol).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 (15 
mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-10 % methanol 
in DCM) to afford the title compound as a white waxy solid, 80 mg, 65 % yield.  m.p. 
60-62 °C, R.f. 0.65 (EtOAc), LCMS: tr = 5.08 min (50 % MeOH in water at 0.5 
mL/min), m/z M+H 449.35, HPLC: tr = 2.69 min (90 % acetonitrile in water at 1.0 
mL/min), 95 %, 1H NMR (CDCl3, 270 MHz): δ 0.73 (6H, d, J = 5.9 Hz, 2CH3), 1.40-
1.57 (2H, m, CH2), 1.68-1.72 (2H, m, CH2), 1.80-1.93 (1H, m, CH), 1.96-2.07 (3H, m, 
CH2, CH), 2.22-2.32 (1H, m, CH), 2.45 (1H, td, J = 12.4, 2.4 Hz, CH2), 2.85 (1H, td, J 
= 12.4, 2.16 Hz, CH2), 3.70 (1H, dd, J = 12.2, CH2), 4.40 (1H, d, J = 11.9 Hz, CH2), 
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6.49 (1H, dd, J = 7.3, 1.1 Hz, ArH), 6.72 (1H, d, J = 7.8 Hz, ArH), 6.77 (1H, td, J = 6.8, 
1.4 ArH), 6.90 (1H, td, J = 7.3, 1.4 Hz, ArH), 6.99 (1H, dd, J = 7.8, 2.2 Hz, ArH), 7.26 
(1H, d, J = 2.4 Hz, ArH), 7.53 (1H, s, NH), 8.16  (1H, d, J = 7.0 Hz, ArH).  13C NMR 
(CDCl3, 101 MHz): δ 22.70, 22.80 (CH3), 25.80, 28.64, 29.03, 40.89, (CH2), 42.13, 
44.24 (CH), 45.14 (CH2), 116.45, 121.42, 124.22, 124.56, 126.36, 128.36, 128.82, 
130.16, 130.66, 145.16, 150.27 (ArC), 170.97, 172.22 (C=O).  HRMS: Calcd for 
C23H26Cl2N2O3 (M+H)
+ 449.1393, found (M+H)+ 449.1381.  Anal. Calcd for 
C23H26Cl2N2O3: C 61.47, H 5.83, N 6.23. Found C 61.70, H 6.02, N 6.33. 
 
4-[2-(3,5-Dichloro-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic acid tert-
butyl ester, 44, C23H26Cl2N2O4, MW 465.38, 
O
HN
Cl
Cl
O
N O
O
 
Using the general procedure for the formation of the amide linker the desired product 
was isolated as a white solid, 0.32 g, 60 % yield.  m.p. 116-117 °C, LCMS: tr= 5.75 min 
(50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 
463.46, HPLC: tr= 4.30 min (90 % acetonitrile in water at 1.0 mL/min), 96 %, 
1H NMR 
(CDCl3, 270 MHz: δ 1.43 (9H, s, CH3), 1.66 (2H, td, J = 1.2, 4.2 Hz, CH2), 1.80 (2H, 
dd, J = 2.5, 12.8 Hz, CH2), 2.30-2.41 (1H, m, CH), 2.74 (2H, t, J = 11.8 Hz, CH2N), 
4.07-4.12 (2H, m, CH2N), 6.87 (2H, d, J = 1.7 Hz, ArH, ArH), 6.87-6.91 (1H, m, ArH), 
7.05 (1H, td, J = 5.0, 6.4 Hz, ArH), 7.11 (1H, t, J = 2.0 Hz, ArH), 7.17 (1H, td, J = 1.5, 
8.1 Hz, ArH), 8.40 (1H, dd, J = 1.2, 8.1 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 28.4 
(CH3), 28.5 (CH2), 44.4 (CH), 116.8, 118.7, 121.6, 124.1, 125.5 (ArCH), 129.9, 135.9, 
144.1, 154.6 (ArC), 157.7, 172.6 (CO).  HRMS: Calcd for C23H26Cl2N2O4 (M+H)
+ 
465.1353, found (M+H)+ 465.1373.  Anal. Calcd for C23H26Cl2N2O4: C 59.36, H 5.63, 
N 6.02 %. Found C 58.90, H 5.55, N 6.49 %. 
 
Piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide, 48b, 
C19H19F3N2O2, MW 364.37, 
O
HN
Cl
O
NHCl
 
4-[2-(3,5-Dichloro-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic acid tert-butyl 
ester (1.09 g, 2.3 mmol) was dissolved in HCl/ dioxane (4 M, 18 mL) and stirred at r.t. 
for 1 h.  The reaction mixture was evaporated to dryness, diluted with DCM (20 mL) 
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and neutralised with sodium hydroxide (1 M).  This was then extracted with DCM (3 x 
30 mL) and the organic layers were combined, dried (MgSO4), filtered and evaporated 
in vacuo to afford the title compound as a off white solid, 183 mg, 21 % yield.  m.p. 
138-139 °C, R.f. 0.3 (10 % Methanol/DCM), 1H NMR (CDCl3, 270 MHz): δ 1.55-1.75 
(3H, m, CH2, NH), 1.78-1.90 (2H, m, CH2), 2.31-2.42 (1H, m, CH), 2.65 (2H, td, J = 
2.7, 9.6 Hz, NCH2), 3.13-3.18 (2H, m, NCH2), 6.89 (2H, d, J = 1.7 Hz, ArH, ArH), 
6.88-6.92 (1H, m, ArH), 7.06 (1H, td, J = 1.5, 7.4 Hz, ArH), 7.12 (1H, t, J = 1.7 Hz, 
ArH), 7.18 (1H, td, J = 8.2, 1.46 Hz, ArH), 7.55 (1H, s, CONH), 8.43 (1H, dd, J = 8.2 
Hz, ArH). 
 
1-Acetyl-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide, 55, 
C20H20Cl2N2O3, MW 407.3, 
O
HN
Cl
O
N
O
Cl
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (60 mg, 0.16 mmol) in DCM (5 mL) at 0 °C, was added acetyl chloride (0.02 
mL, 0.32 mmol) and TEA (0.1 mL, 0.8 mmol).  The reaction mixture was allowed to 
warm to room temperature and stirred for 1 h.  The reaction was quenched with 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL) and the organic layers were washed 
with 1M HCl and finally brine.  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-5 
% MeOH in EtOAc) to afford a white solid, 65 mg, 95 % yield.  m.p. 112-114 °C, R.f: 
0.25 (DCM), LCMS: tr = 1.04 min (95 % MeOH in water at 1.0 mL/min), m/z M+H 
407.30, HPLC: tr = 2.15 min (90 % acetonitrile in water at 1.0 mL/min), 95 %, 
1H NMR 
(CDCl3, 270 MHz): δ 1.69-1.77 (2H, m, CH2), 1.78-1.86 (2H, m, CH2), 2.06 (3H, s, 
CH3), 2.37-2.47 (1H, m, CH), 2.64 (1H, td, J = 3.0, 13.8 Hz, NCH2), 3.07 (1H, td, J = 
2.7, 11.9 Hz, NCH2), 3.85 (1H, d, J = 13.6 Hz, NCH2), 4.56 (1H, d, J = 13.5 Hz, 
NCH2), 6.87 (2H, d, J = 1.7 Hz, ArH, ArH), 6.90 (1H, dd, J = 1.2, 8.2 Hz, ArH), 7.06 
(1H, td, J = 1.5, 7.7 Hz, ArH), 7.11 (1H, t, J = 2.0 Hz, ArH), 7.18 (td, J = 1.2, 7.9 Hz, 
ArH), 7.64 (1H, s, NH), 8.36 (1H, dd, J = 1.0, 8.2 Hz, ArH).  13C NMR (CDCl3, 101 
MHz): δ 21.5 (CH3), 28.5, 28.8, 40.8 (CH2), 44.1 (CH), 45.7 (CH2), 116.8, 118.8, 121.7, 
124.1, 124.7, 125.6 (ArCH), 129.8, 136.0, 144.2, 157.8 (ArC), 168.9, 172.3 (CO).  
Anal. Calcd for C20H20Cl2N2O3: C 58.98, H 4.95, N 6.88 %. Found: C 58.6, H 4.91, N 
6.61 %, HRMS: Calcd for C20H20Cl2N2O3 (M+H)
+ 407.0924, found (M+H)+ 407.0929. 
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1-Benzoyl-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide, 
56, C25H22Cl2N2O3, MW 469.37, 
O
NH
Cl
O
N
O
Cl
 
To a solution of piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide 
(60 mg, 0.16 mmol) in DCM (5 mL) at 0 °C, was added benzoyl chloride (0.02 mL, 
0.16 mmol) and TEA (0.1 mL, 0.8 mmol).  The reaction mixture was allowed to warm 
to room temperature and stirred for 1 h.  The reaction was quenched with sat. NaHCO3 
(15 mL), extracted with DCM (2 x 20 mL), washed with 1M HCl and finally brine (20 
mL).  The organic layers were dried (MgSO4) and evaporated in vacuo.  The crude 
mixture was purified using flash chromatography (0-5 % MeOH in EOAc) to afford the 
desired compound as a white solid, 50 mg, 64 % yield.  m.p. 61-63 °C, R.f. 0.3 (DCM), 
LCMS: tr = 1.3 min (95 % MeOH in water at 1.0 mL/min), m/z M+H 469.37, HPLC: tr 
= 3.6 min (90 % acetonitrile in water at 1.0 mL/min), 98 %, 1H NMR (CDCl3, 400 
MHz): δ 1.77-1.92 (4H, m, 2CH2), 2.46-2.55 (1H, m, CH), 2.86 (1H, s, CH2), 3.01 (1H, 
s, CH2), 3.77 (1H, s, NCH2), 4.65 (1H, s, NCH2), 6.88 (2H, d, J = 1.6 Hz, ArH), 6.91 
(1H, dd, J = 1.2, 8.0 Hz, ArH), 7.08 (1H, td, J = 1.2, 7.6 Hz, ArH), 7.12 (1H, t, J = 1.6 
Hz, ArH), 7.20 (1H, td, J = 1.2, 8.0 Hz, ArH), 7.35-7.42 (5H, m, ArH), 7.71 (1H, s, 
NH), 8.38 (1H, dd, J = 0.8, 8.0 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 14.4, 22.9, 
29.1, 31.9 (CH2), 44.5 (CH), 117.1, 119.1, 122.0, 124.4, 124.9, 125.9, 127.2, 128.8, 
130.0 (ArCH), 130.1, 136.1, 136.3, 144.5, 158.0 (ArC), 170.8, 172.4 (CO).  HRMS: 
Calcd for C25H22Cl2N2O3 (M+H)
+ 469.1080, found (M+H)+ 469.1082.  Anal. Calcd for 
C25H22Cl2N2O3: C 63.97, H 4.72, N 5.97 %. Found: C 63.4, H 4.7, N 5.95 %. 
 
1-Cyclohexanecarbonyl-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-
phenyl]-amide, 64, C25H28Cl2N2O3, MW 475.41, 
O
Cl
Cl
NH
O
N
O
 
To a solution of piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide 
(0.07 g, 0.18 mmol) in DCM (4 mL), at 0 °C, was added TEA (0.15 mL) and 
cyclohexane carbonyl chloride (0.05 mL, 0.36 mmol).  The reaction mixture was 
allowed to warm to room temperature, and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with 
1M HCl (20 mL) and brine (20 mL).  The organic layers were dried (MgSO4) and 
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evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-
100 % EtOAc in hexane) to afford the title compound as a white waxy solid, 71 mg, 83 
% yield.  m.p. 64-67 °C, R.f. 0.6 (EtOAc), LCMS: tr= 2.0 min (50 % to 95 % MeOH in 
water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 475.29, HPLC: tr= 3.16 min 
(90 % acetonitrile in water at 1.0 mL/min), >99%, 1H NMR (CDCl3, 270 MHz): δ 1.21-
1.27 (4H, m, 2CH2), 1.44-1.93 (10H, m, 5CH2), 2.39-2.51 (2H, m, 2CH), 2.61 (1H, t, J 
= 11.6 Hz, CH2), 3.04 (1H, t, J = 11.9Hz, CH2), 3.96 (1H, d, J = 13.6 Hz, CH2), 4.61 
(1H, d, J = 13.4 Hz, CH2), 6.88 (2H, d, J = 2.0 Hz, ArH), 6.90 (1H, dd, J = 8.15, 1.2 Hz, 
ArH), 7.07 (1H, td, J = 7.9, 1.7 Hz, ArH), 7.12 (1H, t, J = 2.0 Hz, ArH), 7.18 (1H, td, J 
= 1.2, 7.6 Hz, ArH), 7.61 (1H, s, NH), 8.39 (1H, dd, J = 1.5, 8.2 Hz, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 25.95, 28.72, 29.36, 29.65 (CH2), 40.56 (CH), 41.05 (CH2), 44.39 
(CH), 44.72 (CH2), 116.90, 118.91, 121.78, 124.18, 124.75, 125.62 (ArCH), 129.90, 
136.07, 144.24, 157.83 (ArC), 172.37, 174.63 (C=O), HRMS: Calcd for C25H28Cl2N2O3 
(M+H)+ 475.1550, found (M+H)+ 475.1544. 
 
1-Cyclopentanecarbonyl-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-
phenyl]-amide, 58, C24H26Cl2N2O3, MW 461.38, 
O
Cl
Cl
HN
O
N
O
 
To a cooled solution of piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-
amide (0.07 g, 0.18 mmol) in DCM (4 mL) at 0 °C, was added TEA (0.15 mL) and 
cyclopentane carbonyl chloride (0.044 mL, 0.36 mmol).  The reaction mixture was 
allowed to warm to room temperature and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with 
hydrochloric acid (1M, 20 mL) and brine (20 mL).  The organic layers were dried 
(MgSO4) and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to afford the title compound as a 
white waxy solid, 52 mg, 63 % yield.  m.p. 154-155 °C, R.f. 0.62 (EtOAc), LCMS: tr= 
1.5 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z 
M+H 461.38, HPLC: tr= 3.04 min (90 % acetonitrile in water at 1.0 mL/min), 99 %, 
1H 
NMR (CDCl3, 270 MHz): δ 1.53-1.92 (12H, m, 6CH2), 2.41-2.52 (1H, m, CH), 2.66 
(1H, t, J = 11.9 Hz, CH2), 2.81-2.92 (1H, m, CH), 3.06 (1H, t, J = 11.1 Hz, CH2), 4.00 
(1H, d, J = 13.9 Hz, CH2), 4.62 (1H, d, J = 12.8 Hz, CH2), 6.88-6.92 (3H, m, ArH), 7.07 
(1H, td, J = 7.4, 1.5 Hz, ArH), 7.13 (1H, t, J = 1.7 Hz, ArH), 7.19 (1H, td, J = 7.9, 1.5 
Hz, ArH), 7.58 (1H, s, NH), 8.40 (1H, d, J = 7.9 Hz, ArH).  13C NMR (CDCl3, 101 
MHz): δ 26.12, 28.70, 29.17, 30.09, 30.34 (CH2), 41.19 (CH), 41.26 (CH2), 44.44 (CH), 
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44.84 (CH2), 116.84, 118.90, 121.73, 124.19, 124.73, 125.64 (ArCH), 129.91, 136.09, 
144.19, 157.83 (ArC), 172.36, 174.53 (C=O).  HRMS: Calcd for C24H26Cl2N2O3 
(M+H)+ 461.1393, found (M+H)+ 461.1394. 
 
1-Isobutyryl-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-
amide, 59, C22H24Cl2N2O3, MW 435.34, 
O
Cl
Cl
HN
O
N
O
 
To a solution of piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide 
(0.07 g, 0.18 mmol) in DCM (4 mL) at 0 °C was added TEA (0.15 mL) and isobutylryl 
chloride (0.038 mL, 0.36 mmol).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 (15 
mL), extracted with DCM (2 x 20 mL) and washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4) and evaporated in vacuo.  
The crude mixture was purified using flash chromatography (0-100 % ethyl acetate in 
hexane) to afford a white wax, 77 mg, 97 % yield.  R.f. 0.7 (EtOAc), LCMS: tr= 1.9 min 
(50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 
435.38, HPLC: tr= 2.7 min (90 % acetonitrile in water at 0.8 mL/min), 98 %, 
1H NMR 
(CDCl3, 270 MHz): δ 1.09 (6H, t, J = 5.5 Hz, 2CH3), 1.62-1.76 (2H, m, CH2), 1.78-1.92 
(2H, m, CH2), 2.41-2.52 (1H, m, CH2), 2.63 (1H, t, J = 11.9 Hz, CH2), 2.72-2.85 (1H, 
m, CH), 3.06 (1H, t, J = 11.4 Hz, CH2), 3.96 (1H, d, J = 13.6 Hz, CH2), 4.60 (1H, d, J = 
13.1 Hz, CH2), 6.86-6.92 (3H, m, ArH), 7.06 (1H, td, J = 1.8, 8.2 Hz, ArH), 7.11 (1H, t, 
J = 1.8 Hz, ArH), 7.18 (1H, td, J = 1.6, 7.7 Hz, ArH), 7.64 (1H, s, NH), 8.37 (1H, dd, J 
= 1.2, 8.2 Hz, ArH).  13C NMR (CDCl3, 68 MHz): δ 19.41, 19.67 (CH3), 28.70, 29.21 
(CH2), 30.19 (CH), 41.13 (CH2), 44.31 (CH), 44.74 (CH2), 116.82, 118.95, 121.86, 
124.14, 124.78, 125.62 (ArCH), 129.91, 136.06, 144.28, 157.85 (ArC), 172.38, 175.41 
(CO).  HRMS: Calcd for C22H24Cl2N2O3 (M+H)
+ 435.1237, found (M+H)+ 435.1240. 
 
1-(3-Methyl-butyryl)-piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-
phenyl]-amide, 60, C22H24Cl2N2O3, MW 448.1, 
O
Cl
Cl
HN
O
N
O
 
To a solution of piperidine-4-carboxylic acid [2-(3,5-dichloro-phenoxy)-phenyl]-amide 
(0.07 g, 0.18 mmol) in DCM (4 mL), at 0 °C was added TEA (0.15 mL) and isovaleryl 
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chloride (0.044 mL, 0.36 mmol).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 (15 
mL), extracted with DCM (2 x 20 mL) and washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4) and evaporated in vacuo.  
The crude mixture was purified using flash chromatography (0-100 % ethyl acetate in 
hexane) to afford the desired compound as a white waxy solid, 52 mg, 72% yield.  mp. 
119-121 °C, R.f. 0.65 (EtOAc), LCMS: tr= 1.8 min (50 % to 95% MeOH in Water at 
0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 449.4, HPLC: tr= 2.9 min (90 % 
acetonitrile in water at 0.8 mL/min), 99 %, 1H NMR (CDCl3, 270 MHz): δ 0.94 (6H, d, 
J = 6.4 Hz, 2CH3), 1.56-1.77 (2H, m, CH2), 1.84-1.91 (2H, m, CH2), 2.02-2.13 (1H, m, 
CH), 2.17-2.21 (2H, m, CH2), 2.40-2.51 (1H, m, CH), 2.64 (1H, t, J = 10.9 Hz, CH2), 
3.05 (1H, t, J = 11.9 Hz, CH2), 3.92 (1H, d, J = 13.6 Hz, CH2), 4.61 (1H, d, J = 13.4 Hz, 
CH2), 6.87 (2H, d, J = 1.7 Hz, ArH), 6.87-6.91 (1H, m, ArH), 7.06 (1H, td, J = 7.9 Hz, 
ArH), 7.12 (1H, t, J = 1.7 Hz, ArH), 7.18 (1H, td, J = 1.5 Hz, ArH), 7.61 (1H, s, NH), 
8.39  (1H, dd, J = 1.2, 8.2 Hz, ArH).  13C NMR (CDCl3, 68 MHz): δ 22.80, 22.92 
(CH3), 25.89 (CH), 28.72, 29.09, 40.95, 42.21 (CH2), 44.26 (CH), 45.19 (CH2), 116.85, 
118.91, 121.78, 124.18, 124.76, 125.63 (ArCH), 129.89, 136.07, 144.24, 157.83 (ArC), 
171.04, 172.34 (C=O).  HRMS: Calcd for C22H24Cl2N2O3 (M+H)
+ 449.1404, found 
(M+H)+ 449.1394. 
 
4-[2-(2,4-Dichlorophenoxy)phenylcarbamoyl]piperidine-1-carboxylic acid tert-
butyl ester, 45, C23H26Cl2N2O4, MW 465.37, 
Cl
O
HN
N O
O
O  
Using the general procedure for the formation of the amide linker the desired product 
was obtained as a white solid, 754 mg, 84 % yield.  R.f: 0.31 (Hexane:EtOAc 7:3), mp 
120-121 ºC, LC/MS tr = 1.39 min, m/z M-H 464.96, 
1H NMR (270 MHz, CDCl3) δ 1.44 
(9H, s, 3CH3), 1.65-1.76 (2H, m, CH2), 1.84-1.86 (2H, br d, CH2), 2.40 (1H, tt, CH), 
2.77 (2 H, br t, CH2), 4.14 (2H, br d, CH2), 6.71 (1H, dd, J = 8.2, 1.7 Hz, ArH), 6.94 
(1H, d, J = 8.9 Hz, ArH), 7.01 (1H, td, J = 8.2, 1.5, ArH), 7.12 (1H, td, J = 8.2, 1.5 Hz, 
ArH), 7.21 (1H, dd, J = 8.9, 2.5 Hz, ArH), 7.48 (1H, d, J = 2.5 Hz, ArH), 7.76 (1H, br s, 
NH) and 8.40 (1H, dd, J = 7.9, 1.5 Hz, ArH). 
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Piperidine-4-carboxylic acid [2-(4-chlorophenoxy)phenyl]amide, 48c, 
C18H19ClN2O2, MW 330.81, 
Cl
O
HN
NH
O  
A solution of 4-[2-(4-chlorophenoxy)phenylcarbamoyl]piperidine-1-carboxylic acid 
tert-butyl ester (410 mg, 0.95 mmol) in 4M HCl in dioxane (2 mL) was stirred at room 
temperature for 2 h. The resulting solution was concentrated under vacuum and the 
residue was dissolved in DCM (20 mL), washed with 1M NaOH (1 x 20 mL), water (20 
mL) and brine (20 mL). The organic layer was dried (MgSO4), filtered and evaporated 
to give the title compound as a white solid, 233 mg, 74 % yield.  R.f: 0.11 (DCM: 
methanol, 4:1 plus 3 drops of TEA), m.p. 138-140 ºC, 1H NMR (270 MHz, CDCl3) δ 
1.55-1.70 (2H, m, CH2), 1.80-1.85 (3H, m, CH2 + NH), 2.35 (1H, tt, CH), 2.62 (2H, br 
t, CH2), 3.13 (2H, br d, CH2), 6.80 (1H, dd, ArH), 6.92 (2H, AA’BB’, ArH), 6.98 (1H, 
td, ArH), 7.11 (1H, td, ArH), 7.29 (1H, ArH), 7.71 (1H, br s, NHCO) and 8.41 (1H, br 
d, J = 7.9 Hz, ArH). 
 
1-Acetylpiperidine-4-carboxylic acid [2-(4-chlorophenoxy)phenyl]amide, 61, 
C20H21ClN2O3, MW 372.85, 
Cl
O
HN
N
O
O  
To an ice cooled solution of piperidine-4-carboxylic acid [2-(4-chlorophenoxy) 
phenyl]amide (100 mg, 0.3 mmol) in dry DCM (6 mL) were added TEA (2.1 mL, 15 
mmol) and acetyl chloride (0.043 mL, 0.6 mmol).  The reaction mixture was stirred at 
room temperature for 1.5 h and quenched with saturated NaHCO3.  The resulting 
solution was extracted with DCM (3 x 20 mL) and the combined organic layers were 
washed with water (20 mL), 1M HCl (20 mL) and brine (20 mL), dried (MgSO4), 
filtered and evaporated.  Flash chromatography of the crude product (0-50% EtOAc in 
hexane) gave the title compound as a white solid, 37 mg, 33 % yield.  R.f: 0.15 
(EtOAc), m.p. 195-196 ºC, LC/MS (APCI) tr = 1.04 min, m/z 373.36 (M+H, 100), 
HPLC tr = 2.2 min, >99 %, 
1H NMR (270 MHz, CDCl3) δ 1.64-1.77 (2H, m, CH2), 
1.79-1.94 (2H, m, CH2), 2.08 (3H, s CH3), 2.46 (1H, tt, CH), 2.66 (1H, m, ½CH2), 3.09 
(1H, m, ½CH2), 3,86 (1H, m, ½CH2), 4.55 (1H, m, ½CH2), 6.82 (1H, dd, J = 8.2, 1.5 
Hz, ArH), 6.93-6.95 (2H, m, ArH), 7.01 (1H, td, ArH), 7.12 (1 H, td, ArH), 7.28-7.32 
(2H, m, ArH), 7.69 (1H, br s, NH) and 8.38 (1H, dd, J = 8.2, 1.2 Hz, ArH).  13C NMR 
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(400 MHz, CDCl3) δ 21.53 (CH3), 28.47, 28.89, 40.81 (CH2), 44.15 (CH), 45.70 (CH2), 
117.77, 119.87, 121.31, 124.44, 124.54, 129.19, 129.45, 130.07, 154.44, 154.94, 168.95 
(ArC), 172.20 (C=O).  HRMS: Calcd for C20H21ClN2O3 (M+H)
+ 373.1313, found 
(M+H)+ 373.1314. 
 
1-Benzoylpiperidine-4-carboxylic acid [2-(4-chlorophenoxy) phenyl]amide, 62, 
C25H23ClN2O3, MW 434.91, 
Cl
O
HN
N
O
O  
To an ice cooled solution of piperidine-4-carboxylic acid [2-(4-
chlorophenoxy)phenyl]amide (73 mg, 0.22 mmol) in dry DCM (6 mL) were added 
pyridine (0.036 mL, 0.44 mmol) and benzoyl chloride (0.038 mL, 0.33 mmol). The 
reaction mixture was stirred at room temperature for 1 h and quenched with saturated 
NaHCO3.  The resulting solution was extracted with DCM (2 x 20 mL) and the 
combined organic layers were washed with water (10 mL), 1M HCl (20 mL) and brine 
(20 mL), dried (MgSO4), filtered and evaporated in vacuo.  Flash chromatography of 
the crude product (0-100 % EtOAc in hexane) gave the desired compound as a white 
solid 80 mg, 83 % yield.  R.f: 0.48 (EtOAc), mp 158-160 ºC, LC/MS (APCI) tr = 1.05 
min, m/z 435.38 (M+H, 100), HPLC tr = 2.6 min, 98 %.  
1H NMR (270 MHz, CDCl3) δ 
1.82-2.03 (4H, m, 2CH2), 2.51 (1H, tt, CH), 2.98 (2H, m, CH2), 3.85 (1H, m, ½CH2), 
4.71 (1H, m, ½CH2), 6.82 (1H, dd, J = 8.2, 1.5 Hz, ArH), 6.93-6.95 (2H, m, ArH), 7.02 
(1H, td, ArH), 7.13 (1H, td, ArH), 7.29-7.33 (1H, m, ArH), 7.39 (5H, s, ArH,), 7.70 
(1H, br s, NH) and 8.39 (1H, dd, J = 8.2, 1.5 Hz, ArH).  Anal. Calcd. for C25H23ClN2O3: 
C 69.04, H 5.33, N 6.44. Found: C 68.9, H 5.33, N 6.37%. 
 
4-[2-(4-Trifluoromethyl-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic acid 
tert-butyl ester, 46, C24H27F3N2O4, MW 464.49 
O
F3C
HN
O
N
O
O
 
Using the general procedure for the formation of the amide linker the desired compound 
was obtained as a white solid, 1.28 g, 72 % yield.  m.p. 48-51 °C, R.f 0.44 (DCM: 
Hexane, 1:1), LCMS: tr= 5.0 min (50 % MeOH in water at 0.5 mL/min), m/z M+H 
463.27, HPLC: tr= 2.6 min (90 % acetonitrile in water at 1.0 mL/min), 99 %, 
1H NMR 
(CDCl3, 270 MHz): δ 1.44 (9H, s, CH3), 1.54-1.70 (2H, m, CH2), 1.75-1.81 (2H, m, 
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CH2), 2.31-2.38 (1H, m, CH), 2.73 (2H, t, J = 11.8 Hz, CH2), 4.13 (2H, s, CH2), 6.91 
(1H, dd, J = 1.5, 8.2 Hz, ArH), 7.06 (1H, td, J = 1.8, 8.2 Hz, ArH), 7.06 (2H, d, J = 8.4 
Hz, ArH), 7.18 (1H, td, J = 1.8, 9.2 Hz, ArH), 7.56 (1H, s, NH), 7.60 (2H, d, J = 8.4 Hz, 
ArH), 8.4  (1H, dd, J = 8.2 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 28.38 (CH3), 
28.46 (CH2), 117.8, 118.9, 121.7, 124.5, 125.4, 127.4, 127.5 (ArCH), 129.9, 144.4 
(ArC), 154.6 (CF3), 159.4, 172.6 (CO).  Anal. Calcd for C24H27F3N2O4: C 62.06, H 
5.86, N 6.03 %. Found C 62.3, H 6.39, N 5.91 %. 
 
Piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-amide, 48d, 
C19H19F3N2O2 MW 364.37, 
O
HN
F3C
O
NH
 
Using the general procedure for the removal of the N-Boc protecting group the desired 
compound was obtained as a cream oil, 0.14 g, 89 % yield.  R.f: 0.47 (DCM), 1H NMR: 
(CDCl3, 270 MHz): δ 1.56-1.72 (2H, m, CH2), 1.73-1.83 (2H, m, CH2), 2.24-2.41 (1H, 
m, CH), 2.64 (2H, td, J = 12.4, 2.7 Hz, NCH2), 3.11-3.16 (2H, m, NCH2), 6.97 (1H, d, J 
= 6.4 Hz, ArH), 7.03-7.08 (3H, m, ArH), 7.17 (1H, t, J = 7.2 Hz, ArH), 7.58,(1H, d, J = 
8.6 Hz, ArH), 8.39 (1H, d, J = 7.9 Hz, ArH). 
 
1-Acetyl-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide, 63, C21H21F3N2O3 MW 406.40, 
O
F3C
HN
O
N
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (70 mg, 0.2 mmol) in DCM (5 mL) at 0 °C, was added acetyl chloride (0.03 mL, 
0.4 mmol) and TEA (0.12 mL).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 (15 
mL), extracted with DCM (2 x 20 mL) and washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-10% methanol/ 
ethyl acetate), to afford a white solid, 38 mg, 49 % yield. m.p. 164-165 °C, R.f. 0.4 (5 % 
MeOH/ EtOAc), LCMS: tr = 1.00 min (95 % MeOH and 5 % water at 1.0 mL/min), m/z 
M+H 405.22, HPLC: tr = 2.2 min (90 % acetonitrile in water at 1.0 mL/min), 95 %, 
1H 
NMR (CDCl3, 270 MHz): δ 1.56-1.75 (2H, m, CH2), 1.83 (2H, s, CH2), 2.09 (3H, s, 
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CH3), 2.37-2.48 (1H, m, CH), 2.64 (1H, td, J = 14.1, 2.7 Hz, NCH2), 3.07 (1H, td, J = 
14.6, 2.9 Hz, NCH2), 3.83 (1H, d, J = 13.9 Hz, NCH2), 4.57 (1H, d, J = 13.4 Hz, 
NCH2), 6.90 (1H, dd, J = 8.2, 1.2 Hz, ArH), 7.04-7.08 (2H, m, ArH), 7.09-7.10 (1H, m, 
ArH), 7.19 (1H, td, J = 1.5, 9.2 Hz, ArH), 7.60 (2H, d, J = 8.9 Hz, ArH), 7.60 (1H, s, 
NH), 8.39 (1H, d, J = 7.9 Hz, ArH).  13C NMR: (CDCl3, 101 MHz): δ 21.4 (CH3), 28.3, 
28.8, 40.7 (CH2), 44.0 (CH), 45.6 (CH2), 117.8, 118.9, 121.7, 124.7, 125.3, 127.4, 
127.4, 127.5 (ArCH), 127.5, 129.8, 144.5, 159.3 (ArC), 168.9, 172.1 (CO).  HRMS: 
Calcd for C21H21F3N2O3 (M+H)
+ 407.1577, found (M+H)+ 407.1574.  Anal. Calcd for 
C21H21F3N2O3: C 62.06, H 5.21, N 6.89 %. Found: C 61.3, H 5.22, N 6.65 %. 
 
1-Benzoyl-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide, 64, C26H23F3N2O3, MW 468.47 
O
F3C
HN
O
N
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (70 mg, 0.2 mmol) in DCM (5 mL) at 0 °C was added benzoyl chloride (0.05 
mL, 0.4 mmol) and TEA (0.1 mL).  The reaction mixture was allowed to warm to room 
temperature and stirred for 30 min.  The reaction was quenched with NaHCO3 (15 mL), 
extracted with DCM (2 x 20 mL) and washed with hydrochloric acid (1M, 20 mL) and 
brine (20 mL).  The organic layers were dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-5% methanol in 
ethyl acetate), to afford the desired compound as a white solid, 57 mg, 63 % yield.  m.p. 
69-72 °C, R.f. 0.45 (5 % MeOH/ EtOAc), LCMS: tr=1.15 min (95 % MeOH and 5% 
water at 1.0 mL/min), M+H 469.44, HPLC: tr= 2.13 min (90 % acetonitrile in water at 
1.0 mL/min), 95 %. 1H NMR: (CDCl3, 270 MHz): δ 1.78-2.02 (4H, m, CH2), 2.42-2.52 
(1H, m, CH), 2.96-3.06 (2H, m, CH2), 3.81-3.91 (1H, m, CH2), 4.73 (1H, s, CH2), 6.85-
6.96 (1H, m, ArH), 7.00-7.08 (2H, m, ArH), 7.13-7.21 (1H, m, ArH), 7.23-7.27 (1H, m, 
ArH), 7.38 (5H, s, ArH), 7.58-7.61 (3H, m, CH2, NH), 8.40 (1H, d, J = 7.9 Hz, ArH).  
 
13C NMR: (CDCl3, 101 MHz): δ 28.5, 28.7, 41.4 (CH2), 44.1 (CH), 46.9 (CH2), 117.8, 
118.9, 121.8 124.7, 125.3, 126.8, 127.4, 127.4, 128.5, 129.7 (ArCH), 129.8, 135.7, 
144.5, 159.3 (ArC), 170.4, 172.2 (CO).  19F NMR (CDCl3, 376 MHz): δ -61.84 (s, CF3).  
HRMS: Calcd for C26H23F3N2O3 (M+H)
+ 469.1734, found (M+H)+ 469.1731.  Anal. 
Calcd for C26H23F3N2O3: C 66.66, H 4.95, N 5.98 %. Found: C 66.4, H 5.03, N 5.72 %. 
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1-Cyclohexanecarbonyl-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-
phenoxy)-phenyl]-amide, 65, C26H29F3N2O3, MW 474.52 
O
HN
O
N
F3C
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
cyclohexane carbonyl chloride (0.08 mL, 0.54 mmol).  The reaction mixture was 
allowed to warm to room temperature and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL) and washed 
with hydrochloric acid (1M, 20 mL) and brine (20 mL).  The organic layers were dried 
(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to afford the title compound as a 
white waxy solid, 128 mg, 98 % yield.  m.p. 78-80 °C, R.f. 0.6 (EtOAc), LCMS: tr= 4.7 
min (50 % MeOH in water at 0.5 mL/min), m/z M+H 475.42, HPLC: tr= 2.6 min (90 % 
acetonitrile in water at 1.0 mL/min), 99 %, 1H NMR (CDCl3, 400 MHz): δ 1.48-1.88 
(14H, m, 7CH2), 2.39-2.48 (2H, m, 2CH), 2.60 (1H, t, J = 11.2 Hz, CH2), 3.02 (1H, t, J 
= 12.0 Hz, CH2), 3.93 (1H, d, J = 13.2 Hz, CH2), 4.59 (1H, d, J = 13.2 Hz, CH2), 6.91 
(1H, dd, J = 8.0, 1.2 Hz, ArH), 7.07 (2H, d, J = 8.8 Hz, ArH), 7.07 (1H, m, ArH), 7.18 
(1H, td, J = 1.2, 8.0 Hz, ArH), 7.60 (2H, d, J = 9.2 Hz, ArH), 7.62 (1H, s, NH), 8.38 
(1H, dd, J = 1.2, 8.0 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 25.79, 28.51, 29.00, 
29.23, 29.50 (CH2), 40.42 (CH), 40.88 (CH2), 44.25 (CH), 44.57 (CH2), 117.79, 118.94, 
121.75, 122.56, 124.62, 125.31, 127.37, 127.40, 127.43, 127.47, 129.86, 144.44 (ArC), 
159.34 (CF3), 172.23, 174.49 (C=O).  HRMS: Calcd for C26H29F3N2O3 (M+H)
+ 
475.2203, found (M+H)+ 475.2198. 
 
1-Cyclopentanecarbonyl-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-
phenoxy)-phenyl]-amide, 66, C25H27F3N2O3, MW 460.49, 
O
HN
O
N
F3C
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
cyclopentane carbonyl chloride (0.07 mL, 0.54 mmol).  The reaction mixture was 
allowed to warm to room temperature and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL) and washed 
with hydrochloric acid (1M, 20 mL) and brine (20 mL).  The organic layers were dried 
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(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to afford the title compound as a 
white waxy solid, 105 mg, 83 % yield.  m.p. 94-97 °C, R.f. 0.65 (EtOAc), LCMS: tr= 
4.86 min (50 % MeOH in water at 0.5 mL/min), m/z M+H 461.44, HPLC: tr= 2.43 min 
(90 % acetonitrile in water at 1.0 mL/min), 99 %, 1H NMR (CDCl3, 400 MHz): δ 1.48-
1.86 (12H, m, 6CH2), 2.40-2.48 (1H, m, CH), 2.63 (1H, td, J = 13.6, 2.8 Hz, CH2), 2.81-
2.89 (1H, m, CH), 3.03 (1H, td, J = 14.4, 2.4 Hz, CH2), 3.98 (1H, d, J = 13.2 Hz, CH2), 
4.59 (1H, d, J = 13.2 Hz, CH2), 6.91 (1H, dd, J = 1.2, 7.6 Hz, ArH), 7.05 (2H, d, J = 8.0 
Hz, ArH), 7.08 (1H, td, J = 1.6 Hz, ArH), 7.18 (1H, td, J = 1.2, 8.8 Hz, ArH), 7.59 (2H, 
d, J = 8.4 Hz, ArH), 7.64 (1H, s, NH), 8.37 (1H, dd, J = 1.2, 7.2 Hz, ArH).  13C NMR 
(CDCl3, 101 MHz): δ 25.95, 28.47, 29.03, 29.92 (CH2), 41.02 (CH), 41.09 (CH2), 44.22 
(CH), 44.69 (CH2), 117.76, 118.94, 121.76, 124.61, 125.29, 127.33, 127.37, 127.41, 
127.45, 129.85, 144.44 (ArC), 159.33 (CF3), 172.26, 174.40 (C=O).  HRMS: Calcd for 
C25H27F3N2O3 (M+H)
+ 461.2047, found (M+H)+ 461.2035. 
 
1-Isobutyryl-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide, 67, C23H25F3N2O3, MW 434.45, 
O
HN
O
N
F3C
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
isobutyryl carbonyl chloride (0.06 mL, 0.5 mmol).  The reaction mixture was allowed to 
warm to room temperature and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL) and washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-
100 % ethyl acetate in hexane) to afford the title compound as a white waxy solid, 98 
mg, 82 % yield.  m.p. 70-72 °C, R.f. 0.60 (EtOAc), LCMS: tr= 4.28 min (50 % MeOH 
in water at 0.5 mL/min), m/z M+H 435.44, HPLC: tr= 2.23 min (90 % acetonitrile in 
water at 1.0 mL/min), 96 %, 1H NMR (CDCl3, 270 MHz): δ 1.08 (6H, t, J = 6.0 Hz, 
CH3), 1.57-1.70 (2H, m, CH2), 1.80-1.86 (2H, m, CH2), 2.41-2.48 (1H, m, CH), 2.60 
(1H, t, J = 12.8 Hz, CH2), 2.71-2.79 (1H, m, CH(CH3)2), 3.03 (1H, t, J = 12.8 Hz, CH2), 
3.94 (1H, d, J = 13.2 Hz, CH2), 4.58 (1H, d, J = 12.8 Hz, CH2), 6.90 (1H, d, J = 8.0 Hz, 
ArH), 7.04 (1H, d, J = 8.0 Hz, ArH), 7.05-7.08 (1H, m, ArH), 7.15-7.20 (1H, m, ArH), 
7.58 (1H, d, J = 8.0 Hz, ArH), 7.69 (1H, s, NH), 8.36  (1H, d, J = 8.0 Hz, ArH).  13C 
NMR (CDCl3, 101 MHz): δ 19.2, 19.5 (CH3), 28.4, 29.0 (CH2), 29.9 (CH), 40.1 (CH2), 
44.1 (CH), 44.5 (CH2), 118.9, 121.8, 124.6, 125.2 (ArCH), 125.9 (ArC), 127.3, 127.4 
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(ArCH), 129.8, 144.5 (ArC), 159.3 (CF3), 172.3, 175.3 (CO).  HRMS: Calcd for 
C23H25F3N2O3 (M+H)
+ 435.1890, found (M+H)+ 435.1883.   
 
1-(3-Methyl-butyryl)-piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-
phenyl]-amide, 68, C24H27F3N2O3, MW 448.48, 
O
HN
O
N
F3C
O
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-
amide (0.1 g, 0.27 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
isovaleryl carbonyl chloride (0.066 mL, 0.54 mmol).  The reaction mixture was allowed 
to warm to room temperature and stirred for 30 min.  The reaction was quenched with 
sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-
100 % ethyl acetate in hexane) to afford the desired compound as a white waxy solid, 
78 mg, 63 % yield.  m.p. 63-64 °C, R.f. 0.60 (EtOAc), LCMS: t r= 4.66 min (50 % 
MeOH in water at 0.5 mL/min), m/z M+H 449.48, HPLC: t r= 2.35 min (90 % 
acetonitrile in water at 1.0 mL/min), >99 %, 1H NMR (CDCl3, 400 MHz): δ 0.94 (6H, 
d, J = 6.0, 2CH3), 1.60-1.70 (2H, m, CH2), 1.82-1.85 (2H, m, CH2), 2.02-2.09 (1H, m, 
CH), 2.17-2.20 (2H, m, CH2), 2.40-2.46 (1H, m, CH), 2.62 (1H, t, J = 13.2 Hz, CH2), 
3.03 (1H, t, J = 14.4 Hz, CH2), 3.88 (1H, d, J = 7.6 Hz, CH2), 4.59 (1H, d, J = 13.2 Hz, 
CH2), 6.91 (1H, d, J = 7.6 Hz, ArH), 7.05 (2H, d, J = 8.4 Hz, ArH), 7.08-7.09 (1H, m, 
ArH), 7.65 (1H, s, NH), 8.38  (1H, dd, J=0.8, 8.0 Hz, ArH).  13C NMR (CDCl3, 101 
MHz): δ 22.63, 22.73 (CH3), 25.74 (CH), 28.48, 28.95, 40.78, 42.05 (CH2), 44.08 (CH), 
45.05 (CH2), 117.79, 118.93, 121.75, 124.64, 125.28, 127.35 (ArCH), 127.38, 127.42, 
129.81, 144.45 (ArC), 159.32 (CF3), 170.93, 172.23 (C=O).  HRMS: Calcd for 
C24H27F3N2O3 (M+H)
+ 449.2058, found (M+H)+ 449.2036.  Anal. Calcd for 
C24H27F3N2O3: C 64.27, H 6.07, N 6.25 %. Found: C 64.5, H 6.17, N 6.39 %. 
 
4-[2-(4-Trifluoromethoxy-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic 
acid tert-butyl ester, 47, C24H27F3N2O5 MW 480.49, 
O
HN
F3CO
O
N O
O
 
Using the general procedure for the formation of the amide linker the desired compound 
was obtained as a yellow wax, 1.59 g, 57 % yield.  R.f: 0.65 (DCM), LCMS: tr = 5.24 
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min (50 % to 95 % MeOH: water over 5 min, at 1.0 mL/min), m/z M+H 479.38, HPLC: 
tr = 3.59 min (90 % acetonitrile in water at 1.0 mL/min), >99 %.  
1H NMR (CDCl3, 270 
MHz): δ 1.44 (9H, s, CH3), 1.67 (2H, td, J = 13.4, 4.4 Hz, CH2), 1.80 (2H, dd, J = 1.8 
Hz, CH2), 2.30-2.41 (1H, m, CH), 2.74 (2H, t, J = 11.9 Hz, CH2N), 4.12 (2H, d, J = 
11.6 Hz, CH2N), 6.85 (1H, dd, J = 6.7, 1.5 Hz, ArH), 7.03 (2H, d, ArH), 6.99-7.06 (1H, 
m, ArH), 7.13 (1H, td, J = 1.5, 6.4 Hz, ArH), 7.20 (2H, d, J = 1.5, 6.4 Hz ArH), 7.64  
(1H, s, NH), 8.40 (1H, d, J = 8.2 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 28.4 
(CH3), 28.5 (CH2), 43.1 (CH), 117.9, 119.2, 119.4, 121.4, 121.7 122.9, 124.3, 124.6, 
129.6, 144.9, 149.3 (ArC), 154.5 (OCF3), 154.8, 172.6 (CO).  HRMS: Calcd for 
C24H27F3N2O5 (M+H)
+ 481.1945, found (M+H)+ 481.1391.  Anal. Calcd for 
C24H27F3N2O5: C 59.99, H 5.66, N 5.83 %. Found: C 60.0, H 5.68, N 5.80 %. 
 
Piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-amide, 48e, 
C19H19F3N2O3, MW 380.0, 
O
HN
O
NH
F3CO
 
Using the general procedure for the removal of the N-Boc protecting group the desired 
product was obtained as an off white oil, 0.21 g, 87 % yield.  R.f: 0.35 (DCM), 1H NMR 
(CDCl3, 270 MHz): δ 1.55-1.68 (2H, m, CH2), 1.79 (2H, dd, J = 2.7, 12.9 Hz, CH2), 
2.30-2.36 (1H, m, CH), 2.61 (2H, td, J = 2.7, 12.3 Hz, NCH2), 2.94 (1H, s, NH), 3.10 
(2H, td, J = 3.3, 12.6 Hz, NCH2), 6.79 (1H, dd, J = 1.2, 8.1, ArH), 6.92-7.00 (3H, m, 
ArH), 7.08 (1H, td, J = 1.5, 7.8 Hz, ArH), 7.13 (2H, d, J = 8.4 Hz, ArH), 7.62 (1H, s, 
NH), 8.34 (1H, dd, J = 1.2, 8.1 Hz, ArH). 
 
1-Acetyl-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide, 69, C21H21F3N2O4, MW 422.41 
O
HN
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (105 mg, 0.28 mmol) in DCM (8 mL) at 0 °C was added acetyl chloride (0.04 
mL, 0.56 mmol) and TEA (0.18 mL).  The reaction mixture was allowed to warm to 
room temperature and stirred for 30 min.  The reaction was quenched with sat. NaHCO3 
(15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid (1M, 20 mL) 
and brine (20 mL).  The organic layers were dried (MgSO4), filtered and evaporated in 
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vacuo.  The crude mixture was purified using flash chromatography (0-5 % methanol in 
ethyl acetate), to afford the desired compound as a white solid, 55 mg, 47 % yield.  m.p. 
44-46 °C, R.f. 0.45 (DCM), LCMS: tr = 1.08 min (95 % MeOH in water at 1.0 mL/min), 
m/z M+H 423.48, HPLC: tr = 2.12 min (90 % acetonitrile in water at 1.0 mL/min), 97 
%, HRMS: Calcd for C21H21F3N2O4 (M+H)
+ 423.1526, found (M+H)+ 423.1525, 1H 
NMR (CDCl3, 270 MHz): δ 1.54-1.72 (2H, m, CH2), 1.78-1.86 (2H, m, CH2), 2.02 (3H, 
s, CH3), 2.35-2.45 (1H, m, CH), 2.60 (1H, td, J = 3.0, 14.7 Hz, CH2), 2.98-3.08 (1H, m, 
CH2), 3.79 (1H, d, J = 13.5 Hz, CH2), 4.52 (1H, d, J = 13.2 Hz, CH2), 6.79 (1H, dd, J = 
1.2, 8.1 Hz, ArH), 6.92-7.01 (3H, m, ArH), 7.08 (1H, td, J = 1.2, 7.8 Hz, ArH), 7.15 
(2H, dd, J = 0.6, 9.0 Hz, ArH), 7.26 (1H, s, NH), 8.32 (1H, dd, J = 1.2, 8.1 Hz, ArH).  
13C NMR (CDCl3, 101 MHz): δ 21.4 (CH2), 28.37, 28.8, 40.7 (CH2), 44.1 (CH), 45.6 
(CH2), 117.9, 119.4, 121.4, 122.9, 124.5, 124.6 (ArCH), 129.4, 145.0, 154.8 (ArC), 
168.9, 172.1 (CO).  19F NMR (CDCl3, 374 MHz): δ -58.26 (s, OCF3).  Anal. Calcd for 
C21H21F3N2O4: C 59.71, H 5.01, N 6.63 %. Found: C 58.0, H 4.93, N 6.37 %. 
 
1-Benzoyl-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide, 70, C26H23F3N2O4, MW 484.45, 
O
HN
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (105 mg, 0.28 mmol) in DCM (8 mL) at 0 °C, was added benzoyl chloride (0.064 
mL, 0.56 mmol) and TEA (0.18 mL).  The reaction mixture was allowed to warm to 
room temperature, and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in vacuo.  The crude mixture was purified using flash chromatography (0-5 
% methanol in DCM), to afford the title compound a white wax, 105 mg, 78 % yield.  
R.f. 0.45 (DCM), LCMS: tr= 4.9 min (50% MeOH in water at 0.5 mL/min), m/z M
+H 
485.43, HPLC: tr= 5.3 (90 % acetonitrile in water at 1.0 mL/min), 98 %, HRMS: Calcd 
for C26H23F3N2O4 (M+H)
+ 485.1683, found (M+H)+ 485.1685, 1H NMR (CDCl3, 270 
MHz): δ 1.74 (4H, s, 2CH2), 2.39-2.49 (1H, m, CH), 2.90 (2H, s, CH2), 3.77 (1H, s, 
CH2), 4.63 (1H, s, CH2), 6.80 (1H, dd, J = 1.2, 8.1 Hz, ArH), 6.92-6.98 (1H, m, ArH), 
6.95 (2H, m, ArH), 7.09 (1H, td, J = 1.5, 7.8 Hz, ArH), 7.15 (2H, dd, J = 0.6, 9.0 Hz, 
ArH), 7.30-7.36 (5H, m, ArH), 7.63 (1H, s, NH), 8.32  (1H, d, J = 7.2 Hz, ArH).  13C 
NMR (CDCl3, 101 MHz): δ 28.6, 28.9, 41.4 (CH2), 44.1 (CH), 46.9 (CH2), 117.9, 
119.4, 121.5, 122.9, 124.5, 124.6, 128.5 (ArCH), 129.4 (ArC), 129.7 (ArCH), 135.8, 
145.0, 145.4, 154.7 (ArC), 170.5, 172.1 (CO).  19F NMR (CDCl3, 374 MHz): δ -58.25 
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(s, OCF3).  Anal. Calcd for C26H23F3N2O4: C 64.46, H 4.79, N 5.78 %. Found: C 63.7, 
H 4.76, N 5.57 %. 
 
1-Cyclohexanecarbonyl-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-
phenoxy)-phenyl]-amide, 71, C26H29F3N2O4, MW 490.51 
O
NH
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
cyclohexane carbonyl chloride (0.072 mL, 0.52 mmol).  The reaction mixture was 
allowed to warm to room temperature and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with 
hydrochloric acid (1M, 20 mL) and brine (20 mL).  The organic layers were dried 
(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to afford the title compounds as a 
white waxy solid, 98 mg, 76 % yield.  m.p. 98-100 °C, R.f. 0.70 (EtOAc), LCMS: tr = 
5.08 min (50 % MeOH in water at 0.5 mL/min), m/z M+H 489.33, HPLC: tr = 2.57 min 
(90 % acetonitrile in water at 1.0 mL/min), 98 %, 1H NMR (CDCl3, 270 MHz): δ 1.47-
1.86 (12H, m, 6CH2), 2.38-2.52 (2H, m, 2CH), 2.61 (1H, t, J = 11.6 Hz, CH2), 3.03 (1H, 
t, J = 12.2 Hz, CH2), 3.94 (1H, d, J = 13.1 Hz, CH2), 4.62 (1H, d, J = 12.9 Hz, CH2), 
6.85 (1H, dd, J = 1.5, 8.2 Hz, ArH), 7.00 (2H, d, J = 9.2 Hz, ArH), 6.99-7.03 (1H, m, 
ArH), 7.14 (1H, td, J = 1.5, 7.9 Hz, ArH), 7.20 (2H, d, J = 8.4 Hz, ArH), 7.68 (1H, s, 
NH), 8.39 (1H, d, J = 8.2 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 25.81, 25.84, 
28.57, 29.25, 29.52 (CH2), 40.46 (CH), 40.94 (CH2), 44.38 (CH), 44.63 (CH2), 117.92, 
119.34, 121.38, 122.92, 124.43, 124.67, 129.47, 129.47, 144.98, 145.28 (ArC), 154.79 
(OCF3), 172.22, 174.53 (C=O).  HRMS: Calcd for C26H29F3N2O4 (M+H)
+ 491.2152, 
found (M+H)+ 491.2154.  Anal. Calcd for C26H29F3N2O4: C 63.66, H5.96, N 5.71.  
Found C 63.6, H 5.86, N 5.58. 
 
1-Cyclopentanecarbonyl-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-
phenoxy)-phenyl]-amide, 72, C25H27F3N2O4, MW 476.49, 
O
NH
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
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cyclopentane carbonyl chloride (0.066 mL, 0.52 mmol).  The reaction mixture was 
allowed to warm to room temperature and stirred for 30 min.  The reaction was 
quenched with sat. NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with 
hydrochloric acid (1M, 20 mL) and brine (20 mL).  The organic layers were dried 
(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to afford the title compound as a 
white waxy solid, 85 mg, 68 % yield.  m.p. 48-50 °C, R.f. 0.68 (EtOAc), LCMS: tr = 5.0 
min (50 % MeOH in water at 0.5 mL/min), m/z M+H 477.56, HPLC: tr = 2.5 min (90 % 
acetonitrile in water at 1.0 mL/min), 99 %, 1H NMR (CDCl3, 270 MHz): δ 1.53-1.91 
(12H, m, 6CH2), 2.41-2.52 (1H, m, CH), 2.64 (1H, td, J = 2.7, 13.4 Hz, CH2), 2.80-2.91 
(1H, m, CH), 3.05 (1H, td, J = 2.5, 13.6 Hz, CH2), 4.01 (1H, d, J = 13.4 Hz, CH2), 4.62 
(1H, d, J = 13.4 Hz, CH2), 6.85 (1H, dd, J = 1.2, 7.9 Hz, ArH), 7.00 (2H, d, J = 9.2 Hz, 
ArH), 7.00-7.06 (1H, m, ArH), 7.14 (1H, td, J = 1.8, 7.9 Hz, ArH), 7.20 (2H, d, J = 0.8, 
9.1 Hz, ArH), 7.69 (1H, s, NH), 8.39 (1H, dd, J = 1.5, 8.2 Hz, ArH).  13C NMR (CDCl3, 
101 MHz): δ 25.99, 28.56, 29.09, 30.22 (CH2), 41.07 (CH), 41.16 (CH2), 44.39 (CH), 
44.76 (CH2), 117.91, 119.41, 121.36, 122.91, 124.41, 124.42, 124.67, 129.49, 145.00, 
145.27 (ArC), 154.78 (OCF3), 172.24, 174.44 (C=O).  HRMS: Calcd for C25H27F3N2O4 
(M+H)+ 477.1996, found (M+H)+ 477.1987.  Anal. Calcd for C25H27F3N2O4: C 63.02, H 
5.71, N 5.88.  Found C 63.2, H 5.77, N 5.86. 
 
1-Isobutyryl-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-
phenyl]-amide, 73, C23H25F3N2O4, MW 450.45, 
O
NH
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (0.1 g, 0.26 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
isobutyryl chloride (0.057 mL, 0.52 mmol).  The reaction mixture was allowed to warm 
to room temperature, and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in-vacuo.  The crude mixture was purified using flash chromatography (0-
100 % ethyl acetate in hexane) to afford the title compound as a white waxy solid, 89 
mg, 75 % yield.  m.p. 101-103 °C, R.f. 0.56 (EtOAc), LCMS: tr = 5.37 min (50 % 
MeOH in water at 0.5 mL/min), m/z M+H 449.35, HPLC: tr = 2.86 min (90 % 
acetonitrile in water at 1.0 mL/min), 98 %, HRMS: Calcd for C23H25F3N2O4 (M+H)
+ 
451.1839, found (M+H)+ 451.1839, 1H NMR (CDCl3, 270 MHz): δ 108-1.12 (6H, m, 
CH3), 1.62-1.78 (2H, m, CH2), 1.86-1.89 (2H, m, CH2), 2.41-2.52 (1H, m, CH2), 2.59-
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2.72 (1H, m, CH2), 2.75-2.85 (1H, m, CH2), 3.06 (1H, t, J = 12.4 Hz, CH2), 3.98 (1H, d, 
J = 12.8 Hz, CH2), 4.63 (1H, d, J = 13.1 Hz, CH2), 6.84 (1H, dd, J = 1.5, 7.9 Hz, ArH), 
7.01 (2H, d, J = 9.1 Hz, ArH), 6.98-7.07 (1H, m, ArH), 7.14 (1H, td, J = 1.5, 7.7 Hz, 
ArH), 7.20 (2H, d, J = 8.9 Hz, ArH), 7.67 (1H, s, NH), 8.39 (1H, dd, J = 1.5, 8.2 Hz, 
ArH).  13C NMR (CDCl3, 101 MHz): δ 19.28, 19.53 (CH3), 28.57, 29.15 (CH2), 30.07 
(CH), 41.04 (CH2), 44.35 (CH), 44.66 (CH2), 117.91, 119.41, 121.36, 122.91, 124.43, 
124.67, 129.47, 144.99, 149.28 (ArC), 154.78 (CF3), 172.20, 175.34 (C=O).  Anal. 
Calcd for C23H25F3N2O4: C 61.33, H 5.59, N 6.22.  Found C 61.3, H 5.61, N 5.93. 
 
1-(3-Methyl-butyryl)-piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-
phenoxy)-phenyl]-amide, 74, C24H27F3N2O4, MW 464.48, 
O
NH
O
N
O
F3CO
 
To a solution of piperidine-4-carboxylic acid [2-(4-trifluoromethoxy-phenoxy)-phenyl]-
amide (0.1 g, 0.3 mmol) in DCM (5 mL) at 0 °C was added TEA (0.2 mL) and 
isovaleryl chloride (0.066 mL, 0.52 mmol).  The reaction mixture was allowed to warm 
to room temperature and stirred for 30 min.  The reaction was quenched with sat. 
NaHCO3 (15 mL), extracted with DCM (2 x 20 mL), washed with hydrochloric acid 
(1M, 20 mL) and brine (20 mL).  The organic layers were dried (MgSO4), filtered and 
evaporated in-vacuo.  The crude mixture was purified using flash chromatography (0-
100 % ethyl acetate in hexane) to afford the title compound as a white waxy solid, 82 
mg, 67 % yield.  m.p. 82-85 °C, R.f. 0.60 (EtOAc), LCMS: tr = 5.38 min (50 % MeOH 
in water at 0.5 mL/min), m/z M+H 463.33, HPLC: tr = 2.42 min (90 % acetonitrile in 
water at 1.0 mL/min), 98 %, 1H NMR (CDCl3, 270 MHz): δ 0.95 (6H, d, J = 6.4 Hz, 
CH3), 1.63-1.76 (2H, m, CH2), 1.85-1.90 (2H, m, CH2), 2.01-2.16 (1H, m, CH), 2.19 
(2H, m, CH2), 2.40-2.51 (1H, m, CH), 2.64 (1H, td, J = 3.0, 13.4 Hz, CH2), 2.99-3.10 
(1H, m, CH2), 3.91 (1H, d, J = 14.1 Hz, CH2), 4.63 (1H, d, J = 13.6 Hz, CH2), 6.85 (1H, 
dd, J = 1.5, 8.2 Hz, ArH), 7.00 (2H, d, J = 9.2 Hz, ArH), 6.97-7.07 (1H, m, ArH), 7.14 
(1H, td, J = 1.5, 7.7 Hz, ArH), 7.20 (2H, d, J = 9.2 Hz, ArH), 7.67 (1H, s, NH), 8.39 
(1H, dd, J = 1.5, 8.2 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 22.67, 22.77 (CH3), 
25.77 (CH), 28.57, 29.02, 40.84, 42.01 (CH2), 44.25 (CH), 45.11 (CH2), 117.91, 119.41, 
121.38, 122.92, 124.44, 124.67, 129.47, 145.01 (ArC), 145.30 (OCF3), 154.78, 170.95 
(C=O).  HRMS: Calcd for C24H27F3N2O4 (M+H)
+ 465.1996, found (M+H)+ 465.1975.  
Anal. Calcd for C24H27F3N2O4: C 62.06, H 5.86, N 6.03. Found C 62.1, H 5.96, N 6.01. 
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1-(1-Acetyl-piperidine-4-carbonyl)-piperidine-4-carboxylic acid [2-(2,4-dichloro-
phenoxy)-phenyl]-amide, 76, C26H29Cl2N3O4, MW 518.43, 
Cl
O
HNCl
N
O
N
OO  
Piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-phenyl]-amide (43a, 100 mg, 
0.27 mmol) was dissolved in anhydrous DCM (10 mL) and stirred under nitrogen.  To 
this was added 1-acetylpiperidine-4-carbonyl chloride (0.1 g, 0.54 mmol) and TEA 
(0.17 mL) this was stirred at room temperature for 1 h.  NaHCO3 (20 mL) was then 
added, and extracted with DCM (2 x 20 mL) and washed with HCl (1M, 20 mL).  The 
organic layers were combined, dried (MgSO4), filtered and evaporated in vacuo. The 
crude mixture was purified using flash chromatography (0-5 % MeOH in DCM) to 
afford the title compound as a white solid, 0.121 g, 86 % yield.  R.f. 0.59 (5 % MeOH 
in DCM), m.p. 99-101 °C, LCMS: tr = 1.16 min (95 % MeOH in water), m/z M-H 
516.43, HPLC: tr = 1.77 min (90 % acetonitrile in water), 99 %, 
1H NMR (CDCl3, 270 
MHz,): δ 1.69-1.74 (8H, m, 4CH2), 2.07 (3H, s, CH3), 2.66-2.75 (4H, m, 2CH2), 3.04-
3.17 (2H, m, CH2), 3.83-3.99 (2H, m, CH2), 4.55 (2H, d, J = 12.4Hz, CH2), 6.71 (1H, 
dd, J = 1.5, 8.2Hz, ArH), 6.94 (1H, d, J = 8.7Hz, ArH), 7.00 (1H, dd, J = 1.5, 7.9Hz, 
ArH), 7.12 (1H, td, J = 1.2, 7.7Hz, ArH), 7.21 (1H, dd, J = 2.5, 8.7Hz, ArH), 7.48 (1H, 
d, J = 2.5, ArH), 7.80 (1H, s, NH), 8.37 (1H, dd, J = 1.5, 8.2Hz, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 21.6 (CH3), 28.3, 28.7, 28.9(CH2), 29.2 (CH), 41.0, 41.3 (CH2), 
44.2 (CH), 44.8, 45.8 (CH2), 116.6, 121.5, 124.4, 124.6, 128.5 (ArCH), 128.9, 130.3 
(ArC), 130.7 (ArCH), 145.3 (ArC), 172.5 (CO).  Anal. Calcd for C26H29Cl2N3O4.H2O: 
C 58.2, H 5.82, N 7.8 %. Found: C 58.8, H 5.6, N 7.8 %.  HRMS: Calcd for 
C26H29Cl2N3O4 (M+H)
+ 518.1608, found (M+H)+ 518.1617. 
 
1-(1-Acetyl-piperidine-4-carbonyl)-piperidine-4-carboxylic acid [2-(4-trifluoro 
methyl-phenoxy)-phenyl]-amide, 77, C27H30F3N3O4, MW 517.54, 
F3C
O
HN
N
O
N
OO  
Piperidine-4-carboxylic acid [2-(4-trifluoromethyl-phenoxy)-phenyl]-amide (43d, 100 
mg, 0.27 mmol) was dissolved in anhydrous DCM (10 mL) and stirred under nitrogen.  
To this was added 1-acetylpiperidine-4-carbonyl chloride (100 mg, 0.54 mmol) and 
TEA (0.17 mL) this was then stirred at room temperature for 40 min.  NaHCO3 (20 mL) 
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was then added and extracted with DCM (2 x 20 mL) and washed with HCl (1M, 20 
mL).  The organic layers were combined, dried (MgSO4), filtered and evaporated in 
vacuo. The crude mixture was purified using flash chromatography (0-10 % MeOH in 
DCM ) to afford the title compound as a white solid, 119 mg, 84 % yield.  R.f. 0.58 (5 
% MeOH in DCM), m.p. 84-89 °C, LCMS: tr = 1.11 min (95 % MeOH in water), m/z 
M-H 516.64, HPLC: tr = 1.30 min (90 % acetonitrile in water), >99 %, 
1H NMR 
(CDCl3, 400 MHz,): δ 1.59-1.85 (8H, m, 4CH2), 2.06 (3H, s, CH3), 2.46 (1H, t, J = 8.0 
Hz, CH), 2.62-2.72 (3H, m, CH and CH2), 3.08 (2H, t, J = 12.4 Hz, CH2), 3.83-3.93 
(2H, m, CH2), 4.55 (2H, d, J = 12.4 Hz, CH2), 6.91 (1H, dd, J = 0.8, 8.0 Hz, ArH), 7.04-
7.09 (3H, m, ArH), 7.16-7.20 (1H, m, ArH), 7.59 (2H, d, J = 8.8 Hz, ArH), 7.68 (1H, s, 
NH), 8.35 (1H, d, J = 8.0 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 21.4 (CH3), 28.4, 
28.7, 29.0, 29.1 (CH2), 38.1 (CH), 40.84 (CH2), 43.9 (CH), 44.6, 45.7 (CH2), 117.8, 
119.0, 121.9, 124.7, 125.3, 127.4 (ArCH), 129.8, 144.5, 159.5, 168.8 (ArC), 172.0, 
172.1, 172.3 (CO).  HRMS: Calcd for C27H30F3N3O4 (M+H)
+ 518.2261, found (M+H)+ 
518.2262. 
 
1-[2-(1-Acetyl-piperidin-4-yl)-acetyl]-piperidine-4-carboxylic acid [2-(2,4-dichloro-
phenoxy)-phenyl]-amide, 78, C27H31Cl2N3O4, MW 532.46, 
Cl
O
HNCl
N
O N
O
O  
(1-Acetyl-piperidin-4-yl)-acetic acid (50 mg, 0.27 mmol) was dissolved in anhydrous 
DCM (20 mL) and stirred under nitrogen.  To this was added N N-4-dimethyl 
aminopyridine (cat.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(160 mg, 0.9 mmol) and TEA (0.05 mL). The reaction was stirred at room temperature 
for 30 min.  To this was added piperidine-4-carboxylic acid [2-(2,4-dichloro-phenoxy)-
phenyl]-amide (50a, 100 mg, 0.27 mmol) and the reaction stirred for 2 days.  The 
reaction mixture was diluted with DCM (30 mL), washed with HCl (1M, 20 mL), 
NaHCO3 (sat. 20 mL) and brine (20 mL).  The organic layers were combined and dried 
(MgSO4) and evaporated in vacuo to afford a white wax, 24 mg, 17 % yield.  R.f. 0.45 
(10% MeOH in DCM), LCMS: tr = 1.18 min (95 % MeOH in water), m/z M-H 530.42, 
532.51, HPLC: tr = 1.60 min (90 % acetonitrile in water), 99 %, 
1H NMR (CDCl3, 400 
MHz,): δ 1.07-1.18 (2H, m, CH2), 1.68-1.75 (4H, m, CH2), 1.85 (1H, d, J = 12.8Hz, 
CH2), 1.91-1.92 (2H, m, CH2), 2.06 (3H, s, CH3), 2.08-2.31 (2H, m, ½CH2 and CH), 
2.49-2.59 (2H, m, ½CH2 and CH), 2.70 (1H, t, J = 12.8Hz, ½CH2), 3.02-3.12 (2H, m, 
CH2), 3.77 (1H, d, J = 14Hz, CH2), 3.91 (1H, d, J = 13.2Hz, ½CH2), 4.59 (2H, dd, J = 
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4.4, 11.2Hz, CH2), 6.72 (1H, dd, J = 1.2, 8.4Hz, ArH), 6.94 (1H, d, J = 8.8Hz, ArH), 
7.00 (1H, td, J = 1.6, 8.0Hz, ArH), 7.13 (1H, td, J = 1.2, 7.6Hz, ArH), 7.22 (1H, dd, J = 
2.8, 8.8Hz, ArH), 7.49 (1H, d, J = 2.4Hz, ArH), 7.78 (1H, s, NH), 8.37 (1H, d, J = 
7.6Hz, ArH).  13C NMR (CDCl3, 68 MHz): δ 21.5 (CH3), 28.5, 28.6, 28.9, 32.0, 32.7, 
32.8 (CH2), 33.1 (CH), 39.3, 39.4, 41.0, 41.7 (CH2), 44.1(CH), 44.9, 46.5 (CH2), 116.5, 
121.4, 121.5, 124.3, 124.5 (ArCH), 126.3 (ArC), 128.4 (ArCH), 128.8, 130.2 (ArC), 
130.6 (ArCH), 145.2, 150.3 (ArC), 168.7, 169.8, 172.1 (CO).  HRMS: Calcd for 
C27H31Cl2N3O4 (M+H)
+ 532.1764, found (M+H)+ 532.1764. 
 
Experimental Details: Chapter 7: Synthesis of the Amine Linked Series of 
Inhibitors 
 
General Microwave Experimental Procedure for Ketones  
This method is as reported by Bailey et al.85  To a solution of aniline (1 mmol) and 
ketone (2 mmol) in DCE (2 mL) in a microwave vial, was added NaBH(OAc)3 (2.5 
mmol) and AcOH (3 mmol).  The vial was capped and the resulting solution was heated 
in a CEM Discover® microwave for 10 minutes (fixed hold time) at 140 °C.  The 
reaction was quenched with a saturated aqueous solution of NaHCO3 (10 mL) was then 
extracted with DCM (3 x 15 mL).  The combined organics were dried (MgSO4), filtered 
and concentrated in vacuo.  Purification by flash chromatography (DCM) then 
proceeded to afford the desired product.  
 
Cyclohexylphenylamine, 79, C12H17N, MW 175.27, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 94 %, LCMS: r.t. 1.31 min (95% MeOH in water), M+H: 175.96, HPLC: 
r.t. 3.04 min (90% acetonitrile in water), 92% pure, 1H NMR (CDCl3, 270 MHz): δ 
1.10-1.48 (5H, m, CH2), 1.65-1.90 (3H, m, CH2), 2.05-2.15 (2H, m, CH2), 3.20-3.35 
(1H, m, CH), 3.53 (1H, s, NH), 6.59-6.75 (3H, m, ArH), 7.15-7.22 (2H, m, ArH).  This 
compound has been previously synthesised via a different route, by Reddy et al.140 
 
Cyclopentylphenylamine, 80, C11H15N, MW 161.24, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 88 %, LCMS: r.t. 1.45 min (95% MeOH in water), M+H: 162.16, HPLC: 
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r.t. 6.02 min (90% acetonitrile in water), 99% pure, 1H NMR (CDCl3, 270 MHz): δ 
1.54-1.79 (6H, m, CH2), 2.04-2.15 (2H, m, CH2), 3.69 (1H, s, NH), 3.82-3.86 (1H, m, 
CH), 6.64-6.82 (3H, m, ArH), 7.20-7.28 (2H, m, ArH).  This compound has been 
previously synthesised via a different route, by Reddy et al.140 
 
(1-Methylpentyl)phenylamine, 81, C12H19N, MW 177.29, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 92 %, LCMS: r.t. 1.34 min (95% MeOH in water), M+H: 178.05, HPLC: 
r.t. 3.19 min (90% acetonitrile in water), 97% pure, 1H NMR (CDCl3, 270 MHz): δ 
0.92-1.01 (3H, m, CH3CH2), 1.20-1.25 (3H, m, CH3CH), 1.35-1.70 (6H, m, CH2), 3.48-
3.51 (2H, m, CH and NH), 6.62-6.73 (3H, m, ArH), 7.21-7.30 (2H, m, ArH).  This 
compound has been previously synthesised via a different route, by Barluenga et al.141 
 
Cyclooctylphenylamine, 82, C14H21N, MW203.32, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 68 %, LCMS: r.t. 1.62 min (95% MeOH in water), M+H: 204.03, HPLC: 
r.t. 9.16 min (90% acetonitrile in water), 93% pure, 1H NMR (CDCl3, 270 MHz): δ 
1.55-2.04 (14H, m, CH2), 3.56-3.58 (2H, m, CH and NH), 6.55-6.75 (3H, m, ArH), 
7.15-7.20 (2H, m, ArH).  This compound has been previously synthesised via a 
different route, by Anderson et al.142 
 
Cyclohexyl-(4-methoxyphenyl)amine, 83, C13H19NO, MW 205.30, 
N
H
O
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated as an off white solid, 77 %, m.p. 42-45 °C (lit. 41-42 °C),143 LCMS: r.t. 
1.20 min (95% MeOH in water), M+H: 205.99, HPLC: r.t. 2.72 min (90% acetonitrile in 
water), 81% pure, 1H NMR (CDCl3, 270 MHz): δ 1.08-1.38 (5H, m, CH2), 1.60-1.78 
(3H, m, CH2), 2.02-22.10 (2H, m, CH2), 3.12-3.20 (2H, m, CH and NH), 3.74 (3H, s, 
OCH3), 6.55-6.59 (2H, m, ArH), 6.75-6.78 (2H, m, ArH). 
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Cyclopentyl-(4-methoxyphenyl)amine, 84, C12H17NO, MW 191.27, 
N
H
O
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 64 %, LCMS: r.t. 1.35 min (95% MeOH in water), M+H 192.35, HPLC: 
r.t. 5.41 min (90% acetonitrile in water), 99% pure, HRMS: Calculated: 192.1383, 
Measured: 192.1384, IR (CDCl3): 3417 (NH), 2959, 2871, 2835, 2247 (CH), 1510, 
1235 (Ar), 1039 cm-1 (CO). 1H NMR (CDCl3, 270 MHz): δ 1.40-1.75 (6H, m, CH2), 
1.95-2.01 (2H, m, CH2), 3.35 (1H, s, NH), 3.71-3.74 (4H, m, OCH3 and CH), 6.57-6.60 
(2H, m, ArH), 6.77-6.80 (2H, m, ArH).  13C NMR (CDCl3, 68 MHz): δ 24.2, 33.7 
(CH2), 55.6 (OCH3), 55.9 (CH), 114.7, 114.9 (ArCH), 142.4, 151.9 (ArC).  This 
compound was previously synthesised via a different route, by Xu et al.144 
 
(4-Methoxyphenyl)-(1-methylpentyl)amine, 85, C13H21NO, MW 207.31, 
N
H
O
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 87 %, LCMS: r.t. 1.25 min (95% MeOH in water), M+H: 207.88, HPLC: 
r.t. 3.22 min (90% acetonitrile in water), 94% pure, HRMS: Calculated: 208.1696, 
Measured: 208.1694, IR (CDCl3): 2960, 2933, 2873, 2248 (CH), 1510, 1465 (Ar), 1234, 
1040 cm-1 (CO).  1H NMR (CDCl3, 270 MHz): δ 0.93 (3H, t, J = 7.7 Hz, CH3CH2), 1.16 
(3H, d, J = 6.4 Hz, CH3CH), 1.34-1.39 (6H, m, CH2), 3.12 (1H, s, NH), 3.36-3.41 (1H, 
m, CH), 3.76 (3H, s, OCH3), 6.56-6.58 (2H, m, ArH), 6.78-6.81 (2H, m, ArH).  
13C 
NMR (CDCl3, 68 MHz): δ 14.3 (CH3CH2), 20.9 (CH3CH), 22.9, 28.5, 37.0 (CH2), 49.6 
(CH), 55.9 (OCH3), 114.8, 115.0 (ArCH), 142.1, 151.9 (ArC). 
 
Cyclooctyl-(4-methoxyphenyl)amine, 86, C15H23NO, MW 233.35, 
N
H
O
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 64 %, LCMS: r.t. 1.70 min (95% MeOH in water), M+H: 234.44, HPLC: 
r.t. 7.91 min (90% acetonitrile in water), 95% pure, IR (CDCl3): 2927, 2856, 2254 
(CH), 1511, 1466 (Ar), 1130, 1039 cm-1 (CO), 1H NMR (CDCl3, 270 MHz): δ 1.41-1.90 
(14H, m, CH2), 3.21 (1H, s, NH), 3.38-3.45 (1H, m, CH), 3.72 (3H, s, OCH3), 6.51-6.55 
(2H, m, ArH), 6.75-6.78 (2H, m, ArH).  13C NMR (CDCl3, 68 MHz): δ 24.2, 26.0, 27.2, 
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32.7 (CH2), 53.7 (OCH3), 55.9 (CH), 115.0, 115.1 (ArCH), 141.5, 151.9 (ArC).  HRMS: 
Calcd for C15H23NO (M+H)
+ 234.1852, found (M+H)+ 234.1852. 
 
Cyclohexyl-o-tolylamine, 87, C13H19N, MW 189.30, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated as a colourless oil, 95 %, LCMS: r.t. 1.66 min (95% MeOH in water), M+H 
189.86, HPLC: r.t. 4.10 min (90% acetonitrile in water), 90% pure, 1H NMR (CDCl3, 
270 MHz): δ 1.20-1.55 (5H, m, CH2), 1.70-1.90 (3H, m, CH2), 2.13-2.19 (5H, m, CH2 
and CH3), 3.39-3.42 (2H, m, NH and CH), 6.67-6.72 (2H, m, ArH), 7.10-7.17 (2H, m, 
ArH).  This compound has been previously synthesised via a different route, by Mićović 
et al.70 
 
Cyclopentyl-o-tolylamine, 88, C12H17N, MW 175.27, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated as a yellow oil, 81 %, LCMS: r.t. 1.79 min (95% MeOH in water), M+H: 
176.28, HPLC: r.t. 7.14 min (90% acetonitrile in water), 99% pure, 1H NMR (CDCl3, 
270 MHz): δ 1.58-1.90 (6H, m, CH2), 2.14-2.18 (2H, m, CH2), 2.20 (3H, s, CH3), 3.55 
(1H, s, NH), 3.90-3.95 (1H, m, CH), 6.70-6.76 (2H, m, ArH), 7.12-7.25 (2H, m, ArH).  
This compound has been previously synthesised via a different route, by Kuhl et al.145 
 
(1-Methylpentyl)-o-tolylamine, 89, C13H21N, MW 191.31, 
N
H  
Using the general microwave experimental procedure for ketones the desired product 
was isolated as an oil, 92 %, LCMS: r.t. 1.78 min (95% MeOH in water), M+H: 191.68, 
HPLC: r.t. 4.25 min (90% acetonitrile in water), 96% pure, IR (CDCl3): 2932, 2873, 
2256 (CH), 1605, 1510, 1319 (Ar), 1260, 1165 cm-1 (CO).  1H NMR (CDCl3, 270 
MHz): δ 1.02-1.04 (3H, m, CH2CH3), 1.30 (3H, d, J = 6.2 Hz, CHCH3), 1.40-1.75 (6H, 
m, CH2), 2.11 (3H, s, CH3), 3.39 (1H, s, NH), 3.56-3.61 (1H, m, CH), 6.68-6.74 (2H, m, 
ArH), 7.12-7.25 (2H, m, ArH).  13C NMR (CDCl3, 68 MHz): δ 14.3 (ArCH3), 17.8 
(CH3CH2), 21.2 (CH3CH), 23.0, 28.6, 37.2 (CH2), 48.4 (CH), 110.1, 116.3 (ArCH), 
121.7 (ArC), 127.3, 130.4 (ArCH), 145.7 (ArC). 
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Cyclohexyl-o-tolylamine, 90, C12H16BrN, MW 254.17, 
N
H
Br
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated as an oil, 56 %, LCMS: r.t. 2.15 min (95% MeOH in water), M+H 253.64, 
HPLC: r.t. 2.15 min (90% acetonitrile in water), 91% pure, 1H NMR (CDCl3, 270 
MHz): δ 1.13-1.45 (5H, m, CH2), 1.60-1.77 (3H, m, CH2), 2.02-2.08 (2H, m, CH2), 
3.20-3.38 (1H, m, CH), 4.23 (1H, s, NH), 6.52 (1H, td, J = 1.5, 7.6 Hz, ArH), 6.65 (1H, 
dd, J = 1.2, 8.2 Hz, ArH), 7.12-7.18 (1H, m, ArH), 7.41 (1H, dd, J = 1.5, 6.4 Hz, ArH).  
This compound has been previously synthesised via a different route, by Basu et al.146 
 
(2-Bromophenyl)cyclopentylamine, 91, C11H14BrN, MW 240.14, 
N
H
Br
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated, 40 %, LCMS: r.t. 2.37 min (95% MeOH in water), M+H: 240.30, 242.32, 
HPLC: r.t. 9.60 min (90% acetonitrile in water), 90% pure, HRMS: Calculated: 
240.0382, Measured: 240.0384, IR (CDCl3): 3413 (NH), 2962, 2873, 2249 (CH), 1595, 
1501, 1325 (Ar), 1019 cm-1 (CO).  1H NMR (CDCl3, 270 MHz): δ 1.53-1.78 (6H, m, 
CH2), 1.95-2.15 (2H, m, CH2), 3.78-3.83 (1H, m, CH), 4.29 (1H, s, NH), 6.55 (1H, td, J 
= 1.5, 7.4 Hz, ArH), 6.68 (1H, dd, J = 1.5, 8.2 Hz, ArH), 7.15-7.22 (1H, m, ArH), 7.41 
(1H, dd, J = 1.5, 7.9 Hz, ArH).  13C NMR (CDCl3, 68 MHz) δ 24.1, 33.6 (CH2), 54.7 
(CH), 109.8 (ArC), 112.1, 117.6, 128.5, 132.5 (ArCH), 144.8 (ArC). 
 
Cyclohexyl-(4-nitrophenyl)amine, 92, C12H16N2O2, MW 220.27, 
N
H
O2N
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated as a yellow oil, 34 %, LCMS: r.t. 2.64 min (95% MeOH in water), M-H: 
218.87, HPLC: r.t. 2.35 min (90% acetonitrile in water), 99% pure, 1H NMR (CDCl3, 
270 MHz): δ 1.12-1.45 (5H, m, CH2), 1.63-1.80 (3H, m, CH2), 1.98-2.05 (2H, m, CH2), 
3.29-3.40 (1H, m, CH), 4.48-4.51 (1H, m, NH), 6.45-6.50 (2H, m, ArH), 7.98-8.05 (2H, 
m, ArH).  This compound has been previously synthesised using a similar method by 
Abdel-Magid et al.77 
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Cyclopentyl-(4-nitrophenyl)amine, 93, C11H14N2O2, MW 206.24, 
N
H
O2N
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated as an oil, 26 %, LCMS: r.t. 2.19 min (95% MeOH in water), M-H: 204.89, 
HPLC: r.t. 2.14 min (90% acetonitrile in water), 94% pure, IR (CDCl3) 3429 (NH), 
3085, 2964, 2874, 2252 (CH), 1599, 1518, 1318 (Ar), 1116 cm-1 (CO), 1H NMR 
(CDCl3, 270 MHz): δ 1.45-1.70 (6H, m, CH2), 2.04-2.06 (2H, m, CH2), 3.80-3.87 (1H, 
m, CH), 4.64 (1H, s, NH), 6.47-6.51 (2H, m, ArH), 8.02-8.06 (2H, m, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 24.1, 33.4 (CH2), 54.5 (CH), 111.4, 126.5 (ArCH), 137.5, 153.2 
(ArC). 
 
General Microwave Experimental Procedure for aldehydes
85
 
This method is as reported by Bailey et al.85  To a solution of aniline (2 mmol) and 
aldehyde (1 mmol) in DCE (2 mL) in a microwave vial, was added NaBH(OAc)3 (2.5 
mmol) and AcOH (3 mmol).  The vial was capped and the resulting solution was heated 
in a CEM Discover® microwave for 10 minutes (fixed hold time) at 140 °C.  The 
reaction was quenched with a saturated aqueous solution of NaHCO3 (10 mL) was then 
extracted with DCM (3 x 15 mL).  The combined organics were dried (MgSO4), filtered 
and concentrated in vacuo.  Purification by flash chromatography (DCM) then 
proceeded to afford the desired product.  
 
Cyclohexylmethylphenylamine, 94, C13H19N, MW 189.30, 
N
H
 
Using the general microwave experimental procedure for aldehydes the desired product 
was isolated as a cream solid, 91 %, m.p. 82-84 °C (lit. 79-81 °C),147 LCMS: r.t. 1.80 
min (95% MeOH in water), M+H: 190.28, HPLC: r.t. 3.46 min (90% acetonitrile in 
water), 95% pure, 1H NMR (CDCl3, 270 MHz): δ 0.93-1.07 (2H, m, CH2), 1.17-1.88 
(9H, m, CH2 and CH), 2.97 (2H, dd, J = 2.0, 6.5 Hz, CH2NH), 3.72 (1H, s, NH), 6.55-
6.72 (3H, m, ArH), 7.15-7.25 (2H, m, ArH). 
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Cyclohexylmethyl-(4-methoxyphenyl)amine, 95, C14H21NO, MW 219.32, 
N
H
O
 
Using the general microwave experimental procedure for aldehydes the desired product 
was isolated, 83 %, LCMS: r.t. 1.36 min (95% MeOH in water), M+H: 220.03, HPLC: 
r.t. 3.07 min (90% acetonitrile in water), 81% pure, 1H NMR (CDCl3, 270 MHz): δ 
0.90-1.05 (2H, m, CH2), 1.15-1.24 (3H, m, CH2 and CH), 1.50-1.85 (6H, m, CH2), 2.90 
(2H, d, J = 6.7 Hz, CH2NH), 3.45 (1H, s, NH), 3.75 (3H, s, OCH3), 6.55-6.58 (2H, m, 
ArH), 6.76-6.80 (2H, m, ArH).  This compound has been previously synthesised via a 
different route, by Cho et al.147 
 
Cyclohexylmethyl-o-tolylamine, 96, C14H21N, MW 203.32, 
N
H
 
Using the general microwave experimental procedure for aldehydes the desired product 
was isolated, 88 %, LCMS: r.t. 1.94 min (95% MeOH in water), M+H: 203.97, HPLC: 
r.t. 4.45 min (90% acetonitrile in water), 98% pure, 1H NMR (CDCl3, 270 MHz): δ 
0.97-1.40 (5H, m, CH2 and CH), 1.60-1.85 (6H, m, CH2), 2.18 (3H, s, CH3), 3.04 (2H, 
d, J = 3.2 Hz, CH2NH), 3.59 (1H, s, NH), 6.62-6.67 (2H, m, ArH), 7.08-7.16 (2H, m, 
ArH).  This compound has been previously synthesised via a different route, by Shim et 
al.148 
 
(2-Bromophenyl)cyclohexylmethylamine, 97, C13H18BrN, MW 268.19,  
N
H
Br
 
Using the general microwave experimental procedure for aldehydes the desired product 
was isolated, 75 %, LCMS: r.t. 2.52 min (95% MeOH in water), M+H: 270.11, 268.83, 
HPLC: r.t. 6.22 min (90% acetonitrile in water), 98% pure, IR (CDCl3): 3421 (NH), 
3073, 2925, 2854 (CH), 1597, 1511, 1324 (Ar), 1019 cm-1 (CO).  1H NMR (CDCl3, 270 
MHz): δ 0.99-1.35 (5H, m, CH2 and CH), 1.55-1.95 (6H, m, CH2), 3.00 (2H, d, J = 5.9 
Hz, CH2NH), 4.40 (1H, s, NH), 6.56-6.65 (2H, m, ArH), 7.10-7.18 (1H, m, ArH), 7.41-
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7.53 (1H, m, ArH).  13C NMR (CDCl3, 68 MHz): δ 26.1, 26.7, 31.4 (CH2), 37.4 (CH), 
50.5 (CH2NH), 109.8 (ArC), 111.3, 117.3, 128.6, 132.5 (ArCH), 145.3 (ArC). 
 
Cyclohexylmethyl-(4-nitrophenyl)amine, 98, C13H18N2O2, MW 234.29, 
N
H
O2N
 
Using the general microwave experimental procedure for aldehydes the desired product 
was isolated, 61 %, LCMS: r.t. 1.27 min (95% MeOH in water), M-H: 232.99, HPLC: 
r.t. 2.68 min (90% acetonitrile in water), 99% pure, 1H NMR (CDCl3, 270 MHz): δ 
0.90-1.30 (5H, m, CH2 and CH), 1.40-1.76 (6H, m, CH2), 3.00-3.02 (2H, m, CH2NH), 
4.70 (1H, s, NH), 6.47-6.51 (2H, m, ArH), 8.02-8.06 (2H, m, ArH).  This compound 
was previously synthesised using a similar method by Abdel-Magid et al.77 
 
(1,4-Dioxaspiro[4.5]dec-8-yl)phenylamine, 99, C14H19NO2, MW 233.31, 
N
H
O
O
 
Using the general microwave experimental procedure for ketones the desired product 
was isolated as an off white solid, 82 %, m.p. 113-115 °C (lit. 112-113 °C),149 LCMS: 
r.t. 1.25 min (95% MeOH in water), M+H: 233.93, HPLC: r.t. 2.28 min (90% 
acetonitrile in water), 95% pure, 1H NMR (CDCl3, 270 MHz): δ 1.42-1.82 (6H, m, 
CH2), 2.01-2.10 (2H, m, CH2), 3.29-3.40 (1H, s, CH), 3.52 (1H, s, NH), 3.94 (4H, m, 
CH2O), 6.57-6.70 (3H, m, ArH), 7.13-7.16 (2H, m, ArH). 
 
1-(4-[2-(2, 4-Chloro-phenoxy)-phenylamino]-piperidin-1-yl)-ethanone, 100, 
C19H20Cl2N2O2, MW 379.29, 
O
NH
Cl
N
O
Cl
 
To a solution of 4-[2-(2,4-dichloro-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic 
acid tert-butyl ester (100 mg, 0.45 mmol), 1-acetyl-4-piperidone (0.12 mL, 0.9 mmol) 
and AcOH (0.24 mL) in DCE (2 mL) was added sodium triacetoxyborohydride (0.26 g, 
1.1 mmol).  The solution was heated using a CEM microwave at 100 °C for 15 min.  
The mixture was allowed to cool and sat. NaHCO3 was added (10 mL) and extracted 
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with EtOAc (2 x 20 mL).  The organic layers were combined, dried (MgSO4), filtered 
and evaporated in vacuo.  The crude mixture was purified using flash chromatography 
(0-100 % EtOAc in hexane) to afford the title compound as a white solid, 148 mg, 99 % 
yield.  R.f: 0.55 (EtOAc), mp. 144-145 °C, LCMS tr= 5.40 min (50 % MeOH in water at 
0.5 mL/min), m/z M+H 379.41, HPLC tr= 2.65 min (90% acetonitrile in water at 1.0 
mL/min), 99 %, 1H NMR (CDCl3, 270 MHz): δ 1.27-1.43 (2H, m, CH2), 2.4-2.11 (5H, 
m, CH3, CH2), 2.84-2.94 (1H, m, CH2), 3.15-3.25 (1H, m, CH2), 3.42-3.55 (1H, m, CH), 
3.74-3.78 (1H, m, CH2), 4.06-4.08 (1H, m, NH), 4.35-4.43 (1H, m, CH2), 6.60-6.66 
(1H, m, ArH), 6.72-6.77 (2H, m, ArH), 6.80 (1H, d, J = 2.5 Hz, ArH), 7.01-7.09 (1H, 
m, ArH), 7.13 (1H, dd, J = 8.9, 2.5 Hz, ArH), 7.44 (1H, d, J = 2.5 Hz, ArH).  13C NMR 
(CDCl3, 101 MHz): δ 21.4 (CH3), 31.8, 32.6, 40.1, 44.9 (CH2), 49.5 (CH), 112.3, 117.0, 
118.6, 119.5, 125.3, 127.9 (ArCH), 128.5 (ArC), 130.3 (ArCH), 138.2, 142.9, 151.4 
(ArC), 168.8 (CO).  Anal. Calcd for C19H21ClN2O2: C 60.17, H 5.32, N 7.39 %, Found 
C 60.2, H 5.57, N 7.22. 
 
1-(4-[2-(4-Chloro-phenoxy)-phenylamino]-piperidin-1-yl)-ethanone, 101, 
C19H21ClN2O2, MW 344.86, 
O
NH
Cl
N
O  
To a solution of 4-[2-(4-chloro-phenoxy)-phenylcarbamoyl]-piperidine-1-carboxylic 
acid tert-butyl ester (100 mg, 0.45 mmol), 1-acetyl-4-piperidone (0.12 mL, 0.9 mmol) 
and AcOH (0.24 mL) in DCE (2 mL) was added sodium triacetoxyborohydride (0.26 g, 
1.13 mmol).  The solution was heated using a CEM microwave at 100 °C for 15 min.  
The mixture was allowed to cool and sat. NaHCO3 was added (10 mL) and the mixture 
was extracted with EtOAc (2 x 20 mL).  The combined organic layers were dried 
(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % EtOAc in hexane) to afford the title compound as a white 
solid, 153 mg, 98 % yield.  mp. 129-130 °C, R.f: 0.41 (DCM), LCMS: tr= 5.05 min (50 
% MeOH in water at 0.5 mL/min), m/z M+H 345.40, HPLC: tr= 2.45 min (90 % 
acetonitrile in water at 1.0 mL/min), >99 %, 1H NMR (CDCl3, 270 MHz): δ 1.23-1.37 
(2H, m, CH2), 2.01-2.14 (5H, m, CH2, CH3), 2.80-2.90 (1H, m, CH2), 3.13-3.23 (1H, m, 
CH2), 3.48-3.52 (1H, m, CH), 3.72-3.78 (1H, m, CH2), 4.00 (1H, s, NH), 4.37-4.42 (1H, 
m, CH2), 6.64 (1H, td, J = 6.4, 1.2 Hz, ArH), 6.74 (1H, dd, J = 8.2, 1.5 Hz, ArH), 6.80 
(1H, dd, J = 6.4, 1.5 Hz, ArH), 6.84-6.88 (2H, m, ArH), 7.03 (1H, td, J = 7.4, 1.5 Hz, 
ArH), 7.21-7.27 (2H, m, ArH).  13C NMR (CDCl3, 101 MHz): δ 21.4 (CH3), 31.9, 32.7, 
40.2, 45.0 (CH2), 49.6 (CH), 112.2, 117.2, 118.6, 119.5, 125.2 (ArCH), 127.8 (ArC), 
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129.7 (ArCH), 138.7, 142.9, 156.0 (ArC), 168.8 (CO).  Anal. Calcd for C19H21ClN2O2: 
C 66.18, H 6.14, N 8.12. Found C 66.0, H 6.06, N 7.90. 
 
4-(2-[2-(4-Chloro-phenoxy)-phenylamino]-di-ethyl)-di-piperidine-1-carboxylic acid 
tert-butyl ester, 106, C36H52ClN3O5, MW 642.27, 
Cl
O
N
N
N
O
O
O
O
 
A mixture of 2-(4-chloro-phenoxy)-phenylamine (200 mg, 0.91 mmol), N-Boc-4-
piperidine acetaldehyde (413 mg, 1.8 mmol), NaBH(OAc)3 (483 mg, 2.3 mmol) and 
AcOH (0.16 mL) in DCE (3 mL) was stirred at r.t. for 1 h.  NaHCO3 (20 mL) was 
added and the mixture was extracted with DCM (2 x 20 mL).  The crude product was 
purified by flash chromatography (0-30 % EtOAc in DCM) to yield the desired product 
as a cream oil, 584 mg, 74 % yield.  R.f. 0.35 (DCM), LCMS: tr = 5.93 min (90 % 
MeOH in water), m/z M+Na 663.6, HPLC: tr = 3.5 min (100 % MeOH), 99 %, 
1H NMR 
(CDCl3, 270 MHz,): δ 0.98-1.05 (4H, m, 2CH2), 1.25-1.33 (4H, m, 2CH2), 1.42 (9H, s, 
tBu), 1.43-1.53 (2H, m, 2CH), 2.55 (4H, t, J = 11.8Hz, 2CH2), 3.07 (4H, t, J = 6.9Hz, 
2CH2), 3.99 (4H, m, 2CH2), 6.71-6.79 (2H, m, ArH), 6.91-7.55 (6H, m, ArH).  
13C 
NMR (CDCl3, 68 MHz): 28.5 (
tBu), 32.2, 33.6 (CH2), 33.9 (CH), 49.6, 62.0 (CH2), 
117.9, 121.7, 122.4, 122.4, 125.1 (ArCH), 126.9 (ArC), 129.4 (ArCH), 142.9, 148.7, 
154.9 (ArC).  HRMS: Calcd for C36H52ClN3O5 (M+H)
+ 642.3668, found (M+H)+ 
642.3679. 
 
[2-(4-Chloro-phenoxy)-phenyl]-bis-(2-piperidin-4-yl-ethyl)-amine, 107, 
C26H36ClN3O, MW 442.04, 
Cl
O
N
HN
NH
 
Using the general procedure for deprotection the desired product was obtained as a 
cream oil, 170 mg, 71 % yield.  R.f. 0.30 (EtOAc), 1H NMR (CDCl3, 270 MHz,): δ 
1.00-1.10 (4H, m, 2CH2), 1.18-1.32 (6H, m, 2CH and 2CH2), 1.55 (4H, d, J = 12.8 Hz, 
 252 
2CH2), 2.47 (4H, t, J = 12.0 Hz, 2CH2), 2.81 (2H, br.s 2NH), 3.00 (4H, d, J = 8.1 Hz, 
2CH2), 3.07 (4H, t, J = 7.6 Hz, 2CH2), 6.73-6.77 (2H, m, ArH), 6.91-6.94 (2H, m, 
ArH), 6.99 (1H, d, J = 8.0 Hz, ArH), 7.07-7.11 (1H, m, ArH), 7.16-.20 (2H, m, ArH). 
13C NMR (CDCl3, 68 MHz): 33.0 (CH2), 33.9 (CH), 34.0, 46.3, 49.4 (CH2), 117.8, 
121.6, 122.1, 122.3, 125.0 (ArCH), 126.7 (ArC), 129.2 (ArCH), 143.0, 148.5, 156.8 
(ArC). 
 
1-[4-(2-([2-(1-Acetyl-piperidin-4-yl)-ethyl]-[2-(4-chloro-phenoxy)-phenyl]-amino)-
ethyl)-piperidin-1-yl]-ethanone, 108, C30H40ClN3O3, MW 526.11, 
Cl
O
N
N
N
O
O
 
[2-(4-chloro-phenoxy)-phenyl]-bis-(2-piperidin-4-yl-ethyl)-amine (97 mg, 0.22 mmol) 
was dissolved in DCM (5 mL) and cooled to 0 °C, to this was added TEA (0.06 mL, 
0.88 mmol) and acetyl chloride (0.1 mL, 1.32 mmol).  The resulting solution was stirred 
at r.t. for 1 h.  NaHCO3 (20 mL) was added and the mixture was extracted with DCM (2 
x 20 mL).  The crude material was purified by flash chromatography (0-95 % EtOAc in 
hexane) to yield the desired product as a clear oil, 83 mg, 72 % yield.  R.f. 0.65 
(EtOAc), LCMS: tr = 1.46 min (90 % MeOH in water), m/z M+H 526.00, HPLC: tr = 
2.35 min (90 % acetonitrile in water), 98 %, 1H NMR (CDCl3, 400 MHz,): δ 0.95-1.04 
(4H, m, 2CH2), 1.28-1.34 (6H, m, 2CH and 2CH2), 1.57 (4H, d, J = 12.8 Hz, 2CH2), 
2.03 (6H, s, 2CH3), 2.38 (2H, td, J = 2.8, 13.2 Hz, 2x ½CH2), 2.86 (2H, td, J = 2.4, 13.2 
Hz, 2x ½CH2), 3.05-3.11 (4H, m, 2CH2), 3.80 (2H, d, J = 12.0 Hz, 2x ½CH2), 4.48-4.52 
(2H, m, 2x ½CH2), 6.72-6.76 (2H, m, ArH), 6.92-6.94 (2H, m, ArH), 6.95-7.00 (1H, m, 
ArH), 7.08-7.12 (1H, m, ArH), 7.16-7.20 (2H, m, ArH).  13C NMR (CDCl3, 101 MHz): 
21.4 (CH3), 31.8, 32.7, 33.3 (CH2), 33.8 (CH), 41.7, 46.5, 49.4 (CH2), 117.7, 121.7, 
122.4, 122.5, 125.1 (ArCH), 126.8 (ArC), 129.3 (ArCH), 142.7, 148.6, 156.7 (ArC), 
168.7 (CO).  HRMS: Calcd for C30H40ClN3O3 (M+H)
+ 526.2831, found (M+H)+ 
526.2840. 
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4-(2-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-piperidine-1-carboxylic acid tert-
butyl ester, 109, C24H31ClN2O3, MW 430.97,  
Cl
O
HN
N O
O  
A mixture of 2-(4-chloro-phenoxy)-phenylamine (400 mg, 1.8 mmol), N-Boc-4-
piperidine acetaldehyde (210 mg, 0.91 mmol), NaBH(OAc)3 (483 mg, 2.3 mmol) and 
AcOH (0.16 mL) in DCE (3 mL) was stirred at r.t. for 1 h.  NaHCO3 (20 mL) was 
added and the mixture was extracted with DCM (2 x 20 mL).  The crude product was 
purified by flash chromatography (0-100 % DCM in hexane) to yield the desired 
product as a colourless oil, 383 mg, 96 % yield.  R.f. 0.30 (DCM), LCMS: tr = 2.8 min 
(90 % MeOH in water), m/z M+Na 453.0, HPLC: tr = 2.47 min (90 % acetonitrile in 
water), 93 %, 1H NMR (CDCl3, 400 MHz,): δ 1.05-1.14 (2H, m CH2), 1.45 (9H, s, 
(CH3)3), 1.46-1.57 (3H, m, CH2 and CH), 1.62 (2H, d, J=12.4Hz, CH2), 2.61-2.68 (2H, 
m, CH2), 3.16 (2H, t, J=7.2Hz, CH2), 3.96 (1H, br.s, NH), 4.05 (2H, d, J=12.4Hz, CH2), 
6.63 (1H, td, J= 0.8, 7.2 Hz, ArH), 6.71 (1H, dd, J=1.6, 8.4Hz, ArH), 6.81 (1H, dd, 
J=1.2, 8.0 Hz, ArH), 6.87-6.89 (2H, m, ArH), 7.05 (1H, td, J= 1.2, 7.6Hz, ArH), 7.23-
7.25 (2H, m, ArH).  13C NMR (CDCl3, 101 MHz): 28.5 ((CH3)3), 32.1 (CH2), 33.9 
(CH), 36.1, 41.0 (CH2), 79.3 (C(CH3)3), 111.5, 116.7, 118.5, 119.5, 125.4 (ArCH), 
127.7 (ArC), 129.6 (ArCH), 140.6, 142.7, 154.9 (ArC), 156.3 (CO).  HRMS: Calcd for 
C24H31ClN2O3 (M+H)
+ 431.2096, found (M+H)+ 431.2113. 
 
[2-(4-Chloro-phenoxy)-phenyl]-(2-piperidin-4-yl-ethyl)-amine, 110, C19H23ClN2O, 
MW 330.85, 
Cl
O
HN
NH
 
Using the general procedure for deprotection the desired product was obtained as a 
cream oil, 209 mg, 97 % yield.  R.f. 0.32 (EtOAc), HPLC: tr = 1.55 min (90 % 
acetonitrile in water), 80 %. 1H NMR (CDCl3, 400 MHz,): δ 1.28-1.36 (2H, m, CH2), 
1.49-1.59 (3H, m, CH2 and CH), 1.75 (2H, d, J = 13.2Hz, CH2), 2.66 (2H, td, J = 2.8, 
12.8Hz, CH2), 3.13-3.21 (4H, m, CH2), 3.95 (1H, t, J = 5.2Hz, NHCH2), 5.97 (1H, br.s, 
NH), 6.64 (1H, td, J = 1.2, 7.2Hz, ArH), 6.67-6.71 (1H, m, ArH), 6.81 (1H, dd, J = 7.6, 
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0.8Hz, ArH), 6.86-6.90 (1H, m, ArH), 7.05 (1H, td, J = 1.6, 8.0Hz, ArH), 7.12-7.14 
(1H, m, ArH), 7.22-7.26 (2H, m, ArH). 
 
N-[2-(1-Acetyl-piperidin-4-yl)-ethyl]-N-[2-(4-chloro-phenoxy)-phenyl]-acetamide, 
111, C23H27ClN2O3, MW 414.93, 
Cl
O
N
O N
O  
[2-(4-Chloro-phenoxy)-phenyl]-(2-piperidin-4-yl-ethyl)-amine (114 mg, 0.35 mmol) 
was dissolved in DCM (5 mL) and cooled to 0 °C, to this was added TEA (0.06 mL, 
0.88 mmol) and acetyl chloride (0.03 mL, 1.05 mmol).  The resulting solution was 
stirred at r.t. for 1 h.  NaHCO3 (20 mL) was added and the mixture was extracted with 
DCM (2 x 20 mL).  The crude material was purified by flash chromatography (0-95 % 
EtOAc in hexane) to yield the desired product as a clear oil, 93 mg, 65 % yield.  R.f. 
0.48 (EtOAc), LCMS: tr = 1.45 min (90 % MeOH in water), m/z M+H 415.00, HPLC: tr 
= 1.81 min (90 % acetonitrile in water), 95 %, 1H NMR (CDCl3, 270 MHz,): δ 0.97-
1.11(2H, m, CH2), 1.38-1.57 (3H, m, CH and CH2), 1.66-1.78 (2H, m, CH2), 1.85 (3H, 
s, CH3), 2.03 (3H, s, CH3), 2.38-2.51 (1H, m, ½CH2), 2.89-2.99 (1H, m, ½CH2), 3.51-
3.58 (1H, m, ½CH2), 3.69-3.86 (2H, m, 2x ½CH2), 4.47-4.55 (1H, m, ½CH2), 6.88-6.96 
(3H, m, ArH), 7.13-7.20 (2H, m, ArH), 7.27-7.32 (3H, m, ArH).  13C NMR (CDCl3, 68 
MHz): 21.5, 22.3 (CH3), 31.8, 31.8, 32.4, 32.5 (cyclic CH2), 33.7 (CH2), 34.2, 34.3 
(cyclic CH2), 41.7 (CH2), 45.8, 45.9 (cyclic CH2), 46.6 (CH2), 119.1, 120.0, 124.5, 
129.4, 130.0, 130.4 (ArCH), 130.4, 133.4, 152.9, 154.6 (ArC), 168.7, (170.7, 170.7) 
(CO).  HRMS: Calcd for C23H27ClN2O3 (M+H)
+ 415.1783, found (M+H)+ 415.1778. 
 
1-(4-(2-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-piperidin-1-yl)-ethanone, 112, 
C21H25ClN2O2, MW 372.89, 
Cl
O
HN
N
O  
[2-(4-Chloro-phenoxy)-phenyl]-(2-piperidin-4-yl-ethyl)-amine (50 mg, 0.15 mmol) was 
dissolved in DCM (2 mL) and cooled to -10 °C, to this was added TEA (0.021 mL, 0.15 
mmol) and acetyl chloride (0.011 mL, 0.15 mmol).  The resulting solution was stirred at 
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-10 °C for 10 min.  NaHCO3 (20 mL) was added and the mixture was extracted with 
DCM (2 x 20 mL).  The crude material was purified by flash chromatography (0-10 % 
MeOH in DCM) to yield the desired product as an off white oil, 31 mg, 55 % yield.  
R.f. 0.55 (EtOAc), LCMS: tr = 2.60 min (90 % MeOH in water), m/z M-H 371.4, HPLC: 
tr = 4.58 min (90 % acetonitrile in water), 96 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.07-
1.18 (2H, m, CH2), 1.51-1.59 (3H, m, CH2 and CH), 1.69-1.72 (2H, m, CH2), 2.07 (3H, 
s, CH3), 2.48 (1H, td, J = 3.2, 12.8 Hz, ½CH2), 2.97 (1H, td, J = 2.8, 13.2 Hz, ½CH2), 
3.17 (2H, t, J = 6.8 Hz, ½CH2), 3.73-3.78 (1H, m, ½CH2), 3.97 (1H, br.s, NH), 4.55-
4.61 (1H, m, ½CH2), 6.65 (1H, td, J = 1.6, 7.6 Hz, ArH), 6.71 (1H, dd, J = 1.2, 7.6 Hz, 
ArH), 6.82 (1H, dd, J = 1.6, 8.4 Hz, ArH), 6.86-6.90 (2H, m, ArH), 7.06 (1H, td, J = 
1.2, 8.0 Hz, ArH), 7.23-7.32 (2H, m, ArH).  13C NMR (CDCl3, 101 MHz): 21.5 (CH3), 
31.7, 32.7 (CH2), 33.8 (CH), 35.8, 40.8, 41.6, 46.5 (CH2), 111.4, 116.7, 118.4, 119.4, 
125.4 (ArCH), 127.6 (ArC), 129.6 (ArCH), 129.6 (ArC), 129.6 (ArCH), 140.3, 142.5, 
156.2 (ArC), 168.7 (CO).  HRMS: Calcd for C21H25ClN2O2 (M+H)
+ 373.1677, found 
(M+H)+ 373.1663. 
 
1-(Furan-2-carbonyl)-piperidin-4-one, 113, C10H11NO3, MW 193.07, 
N
O
O
O
 
To a solution of 4-piperidone hydrochloride monohydrate (230 mg, 1.5 mmol) in DCM 
(5 mL) was added MP-Carbonate resin (0.58 g).  The mixture was stirred at room 
temperature for 2 h.  In a separate flask, 2-furoic acid (200 mg, 1.8 mmol), N N-4-
dimethylaminopyridine (cat.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (0.85 g, 4.44 mmol) and TEA (0.15 mL) were dissolved in DCM (5 mL) 
and stirred at room temperature for 2 h.  The two reaction mixtures were then combined 
and stirred at room temperature for a further 18 h.  The resulting solution was then 
filtered to remove the resin.  HCl (1M, 20 mL) was added and the mixture was 
extracted.  The organic layers were washed with NaHCO3 (20 mL) and then brine (20 
mL).  The organic layers was dried (MgSO4), filtered and evaporated in vacuo, to yield 
the title compound as a yellow oil, 250 mg, 86 % yield.  LCMS: tr = 1.99 min (50 % 
MeOH in water at 0.5 mL/min), m/z M+H 194.16, HPLC: tr = 1.85 min (90 % 
acetonitrile in water at 1.0 mL/min), 97 %, 1H NMR (CDCl3, 270 MHz): δ 2.53 (4H, t, J 
= 6.5 Hz, CH2), 4.03 (4H, s, CH2), 9.49 (1H, q, J = 1.7 Hz, ArH), 7.07 (1H, dd, J = 0.7, 
3.5 Hz, ArH), 7.48 (1H, q, J = 1.0 Hz, ArH). 
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4-[2-(2, 4-Dichloro-phenoxy)-phenylamino]-piperidin-1-yl-furan-2-yl-methanone, 
114, C22H20Cl2N2O3, MW 431.31, 
O
Cl
Cl HN
N
O
O
 
To a solution of 2-(2,4-dichloro-phenoxy)-phenylamine (100 mg, 0.39 mmol), 1-(furan-
2-carbonyl)-piperidin-4-one (91 mg, 0.47 mmol) and sodium triacetoxyborohydride 
(116 mg, 0.55 mmol) in DCE, was added AcOH (0.1 mL).  The resulting reaction 
mixture was stirred at r.t. for 4 days.  NaHCO3 (20 mL) was then added and the solution 
was extracted with ethyl acetate (3 x 20 mL).  The organic layers were combined, dried 
(MgSO4), filtered and evaporated to in vacuo.  The crude mixture was purified using 
flash chromatography (0-100 % ethyl acetate in hexane) to afford the desired product as 
a yellow oil, 25 mg, 15 % yield.  R.f. 0.7 (5 % Methanol–DCM), LCMS: tr = 5.66 min 
(50 % MeOH in water at 0.5 mL/min), m/z M+H 431.41, HPLC: tr = 2.99 min (90% 
acetonitrile in water at 1.0 mL/min), 99 %, 1H NMR (CDCl3, 270 MHz): δ 1.39-1.54 
(2H, m, CH2), 2.13 (2H, dd, J = 3.6, 12.8 Hz, CH2), 3.21 (2H, s, CH2) 3.58-3.65 (1H, m, 
CH2), 4.11 (1H, s, NH), 4.38 (2H, d, J = 12.8 Hz, CH2), 6.46 (1H, dd, J = 1.6, 3.6 Hz, 
ArH), 6.64 (1H, td, J = 1.6, 7.6 Hz, ArH), 6.74 (1H, dd, J = 1.6, 8.0 Hz, ArH), 6.78 
(1H, dd, J = 1.2, 8.4 Hz, ArH), 6.81 (1H, d, J = 8.8 Hz, ArH), 6.96 (1H, d, J = 3.2 Hz, 
ArH), 7.05 (1H, td, J = 1.2, 8.0 Hz, ArH), 7.13 (1H, dd, J = 2.4, 8.8 Hz, ArH), 7.44 (1H, 
d, J = 2.4 Hz, ArH), 7.46 (1H, d, J = 2.0 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 
49.69 (CH), 112.21, 112.29, 116.15, 116.99, 118.63, 119.48, 125.31, 127.94, 128.55, 
130.30, 138.25, 142.89, 143.59, 147.89 (ArC), 151.47, 159.16 (C=O). HRMS: Calcd for 
C22H20Cl2N2O3 (M+H)
+431.0924, found (M+H)+ 431.0925. 
 
1-(Thiophene-2-carbonyl)-piperidin-4-one, 115, C10H11NO2S, MW 209.26, 
N
O
O
S
 
To a solution of 4-piperidone hydrochloride monohydrate (320 mg, 2.1 mmol) in DCM 
(7 mL) was added MP-Carbonate resin (0.8 g).  This was stirred at room temperature for 
2 h.  In a separate flask, 2-thiophenecarboxylic acid (320 mg, 2.5 mmol), N, N-4-
dimethylaminopyridine (cat.), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide 
hydrochloride (1.2 g, 6.3 mmol) and TEA (0.25 mL) were dissolved in DCM (7 mL) 
and stirred at room temperature for 2 h.  The two reaction mixtures were then combined 
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and stirred at room temperature for a further 18 h.  The resulting solution was then 
filtered to remove the resin.  HCl (1M, 20 mL) was then added and the mixture was 
extracted.  The organic layers were then washed with NaHCO3 (20 mL) and then brine 
(20 mL).  The organic layers were combined, dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-100 % ethyl 
acetate in hexane) to yield the desired product as a white solid, 220 mg, 56 % yield.  
m.p. 81-83 °C, R.f. 0.5 (1:9, MeOH: DCM), LCMS: tr= 2.29 min (50 % MeOH in water 
at 0.5 mL/min), m/z M+H 210.11, HPLC: tr= 1.89 min (90 % acetonitrile in water at 1.0 
mL/min), >99 %, 1H NMR (CDCl3, 270 MHz): δ 2.47 (4H, t, J = 6.2 Hz, CH2), 3.94 
(4H, t, J = 6.4 Hz, CH2), 7.00 (1H, dd, J = 3.5, 4.9 Hz, ArH), 7.31 (1H, dd, J = 1.2, 3.7 
Hz, ArH), 7.43 (1H, dd, J = 1.2, 4.9 Hz, ArH),  
 
4-[2-(2,4-Dichloro-phenoxy)-phenylamino]-piperidin-1-yl-thiophen-2-yl-
methanone, 116, C22H20Cl2N2O2S, MW 447.38 
O
Cl
Cl HN
N
O
S
 
To a solution of 2-(2,4-dichloro-phenoxy)-phenylamine (185 mg, 0.72 mmol) in DCE 
(5 mL) was added 1-(thiophene-2-carbonyl)-piperidin-4-one (150 mg, 0.72 mmol), 
sodium triacetoxyborohydride (230 mg, 1.08 mmol) and AcOH (0.21 mmol, 3.6 mmol).  
The resulting reaction mixture was stirred at r.t. for 7 days and the reaction was 
monitored by TLC.  NaHCO3 (20 mL) was then added and extracted with EtOAc (3 x 
25 mL).  The organic layers were combined, dried (MgSO4), filtered and evaporated in 
vacuo.  The crude mixture was purified using flash chromatography (0-100 % ethyl 
acetate in hexane) to afford the title compound as a light brown oil, 162 mg, 50 % yield.  
m.p. 128-129 °C, LCMS: tr = 5.7 min (50 % to 95 % MeOH in water at 0.5 mL/min to 
1.0 mL/min over 5 min), m/z M+H 447.34, HPLC: tr = 4.03 min (90% acetonitrile in 
water at 0.8 mL/min), >99 %, 1H NMR (CDCl3, 400 MHz, 50 °C): δ 1.42-1.52 (2H, m, 
CH2), 2.11 (2H, dd, J = 13.2, 3.2 Hz, CH2), 3.22 (2H, t, J = 11.6 Hz, CH2), 3.61 (1H, s, 
CH), 4.12 (1H, s, NH), 4.29 (2H, s, CH2), 6.64 (1H, td, J = 1.6, 7.2 Hz, ArH), 6.74 (1H, 
dd, J = 1.6, 7.6 Hz, ArH), 6.77 (1H, dd, J = 1.6, 8.0 Hz, ArH), 6.81 (1H, d, J = 8.4 Hz, 
ArH), 7.02 (1H, dd, J = 3.6, 5.2 Hz, ArH), 7.04 (1H, td, J = 7.6, 1.6 Hz, ArH), 7.13 (1H, 
dd, J = 2.0, 8.4 Hz, ArH), 7.26 (1H, dd, J = 1.2, 3.6 Hz, ArH), 7.42 (1H, dd, J = 1.2, 5.2 
Hz, ArH), 7.44 (1H, d, J = 2.4 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 29.59, 32.38 
(CH2), 49.57 (CH), 112.23, 116.98, 118.54, 119.48, 125.25 126.58, 127.89, 128.42, 
128.49, 128.54, 130.23 (ArCH), 137.00, 138.14, 142.84, 151.40 (ArC), 163.47 (C=O). 
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1-(2-Adamantan-1-yl-acetyl)-piperidin-4-one, 117, C17H25NO2, MW 275.39, 
N
O
O  
To a solution of 4-piperidone hydrochloride monohydrate (320 mg, 2.1 mmol) in DCM 
(7 mL) was added MP-Carbonate resin (0.8 g).  This was stirred at room temperature for 
2 h.  In a separate flask, 1-adamantane acetic acid (490 mg, 2.5 mmol), N N-4-
dimethylaminopyridine (cat.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (1.2 g, 6.3 mmol) and TEA (0.25 mL) were dissolved in DCM (7 mL) 
and stirred at room temperature for 2 h.  The two reaction mixtures were then combined 
and stirred at room temperature for a further 18 h.  The resulting solution was then 
filtered to remove the resin.  HCl (1M, 20 mL) was added to the filtrate, which was 
extracted with DCM (3 x 20 mL).  The organic portions were washed with NaHCO3 (20 
mL) then brine (20 mL).  The organic layers were combined, dried (MgSO4), filtered 
and evaporated in vacuo.  The crude mixture was purified using flash chromatography 
(0-100 % ethyl acetate in hexane) to yield a white solid, 310 mg, 60 % yield.  m.p. 114-
115 °C, LCMS: tr = 4.68 min (50 % to 95 % MeOH in water at 0.5 mL/min), m/z M+H 
276.44, HPLC: tr = 2.56 min (90 % acetonitrile in water at 1.0 mL/min), 99 %, 
1H NMR 
(CDCl3, 270 MHz): δ 1.57-1.67 (12H, m, CH2), 1.96 (3H, s, CH), 2.22 (2H, s, CH2CO), 
2.46 (4H, t, J = 6.2 Hz, CH2CH2N), 3.80 (2H, t, J = 6.2 Hz, CH2N), 3.89 (2H, t, J = 6.2 
Hz, CH2N). 
 
2-Adamantan-1-yl-1-(4-[2-(2,4-dichloro-phenoxy)-phenylamino]-piperidin-1-yl)-
ethanone, 118, C29H34Cl2N2O2, MW 513.50, 
O
Cl
Cl HN
N
O  
A solution of 2-(2,4-dichloro-phenoxy)-phenylamine (140 mg, 0.55 mmol), 1-(2-
adamantan-1-yl-acetyl)-piperidin-4-one (150 mg, 0.55 mmol), sodium 
triacetoxyborohydride (175 mg, 0.83 mmol) and AcOH (0.16 mmol, 2.75 mmol) in 
DCE (5 mL) was stirred at r.t. for 7 days.  NaHCO3 (20 mL) was then added and the 
mixture was extracted with EtOAc (3 x 30 mL).  The organic layers were combined, 
dried (MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using 
flash chromatography (0-100 % ethyl acetate in hexane) to afford the desired compound 
as a brown oil, 100 mg, 35 % yield.  LCMS: tr = 3.6 min (50 % to 95 % MeOH in water 
at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 513.50, HPLC: tr = 9.94 min (90 % 
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acetonitrile in water at 0.8 mL/min), 98 %, 1H NMR (CDCl3, 400 MHz): δ 1.29-1.41 
(2H, m, CH2), 1.61-1.70 (12H, m, 6CH2), 1.95 (3H, s, CH), 2.04-2.07 (2H, m, CH2), 
2.14 (2H, d, J = 1.2 Hz, CH2CO), 2.88 (1H, ddd, J = 3.2, 11.2, 14.0 Hz, CH2), 3.19 (1H, 
ddd, J = 2.8, 11.2, 14.0 Hz, CH2), 3.50-3.55 (1H, m, CH), 3.86 (1H, d, J = 12.8 Hz, 
CH2), 4.09 (1H, s, NH), 4.43 (1H, d, J = 12.4 Hz, CH2), 6.62 (1H, td, J = 1.2, 8.0 Hz, 
ArH), 6.74 (2H, td, J = 1.2, 8.4 Hz, ArH), 6.81 (1H, d, J = 9.2 Hz, ArH), 7.03 (1H, td, J 
= 1.6, 7.6 Hz, ArH), 7.12 (1H, dd, J = 2.4, 8.8 Hz, ArH), 7.43 (1H, d, J = 2.4 Hz, ArH).  
13C NMR (CDCl3, 101 MHz): δ 28.60 (CH), 29.63, 32.07, 32.76 (CH2), 33.56 (C), 
36.68, 40.04, 42.76, 45.49 (CH2), 46.03 (CH2CO), 49.60 (CH2), 112.23, 116.91, 118.51, 
119.56, 125.25, 125.29 (ArCH), 127.91 (ArC), 128.52 (ArCH), 130.25, 138.25, 142.89, 
151.45 (ArC), 169.60 (CO).  HRMS: Calcd for C29H34Cl2N2O2 (M+H)
+ 513.2070, 
found (M+H)+ 513.2069. 
 
1-(Furan-3-carbonyl)-piperidin-4-one, 119, C10H11NO3, MW 193.20, 
N
O
O
O
 
To a solution of 4-piperidone hydrochloride monohydrate (320 mg, 2.1 mmol) in DCM 
(7 mL), was added MP-Carbonate resin (0.8 g).  This was stirred at room temperature 
for 2 h.  In a separate flask, 3-furoic acid (280 mg, 2.52 mmol), N, N-4-
dimethylaminopyridine (cat.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (1.2 g, 6.3 mmol) and TEA (0.25 mL) were dissolved in DCM (7 mL) 
and stirred at room temperature for 2 h.  The two reaction mixtures were then combined 
and stirred at room temperature for a further 18 h.  The resulting solution was then 
filtered to remove the resin.  HCl (1M, 20 mL) was then added to the filtrate, which was 
extracted with DCM (3 x 30 mL).  The organic layers were washed with, 20 mL), 
NaHCO3 (20 mL) then brine (20 mL).  The organic layers were combined, dried 
(MgSO4), filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-100 % ethyl acetate in hexane) to yield the title compound as a 
cream oil, 225 mg, 63 % yield.  LCMS: tr = 1.96 min (50 % MeOH in water at 0.5 
mL/min), m/z M+H 194.16, HPLC: tr = 1.82 min (90 % acetonitrile in water at 1.0 
mL/min), >99 %, 1H NMR (CDCl3, 270 MHz): δ 2.41 (4H, t, J = 6.2 Hz, CH2), 3.85 
(4H, t, J = 6.2 Hz, CH2), 6.50 (1H, dd, J = 1.0, 2.0 Hz, ArH), 7.37 (1H, t, J = 1.7 Hz, 
ArH), 7.68 (1H, dd, J = 1.0, 1.7 Hz, ArH). 
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(4-[2-(2,4-Dichloro-phenoxy)-phenylamino]-piperidin-1-yl)-furan-3-yl-methanone, 
120, C22H20Cl2N2O3, MW 431.31, 
O
Cl
Cl HN
N
O
O
 
A solution of 2-(2,4-dichloro-phenoxy)-phenylamine (165 mg, 0.7 mmol), 1-(furan-3-
carbonyl)-piperidin-4-one (125 mg, 0.65 mmol), sodium triacetoxyborohydride (206 
mg, 0.97 mmol) and AcOH (0.1 mmol, 3.3 mmol) in DCE (5 mL) was stirred at r.t. for 
6 days.  NaHCO3 (20 mL) was then added and the mixture was extracted with EtOAc (3 
x 20 mL).  The organic layers were combined, dried (MgSO4), filtered and evaporated 
in vacuo.  The crude mixture was purified using flash chromatography (0-100 % ethyl 
acetate in hexane) to afford a brown oil, 62 mg, 22 % yield.  LCMS: tr = 6.3 min (50 % 
to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 431.41,  
HPLC: tr = 3.35 min (90 % acetonitrile in water at 0.8 mL/min), 99 %, 
1H NMR 
(CDCl3, 400 MHz, 50 °C): δ 1.38-1.48 (2H, m, CH2), 2.09 (2H, dd, J = 3.6, 12.8 Hz, 
CH2), 3.19 (2H, t, J = 11.6 Hz, CH2), 3.56-3.63 (1H, m, CH), 4.10 (1H, s, NH), 4.20 
(1H, s, CH2), 6.52 (1H, d, J = 2.0 Hz, CH=CH-O-CH), 6.64 (1H, td, J = 1.2, 7.2 Hz, 
ArH), 6.76 (2H, m, ArH), 6.82 (1H, d, J = .4 Hz, ArH), 7.04 (1H, td, J = 1.6, 7.6 Hz, 
ArH), 7.13 (1H, dd, J = 2.8, 8.8 Hz, ArH), 7.40 (1H, t, J = 1.6 Hz, CH=CH-O-CH), 7.45 
(1H, d, J = 2.4 Hz, ArH), 7.67 (1H, t, J = 0.8 Hz, C=CH-O).  13C NMR (CDCl3, 101 
MHz, 50 °C): δ 29.69, 32.56, 44.00 (CH2), 49.82 (CH), 110.02, 112.51, 117.20, 118.73, 
119.56 (ArH), 121.19 (ArC), 125.37, 125.46, 127.98 (ArCH), 128.71 (ArC), 130.41, 
138.38 (ArCH), 142.89, 143.14, 143.30, 151.30 (ArC), 163.76 (CO). 
 
Experimental Details: Chapter 8: Synthesis of Benzylamine Linked 17β-HSD3 
Inhibitors 
 
General Procedure for the Reduction of Substituted 2-Nitrobenzaldehyde 
OH
NO2
X
 
A solution of the desired substituted 2-nitrobenzaldehyde in EtOH (5 mL/mmol) was 
cooled to 0°C and to this was added NaBH4 (1.5 eq) and the resulting solution was 
stirred at r.t. for 2 h.  The EtOH was removed in vacuo and sat. NH4Cl solution was 
added and the mixture was then extracted with DCM and dried (MgSO4).  It was then 
evaporated in vacuo to yield the desired substituted 2-nitrobenzyalcohol. 
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General Procedure for the Reduction of the Substituted 2-Nitrobenzylalcohol 
OH
NH2
X
 
This procedure is as described by Matsuo et al.65  To a refluxing mixture of iron (5.5 
eq.) and ammonium chloride (0.7 eq.) in a 10:1 mixture of EtOH: H2O, the substituted 
2-nitrobenzylalcohol (1 eq.) was added.  This reaction mixture was stirred at reflux for 
between 1 and 4 h, and followed by TLC, it was then allowed to cool to room 
temperature and the solvent was removed in vacuo.  The residue was re-dissolved in 
DCM and washed with sat. aqueous sodium bicarbonate.  The organic layer was dried 
(MgSO4) filtered and evaporated in vacuo to afford the desired 2-aminobenzyalcohol.   
 
General Procedure for the Acylation of Substituted 2-Aminobenzylalcohols 
OH
NH
X
O  
To a solution of the substituted 2-aminobenzylalcohol and TEA (3 eq) in DCM (10 
mL/1mmol) at 0 °C, was added acetyl chloride (6 eq.).  The resulting solution was 
allowed to warm to r.t. and stirred for 18 h.  NaHCO3 was then added and the crude 
mixture was repeatedly extracted with DCM (with a trace of MeOH).  The organic 
layers were then washed with 1M HCl.  The organic layers were combined and dried 
(MgSO4) filtered and evaporated in vacuo.  The resulting solid was redissolved in 
MeOH (40 mL/1mmol) and to this was added NaOH (3 eq) and the reaction was stirred 
at r.t. for 2 h.  The solvent was evaporated in vacuo and H2O was added, the crude 
mixture was repeatedly extracted with EtOAc.  The organic layers were combined and 
dried (MgSO4), filtered and evaporated in vacuo to obtain the desired 2-acetamide 
benzylalcohol. 
 
General Procedure for the Dess-Martin Periodinane Oxidation of Alcohols 
H
NH
X
O
O
 
This procedure is based upon work by Dess et al.92, 93  To a solution of the 2-acetamide 
alcohol in DCM (50 mL/1mmol) was added Dess-Marin Periodinane (1.5 eq.) the 
resulting solution was stirred at r.t for 10 min.  Sodium thiosulphate (4.5 eq) in NaHCO3 
was then added and the mixture was repeatedly extracted with DCM.  The organic 
layers were combined, dried (MgSO4) filtered and evaporated in vacuo. The crude 
mixture was purified using flash chromatography to afford the desired aldehyde. 
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General procedure for the Reductive Amination of the Substituted Diphenylether 
Aniline with the Substituted 2-acetamide benzaldehyde 
O
HN
H
N
O
Z Y
X  
To a solution of the diphenylether aniline (1.5 eq) and aldehyde (1 eq) in DCE (2 mL/ 
1mmol) was added acetic acid (3 eq) and sodium triacetoxyborohydride (2.5 eq).  The 
resulting reaction mixture was stirred at r.t. for 2-18 h.  NaHCO3 was then added and 
repeatedly extracted with DCM.  The organic layers were combined, dried (MgSO4) 
filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography to afford the desired compound. 
 
2-Amino-benzaldehyde, 124, C7H7NO, MW 121.14, 
NH2
HO
 
Using the general procedure for the reduction of the 2-nitrobenzylalcohol the desired 
compound was isolated as a yellow oil, 794 mg, 99 % yield.  R.f. 0.35 (DCM), LCMS: 
tr = 3.04 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), 
m/z M+H 122.15, 1H NMR (CDCl3, 270 MHz,): δ 6.12 (2H, s, NH2), 6.63 (1H, d, J = 
8.4 HZ, ArH), 6.70-6.76 (1H, m, ArH), 7.26-7.32 (1H, m, ArH), 7.46 (1H, dd, J = 1.5, 
7.7 Hz, ArH), 9.85 (1H, s, CHO).  This compound has been previously synthesised 
using a similar method by Malecki et al.150 
 
N-(2-Formyl-phenyl)-acetamide, 125, C9H9NO2, MW 163.17, 
H
N
O
HO
 
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a yellow solid, 190 mg, 71% yield.  R.f. 0.68 (DCM), 
m.p. 54-57 °C, LCMS: tr = 1.67 min (90 % MeOH in water), m/z M+H 164.1, 
1H NMR 
(CDCl3, 270 MHz,): δ 2.24 (3H, s, CH3), 7.21 (1H, td, J = 1.2, 7.7 Hz, ArH), 7.56-7.63 
(1H, m, ArH), 7.65 (1H, dd, J = 1.5, 7.7 Hz, ArH), 8.72 (1H, d, J = 8.4 Hz, ArH), 9.85 
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(1H, s, CHO), 11.12 (1H, s, NH).  13C NMR (CDCl3, 68 MHz): δ 25.6 (CH3), 119.9 
(ArCH), 121.5 (ArC), 123.0, 136.2, 136.4 (ArCH), 141.0 (ArC), 169.8 (CO), 195.7 
(CHO).  HRMS: Calcd for C9H9NO2 (M+H)
+ 164.0706, found (M+H)+ 164.0699. 
 
N-(2-([2-(4-Chloro-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide, 126, 
C21H19ClN2O2, MW 366.84, 
Cl
O
HN
H
N
O
 
To a solution of 2-(4-chloro-phenoxy)-phenylamine (0.128 g, 0.58 mmol) and N-(2-
formyl-phenyl)-acetamide (0.19 g, 1.16 mmol) in DCE (2.6 mL) was added acetic acid 
(0.25 mL) and sodium triacetoxyborohydride (0.31 g, 1.45 mmol).  The resulting 
reaction mixture was heated in a CEM microwave for 10 minutes at 140 ºC.85  NaHCO3 
was then added and the mixture was repeatedly extracted with EtOAc.  The organic 
layers were combined, dried (MgSO4) filtered and evaporated in vacuo. The crude 
mixture was purified using flash chromatography (0-100% DCM in hexane) to afford 
the title compound as a white solid, 80 mg, 38 % yield.  R.f. 0.33 (DCM), m.p. 194-196 
°C, LCMS: tr = 1.36 min (95 % MeOH in H2O), m/z M-H 365.4, HPLC: tr = 5.1 min (90 
% acetonitrile in H2O, 0.5mL/min), 98 %, 
1H NMR (DMSO, 400 MHz): δ 2.02 (3H, s, 
CH3), 4.27 (2H, d, J = 5.6 Hz, CH2), 5.95 (1H, s, NH), 6.46 (1H, d, J = 8.4 Hz, ArH), 
6.55 (1H, td, J = 0.8, 7.6 Hz, ArH), 6.84 (1H, dd, J = 1.6, 8.0, ArH), 6.89-6.95 (3H, m, 
ArH), 7.07-7.11 (1H, m, ArH), 7.16-7.22 (2H, m, ArH), 7.35-7.41 (3H, m, ArH), 9.47 
(1H, br.s, NHCO).  13C NMR (DMSO, 101 MHz): 23.2 (CH3), 42.6 (CH2), 111.7, 
116.0, 118.3, 120.2, 125.2, 125.3, 125.6 (ArCH), 126.0 (ArC), 126.7, 126.9, 129.6 
(ArCH), 133.5, 135.8, 140.5, 141.6, 156.7 (ArC), 168.5 (CO).  HRMS: Calcd for 
C21H19ClN2O2 (M+H)
+ 367.1208, found (M+H)+ 367.1204.  Anal. calcd for 
C21H19ClN2O2: C 68.76, H 5.22, N 7.64 %. Found: C 69.0, H 5.28, N 7.52%. 
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N-(2-([2-(4-Trifluoromethoxy-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide, 
127, C22H19F3N2O3, MW 416.39, 
O
O
HN
F
F
F
H
N
O
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a white solid, 155 mg, 55 % yield.  R.f. 0.4 (1:1, EtOAc: Hexane), m.p. 98-
100 °C, LCMS: tr = 1.07 min (95 % MeOH in H2O), m/z M-H 415.09, HPLC: tr = 2.22 
min (90 % acetonitrile in H2O), 99 %, 
1H NMR (CDCl3, 270 MHz): δ 1.94 (3H, s, CH3), 
4.3 (3H, s, CH2 and NH), 6.79-6.96 (5H, m, ArH), 7.06-7.17 (3H, m, ArH), 7.25-7.34 
(3H, m, ArH), 8.01 (1H, d, J = 8.15, ArH), 8.54 (1H, br.s, NHCO).  13C NMR (CDCl3, 
68 MHz): δ 24.5 (CH3), 47.8 (CH2), 113.8, 118.1, 119.6, 119.7 (ArCH), 122.5 (ArC), 
122.8, 124.6, 125.7 (ArCH), 127.6 (ArC), 128.9, 129.6 (ArCH), 137.5, 139.9, 143.9, 
144.4 (ArC), 155.9 (OCF3), 168.5 (CO).  
19F NMR (CDCl3, 376 MHz): δ -58.29 
(OCF3).  HRMS: Calcd for C22H19F3N2O3 (M+Na)
+ 439.1240, found (M+Na)+ 
439.1240.  Anal. calcd for C22H19F3N2O3: C 63.46, H 4.60 N 6.73 %. Found: C 63.5, H 
4.62, N 7.0 %. 
 
N-(2-([2-(4-Chloro-phenoxy)-5’-fluoro-phenylamino]-methyl)-phenyl)-acetamide, 
128, C21H18ClFN2O2, MW 384.83, 
Cl
O
HN
H
N
O
F
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a white solid, 68 mg, 27 % yield.  R.f. 0.4 (1:1, EtOAc: Hexane), m.p. 178-
180 °C, LCMS: tr = 0.98 min (95 % MeOH in H2O), m/z M-H 383.28, HPLC: tr = 2.87 
min (90 % acetonitrile in H2O), 99 %, 
1H NMR (CDCl3, 270 MHz): δ 2.03 (3H, s, CH3), 
4.23 (2H, d, J = 5.0Hz, CH2), 4.42 (1H, t, J = 4.9 Hz, NH), 6.41-6.58 (2H, m, ArH), 
6.80-6.88 (3H, m, ArH), 7.10 (1H, t, J = 7.2 Hz, ArH), 7.22-7.32 (4H, m, ArH), 7.86 
(1H, d, J = 7.9 Hz, ArH), 8.19 (1H, br.s, NHCO).  13C NMR (CDCl3, 68 MHz): δ 24.3 
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(CH3), 46.8 (CH2), 100.7 (d, J = 28.1Hz, ArH), 104.6 (d, J = 23.7Hz, ArCH), 118.0 
(ArCH), 120.8 (d, J = 10.0Hz, ArCH), 123.6 (ArCH), 128.1 (d, J = 11.8Hz, ArC), 
128.9, 129.4, 129.9 (ArCH), 136.9, 139.2 (ArC), 141.3 (d, J = 10.6Hz, ArC), 156.3, 
158.8, 162.3 (ArC), 168.7 (CO).  19F NMR (CDCl3, 376 MHz): δ 
-115.43-115.57 (m, 
ArF).  HRMS: Calcd for C21H18ClFN2O2 (M+H)
+ 383.0968, found (M+H)+ 383.0965. 
 
6-Amino-benzo[1,3]dioxole-5-carbaldehyde, 129, C8H7NO3, MW 165.15, 
O
O
H
O
NH2  
Using the general procedure for the reduction of substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a brown solid, 360 mg, 85 % yield.  R.f. 0.67 
(DCM), 1H NMR (CDCl3, 270 MHz,): δ 5.90 (2H, s, CH2), 6.11 (1H, s, ArH), 6.29 (2H, 
br.s, NH), 6.79 (1H, s, ArH), 9.57 (1H, s, CHO). 
 
N-(6-Formyl-benzo[1,3]dioxol-5-yl)-acetamide, 130, C10H9NO4, MW 207.18, 
O
O
O
O
NH
H
 
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a dark yellow solid, 180 mg, 78 % yield.  m.p. 133-137 
°C, R.f. 0.35 (DCM), m.p. 133-137 °C, 1H NMR (CDCl3, 270 MHz,): δ 2.21 (3H, s, 
CH3), 6.05 (2H, s, CH2), 6.98 (1H, s, ArH), 8.34 (1H, s, ArH), 9.65 (1H, s, CHO), 11.46 
(1H, s, NH). 
 
N-(6-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-benzo[1,3]dioxol-5-yl)-
acetamide, 131, C22H19ClN2O4, MW 410.85, 
Cl
O
HN
H
N
O
O
O  
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
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isolated as a light cream solid, 540 mg, 29 % yield.  R.f. 0.75 (DCM), m.p. 154-156 °C, 
LCMS: tr = 1.3 min (95 % MeOH in water), m/z M
-H 409.45, HPLC: tr = 4.7 min (90 % 
acetonitrile in H2O), 98 %, 
1H NMR (CDCl3, 400 MHz,): δ 1.95 (3H, s, CH3), 4.18 (2H, 
s, NHCH2), 4.23 (1H, s, NH), 5.93 (2H, s, CH2O), 6.74 (1H, s, ArH), 6.77-6.81 (1H m, 
ArH), 6.86-6.89 (3H, m, ArH), 7.10 (1H, td, J = 4.0, 8.8 Hz, ArH), 7.24-7.27 (2H, m, 
ArH), 7.44 (1H, s, ArH), 8.23 (1H, s, ArH).  13C NMR (CDCl3, 101 MHz): δ 24.2 
(CH3), 47.2 (CH2NH), 101.4 (CH2O), 105.3, 109.1, 113.4, 118.5, 119.2, 119.4 (ArCH), 
121.7 (ArC), 125.4 (ArCH), 128.0 (ArC), 129.8 (ArCH), 131.1, 139.6, 143.7, 144.7, 
147.4, 155.9 (ArC), 168.3 (CO).  HRMS: Calcd for C22H19ClN2O4 (M+H)
+ 409.0961, 
found (M+H)+ 409.0957. 
 
(2-Amino-4,5-dimethoxy-phenyl)-methanol, 135a, C9H13NO3, MW 183.20, 
OH
NH2
O
O  
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a brown oil, 764 mg, 93 % yield.  R.f. 0.17 (EtOAc), 
1H NMR (CDCl3, 270 MHz,): δ 3.30 (2H, br.s, NH2), 3.78 (3H, s, OCH3), 3.81 (3H, s, 
OCH3), 4.58 (2H, s, CH2), 6.29 (1H, s, ArH), 6.63 (1H, s, ArH). 
 
N-(2-Hydroxymethyl-4,5-dimethoxy-phenyl)-acetamide, 136a, C11H15NO4, MW 
225.24, 
OH
O
O NH
O  
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a yellow, waxy solid, 277 mg, 59 % yield.  R.f. 0.48 
(EtOAc), 1H NMR (CDCl3, 270 MHz,): δ 2.14 (3H, s, CH3), 2.85, (1H, br.s, OH), 3.82 
(3H, s, OCH3), 3.84 (3H, s, OCH3), 4.56 (2H, s, CH2), 6.69 (1H, s, ArH), 7.46 (1H, s, 
ArH). 
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N-(2-Formyl-4,5-dimethoxy-phenyl)-acetamide, 137a, C11H13NO4, MW 223.23, 
H
N
O
O
O
O H
 
Using the general procedure for the Dess-Martin Periodinane oxidation of alcohols the 
title compound was obtained as a pale yellow solid, 137 mg, 50 % yield.  R.f. 0.22 
(EtOAc), m.p. 175-178 °C, HPLC tr = 1.05min (90 % acetonitrile in H2O) 96 %, LCMS 
tr = 0.86min (95 % MeOH in H2O) M-H 221.77, 
1H NMR (CDCl3, 270 MHz): δ 2.23 
(3H, s, CH3), 3.90 (3H, s, OCH3), 3.98 (3H, s, OCH3), 7.02 (1H, s, ArH), 8.46 (1H, s, 
ArH), 9.74 (1H, s, CHO), 11.32 (1H, br.s, NH). 
 
N-(2-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-4,5-dimethoxy-phenyl)-
acetamide, 136, C23H23ClN2O4, MW 426.89, 
Cl
O
HN
H
N
O
O
O  
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the resulting reaction mixture 
was stirred at r.t. for 2 h, then it was subjected to microwave heating for 5 min at 140 
°C.  NaHCO3 was then added and the mixture was repeatedly extracted with DCM.  The 
organic layers were combined, dried (MgSO4) filtered and evaporated in vacuo. The 
crude mixture was purified using flash chromatography (100 % EtOAc) to afford the 
title compound as a cream solid, 20 mg, 11 % yield.  R.f. 0.44 (EtOAc), m.p. 117-118 
°C, LCMS: tr = 0.97 min (95 % MeOH in water), m/z M-H 425.16, HPLC: tr = 1.99 min 
(90 % acetonitrile in H2O), 98 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.94 (3H, s, CH3), 
3.81 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.22 (3H, br.s, CH2 and NH), 6.74-6.90 (6H, 
m, ArH), 7.06-7.12 (1H, m, ArH), 7.21-7.26 (2H, m, ArH), 7.57 (1H, s, ArH), 8.26 (1H, 
br.s, NHCO).  13C NMR (CDCl3, 68 MHz): δ 24.4 (CH3), 47.2 (CH2), 56.11, 56.27 
(OCH3), 107.4, 112.5, 113.6, 118.5, 119.3, 119.6 (ArCH), 120.2 (ArC), 125.6 (ArCH), 
128.1 (ArC), 129.9, (ArCH), 130.6, 139.9, 143.7, 148.7, 156.0 (ArC), 168.5 (CO).  
HRMS: Calcd for C23H23ClN2O4 (M+Na)
+ 449.1230, found (M+Na)+ 449.1239. 
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N-(2-([2-(2,4-Dichloro-phenoxy)-phenylamino]-methyl)-4,5-dimethoxy-phenyl)-
acetamide, 139, C23H22Cl2N2O4, MW 461.34, 
Cl
O
HN
H
N
O
O
O
Cl
 
2-(2, 4-Dichloro-phenoxy)-phenylamine hydrochloride (135 mg, 0.47 mmol) was 
dissolved in DCM (10 mL) and to this was added K2CO3 (128 mg, 0.94 mmol) the 
reaction was then stirred at r.t. for 30 min.  H2O was added to the reaction and the 
mixture was extracted with DCM.  The organic layers were combined, dried (MgSO4) 
filtered and evaporated in vacuo.  The resulting free amine was dissolved in DCE (2 
mL) and to this was added N-(2-formyl-4,5-dimethoxy-phenyl)-acetamide (69 mg, 0.31 
mmol) acetic acid (0.12 mL) and sodium triacetoxyborohydride (164 mg, 0.8 mmol).  
The resulting reaction mixture was stirred at r.t. for 2 h.  NaHCO3 was then added, and 
repeatedly extracted with DCM.  The organic layers were combined, dried (MgSO4), 
filtered and evaporated in vacuo. The crude mixture was purified using flash 
chromatography (0-50 % EtOAc in hexane) to afford the title compound as an off-white 
solid, 55 mg, 38 % yield.  R.f. 0.58 (EtOAc), m.p. 128-131 °C, LCMS: tr = 1.1 min (95 
% MeOH in water), m/z M-H 459.24, HPLC: tr = 2.2 min (90 % acetonitrile in H2O), 96 
%, 1H NMR (CDCl3, 270 MHz,): δ 1.98 (3H, s, CH3), 3.83 (3H, s, OCH3), 3.87 (3H, s, 
OCH3), 4.26 (2H, s, CH2), 4.34 (1H, br.s, NH), 6.75-6.77 (3H, m, ArH), 6.83-6.91 (2H, 
m, ArH), 7.02-7.11 (1H, m, ArH), 7.15 (1H, dd, J = 1.7, 8.7Hz, ArH), 7.61 (1H, s, 
ArH), 8.31 (1H, br.s, NHCO).  13C NMR (CDCl3, 101 MHz): δ 24.5 (CH3), 47.2 (CH2), 
56.1, 56.3 (OCH3), 104.0 (ArC), 107.4, 112.5, 113.6, 118.0, 119.1, 120.0, 125.4 
(ArCH), 125.5, 125.8 (ArC), 128.1 (ArCH), 129.0 (ArC), 130.6 (ArCH), 139.1, 143.7, 
146.0, 148.7, 151.5 (ArC), 168.5 (CO).  HRMS: Calcd for C23H22Cl2N2O4 (M+H)
+ 
461.1029, found (M+H)+ 461.1028. 
 
(1-Nitro-naphthalen-2-yl)-methanol, 134b, C11H9NO3, MW 203.19, 
NO2
OH
 
Using the general procedure for the reduction of substituted 2-nitrobenzaldehyde the 
desired product was obtained as a dark yellow solid, 1 g, >99 % yield.  R.f. 0.59 
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(EtOAc), m.p 78-80 °C, 1H NMR (CDCl3, 270 MHz,): δ 2.32 (1H, br.s, OH), 4.82 (2H, 
s, CH2), 7.48-7.65 (3H, m, ArH), 7.81-7.90 (2H, m, ArH), 7.99 (1H, d, J = 8.4, ArH). 
 
(1-Amino-naphthalen-2-yl)-methanol, 135b, C11H11NO, MW 173.21, 
OH
NH2
 
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol, 
the desired product was obtained, 730 mg, 86 % yield.  R.f. 0.62 (EtOAc), LCMS: tr = 
1.3 min (80 % MeOH in water), m/z M-H 171.88, HPLC: tr = 2.19 min (70 % 
acetonitrile in water), 87 %, 1H NMR (CDCl3, 270 MHz,): δ 4.85 (2H, s, CH2), 7.21-
7.25 (2H, m, ArCH), 7.41-7.47 (2H, m, ArH), 7.74-7.85 (2H, m, ArH). 
 
N-(2-Hydroxymethyl-naphthalen-1-yl)-acetamide, 136b, C13H13NO2, MW 215.25,  
OH
NH
O  
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
desired product was obtained as a yellow solid, 377 mg, 82 % yield.  R.f. 0.58 (EtOAc), 
m.p. 105-108 °C, HPLC tr = 1.45 min (90 % acetonitrile in H2O) >99 %, LCMS tr = 
0.92 min (95 % MeOH in H2O) M+Na 237.90, 
1H NMR (CDCl3, 270 MHz,): δ 2.32 
(3H, s, CH3), 3.29 (1H, br.s, OH), 4.63 (2H, s, CH2), 7.40-7.44 (3H, m, ArH), 7.77-7.80 
(3H, m, ArH). 
 
N-(2-Formyl-naphthalen-1-yl)-acetamide, 137b, C13H11NO2, MW 213.23,  
O
NH
H
O 
Using the general procedure for the Dess-Martin Periodinane oxidation of alcohols the 
desired product was obtained, 59 mg, 77 % yield.  R.f. 0.45 (EtOAc), 1H NMR (CDCl3, 
270 MHz,): δ 2.28 (3H, s, CH3), 7.55-7.92 (5H, m, ArH), 7.99-8.03 (1H, m, ArH), 9.31 
(1H, br.s, NH), 10.18 (1H, s, CHO). 
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N-(2-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-naphthalen-1-yl)-acetamide, 
140, C25H21ClN2O2, MW 416.90, 
H
N
Cl
O
HN
O
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated, 28 mg, 24 % yield.  R.f. 0.38 (EtOAc), m.p. 153-155 °C, LCMS: tr = 1.14 min 
(95 % MeOH in water), m/z M-H 415.34, HPLC: tr = 2.26 min (90 % acetonitrile in 
water), 96 %, 1H NMR (CDCl3, 270 MHz,): δ 2.28 (3H, s, CH3), 4.42 (2H, s, CH2), 4.53 
(1H, br.s, NH), 6.63-6.73 (2H, m, ArH), 6.83-6.91 (3H, m, ArH), 6.97-7.03 (1H, m, 
ArH), 7.21-7.24 (2H, m, ArH), 7.42-7.51 (4H, m, ArH), 7.75 (1H, d, J = 8.4Hz, ArH), 
7.80-7.85 (2H, m, ArH and NHCO).  13C NMR (CDCl3, 68 MHz): 23.5 (CH3), 45.4 
(CH2), 112.4, 117.7, 118.5, 119.6, 122.6, 125.5, 126.0, 126.1 (ArCH), 127.8 (ArC), 
128.2, 128.4, 129.8 (ArCH), 130.5, 130.6, 133.4, 133.7, 140.2, 142.9, 156.5 (ArC), 
169.4 (CO).  HRMS: Calcd for C25H21ClN2O2 (M+H)
+ 439.1184, found (M+H)+ 
439.1190. 
 
(2-Amino-5-methyl-phenyl)-methanol, 135c, C8H11NO, MW 137.18, 
OH
NH2  
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a brown solid, 162 mg, 79 % yield.  R.f. 0.45 
(EtOAc), m.p. 118-121 °C, LCMS: tr = 0.93 min (95 % MeOH in water), m/z M+H 
137.80, HPLC: tr = 1.53 min (90 % acetonitrile in H2O), 96 %, 
1H NMR (CDCl3, 270 
MHz,): δ 2.22 (3H, s, CH3), 4.02 (2H, br.s, NH), 4.64 (2H, s, CH2), 6.62 (1H, d, J = 9.3 
Hz, ArH), 6.89-6.95 (2H, m, ArH), 7.25 (1H, s, OH). 
 
N-(2-Hydroxymethyl-4-methyl-phenyl)-acetamide, 136c, C10H13NO2, MW 179.22, 
OH
NH
O  
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a cream solid, 180 mg, 79 % yield.  R.f. 0.35 (EtOAc), 
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m.p. 134-136 °C (from hexane), LCMS tr = 1.4 min (80 % MeOH in H2O) M+Na 
210.99, 1H NMR (CDCl3, 270 MHz,): δ 2.17 (3H, s, CH3), 2.29 (3H, s, CH3), 4.63 (2H, 
d, J = 4.9Hz, CH2), 7.02 (1H, s, ArH), 7.12 (1H, d, J = 8.4 Hz, ArH), 7.80 (1H, d, J = 
8.2 Hz, ArH), 8.28 (1H, s, NH). 
 
N-(2-Formyl-4-methyl-phenyl)-acetamide, 137c, C10H11NO2, MW 177.20, 
O
NH
O
H
 
Using the general procedure for the Dess-Martin Periodinane oxidation of alcohols the 
title compound was obtained as a red oil, 44 mg, 25 % yield.  R.f. 0.8 (10 % MeOH in 
DCM), 1H NMR (CDCl3, 270 MHz): δ 2.21 (3H, s, CH3), 2.36 (3H, s, CH3), 7.37-7.41 
(2H, m, ArH), 8.55-8.61 (1H, m, ArH), 9.84 (1H, s, CHO), 10.98 (1H, br.s, NH). 
 
N-(2-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-4-methyl-phenyl)-acetamide, 
141, C22H21ClN2O2, MW 380.87, 
Cl
O
HN
H
N
O
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a light cream solid, 37 mg, 47 % yield.  R.f. 0.35 (EtOAc), m.p. 138-140 °C 
(from hexane), LCMS: tr = 1.21 min (95 % MeOH in water), m/z M+H 381.20, HPLC: tr 
= 2.38 min (90 % acetonitrile in H2O), 96 %.  
1H NMR (CDCl3, 270 MHz,): δ 1.97 (3H, 
s, CH3), 2.29 (3H, s, CH3), 4.25 (3H, s, CH2 and NH), 6.76-6.93 (5H, m, ArCH), 7.07-
7.13 (3H, m, ArH), 7.22-7.27 (2H, m, ArH), 7.83 (1H, d, J = 8.2Hz, ArH), 8.35 (1H, 
br.s, NH).  13C NMR (CDCl3, 68 MHz): δ 20.9, 24.5 (CH3), 47.5 (CH2), 113.6, 118.6, 
119.3, 119.6, 123.1, 125.5 (ArCH), 128.0, 128.1 (ArC), 129.3, 129.9, 130.2 (ArCH), 
134.4, 134.7, 139.9, 143.8, 156.0 (ArC), 168.5 (CO).  HRMS: Calcd for C22H21ClN2O2 
(M+H)+ 381.1364, found (M+H)+ 381.1365. 
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N-(4-Chloro-2-hydroxymethyl-phenyl)-acetamide, 136d, C9H10ClNO2, MW 199.63, 
OH
Cl
NH
O  
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a cream wax, 1.12 g, 89 % yield.  R.f. 0.35 (EtOAc), 1H 
NMR (CDCl3, 270 MHz,): δ 1.46 (2H, s, NH and OH), 2.19 (3H, s, CH3), 4.60 (2H, s, 
CH2), 7.14-7.26 (2H, m, ArH), 7.94-7.98 (1H, m, ArH). 
 
N-(4-Chloro-2-formyl-phenyl)-acetamide, 137d, C9H8ClNO2, MW 197.62, 
H
O
Cl
NH
O  
Using the general procedure for the Dess-Martin Periodinane oxidation of alcohols the 
title compound was obtained as a red solid, 383 mg, 70 % yield.  R.f. 0.72 (10% MeOH 
in EtOAc), m.p. 152-154 °C, 1H NMR (CDCl3, 270 MHz): δ 2.24 (3H, s, CH3), 7.55 
(1H, dd, J = 2.5, 8.9 Hz, ArH), 7.61 (1H, dd, J = 2.5 Hz, ArH), 8.71 (1H, d, J = 9.2 Hz, 
ArH), 9.84 (1H, s, CHO), 11.00 (1H, br.s, NH). 
 
N-(4-chloro-2-[2-(4-chloro-phenoxy)-phenylamino]-methyl-phenyl)-acetamide, 142, 
C21H18Cl2N2O2, MW 401.29, 
Cl
O
HN
H
N
O
Cl  
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a light brown wax, 68mg, 26 % yield.  R.f. 0.43 (1:1, EtOAc: Hexane), 
LCMS: tr = 1.21 min (95 % MeOH in water), m/z M-H 399.15, 401.1, HPLC: tr = 2.62 
min (90 % acetonitrile in H2O), 97 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.95 (3H, s, 
CH3), 4.22 (3H, s, NH and CH2), 6.79-6.91 (5H, m, ArH), 7.07-7.13 (1H, m, ArH), 
7.24-7.28 (4H, m, ArH), 7.98 (1H, d, J = 8.4 Hz, ArH), 8.56 (1H, br.s, NHCO).  13C 
NMR (CDCl3, 101 MHz): δ 24.5 (CH3), 47.5 (CH2), 113.8, 118.7, 119.5, 119.9, 124.1, 
 273 
125.5, 128.7, 129.3 (ArCH), 129.5 (ArC), 129.9 (ArCH), 136.0, 139.4, 144.1, 155.9, 
168.5, 200.5 (ArC), 205.1 (CO).  HRMS: Calcd for C21H18Cl2N2O2 (M+H)
+ 401.0818, 
found (M+H)+ 401.0803. 
 
N-(4-Chloro-2-[2-(2,4-dichloro-phenoxy)-phenylamino]-methyl-phenyl)-acetamide, 
143, C21H17Cl3N2O2, MW 435.73, 
Cl
O
HN
H
N
O
Cl
Cl  
2-(2,4-Dichloro-phenoxy)-phenylamine hydrochloride (350 mg, 1.22 mmol) was 
dissolved in DCM (10 mL) and to this was added K2CO3 (335 mg, 2.44 mmol), the 
reaction was then stirred at r.t. for 30 min.  H2O was then added and the mixture was 
extracted with DCM.  The organic layers were combined, dried (MgSO4), filtered and 
evaporated in vacuo.  The resulting amine was dissolved in DCE (2 mL) and to this was 
added N-(4-chloro-2-formyl-phenyl)-acetamide (160 mg, 0.81 mmol), acetic acid (0.15 
mL) and sodium triacetoxyborohydride (0.43 g, 2.02 mmol).  The resulting reaction 
mixture was stirred at r.t. for 2 h.  NaHCO3 was then added and the mixture was 
repeatedly extracted with DCM.  The organic layers were combined, dried (MgSO4), 
filtered and evaporated in vacuo.  The crude mixture was purified using flash 
chromatography (0-50% EtOAc in hexane) to afford the title compound as a cream 
solid, 210 mg, 60 % yield.  R.f. 0.38 (EtOAc), m.p. 135-137 °C, LCMS: tr = 1.3 min (95 
% MeOH in water), m/z M-H 433.1, 435.1, HPLC: tr = 2.8 min (90 % acetonitrile in 
H2O), 99 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.98 (3H, s, CH3), 4.28-4.29 (2H, m, CH2), 
4.40 (1H, br.s, NH), 6.70-6.88 (4H, m, ArH), 7.04-7.10 (1H, m, ArH), 7.17 (1H, dd, J = 
2.5 Hz, ArH), 7.25-7.27 (2H, m, ArH), 7.45 (1H, d, J = 2.5 Hz, ArH), 7.96-7.99 (1H, m, 
ArCH), 8.64 (1H, br.s. NH).  13C NMR (CDCl3, 101 MHz): δ 24.6 (CH3), 47.4 (CH2), 
113.8, 117.8, 119.7, 120.3, 124.1, 125.3 (ArCH), 125.9 (ArC), 128.2, 128.7, 129.3 
(ArCH), 129.4, 129.6 (ArC), 130.7 (ArCH), 136.0, 138.6, 144.4, 151.1 (ArC), 168.5 
(CO).  HRMS: Calcd for C21H17Cl3N2O2 (M+H)
+ 435.0428, found (M+H)+ 437.0387. 
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N-(4-Chloro-2-[2-(4-trifluoromethoxy-phenoxy)-phenylamino]-methyl-phenyl)-
acetamide, 144, C22H18ClF3N2O3, MW 450.84 
O
O
HN
H
N
O
F
F
F
Cl  
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a brown solid, 86 mg, 30 % yield.  R.f. 0.35 (1:1, EtOAc: Hexane), m.p. 121-
123 °C, LCMS: tr = 1.07 min (95 % MeOH in water), m/z M-H 449.29, HPLC: tr = 3.28 
min (90 % acetonitrile in H2O), >99 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.94 (3H, s, 
CH3), 4.23 (3H, s, CH2 and NH), 6.80-6.96 (5H, m, ArH), 7.08-7.18 (3H, m, ArH), 
7.25-7.30 (3H, m, ArH), 7.99 (1H, dd, J = 8.4 Hz, ArH), 8.54 (1H, br.s, NHCO).  13C 
NMR (CDCl3, 101 MHz): 24.4 (CH3), 47.4 (CH2), 113.8, 118.1, 119.6, 119.8, 112.8, 
123.9, 125.5, 128.6, 129.2 (ArCH), 135.9, 139.3 (ArC), 155.6 (OCF3), 207.9 (CO).  
19F 
NMR (CDCl3, 376 MHz): δ -58.3 (OCF3).  Anal. Calcd for C22H18ClF3N2O3: C 58.61, 
H 4.02, N 6.21 %. Found: C 58.1, H 4.12, N 5.96 %.  HRMS: Calcd for 
C22H18ClF3N2O3 (M+H)
+ 451.1031, found (M+H)+ 451.1024. 
 
N-[2-(4-chloro-phenoxy)-phenyl]-2-nitro-benzamide, 145, C19H13ClN2O4, MW 
368.77, 
Cl
O
HN O
NO2
 
To a solution of 2-(4-chloro-phenoxy)-phenylamine (200 mg, 0.91 mmol) in DCM (5 
mL) at 0 °C was added 2-nitrobenzoyl chloride (338 mg, 1.82 mmol) and TEA (0.15 
mL).  The reaction was then stirred at r.t. for 30 min.  NaHCO3 was added and the 
mixture was extracted with DCM, dried (MgSO4) and purified by flash chromatography 
(0-100 % DCM in hexane) to yield the desired product as an off white oil, 258 mg, 77 
% yield.  LCMS: tr = 1.91 min (80 % MeOH in water), m/z M-H 367.09, HPLC: tr = 
2.16 min (90 % acetonitrile in water), 90 %, 1H NMR (CDCl3, 270 MHz,): δ 6.83 (1H, 
dd, J = 1.4, 8.0 Hz, ArH), 6.91-6.99 (2H, m, ArH), 7.07 (1H, td, J = 1.6, 8.0 Hz, ArH), 
7.17 (1H, t, J = 7.2Hz, ArH), 7.24-7.31 (2H, m, ArH), 7.48 (1H, dd, J = 1.4, 7.2Hz, 
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ArH), 7.58 (1H, td, J = 1.4, 7.5 Hz, ArH), 7.65 (1H, dd, J = 1.1, 7.4 Hz, ArH), 8.00-8.06 
(2H, m, ArH and NH), 8.47 (1H, dd, J = 1.1, 8.0 Hz, ArH). 
 
2-Amino-N-[2-(4-chloro-phenoxy)-phenyl]-benzamide, 146, C19H15ClN2O2, MW 
338.79, 
Cl
O
HN O
NH2
 
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired product was obtained as a white wax, 143 mg, 62 % yield.  R.f. 0.39 (DCM), 
LCMS: tr = 2.67 min (80 % MeOH in water), m/z M-H 337.05, HPLC: tr = 2.59 min (90 
% acetonitrile in water), 98 %, 1H NMR (CDCl3, 270 MHz,): δ 5.55 (2H, br.s., NH2), 
6.62-6.70 (2H, m, ArH), 6.87 (1H, dd, J = 1.4, 8.0 Hz, ArH), 6.96-6.99 (2H, m, ArH), 
7.04 (1H, td, J = 1.4, 7.5 Hz, ArH), 7.15-7.25 (2H, m, ArH), 7.39-7.34 (3H, m, ArH), 
8.34 (1H, br.s, NH), 8.50 (1H, dd, J = 1.4, 8.0 Hz, ArH). 
 
2-Acetylamino-N-[2-(4-chloro-phenoxy)-phenyl]-benzamide, 147, C21H17ClN2O3, 
MW 380.82, 
Cl
O
HN O
H
N
O
 
2-Amino-N-[2-(4-chloro-phenoxy)-phenyl]-benzamide (120 mg, 0.36 mmol) was 
dissolved in DCM (3 mL) and cooled to 0 °C, to this was added acetyl chloride (0.05 
mL, 0.72 mmol) and TEA (0.07 mL, 1.1 mmol).  The resulting solution was stirred at 
r.t. for 1 h, NaHCO3 was then added and the mixture extracted repeatedly with DCM.  
The organic portions were then washed with HCl (1M) and dried (MgSO4).  The crude 
mixture was then purified by flash chromatography (0-50 % EtOAc in DCM) to yield 
the desired product as a white solid, 65 mg, 48 % yield.  R.f. 0.46 (25 % EtOAc in 
DCM), m.p. 158-160 °C, LCMS: tr = 1.05 min (95 % MeOH in water), m/z M-H 
379.00, HPLC: tr = 2.48 min (90 % acetonitrile in water), 99 %, 
1H NMR (CDCl3, 270 
MHz,): δ 2.2 (3H, s, CH3), 6.87 (1H, dd, J = 1.6, 8.3Hz, ArH), 6.96-7.01 (2H, m, ArH), 
7.05-7.13 (2H, m, ArH), 7.19 (1H, td, J = 1.6, 7.7Hz, ArH), 7.29-7.34 (2H, m, ArH), 
7.45-7.52 (2H, m, ArH), 8.40-8.44 (2H, m, ArH and NH), 8.58 (1H, d, J = 15.7 Hz, 
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ArH).  13C NMR (CDCl3, 68 MHz): 28.0 (CH3), 117.7, 120.3 (ArCH), 121.0 (ArC), 
121.5, 121.9, 123.1, 124.4, 125.2, 126.6 (ArCH), 128.9, 129.6 (ArC), 130.2, 133.2 
(ArCH), 139.9, 146.4, 154.6 (ArC), 167.3, 169.1 (CO).  HRMS: Calcd for 
C21H17ClN2O3 (M+H)
+ 381.1000, found (M+H)+ 381.0994. 
 
2-Benzoylamino-N-[2-(4-chloro-phenoxy)-phenyl]-benzamide, 148, C26H19ClN2O3, 
MW 442.89, 
Cl
O
HN O
H
N
O
 
2-Amino-N-[2-(4-chloro-phenoxy)-phenyl]-benzamide (120 mg, 0.36 mmol) was 
dissolved in DCM (3 mL) and cooled to 0°C, to this was added benzoyl chloride (0.08 
mL, 0.72 mmol) and TEA (0.07 mL, 1.1 mmol).  The resulting solution was stirred at 
r.t. for 1 h and NaHCO3 was then added and the mixture was repeatedly extracted with 
DCM.  This was then washed with HCl (1M) and dried (MgSO4).  The crude mixture 
was then purified by flash chromatography (0-100 % DCM in hexane) to yield the 
desired product as a white solid, 60 mg, 38 % yield.  R.f. 0.46 (DCM), m.p. 183-185 °C, 
LCMS: tr = 1.29 min (95 % MeOH in water), m/z M-H 440.97, HPLC: tr = 3.89 min (90 
% acetonitrile in water), >99 %, 1H NMR (CDCl3, 270 MHz,): δ 6.88 (1H, d, J = 7.6 
Hz, ArH), 6.99 (2H, d, J = 2.0 Hz, ArH), 7.08-7.15 (2H, m, ArH), 7.21 (1H, t, J = 7.2 
Hz, ArH), 7.31 (2H, dd, J = 0.8, 6.8 Hz, ArH), 7.50-7.59 (5H, m, ArH and NH), 8.04 
(2H, dd, J = 1.2, 4.8 Hz, ArH), 8.49-8.51 (2H, m, ArH), 8.83 (1H, d, J = 8.0 Hz, ArH), 
11.89 (1H, br.s, NH).  13C NMR (CDCl3, 68 MHz): δ 117.6, 120.2 (ArCH), 128.8 
(ArC), 121.6, 121.9, 123.1, 124.3, 125.1, 127.4, 128.8 (ArCH), 128.9, 129.4 (ArC), 
130.1, 131.9, 133.3(ArCH), 134.7, 140.3, 146.3, 154.6 (ArC), 165.6, 167.3 (CO).  
HRMS: Calcd for C26H19ClN2O3 (M+H)
+ 443.1157, found (M+H)+ 443.1162. 
 
N-(2-Formyl-phenyl)-N-methyl-acetamide, 149,C10H11NO2, MW 177.20,
151 
H
O
N
O 
To a solution of N-(2-formyl-phenyl)-acetamide (100 mg, 0.61 mmol) in DMF (10 mL) 
was added NaH (60 % dispersion in mineral oil, 30 mg, 0.73 mmol).  After 1h had 
elapsed MeI (0.08 mL, 1.2 mmol) was added and this was then stirred at r.t. under N2 
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for 3 days.  This was poured onto water (20 mL), extracted with EtOAc and dried 
(MgSO4).  The crude product was purified by flash chromatography (0-100 % DCM in 
hexane) to yield the desired product as an off white wax, 60 mg, 56 % yield.  R.f. 0.35 
(DCM), LCMS: tr = 1.0 min (95 % MeOH in water), m/z M+H 177.80, HPLC: tr = 1.0 
min (95 % MeOH in water), 97 %, 1H NMR (CDCl3, 270 MHz,): δ 1.79 (3H, s, 
CH3CO), 3.28 (3H, s, CH3N), 7.26-7.29 (1H, m, ArH), 7.50-7.55 (1H, m, ArH), 7.69 
(1H, td, J = 1.6, 7.5 Hz, ArH), 7.97 (1H, J = 1.6, 7.7 Hz, ArH), 10.13 (1H, s, CHO). 
 
N-(2-([2-(4-Chloro-phenoxy)-phenylamino]-methyl)-phenyl)-N-methyl-acetamide, 
150, C22H21ClN2O2, MW 380.87, 
Cl
O
HN
N
O
 
To a solution of 2-(4-chloro-phenoxy)-phenylamine (174 mg, 0.78 mmol) and N-(2-
formyl-phenyl)-N-methyl-acetamide (70 mg, 0.39 mmol) in DCE (2mL) was added 
NaHB(OAc)3 (210 mg, 0.98 mmol) and AcOH (0.07 mL).  The resulting solution was 
stirred at r.t. for 2 h.  NaHCO3 was then added and the mixture was extracted with DCM 
and dried (MgSO4).  The crude product was purified by flash chromatography (0-100 % 
DCM in hexane) to yield the desired product as a brown oil, 65 mg, 44 % yield.  R.f. 
0.51 (DCM), LCMS: tr = 1.19 min (95 % MeOH in water), m/z M-H 378.93, HPLC: tr = 
2.64 min (90 % acetonitrile in water), 98 %, 1H NMR (CDCl3, 270 MHz,): δ 1.78 (3H, 
s, CH3CO), 3.24 (3H, s, CH3N), 4.25-4.29 (2H, m, CH2), 6.59 (1H, dd, J = 1.4, 8.0 Hz, 
ArH), 6.67 (1H, td, J = 1.4, 7.7 Hz, ArH), 6.83 (1H, dd, J = 1.4, 7.7 Hz, ArH), 6.88-6.92 
(2H, m, ArH), 7.00 (1H, td, J = 1.6, 7.7 Hz, ArH), 7.11-7.17 (1H, m, ArH), 7.23-7.26 
(2H, m, ArH), 7.31-7.34 (2H, m, ArH), 7.41-7.44 (1H, m, ArH).  13C NMR (CDCl3, 68 
MHz): 26.5, 36.6 (CH3), 43.7 (CH2), 117.7, 118.7, 119.5, 125.4 (ArCH), 127.9 (ArC), 
128.5, 128.9, 129.1, 129.7 (ArCH), 136.3, 139.9, 142.5, 142.8, 156.1 (ArC), 170.8 
(CO).  HRMS: Calcd for C22H21ClN2O2 (M+H)
+ 381.1364, found (M+H)+ 381.1378. 
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N-[2-(([2-(4-Chloro-phenoxy)-phenyl]-methyl-amino)-methyl)-phenyl]-N-methyl-
acetamide, 151, C23H23ClN2O2, MW 394.89, 
Cl
O
N
N
O
 
N-(2-([2-(4-chloro-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide, (100 mg, 0.27 
mmol) in DMF (10 mL) was cooled to 0 °C, to this was added NaH (35mg, 0.81mmol) 
and the resulting solution was stirred for 1 h.  MeI (0.05 mL, 0.81 mmol) was then 
added and the solution stirred for a further 18 h.  The reaction mixture was then poured 
onto water, extracted with EtOAc and dried (MgSO4).  NMR analysis showed the crude 
product to be a mixture of product and the related mono-methylated compound.  
Preparative-HPLC was used for purification to yield the desired product as a white wax, 
25 mg, 23 % yield.  Please note N-(2-([2-(4-chloro-phenoxy)-phenylamino]-methyl)-
phenyl)-N-methyl-acetamide (157) was also isolated, 46 mg, 43 % yield.  R.f. 0.45 
(EtOAc), LCMS: tr = 5.6 min (80 % MeOH in water), m/z M+H 395.18, HPLC: tr = 3.75 
min (90 % acetonitrile in water), 98 %, 1H NMR (CDCl3, 270 MHz,): δ 1.70 (3H, s, 
CH3), 2.66 (3H, s, NCH3), 3.09 (3H, s, NCH3), 4.10 (2H, s, CH2), 6.67-6.73 (2H, m, 
ArH), 6.96 (2H, d, J = 3.9 Hz, ArH), 7.04-7.27 (8H, m, ArH).  13C NMR (CDCl3, 68 
MHz): δ 22.0, 36.3, 39.7 (CH3), 54.9 (CH2), 117.8, 119.7, 122.2, 122.5, 125.6 (ArCH), 
127.1 (ArC), 142.4, 145.0, 147.4 (ArC), 170.8 (CO).  HRMS: Calcd for C23H23ClN2O2 
(M+H)+ 395.1521, found (M+H)+ 395.1533. 
 
 N-[2-(([2-(4-Chloro-phenoxy)-phenyl]-methyl-amino)-methyl)-phenyl]-acetamide, 
152, C22H21ClN2O2, MW 380.87, 
Cl
O
N
H
N
O
 
To a solution of N-(2-[2-(4-chloro-phenoxy)-phenylamino]-methyl-phenyl)-acetamide, 
(100 mg, 0.27 mmol), paraformaldehyde (81 mg, 2.7 mmol) and NaBH4 (55 mg, 1.35 
mmol) in THF (5 mL) was added TFA (1.3 mL).  The resulting solution was stirred at 
r.t. for 18 h.94  This was then poured into NaOH solution (25 %) with ice chips, 
extracted with DCM and dried (MgSO4).
94  The crude product was then purified by 
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flash chromatography (0-100 % EtOAc in hexane) to produce the desired compound as 
a colourless oil, 64 mg, 62 % yield.  R.f. 0.66 (EtOAc), LCMS: tr = 4.02 min (80 % 
MeOH in water), m/z M+H 379.12, HPLC: tr = 2.88 min (90 % MeOH in water), 99 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.99 (3H, s, CH3), 2.65 (3H, s, CH3N), 4.19 (2H, s, 
CH2), 6.81 (1H, dd, J = 1.6, 8.4 Hz, ArH), 6.93-6.95 (2H, m, ArH), 6.99-7.04 (2H, m, 
ArH), 7.10 (1H, td, J = 1.6, 8.0 Hz, ArH), 7.14-7.15 (1H, m, ArH), 7.23-7.32 (4H, m, 
ArH), 8.27 (1H, d, J = 8.4 Hz, ArH), 10.12 (1H, br.s, NHCO).  13C NMR (CDCl3, 101 
MHz): 24.8, 40.7 (CH3), 59.5 (CH2), 118.7, 120.3, 120.9, 121.3, 123.2, 124.1, 124.6 
(ArCH), 125.1 (ArC), 128.6 (ArCH), 129.0 (ArC), 130.1 (ArCH), 138.6, 142.4, 150.8, 
155.1 (ArC), 168.6 (CO).  HRMS: Calcd for C22H21ClN2O2 (M+H)
+ 381.1364, found 
(M+H)+ 381.1363. 
 
N-(2-Acetylamino-benzyl)-N-[2-(4-chloro-phenoxy)-phenyl]-acetamide, 153, 
C23H21ClN2O3, MW 408.88, 
Cl
O
N
H
N
O
O
 
A solution of N-(2-[2-(4-chloro-phenoxy)-phenylamino]-methyl-phenyl)-acetamide 
(100 mg, 0.27 mmol) in DCM (5 mL) and cooled to 0 °C, to this was added TEA (0.2 
mL) and acetyl chloride (0.34 mL, 0.81 mmol) the resulting solution was stirred at r.t. 
for 1 h.  Saturated NaHCO3 was added, extracted with DCM and dried (MgSO4).  The 
crude product was purified by flash chromatography (0-100 % EtOAc in hexane) and 
preparative HPLC to yield the desired product as an off white waxy solid, 53 mg, 48 % 
yield.  R.f. 0.54 (EtOAc), LCMS: tr = 2.17 min (95 % MeOH in water), m/z M-H 
407.15, HPLC: tr = 2.40 min (90 % acetonitrile in water), 95 %, 
1H NMR (CDCl3, 270 
MHz,): δ 1.93 (3H, s, CH3), 2.24 (3H, s, CH3), 4.80 (2H, s, CH2), 7.02-7.12 (2H, m, 
ArH), 7.21-7.30 (4H, m, ArH), 8.20 (1H, dd, J = 7.7 Hz, ArH), 9.89 (1H, s, NHCO).  
13C NMR (CDCl3, 68 MHz): 22.1, 24.6 (CH3), 49.8 (CH2), 118.1, 120.7, 122.1, 123.0, 
124.0 (ArCH), 125.0 (ArC), 129.2 (ArCH), 129.8 (ArC), 130.1, 130.2, 131.5 (ArCH), 
137.7, 153.2, 153.8 (ArC), 169.5, 172.7 (CO).  HRMS: Calcd for C23H21ClN2O3 
(M+Na)+ 431.1313, found (M+Na)+ 431.1105. 
 
 280 
N-(4-([2-(4-chloro-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide, 154, 
C21H19ClN2O2, MW 366.84, 
Cl
O
HN
HN
O  
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a light pink solid, 195 mg, 78 % yield.  R.f. 0.55 (5 % MeOH in DCM), m.p. 
137-139 °C, LCMS: tr = 1.39 min (95 % MeOH in H2O), m/z M-H 365.48, HPLC: tr = 
2.0 min (90 % acetonitrile in H2O), 98 %, 
1H NMR (CDCl3, 270 MHz): δ 2.15 (3H, s, 
CH3), 4.30 (2H, d, J = 5.7Hz, CH2), 6.60-6.69 (2H, m, ArH), 6.82 (1H, dd, J = 1.5, 
7.7Hz, ArH), 6.86-6.91 (2H, m, ArH), 6.96-7.02 (1H, m, ArH), 7.12 (1H, s, NH), 7.21-
7.26 (4H, m, ArH), 7.41-7.44 (2H, m, ArH).  13C NMR (CDCl3, 101 MHz): δ 24.6 
(CH3), 47.2 (CH2), 111.9, 117.1, 118.5, 119.3, 120.1, 125.3 (ArCH), 127.6 (ArC), 
127.9, 129.6 (ArCH), 135.1, 136.8, 140.1, 142.6, 156.2 (ArC), 168.2 (CO).  HRMS: 
Calcd for C21H19ClN2O2 (M+Na)
+ 389.1025, found (M+Na)+ 389.1028.  Anal. calcd for 
C21H19ClN2O2: C 68.76, H 5.22 N 7.64 %. Found: C 68.5, H 5.26, N 7.61 %. 
 
N-(4-([2-(2,4-Dichloro-phenoxy)-phenylamino]-methyl)-phenyl)-acetamide, 155, 
C21H18Cl2N2O2, MW 401.29, 
Cl
Cl
O
HN
HN
O  
To a solution of 2-(2,4-dichloro-phenoxy)-phenylamine hydrochloride (0.15g, 
0.52mmol) in DCM (10mL) was added K2CO3 (0.22g, 1.04mmol), the resulting 
solution was stirred at r.t for 30 min.  Water was then added and the mixture was 
extracted with DCM.  The organic layers were combined, dried (MgSO4), filtered and 
evaporated in vacuo.  The resulting amine was dissolved in DCE (3mL) and to this was 
added 4-acetamidobenzaldehyde (0.126 g, 0.0.75mmol), acetic acid (0.11 mL) and 
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sodium triacetoxyborohydride (0.27g, 1.3mmol).  The resulting reaction mixture was 
stirred at r.t. for 2h. NaHCO3 was then added and the mixture was repeatedly extracted 
with DCM.  The organic layers were combined, dried (MgSO4), filtered and evaporated 
in vacuo. The crude mixture was purified using flash chromatography (0-100 % EtOAc 
in hexane) to afford the title compound as a white wax, 142 mg, 69 % yield.  R.f. 5.8 
(EtOAc), LCMS: tr = 1.2 min (95 % MeOH in H2O), m/z M-H 399.03, 401.04, HPLC: tr 
= 2.42 min (90 % acetonitrile in H2O), 98 %, 
1H NMR (CDCl3, 270 MHz): δ 2.15 (3H, 
s, CH3), 4.31 (2H, s, CH2), 4.59 (1H, br.s, NH), 6.59-6.68 (2H, m, ArH), 6.75 (1H, dd, J 
= 1.5, 7.9Hz, ArH), 6.80 (1H, d, J = 8.7 Hz, ArH), 6.96-7.02 (1H, m, ArH), 7.12 (1H, 
dd, J = 2.5, 8.9 Hz, ArH), 7.22-7.31 (1H, m, ArH), 7.41-7.45 (2H, m, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 24.7 (CH3), 47.3 (CH2), 112.2, 117.1, 118.5, 119.4, 120.2 (ArCH), 
125.3 (ArC), 125.5, 127.9, 128.0 (ArCH), 128.2 (ArC), 130.4 (ArCH), 135.1, 136.9, 
139.7, 142.7, 151.8 (ArC), 168.4 (CO).  HRMS: Calcd for C21H18Cl2N2O2 (M+H)
+ 
399.0673, found (M+H)+ 399.0674.  Anal. calcd for C21H18Cl2N2O2 C 62.85, H 4.52 N 
6.98 %. Found: C 62.7, H 4.52, N 6.92 %. 
 
3-Amino-benzaldehyde, 156, C7H7NO, MW 121.14, 
H
O
NH2  
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a yellow solid, 1.7 g, 71 % yield.  R.f. 0.25 (DCM).  
Due to the instability of this compound it was not possible to carry out further 
purification or analysis and so the product was used crude in the following reactions. 
 
N-(3-Formyl-phenyl)-acetamide, 157, C9H9NO2, MW 163.17 
H
O
NH
O  
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a cream oil, 250 mg, 37 % yield.  R.f. 0.43 (10 % 
MeOH in DCM), 1H NMR (CDCl3, 270 MHz,): δ 2.19 (3H, s, CH3), 7.42 (1H, t, J = 7.9 
Hz, ArH), 7.56 (1H, d, J = 7.7 Hz, ArH), 7.83-7.86 (1H, m, ArH), 8.03 (1H, s, ArH), 
8.60 (1H, s, NH), 9.90 (1H, s, CHO). 
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N-(3-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-phenyl)-acetamide, 158, 
C21H19ClN2O2, MW 366.84, 
Cl
O
HN
N
H
O
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a cream solid, 110 mg, 63 % yield.  R.f. 0.6 (EtOAc), m.p. 187-190 °C, 
LCMS: tr = 1.39 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 
5 min), m/z M-H 365.55, HPLC: tr = 1.89 min (90 % acetonitrile in H2O), 93 %, 
1H 
NMR (CDCl3, 270 MHz,): δ 2.13 (3H, s, CH3), 4.32 (2H, d, J = 5.4 Hz, CH2), 4.55 (1H, 
d, J = 5.4 Hz, NH), 6.61-6.66 (2H, m, ArH), 6.81-6.84 (1H, m, ArH), 6.68-6.92 (2H, m, 
ArH), 6.98-7.04 (2H, m, ArH), 7.21-7.27 (4H, m, ArH and NH), 7.38-7.43 (2H, m, 
ArH).  13C NMR (CDCl3, 68 MHz): δ 24.6 (CH3), 47.5 (CH2), 112.1, 117.2, 118.4, 
118.7, 119.4, 123.0, 125.4 (ArCH), 127.7 (ArC), 129.0, 129.7, 129.9 (ArC), 138.2, 
140.1, 140.4, 142.7, 156.3 (ArC), 168.5 (CO).  HRMS: Calcd for C21H19ClN2O2 
(M+Na)+ 389.1027, found (M+Na)+ 389.1021. 
 
[2-(4-Chloro-phenoxy)-phenyl]-2-nitro-benzylamine, 159, C19H15ClN2O3, MW 
354.79, 
Cl
O
HN
NO2
 
To a solution of 2-(4-chloro-phenoxy)-phenylamine (150 mg, 0.68 mmol) and 2-
nitrobenzaldehyde (310 mg, 2.04 mmol) in DCE (3.5 mL) was added acetic acid (0.36 
mL) and sodium triacetoxyborohydride (0.36 g, 1.7 mmol).  The resulting reaction 
mixture was heated in a microwave at 140 °C for 10 min.85 NaHCO3 was then added 
and the mixture was repeatedly extracted with EtOAc.  The organic layers were 
combined, dried (MgSO4), filtered and evaporated in vacuo. The crude mixture was 
purified using flash chromatography (0-100 % EtOAc in hexane) to afford the title 
compound as a yellow wax, 194 mg, 77 % yield.  R.f. 0.63 (1:1, EtOAc: Hexane), 
LCMS: tr = 1.66 min (95 % MeOH in H2O), m/z M+H 355.48, HPLC: tr = 6.6 min (90 
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% acetonitrile in H2O), 92 %, 
1H NMR (CDCl3, 270 MHz): δ 4.75 (2H, s, CH2), 4.97 
(1H, s, NH), 6.52 (1H, dd, J = 1.2, 7.9 Hz, ArH), 6.66 (1H, td, J = 1.5, 7.7 Hz, ArH), 
6.83-6.99 (4H, m, ArH), 7.21-7.27 (2H, m, ArH), 7.37-7.44 (1H, m, ArH), 7.54-7.57 
(2H, m, ArH), 8.05 (1H, dd, J = 1.0, 7.7 Hz, ArH). 
 
N-[2-(4-Chloro-phenoxy)-phenyl]-N-(2-nitro-benzyl)-acetamide, 160, 
C21H17ClN2O4, MW 396.82, 
Cl
O
N
NO2O
 
Using the general procedure for the acylation of substituted 2-aminobenzylalcohols the 
title compound was obtained as a brown oil, 92 mg, 48 % yield.  R.f. 0.21 (1:1, 
DCM:hexane), LCMS: tr = 5.12 min (50 % to 95 % MeOH in water at 0.5 mL/min to 
1.0 mL/min over 5 min), m/z M+H 397.48, HPLC: tr = 5.0 min (90 % acetonitrile in 
H2O), 91 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.98 (3H, s, CH3), 5.13 (1H, d, J = 16.3 
Hz, ½CH2), 5.33 (1H, d, J = 16.3 Hz, ½CH2), 6.79-6.87 (3H, m, ArH), 7.00-7.11 (2H, 
m, ArH), 7.20-7.35 (4H, m, ArH), 7.46 (1H, td, J = 1.5, 7.4 Hz, ArH), 7.72 (1H, dd, J = 
1.2, 7.9 Hz, ArH), 7.83 (1H, dd, J = 1.2, 8.2 Hz, ArH). 
 
N-(2-Amino-benzyl)-N-[2-(4-chloro-phenoxy)-phenyl]-acetamide, 161, 
C21H19ClN2O2, MW 366.84, 
Cl
O
N
NH2O
 
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a pale yellow solid, 53 mg, 62 % yield.  R.f. 0.25 
(1:1, DCM:EtOAc), 1H NMR (CDCl3, 270 MHz,): δ 1.92 (3H, s, CH3), 4.55 (2H, br.s, 
NH2), 4.73-4.87 (2H, m, CH2), 6.38-6.52 (3H, m, ArH), 6.58-6.64 (2H, m, ArH), 6.77 
(1H, d, J = 8.2 Hz, ArH), 6.96-7.05 (3H, m, ArH), 7.19-7.25 (3H, m, ArH).  13C NMR 
(CDCl3, 68 MHz): δ 22.2 (CH3), 49.3 (CH2), 115.41, 116.7, 118.3 (ArCH), 119.8 (ArC), 
120.7, 123.8, 129.3, 129.6, 129.9, 130.4, 131.9 (ArCH), 132.1, 146.5, 153.4, 154.4 
(ArC), 171.7 (CO). 
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N-[2-(1-Acetyl-piperidin-4-ylamino)-benzyl]-N-[2-(4-chloro-phenoxy)-phenyl]-
acetamide, 162, C28H30ClN3O3, MW 492.01, 
Cl
O
N
H
N
N
O
O
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a cream oil, 45 mg, 63 % yield.  R.f. 0.72 (10 % MeOH in EtOAc), LCMS: tr 
= 5.4 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z 
M+H 492.49, HPLC: tr = 6.42 min (90 % acetonitrile in H2O), 99 %, 
1H NMR (CDCl3, 
400 MHz): δ (Multiple signals observed due to restricted rotation and therefore the 
presence of rotamers) 1.34-1.51 (1H, m, ½CH2),1.55-1.66 (1H, m, ½CH2),1.75-1.79 
(1H, m, ½CH2), 1.91, 1.93 (3H, s, CH3), 1.96-2.01 (1H, m, ½CH2), 2.08, 2.09 (3H, s, 
CH3), 2.91-2.97 (½H, m, ¼CH2), 3.02-3.09 (½H, m, ¼CH2), 3.11-3.18 (½H, m, ¼CH2), 
3.21-3.27 (½H, m, ¼CH2), 3.33-3.41 (1H, m, CH), 3.68-3.74 (½H, m, ¼CH2), 3.81-3.86 
(½H, m, ¼CH2), 3.99-4.04 (½H, m, ¼CH2), 4.23-4.28 (½H, m, ¼CH2), 4.36 (½H, d, J = 
14.4Hz, ¼CH2), 4.65 (½H, d, J = 14.8Hz, ¼CH2), 4.92 (½H, d, J = 14.4Hz, ¼CH2), 
5.25 (½H, d, J = 14.4Hz, ¼CH2), 5.58-5.66 (1H, m, NH), 6.30-6.37 (3H, m, ArH), 6.44-
6.50 (2H, m, ArH), 6.63-6.66 (½H, m, ArH), 6.72-6.74 (½H, m, ArH), 7.03-7.12 (3H, 
m, ArH), 7.13-7.16 (1H, m, ArH), 7.17-7.23 (2H, m, ArH).  13C NMR (CDCl3, 101 
MHz): δ 21.5, 21.5, 22.0 (CH3), 30.6, 31.3, 31.9, 32.3, 39.5, 39.7, 44.7 (CH2), 48.4, 48.7 
(CH), 49.5, 49.9 (CH2), 110.1, 110.2, 114.9, 115., 117.8, 118.1, 119.6, 119.7, 120.5, 
120.9, 123.7, 123.8, 129.1, 129.1, 129.3, 129.4, 129.6, 129.7, 129.9 (ArCH), 131.6, 
131.7 (ArC), 132.1, 132.2 (ArCH), 145.8, 145.9, 153.3, 153.8, 154.0, 154.3 (ArC), 
168.7, 168.7, 171.6, 171.7 (CO).  HRMS: Calcd for C28H30ClN3O3 (M+H)
+ 492.2048, 
found (M+H)+ 492.2049. 
 
[2-(4-Chloro-phenoxy)-phenyl]-(2-amino-benzyl)-amine, 163, C19H17ClN2O, MW 
324.80, 
Cl
O
HN
NH2
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Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol the 
desired compound was obtained as a pale yellow solid, 118 mg, >100 % yield.  R.f. 0.35 
(EtOAc), m.p. 178-180 °C (from hexane), LCMS: tr = 5.51 min (50 % to 95 % MeOH in 
water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M-H 323.4, HPLC: tr = 5.95 min 
(90 % acetonitrile in H2O), 85 %, 
1H NMR (CDCl3, 270 MHz,): δ 3.99 (2H, s, NH2), 
4.16 (1H, s, NH), 4.23 (2H, s, CH2), 6.66-6.77 (3H, m, ArH), 6.83-6.91 (4H, m, ArH), 
7.07-7.16 (3H, m, ArH), 7.20-7.26 (2H, m, ArH). 
 
1-[4-(2-[2-(4-Chloro-phenoxy)-phenylamino]-methyl-phenylamino)-piperidin-1-yl]-
ethanone, 164, C26H28ClN3O2, MW 449.97, 
Cl
O
HN
H
N
N
O  
To a solution of [2-(4-chloro-phenoxy)-phenyl]-(2-amino-benzyl)-amine (50 mg, 0.15 
mmol) and N-benzoyl-4-piperidone (0.038 mL, 0.30 mmol) in DCE (1.5 mL) was added 
acetic acid (0.03 mL) and sodium triacetoxyborohydride (82 mg, 0.38 mmol).  The 
resulting reaction mixture was then subjected to microwave heating for 20 min at 140 
°C.85  A further portion of sodium triacetoxyborohydride (0.45 g, 0.2 mmol) was added 
and the solution was subjected to microwave heating for a further 10 min at 140 °C.  
NaHCO3 was then added and the mixture was repeatedly extracted with DCM.  The 
organic layers were combined, dried (MgSO4), filtered and evaporated in vacuo.  The 
crude mixture was purified using flash chromatography (0-10 % MeOH in DCM) to 
afford the title compound as a cream oil, 23 mg, 33 % yield.  R.f. 0.2 (1:1, EtOAc: 
Hexane), LCMS: tr = 5.75 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 
mL/min over 5 min), m/z M+Na 472.41, HPLC: tr = 6.19 min (90 % acetonitrile in 
H2O), 96 %, 
1H NMR (CDCl3, 400 MHz): δ 1.25 (2H, s, CH2), 1.83-1.92 (2H, m, CH2), 
2.07 (3H, s, CH3), 2.98-3.04 (1H, m, ½CH2), 3.11-3.17 (1H, m, ½CH2), 3.47-3.51 (1H, 
m, ½CH2), 3.56-3.62 (1H, m, ½CH2), 4.09-4.17 (1H, m, NH), 4.21 (2H, td, J = 9.6 Hz, 
CH2NH), 4.70 (1H, s, NH), 6.65-6.71 (2H, m, ArH), 6.75 (1H, td, J = 1.6, 7.6 Hz, ArH), 
6.81-6.86 (3H, m, ArH), 6.92 (1H, dd, J = 1.2, 8.0 Hz, ArH), 7.12 (1H, td, J = 1.2, 
8.0Hz, ArH), 7.15-7.17 (1H, m, ArH), 7.19-7.23 (3H, m, ArH).  13C NMR (CDCl3, 101 
MHz): δ 21.5 (CH3), 29.7, 32.1, 39.7, 44.6 (CH2), 47.5 (CH2NH), 48.7 (CH), 110.9, 
112.8, 116.8, 118.4, 119.4 (ArCH), 122.1 (ArC), 125.4 (ArCH), 127.7 (ArC), 129.2, 
129.6, 130.4 (ArCH), 140.2, 143.3, 145.9, 156.1 (ArC), 168.8 (CO).  HRMS: Calcd for 
C26H28ClN3O2 (M+H)
+ 450.1943, found (M+H)+ 450.1943. 
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1-Acetyl-piperidine-4-carboxylic acid (2-[2-(4-chloro-phenoxy)-phenyl amino]-
methyl-phenyl)-amide, 165, C27H28ClN3O3, MW 477.98, 
Cl
O
HN
H
N
O
N
O
 
To a solution of [2-(4-chloro-phenoxy)-phenyl]-(2-amino-benzyl)-amine (48 mg, 0.15 
mmol) and TEA (0.09 mL) in DCM (6 mL) at 0 °C, was added 1-acetylpiperidine-4-
carbonyl chloride (58 mg, 0.6 mmol) and the resulting solution stirred was allowed to 
warm to room temperature and stirred for 24 h.  NaHCO3 was then added and the 
mixture was repeatedly extracted with DCM.  The organic portions were then washed 
with 1M HCl.  The organic layers were combined, dried (MgSO4), filtered and 
evaporated in vacuo.  The title compound was obtained as an off white solid, 44 mg, 62 
% yield.  R.f. 0.15 (10 % MeOH in DCM), m.p. 140-143 °C (from hexane), LCMS: tr = 
1.25 min (95 % MeOH in water), m/z M-H 476.56 HPLC: tr = 1.71 min (90 % 
acetonitrile in H2O), 95 %, 
1H NMR (CDCl3, 400 MHz): δ 1.49-1.63 (2H, m, CH2), 
1.74-1.83 (2H, m, CH2), 1.99 (3H, s, CH3), 2.18-2.24 (1H, m, CH), 2.49-2.57 (1H, m, 
CH2), 2.92-2.99 (1H, m, CH2), 3.69-3.73 (1H, m, CH2), 4.28 (3H, s, CH2NH and NH), 
4.42-4.46 (1H, m, CH2), 6.77-6.86 (3H, m, ArH), 6.92-6.94 (1H, m, ArH), 7.06-7.10 
(2H, m, ArH), 7.22-7.33 (5H, m, ArH), 8.05 (1H, d, J = 8.0 Hz, ArH), 8.85 (1H, s, 
NHCO).  13C NMR (CDCl3, 101 MHz): δ 21.4 (CH3), 28.5, 28.7, 40.8 (CH2), 43.8 
(CH), 45.6, 47.8 (CH2), 113.5, 118.7, 119.2, 119.7, 122.4, 124.5, 125.3 (ArCH), 127.2, 
128.2 (ArC), 128.9, 129.7, 129.8 (ArCH), 137.4, 139.3, 144.0, 155.7 (ArC), 168.7, 
172.1 (CO).  HRMS: Calcd for C27H28ClN3O3 (M+Na)
+ 500.1711, found (M+Na)+ 
500.1705. 
 
1-Acetyl-piperidine-4-carboxylic acid (3-formyl-phenyl)-amide, 166, C15H18N2O3, 
MW 274.32, 
H
O
HN
O
N
O
 
To a solution of 3-amino-benzaldehyde (200 mg, 1.65 mmol) and TEA (0.13 mL) in 
DCM (4 mL) at 0 °C, was added 1-acetylpiperidine-4-carbonyl chloride (0.6g, 3.3 
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mmol) and the resulting solution was allowed to warm to room temperature and stirred 
for 2 days.  NaHCO3 was then added and the mixture was repeatedly extracted with 
DCM, the organic layers were then washed with HCl (1 M).  The organic layers were 
combined, dried (MgSO4), filtered and evaporated in vacuo.  The title compound was 
obtained as a cream oil, 97 mg, 22 % yield.  R.f. 0.42 (10 % MeOH in DCM), LCMS: tr 
= 0.99 min (95 % MeOH in water), m/z M-H 273.39, HPLC: tr = 1.26 min (90 % 
acetonitrile in H2O), 81 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.66-1.90 (2H, m, CH2), 
1.95-2.03 (2H, m, CH2), 2.11 (3H, s, CH3), 2.50-2.61 (1H, m, CH), 2.66-2.76 (1H, m, 
½CH2), 3.09-3.20 (1H, m, ½CH2), 3.89-3.94 (1H, m, ½CH2), 4.61-4.65 (1H, m, ½CH2), 
7.48 (1H, t, J = 7.9 Hz, ArH), 7.61 (1H, td, J = 1.2, 7.7 Hz, ArH), 7.90-8.00 (4H, m, 
ArH and NH), 9.97 (1H, s, CHO). 
 
1-Acetyl-piperidine-4-carboxylic acid (3-[2-(4-chloro-phenoxy)-phenyl amino]-
methyl-phenyl)-amide, 167, C27H28ClN3O3, MW 477.98, 
N
H
O
N
O
Cl
O
HN
 
Using the general procedure for the reductive amination of the substituted diphenylether 
aniline with the substituted 2-acetamide benzaldehyde the desired compound was 
isolated as a cream wax, 70 mg, 41 % yield.  R.f. 0.22 (10 % MeOH in EtOAc), LCMS: 
tr = 5.5 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), 
m/z M-H 476.42, HPLC: tr = 1.73 min (90 % acetonitrile in H2O), 93 %, 
1H NMR 
(CDCl3, 270 MHz,): δ 1.63-1.77 (2H, m, CH2), 1.78-1.90 (2H, m, CH2), 2.09 (3H, s, 
CH3), 2.38-2.50 (1H, m, CH), 2.63-2.73 (1H, m, ½CH2), 3.11 (1H, td, J = 2.7, 13.9 Hz, 
½CH2), 3.88 (1H, d, J = 13.6 Hz, ½CH2), 4.33 (2H, s, CH2), 4.58-4.63 (2H, m, ½CH2 
and NH), 6.60-6.66 (2H, M, ArH), 6.82- (1H, dd, J = 1.5, 8.4 Hz, ArH), 6.86-6.92 (2H, 
m, ArH), 6.95-7.06 (2H, m, ArH), 7.21-7.28 (3H, m, ArH), 7.39-7.44 (3H, m, ArH and 
NH).  13C NMR (CDCl3, 68 MHz): δ 21.6 (CH3), 28.6, 28.9, 41.0, (CH2), 44.1 (CH), 
45.8, 47.6 (CH2), 112.0, 117.2, 118.5, 118.7, 118.8, 119.4, 123.2, 125.4 (ArCH), 127.7 
(ArC), 129.4, 129.8 (ArCH), 129.8, 138.1, 140.2, 140.5 (ArC), 169.0, 172.3 (CO).  
HRMS: Calcd for C27H28ClN3O3 (M+H)
+ 478.1892, found (M+H)+ 478.1878. 
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N-(2-Acetyl-phenyl)-acetamide, 168, C10H11NO2, MW 177.20, 
O
NH
O 
A solution of 2-aminoacetopheone (2.0 g, 14.8 mmol) in DCM (80 mL) was cooled to 0 
°C, to this was added TEA (2.4 mL) and acetyl chloride (2.06 mL, 30 mmol).  The 
resulting solution was stirred at r.t. for 30 min.  NaHCO3 was added and the solution 
was extracted, the organic layers were then washed with HCl (1M) and brine.  The 
organic layers were dried (MgSO4), filtered and evaporated in vacuo to yield the desired 
product as a brown solid, 2.3 g, 89 % yield.  R.f. 0.49 (EtOAc), m.p. 68-70 °C, LCMS: 
tr = 1.32 min (80 % MeOH in water), m/z M-H 175.79, HPLC: tr = 1.60 min (90 % 
acetonitrile in H2O), 94 %, 
1H NMR (CDCl3, 270 MHz,): δ 2.15 (3H, s, CH3), 2.58, 
(3H, s, CH3), 6.99-7.06 (1H, m, ArH), 7.43-7.49 (1H, m, ArH), 7.80 (1H, dd, J = 1.5, 
8.15 Hz, ArH), 8.65 (1H, dd, J = 1.0, 8.4 Hz, ArH), 11.63 (1H, br.s, NH).  13C NMR 
(CDCl3, 68 MHz): δ 25.7, 28.8 (CH3), 120.8 (ArCH), 121.7 (ArC), 122.4, 131.7, 135.3 
(ArCH), 141.1 (ArC), 169.6, 202.9 (CO).  HRMS: Calcd for C10H11NO2 (M+H)
+ 
178.0863, found (M+H)+ 178.0858. 
 
N-(2-1-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl-phenyl)-ethylamine, 169, 
C22H23ClN2O, MW 366.88, 
HN
O
Cl
H
N
 
A solution of 2-(4-chloro-phenoxy)-phenylamine (298 mg, 1.4 mmol), N-(2-acetyl-
phenyl)-acetamide, (200 mg, 1.13 mmol) and chlorotriisopropoxytitanium IV (0.53 mL, 
2.26 mmol) in toluene (15 mL) was stirred at r.t. for 4 days.  NaHCO3 was added and 
the mixture was extracted repeatedly with EtOAc, dried (MgSO4) and evaporated to 
dryness.  The residue was re-dissolved in THF (20 mL) and cooled to 0 °C, to this was 
added succinic acid (270 mg, 2.26 mmol) and borane (1M in THF, 2.3 mL, 2.26 mmol).  
The reaction was slowly warmed to r.t. and stirred for 8 h.96  NaHCO3 was added and 
the volatile solvents removed in vacuo, the mixture was then extracted with EtOAc and 
dried (MgSO4).  The crude material was purified by flash chromatography (0-100 % 
DCM in hexane) to yield the product as an off white oil, 79 mg, 19 % yield.  LCMS: tr = 
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1.42 min (95 % MeOH in water), m/z M-H 365.33, HPLC: tr = 4.49 min (90 % 
acetonitrile in water), 97 %, 1H NMR (CDCl3, 270 MHz,): δ 1.17 (3H, t, J = 7.2 Hz, 
CH3CH2), 1.56 (3H, d, J = 6.7 Hz, CH3CH), 3.10 (2H, q, J = 14.1 Hz, CH2), 4.22 (1H, 
d, J = 6.0 Hz, NH), 4.53 (1H, q, J = 13.3 Hz, CH), 4.59 (1H, br.s, NH), 6.66-6.93 (7H, 
m, ArH), 7.01 (1H, td, J = 7.9, 1.5 Hz, ArH), 7.16-7.31 (4H, m, ArH).  13C NMR 
(CDCl3, 68 MHz): 14.9, 19.9 (CH3), 38.1 (CH2), 50.9 (CH), 111.1, 113.6, 117.0, 118.0, 
118.6, 119.5, 125.5, 126.5 (ArCH), 128.6, 127.8 (ArC), 128.3, 129.7 (ArCH), 13.7, 
143.3, 146.7, 156.4 (ArC).  HRMS: Calcd for C22H23ClN2O (M+Na)
+ 389.1386, found 
(M+Na)+ 389.1391. 
 
N-(4-(1-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-phenyl)-N-ethyl-acetamide, 
170, C24H25ClN2O2, MW 408.92, 
Cl
O
HN
N
O
 
N-(4-(1-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-phenyl)-ethane (50 mg, 0.14 
mmol) was dissolved in DCM (1 mL) and cooled to 0°C, to this was added acetyl 
chloride (0.04 mL, 0.56 mmol) and TEA (0.02 mL, 0.42 mmol).  This was then allowed 
to warm to room temperature and stirred for 1h.  Saturated NaHCO3 solution was added 
and the mixture was extracted with DCM, dried (MgSO4) and purified by flash 
chromatography to yield the title compound as an off-white oil, 23 mg, 40 % yield.  R.f. 
0.55 (EtOAc), LCMS: tr = 1.37 min (95 % MeOH in water), m/z M-H 407.34, HPLC: tr 
= 3.03 min (90 % acetonitrile in H2O), 96 %, 
1H NMR (CDCl3, 270 MHz,): δ 1.15 (3H, 
dt, J = 6.8, 10.4 Hz, CH3CH2), 1.43 (3H, dd, J = 6.4, 15.6 Hz, CH3CH), 1.74 (3H, d, J = 
25.6 Hz, CH3CO), 3.07-3.15 (1H, m, ½CH2), 4.24-4.36 (2H, m, ½CH2 and NH), 4.64-
4.75 (1H, m, CH), 6.51 (1H, dd, J = 1.6, 8.4 Hz, ArH), 6.57-6.67 (2H, m, ArH), 6.74-
6.84 (2H, m, ArH), 6.86-6.90 (1H, m, ArH), 6.92-6.97 (1H, m, ArH), 7.06 (1H, td, J = 
1.6, 8.0 Hz, ArH), 7.21-7.35 (4H, m, ArH), 7.39-7.47 (1H, m, ArH).  13C NMR (CDCl3, 
68 MHz): 12.8, 22.5, 23.1 (CH3), 43.5 (CH2), 47.5 (CH), 112.7, 117.7, 118.8, 119.4, 
125.3, 126.9, 128.3, 129.4, 129.7, 130.3 (ArCH), 138.9, 139.9, 141.7, 142.4, 143.1, 
156.3 (ArC), 170.5 (CO).  HRMS: Calcd for C24H25ClN2O2 (M+Na)
+ 431.1497, found 
(M+Na)+ 431.1487. 
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N-(2-([2-(4-Chloro-phenoxy)-phenylimino]-methyl)-phenyl)-acetamide, 171, 
C21H17ClN2O2, MW 364.82, (Method 1), 
Cl
O
N
H
N
O
 
A solution of 2-(4-chloro-phenoxy)-phenylamine (100 mg, 0.46 mmol) and N-(2-
formyl-phenyl)-acetamide (74 mg, 0.46 mmol) in anhydrous DCM (5mL) was stirred at 
r.t. and to this was added MgSO4 (550 mg, 4.6 mmol) and the resulting mixture stirred 
for a further 18 h at r.t.  The mixture was then filtered and the solid was washed with 
DCM.  The filtrate was then evaporated to dryness to yield the desired product as an oil.  
The product was identified by NMR, as no CHO peak was visible in the 1H NMR and it 
had been replaced with an imine peak.  The product was used crude in all following 
experiments.  A small sample was purified for analytical purposes.  1H NMR (CDCl3, 
270 MHz,): δ 2.03 (3H, s, CH3), 6.87-7.46 (11H, m, ArH), 8.60 (1H, s, N=CH), 8.72 
(1H, d, J = 8.5 Hz, ArH).  13C NMR (CDCl3, 101 MHz): 24.9 (CH3), 116.7, 119.2, 
119.6, 120.3 (ArCH), 120.6 (ArC), 122.5, 125.0, 127.9 (ArCH), 128.2 (ArC), 129.8, 
132.7 (ArCH), 140.4, 141.7, 149.6, 156.1 (ArC), 163.4 (CH), 169.9 (CO). 
 
N-(2-([2-(4-Chloro-phenoxy)-phenylimino]-methyl)-phenyl)-acetamide, 171, 
C21H17ClN2O2, MW 364.82, (Method 2),
95 
Cl
O
N
H
N
O
 
A solution of 2-(4-chloro-phenoxy)-phenylamine (100 mg, 0.46 mmol) and N-(2-
formyl-phenyl)-acetamide (74 mg, 0.46 mmol) in anhydrous DCM (5mL) was stirred at 
r.t. and to this was added TiCl(OiPr)3 (0.25 mL, 1 mmol).  The resulting mixture was 
stirred for a further 4 h at room temperature.  The mixture was then evaporated to 
dryness to yield the desired product as an oil.  As in Method 1 (see above) the product 
could easily be identified by 1H NMR.  The product was used crude in all susequent 
experiments. 
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N-(2-(1-[2-(4-Chloro-phenoxy)-phenylamino]-but-2-enyl)-phenyl)-acetamide, 172, 
C24H23ClN2O2, MW 406.90, 
Cl
O
HN
H
N
O
 
N-(2-([2-(4-Chloro-phenoxy)-phenylimino]-methyl)-phenyl)-acetamide (500 mg, 
assumed 100 % pure, 1.4 mmol) was dissolved in THF (15 mL) and cooled to 0 °C 
under a N2 atmosphere, to this was added BF3OEt2 (0.18 mL, 1.4 mmol) and 
allylmagnesium bromide (1 M in ether, 4.2 mL, 4.2 mmol).  The resulting solution was 
stirred at r.t. for 18 h.  The reaction was then quenched with sat. NH4Cl solution then 
extracted with EtOAc and dried (MgSO4).  The crude product was purified by flash 
chromatography (0-50 % EtOAc in hexane) to yield the desired product as a light brown 
solid, 320 mg, 57 % yield.  R.f. 0.36 (DCM), LCMS: tr = 1.59 min (95 % MeOH in 
water), m/z M+H (+Na) 429.13, M+H 407.15, HPLC: tr = 2.45min (90 % acetonitrile in 
water), 92 %, HRMS: Calcd for C24H23ClN2O2 (M+H)
+ 407.1521, found (M+H)+ 
407.1503.  1H NMR (CDCl3, 400 MHz,): δ 1.86 (3H, s, CH3), 2.54-2.62 (2H, m, CH2), 
4.31 (1H, t, J = 6.4 Hz, CHNH), 4.60 (1H, s, NH), 5.10 (1H, s, ½CH2CH), 5.13 (1H, d, 
J = 5.2 Hz, ½CH2CH), 5.65-5.75 (1H, m, CHCH2), 6.66 (1H, d, J = 8.0 Hz, ArH), 6.77 
(1H, t, J = 8.0 Hz, ArH), 6.87-6.96 (4H, m, ArH), 7.13 (1H, t, J = 7.6 Hz, ArH), 7.26-
7.31 (4H, m, ArH), 8.05 (1H, d, J = 8.4 Hz, ArH), 9.40 (1H, br.s, NHCO).  13C NMR 
(CDCl3, 101 MHz): 24.3 (CH3), 40.6 (CH), 58.9 (CH2), 114.9, 118.0 (ArCH), 119.3 
(CH2), 119.8, 120.0, 123.1, 124.7, 125.6 (ArCH), 128.0 (ArC), 128.2, 128.2, 129.8 
(ArCH), 130.7 (ArC), 134.0 (CH), 136.9, 139.3, 143.5, 156.1 (ArC), 168.1 (CO).   
 
N-(2-(1-[2-(4-Chloro-phenoxy)-phenylamino]-2-phenyl-ethyl)-phenyl)-acetamide, 
173, MW 456.96, 
Cl
O
HN
H
N
O
 
N-(2-([2-(4-Chloro-phenoxy)-phenylimino]-methyl)-phenyl)-acetamide (111 mg, 
assumed 100 % pure, 0.3 mmol) was dissolved in THF (5 mL) and cooled to 0 °C under 
a N2 atmosphere, to this was added BF3OEt2 (0.04 mL, 0.3 mmol) and 
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benzylmagnesium bromide (2 M in THF, 0.3 mL, 1.2 mmol).  The resulting solution 
was stirred at r.t. for 18 h.  The reaction was then quenched with sat. NH4Cl solution, 
extracted with EtOAc and dried (MgSO4).  The crude product was purified by flash 
chromatography (0-20 % EtOAc in DCM) to yield the desired product as an oil, 20 mg, 
14 % yield.  R.f. 0.25 (DCM), LCMS: tr = 1.26 min (95 % MeOH in water), m/z M
-H 
455.15, HPLC: tr = 2.73 min (90 % acetonitrile in water), 97 %, 
1H NMR (CDCl3, 400 
MHz,): δ 1.82 (3H, s, CH3), 3.02-3.04 (2H, m, CH2), 4.43 (1H, t, J = 8.0 Hz, CH), 4.50 
(1H, br.s, NH), 6.52 (1H, d, J = 6.8 Hz, ArH), 6.63-6.74 (4H, m, ArH), 6.79-6.84 (1H, 
m, ArH), 6.98-7.00 (1H, m, ArH), 7.05 (1H, t, J = 7.2 Hz, ArH), 7.15-7.24 (7H, m, 
ArH), 7.91 (1H, d, J = 8.4 Hz, ArH), 8.90 (1H, br.s, NHCO).  13C NMR (CDCl3, 101 
MHz): δ 24.3 (CH3), 42.9 (CH2), 60.8 (CH), 114.9, 117.9, 119.6, 119.7, 123.4, 124.9, 
125.6, 127.2 (ArCH), 127.9 (ArC), 128.1, 128.2, 128.9, 129.1, 129.8 (ArCH), 131.2, 
136.7, 136.8, 139.3, 143.4, 156.0 (ArC), 168.2 (CO).  HRMS: Calcd for C28H25ClN2O2 
(M+H)+ 457.1677, found (M+H)+ 457.1666. 
 
N-(2-(1-[2-(4-Chloro-phenoxy)-phenylamino]-butyl)-phenyl)-acetamide, 174, 
C24H25ClN2O2, MW 408.92, 
Cl
O
HN
H
N
O
 
To a solution of N-(2-(1-[2-(4-chloro-phenoxy)-phenylamino]-but-2-enyl)-phenyl)-
acetamide, (50 mg, 0.12 mmol) in EtOAc (25 mL) was added Pd/C (15 mg).  The 
solution was then stirred under a H2 atmosphere for 15 min and filtered through Celite.  
Purification by flash chromatography (0-50 % EtOAc in hexane) afforded the desired 
product, 44 mg, 88 % yield.  R.f. 0.42 (EtOAc), LCMS: tr = 3.72 min (90 % MeOH in 
water), m/z M+H 409.00, HPLC: tr = 4.69 min (90 % MeOH in water), 99 %, 
1H NMR 
(CDCl3, 400 MHz,): δ 0.90 (3H, t, J = 7.6 Hz, CH2CH3), 1.21-1.39 (2H, m, CH2), 1.79-
1.86 (2H, m, CH2), 1.87 (3H, s, CH3CO), 4.29 (1H, t, J = 7.6 Hz, CH), 4.37 (1H, br.s, 
NH), 6.70 (1H, d, J = 8.0 Hz, ArH), 6.73-6.78 (1H, m, ArH), 6.85-6.87 (1H, m, ArH), 
6.90-6.96 (3H, m, ArH), 7.11 (1H, t, J = 7.2 Hz, ArH), 7.25-7.31 (4H, m, ArH), 8.05 
(1H, d, J = 8.0 Hz, ArH), 9.36 (1H, br.s, NHCO).  13C NMR (CDCl3, 101 MHz): 13.7 
(CH3CH2), 19.6 (CH2), 24.4 (CH3CO), 38.0 (CH2), 60.0 (CH), 114.7, 118.3, 119.4, 
119.5, 123.0, 124.4, 125.4, 127.9, 128.1, 128.5, 129.9 (ArCH), 130.9, 136.8, 139.3, 
143.7, 156.0 (ArC), 168.1 (CO).  HRMS: Calcd for C24H25ClN2O2 (M+H)
+ 409.1677, 
found (M+H)+ 409.1677. 
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N-(2-(1-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-phenyl)-acetamide, 175, 
C22H21ClN2O2, MW 380.87, 
Cl
O
HN
H
N
O
 
A cerium chloride suspension was prepared, based upon methods described by Lui103 
and Imamoto104.  CeCl3.7H2O (stored in the oven, 515 mg, 1.38 mmol) was heated 
under high-vac for 15 min and allowed to cool to r.t. then 0 °C in an ice bath.  To this 
was added THF (3 mL) and methylmagnesium bromide (3 M in diethyl ether, 0.46 mL, 
1.38 mmol), this was then stirred at r.t. for 2 h.  To this was added N-(2-([2-(4-chloro-
phenoxy)-phenylimino]-methyl)-phenyl)-acetamide intermediate (166 mg, 0.46 mmol) 
and stirred at r.t. for a further 18 h.  NaHCO3 was added and the mixture was extracted 
with EtOAc, dried (MgSO4) and purified by flash chromatography (0-100 % DCM) to 
yield the desired product as an off white oil, 14 mg, 8 % yield.  R.f. 0.56 (DCM with 
TEA), LCMS: tr = 1.08 min (90 % MeOH in water), m/z M+Na 403.20, HPLC: tr = 2.6 
min (90 % acetonitrile in water), 94 %, 1H NMR (CDCl3, 270 MHz,): δ 1.55 (3H, d, J = 
6.6 Hz, CH3CH), 1.90 (3H, s, CH3CO), 4.25 (1H, d, J = 3.0 Hz, CHNH), 4.52-4.54 (1H, 
m, CH), 6.73-6.78 (2H, m, ArH), 6.84-6.99 (4H, m, ArH), 7.11 (1H, t, J = 7.7 Hz, ArH), 
7.24-7.31 (4H, m, ArH), 8.02 (1H, d, J = 8.0 Hz, ArH), 9.16 (1H, br.s, NH).  13C NMR 
(CDCl3, 101 MHz): 21.5, 24.4 (CH3), 53.9 (CH), 114.6, 118.5, 119.4, 119.6, 123.2, 
124.7, 125.4, 127.3, 128.1 (ArCH), 128.2 (ArC), 129.9 (ArCH), 132.0, 136.8, 138.9, 
143.9, 155.9 (ArC), 168.2 (CO).  HRMS: Calcd for C22H21ClN2O2 (M+H)
+ 381.1364, 
found (M+H)+ 381.1352. 
 
1-Bromo-2-phenoxy-benzene, 176, C12H9BrO, MW 249.10, 
O
Br  
The above compound was prepared using a method by Nie et al.107  A mixture of 2-
bromophenol (0.211 mL, 2 mmol), phenylboronic acid (490 mg, 4 mmol), copper 
acetate (364 mg, 2 mmol), TEA (1.38 mL, 10 mmol) and 4Å molecular sieves in DCM 
(25 mL) was stirred at r.t. for 18 h.107  The slurry was filtered through Celite and 
concentrated in vacuo.  This was then diluted with EtOAc and NaHCO3 solution, 
extracted and the organic portions were washed with brine and dried (MgSO4).  The 
crude mixture was purified by flash chromatography (hexane) to yield the desired 
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product as a colourless oil, 232 mg, 47 % yield.  R.f. 0.75 (DCM), LCMS: tr = 1.3 min 
(95 % MeOH in water), m/z M-H 246.84, 248.86, HPLC: tr = 2.88 min (90 % 
acetonitrile in water), 98%, 1H NMR (CDCl3, 270 MHz,): δ 6.95-7.04 (4H, m, ArH), 
7.11 (1H, td, J=1.1, 8.0 Hz, ArH), 7.22-7.37 (3H, m, ArH), 7.61-7.65 (1H, m, ArH).  
13C NMR (CDCl3, 68 MHz): 115.0 (ArC), 118.2, 120.7, 123.5, 125.1, 128.8, 129.9, 
133.9 (ArCH), 153.8, 156.9 (ArC). 
 
1-Bromo-2-phenoxy-4'chlorobenzene, 177, C12H8BrClO, MW 283.55, 
O
Br
Cl
 
The above compound was prepared using a method by Nie et al.107  A mixture of 2-
bromophenol (0.2 mL, 2 mmol), phenylboronic acid (600 mg, 4 mmol), copper acetate 
(350 mg, 2 mmol), TEA (1.4 mL, 10 mmol) and powdered 4Å molecular sieves (~ 2 g) 
in DCM (25 mL) was stirred at r.t. for 18 h.  The slurry was filtered through Celite and 
concentrated in vacuo.  This was then diluted with EtOAc and NaHCO3 solution, 
extracted and the organic portions were washed with brine and dried (MgSO4).  The 
crude mixture was purified by flash chromatography (hexane) to yield the desired 
product as a colourless oil, 320 mg, 59 % yield.  R.f. 0.72 (DCM), HPLC: tr = 3.29 min 
(90 % acetonitrile in water), >99 %, 1H NMR (CDCl3, 270 MHz,): δ 6.85-6.91 (1H, m, 
ArH), 6.96 (1H, dd, J = 1.4, 8.0Hz, ArH), 7.00-7.07 (1H, m, ArH), 7.25-7.29 (3H, m, 
ArH), 7.62 (1H, dd, J = 1.6, 8.0Hz, ArH). 
 
1-(2-Nitro-phenyl)-ethanone-O-methyl-oxime, 178, C9H10N2O3, MW 194.19, 
N
O
NO2  
The above compound was synthesised using a method as described by Salerno et al.111  
To a solution of 2-nitroacetophenone (1.9 g, 10.9 mmol), methoxyamine hydrochloride 
(0.96 g, 10.9 mmol) in anhydrous pyridine (38 mL) and anhydrous EtOH (38 mL) was 
added powdered 4Å molecular sieves (~1 g).  The resulting mixture was heated at reflux 
for 3h.  The resulting mixture was filtered through Celite to remove the molecular 
sieves and then evaporated to dryness.  The solid was re-dissolved in EtOAc and 
extracted with 20 % NaHCO3 solution, this was then dried (MgSO4) and evaporated in 
vacuo to yield the desired compound as a mixture of enantiomers, yellow oil, 1.95 g, 87 
% yield.  The product was used crude in following reactions.  R.f. 0.55 (DCM), HPLC: 
tr = 1.87 min, 58 %, tr = 2.39 min, 29 % (90 % acetonitrile in water), LCMS: tr = 3.30 
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min, m/z M+H 195.4, tr = 4.00 min, m/z M
+H 195.3 (70 % MeOH in water).  1H NMR 
(CDCl3, 400 MHz,): Major isomer: δ 2.54 (3H, s, CH3), 3.69 (3H, s, OCH3), 7.23-8.08 
(4H, m, ArH).  Minor isomer: δ 2.14 (3H, s, CH3), 3.94 (3H, s, OCH3), 7.23-8.08 (4H, 
m, ArH). 
 
1-(2-Nitro-phenyl)-ethylamine hydrochloride, 179, C8H11ClN2O2, MW 202.64,
111  
NH2
NO2
.HCl
 
The above compound was synthesised using a method as described by Salerno et al.111  
A solution of 1-(2-nitro-phenyl)-ethanone-O-methyl-oxime (1.95 g, 10.05 mmol) in 
THF (7 mL) was cooled to 0 °C, to this was added borane/ THF complex (28 mL, 28.1 
mmol) and the resulting solution was then heated at reflux for 6 h.  The reaction was 
then cooled to -20 °C and water (2 mL) was added slowly followed by aq. 20 % KOH 
solution (2 mL) over 20 min.  The resulting mixture was then heated at reflux for a 
further 2 h and then poured into DCM.  The mixture was then extracted with brine and 
dried (MgSO4).  To form the salt, the product was re-dissolved in DCM and then 
concentrated HCl (1.5 mL) was added and the mixture was stirred for 1 h.  The resulting 
solid was removed by filtration and washed with ether and dried, 345 mg, 17 % yield.  
R.f. 0.32 (Hexane: DCM, 1:1), LCMS: tr = 1.33 min (70 % MeOH in water), m/z M+H 
167.2 (free base), HPLC: tr = 2.09 min (90 % acetonitrile in water), >99 %, 
1H NMR 
(CDCl3, 400 MHz,): δ 1.60 (3H, d, J = 6.8Hz, CH3), 4.77-4.80 (1H, m, CH), 7.63-7.67 
(1H, m, ArH), 7.86 (1H, td, J = 1.2, 7.6 Hz, ArH), 8.03-8.05 (2H, m, ArH), 8.72 (2H, 
br.s, NH2). 
 
(2-Phenoxy-phenyl)-(1-phenyl-ethyl)-amine, 180, C20H19NO, MW 289.37, 
O
HN
 
The above compound was synthesised using a modified method from Harris et al.113 
Palladium acetate (19 mg, 10 mol%) and rac-BINAP (51 mg, 10 mol%) were placed 
into an oven-dried flask, this was then evacuated and back filled with N2.  To this was 
then added (via syringe) 1-phenylethylamine (100 mg, 0.83 mmol), 1-bromo-2-
phenoxy-benzene (185 mg, 0.74 mmol) and toluene (1 mL).  This was stirred for 10 min 
at r.t.  Sodium t-butoxide (95 mg, 1 mmol) and further toluene (1 mL) were then added.  
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The resulting solution was heated to reflux for 18 h.  The mixture was then filtered 
through Celite and purified by flash chromatography (0-50 % DCM in hexane) to yield 
the desired product as an off white oil, 104 mg, 49 % yield.  R.f. 0.45 (1:1, DCM: 
Hexane), LCMS: tr = 2.18 min (90 % MeOH in water), m/z M+H 290.10, HPLC: tr = 
3.11 min (90 % acetonitrile in water), 98 %, 1H NMR (CDCl3, 270 MHz,): δ 1.47 (3H, 
d, J = 6.3 Hz, CH3), 4.45-4.58 (2H, m, CH and NH), 6.46 (1H, dd, J = 1.1, 8.0 Hz, 
ArH), 6.56 (1H, td, J = 1.4, 7.9 Hz, ArH), 6.80-6.89 (2H, m, ArH), 6.99-7.11 (3H, m, 
ArH), 7.18-7.36 (7H, m, ArH).  13C NMR (CDCl3, 68 MHz): 25.2 (CH3), 53.3 (CH), 
112.7, 116.7, 117.6, 119.2, 122.8, 124.8, 125.9, 126.9, 128.7, 129.8 (ArCH), 139.6, 
143.0, 145.2, 157.7 (ArC).  HRMS: Calcd for C20H19NO (M+H)
+ 290.1539, found 
(M+H)+ 290.1529. 
 
[2-(4-Chloro-phenoxy)-phenyl]-(1-phenyl-ethyl)-amine, 181, C20H18ClNO, MW 
323.82, 
O
HN
Cl
 
The above compound was synthesised using a modified method from Harris et al.113  
Palladium acetate (10 mg, 10 mol%) and rac-BINAP (26 mg, 10 mol%) were placed 
into an oven dried flask, this was evacuated and back filled with N2.  To this was then 
added (via syringe) 1-phenylethylamine (50 mg, 0.42 mmol), 1-bromo-2-phenoxy-
4'chlorobenzene (105 mg, 0.38 mmol) and toluene (1 mL).  This was stirred for 10min 
at r.t.  Sodium t-butoxide (50 mg, 0.5 mmol) and a further portion of toluene (1 mL) 
was then added.  The resulting solution was heated to reflux for 3 h.113  This was then 
filtered through Celite and purified by flash chromatography (hexane) to yield the 
desired product as a white solid, 51 mg, 41 % yield.  R.f. 0.35 (hexane), m.p. 84-86 °C, 
LCMS: tr = 4.67 min (90 % MeOH in water), m/z M-H 322.3, HPLC: tr = 4.30 min (90 
% acetonitrile in water), 97%, 1H NMR (CDCl3, 270 MHz,): δ 1.48 (3H, d, J = 6.0 Hz, 
CH3), 4.49-4.53 (2H, m, CH and NH), 6.48 (1H, t, J = 8.0 Hz, ArH), 6.92-6.95 (2H, m, 
ArH), 7.20-7.31 (7H, m, ArH).  13C NMR (CDCl3, 68 MHz): 25.2 (CH3), 53.3 (CH), 
113.0, 116.9, 118.8, 119.3, 125.3, 125.9, 127.1 (ArCH), 127.8 (ArC), 128.8, 129.8 
(ArCH), 139.5, 142.6, 145.1, 156.4 (ArC).  HRMS: Calcd for C20H18ClNO (M+H) 
324.1150, found (M+H)+ 324.1136. 
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[2-(4-Chloro-phenoxy)-phenyl]-[1-(2-nitro-phenyl)-ethyl]-amine, 182, 
C20H17ClN2O3, MW 368.81, 
Cl
O
HN
NO2
 
The above compound was synthesised using a modified method from Harris et al.113  
Palladium acetate (15 mg, 10 mol%), rac-BINAP (45 mg, 10 mol%) and 1-(2-nitro-
phenyl)-ethylamine hydrochloride (151 mg, 0.75 mmol) were placed into an over dried 
flask, this was evacuated and back filled with N2.  To this was then added (via syringe) 
1-bromo-2-phenoxy-4'chlorobenzene (190 mg, 0.68 mmol) and toluene (2 mL).  This 
was stirred for 10 min at r.t.  Sodium t-butoxide (195 mg, 2.04 mmol) and a further 
portion of toluene (2 mL) was then added.  The resulting solution was heated to reflux 
for 24 h.113  The slurry was then filtered through Celite and purified by flash 
chromatography (0-100 % DCM in hexane) to yield the desired product as a yellow oil, 
120 mg, 48 % yield.  R.f. 0.45 (1:1, Hexane: DCM),  LCMS: tr = 3.85 min (90 % MeOH 
in water), m/z M-H 367.50, 1H NMR (CDCl3, 400 MHz,): δ 1.51 (3H, d, J = 6.8Hz, 
CH3), 5.16 (1H, q, J = 6.4 Hz, CH), 6.28 (1H, dd, J = 1.2, 7.6 Hz, ArH), 6.56 (1H, td, J 
= 1.2, 7.6 Hz, ArH), 6.76 (1H, dd, J = 1.6, 8.4 Hz, ArH), 6.82 (1H, td, J = 1.2, 7.2 Hz, 
ArH), 6.89-6.93 (2H, m, ArH), 7.24-7.28 (2H, m, ArH), 7.31-7.35 (1H, m, ArH), 7.47 
(1H, td, J = 1.2, 7.6 Hz, ArH), 7.54 (1H, dd, J = 1.2, 8.0 Hz, ArH), 7.88 (1H, dd, J = 
1.2, 8.4 Hz, ArH).  13C NMR (CDCl3, 101 MHz): δ 24.1 (CH3), 48.7 (CH), 112.3, 
117.5, 118.7, 119.1, 124.7, 125.2, 127.3, 127.8 (ArCH), 127.9 (ArC), 129.7, 133.6 
(ArCH), 138.4, 140.4, 142.6, 148.7, 156.1 (ArC). 
 
[2-(4-Chloro-phenoxy)-phenyl]-[1-(2-amino-phenyl)-ethyl]-amine, 183, 
C20H19ClN2O, MW 338.83,  
Cl
O
HN
NH2
 
Using the general procedure for the reduction of the substituted 2-nitrobenzylalcohol, 
but with a shortened reaction time of 10min at reflux, the product was isolated as a 
yellow oil, 12 mg, 25 % yield.  R.f. 0.32 (DCM), LCMS: tr = 2.81 min (90 % MeOH in 
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water), m/z M-H 337.60, 1H NMR (CDCl3, 400 MHz,): δ 1.53 (3H, d, J = 6.8 Hz, CH3), 
4.06 (2H, br.s, NH2), 4.21 (1H, br.s, NH), 4.54-4.56 (1H, m, CH), 6.63-6.67 (2H, m, 
ArH), 6.70-6.77 (2H, m, ArH), 6.81 (1H, dd, J = 0.8, 7.6 Hz, ArH), 6.87-6.91 (2H, m, 
ArH), 6.95-6.99 (1H, m, ArH), 7.07 (1H, td, J = 0.8, 7.2 Hz, ArH), 7.19 (1H, dd, J = 
1.2, 7.6 Hz, ArH), 7.23-7.27 (2H, m, ArH). 13C NMR (CDCl3, 101 MHz): 20.2 (CH3), 
50.1 (CH), 113.3, 116.6, 117.7, 118.6, 118.7, 119.3, 125.3, 126.7 (ArCH), 127.5, 127.7 
(ArC), 128.0, 129.6 (ArCH), 139.5, 143.1, 144.8, 156.2 (ArC). 
 
N-(2-(1-[2-(4-Chloro-phenoxy)-phenylamino]-ethyl)-phenyl)-acetamide, 175, 
C22H21ClN2O2, MW 380.87, 
Cl
O
HN
H
N
O
 
To a solution of [2-(4-chloro-phenoxy)-phenyl]-[1-(2-amino-phenyl)-ethyl]-amine (20 
mg, 0.06 mmol) and TEA (0.008 mL) in DCM (1 mL) at 0 °C, was added acetyl 
chloride (0.009 mL) and the resulting solution was allowed to warm to r.t. and stirred 
for 1 h.  NaHCO3 was then added and the mixture was repeatedly extracted with DCM, 
the organic layers were then washed with 1M HCl.  The organic layers were combined, 
dried (MgSO4) and evaporated in vacuo.  Purification by flash chromatography (0-10 % 
MeOH in DCM) afforded the desired product as an off white oil, 22 mg, 96 % yield.  
Analysis as previous (182). 
 
Chiral Separation of R-(-)-N-(2-(1-[2-(4-chloro-phenoxy)-phenylamino]-but-2-enyl)-
phenyl)-acetamide, 184, C24H23ClN2O2, MW 406.90,  
Cl
O
HN
H
N
O
 
m.p. 139-140 °C (from hexane/DCM), LCMS (Chiracel AD-H column): tr = 11.5 min 
(80 % MeOH in water), m/z M-H 405.2, HPLC (Chiracel AD-H column): tr = 9.00min 
(80 % MeOH in water), >99%, [α]D= -155.7, 
1H NMR (CDCl3, 400 MHz,): δ 1.86 (3H, 
s, CH3), 2.54-2.62 (2H, m, CH2), 4.31 (1H, t, J = 6.4 Hz, CHNH), 4.60 (1H, s, NH), 
5.10 (1H, s, ½CH2CH), 5.13 (1H, d, J = 5.2 Hz, ½CH2CH), 5.65-5.75 (1H, m, CHCH2), 
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6.66 (1H, d, J = 8.0 Hz, ArH), 6.77 (1H, t, J = 8.0 Hz, ArH), 6.87-6.96 (4H, m, ArH), 
7.13 (1H, t, J = 7.6 Hz, ArH), 7.26-7.31 (4H, m, ArH), 8.05 (1H, d, J = 8.4 Hz, ArH), 
9.40 (1H, br.s, NHCO).  13C NMR (CDCl3, 101 MHz): 24.3 (CH3), 40.6 (CH2), 58.9 
(CH2), 114.9, 118.0 (ArCH), 119.3 (CH2), 119.8, 120.0, 123.1, 124.7, 125.6 (ArCH), 
128.0 (ArC), 128.2, 128.2, 129.8 (ArCH), 130.7 (ArC), 134.0 (CH), 136.9, 139.3, 
143.5, 156.1 (ArC), 168.1 (CO).  Anal. Calcd for C24H23ClN2O2. ½H2O C 69.31, H 
5.82, N 6.74 %. Found: C 68.9, H 5.75, N 6.50 %.  HRMS: Calcd for C24H23ClN2O2 
(M+H)+ 407.1521, found (M+H)+ 407.1503.  X-Ray Crystallography used to determine 
absolute stereochemistry (See Appendix III). 
 
Chiral Separation of S-(+)- N-(2-(1-[2-(4-chloro-phenoxy)-phenylamino]-but-2-enyl)-
phenyl)-acetamide, 185, C24H23ClN2O2, MW 406.90, 
Cl
O
HN
H
N
O
 
m.p. 139-141 °C (from hexane/DCM), LCMS (Chiracel AD-H column): tr = 14.8 min 
(80 % MeOH in water), m/z M-H 405.4, HPLC (Chiracel AD-H column): tr = 11.50min 
(90 % acetonitrile in water), >99 %, [α]D= +158.0, 
1H NMR: As 191, 13C NMR: As 191, 
Anal. Calcd for C24H23ClN2O2. ½H2O C 69.31, H 5.82, N 6.74 %. Found: C 69.7, H 
5.74, N 6.75 %. HRMS: Calcd for C24H23ClN2O2 (M+H)
+ 407.1521, found (M+H)+ 
407.1502. 
 
Experimental Details: Chapter 9: Synthesis of Compounds with an Amide Linked 
Hydrophobic Headgroup 
 
2-(1-Acetyl-piperidin-4-ylamino)-N-phenyl-benzamide, 186, C20H23N3O2, MW 
337.42, 
N
H
O HN
N
O
 
2-Aminobenzanilide (100 mg, 0.47 mmol), 1-acetyl-4-piperidone (0.12 mL, 0.96 
mmol), sodium triacetoxyborohydride (0.25 g, 1.18 mmol) and AcOH (0.24 mL) were 
all mixed in toluene (2 mL) and subjected to microwave heating for 10 min and 120 °C.  
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NaHCO3 was added and the reaction was extracted with EtOAc, dried (MgSO4), and 
evaporated in vacuo.  The crude product was purified by flash chromatography (0-10 
MeOH in DCM) to afford the desired product as a cream solid, 75 mg, 47 % yield.  R.f. 
0.35 (5 % MeOH in DCM), LCMS tr = 3.58 min (50 % to 95 % MeOH in water at 0.5 
mL/min to 1.0 mL/min over 5 min), m/z M+H 338.22, HPLC tr = 6.72 min (70 % 
acetonitrile in water at 0.3 mL/min), 97 %, 1HNMR (CDCl3, 270 MHz) δ 1.25-1.35 
(2H, m, CH2), 2.09 (3H, s, CH3), 2.40-2.47 (1H, m, ½CH2), 2.77-2.86 (1H, m, ½CH2), 
3.19-3.23 (1H, m, ½CH2) 3.50-3.60 (1H, m, ½CH2), 3.70-3.91 (2H, m, CH2), 4.05-4.11 
(1H, m, ½CH2), 4.45 (1H, br.s, NH), 6.56-6.59 (2H, m, ArH), 7.06-7.11 (1H, m, ArH), 
7.29-7.34 (2H, m, ArH), 7.59-7.63 (2H, m, ArH), 7.69-7.73 (2H, m, ArH), 7.88 (1H, s, 
NH).  13CNMR (CDCl3, 68 MHz) δ 21.6 (CH3), 31.9, 32.7, 40.4, 45.1 (CH2), 48.7 (CH), 
112.3, 120.2 (ArCH), 124.0 (ArC), 124.1, 129.1, 129.1 (ArCH), 138.5, 149.7 (ArC), 
165.5, 169.1 (CO).  HRMS: Calcd for C20H23N3O2 (M+H)
+ 400.2020, found (M+Na)+ 
400.2017. 
 
2-(1-Benzoyl-piperidin-4-ylamino)-N-phenyl-benzamide, 187, C25H25N3O2, MW 
399.48, 
N
H
O HN
N
O
 
4-Aminobenzanilide (100 mg, 0.47 mmol), N-benzoyl-4-piperidone (190 mg, 0.96 
mmol), sodium triacetoxyborohydride (0.25 g, 1.18 mmol) and AcOH (0.24 mL) were 
all mixed in toluene (2 mL) and subjected to microwave heating for 15 min at 100 °C.  
NaHCO3 was added and the reaction was extracted with EtOAc, dried (MgSO4), and 
evaporated in vacuo.  The crude product was purified by flash chromatography (0-100% 
EtOAc in hexane) to afford the desired product as a cream solid, 40 mg, 21 % yield.  
R.f. 0.65 (EtOAc), LCMS tr = 4.19 min (50 % to 95 % MeOH in water at 0.5 mL/min to 
1.0 mL/min over 5 min), m/z M+H 400.50, HPLC tr = 4.69 min (100 % MeOH at 0.4 
mL/min), 99 %, 1HNMR (CDCl3, 270 MHz) δ 1.41-1.50 (2H, m, CH2), 2.04-2.19 (2H, 
m, CH2), 3.14 (2H, s, CH2), 3.63 (1H, s, CH2), 3.80 (1H, s, CH2), 4.00-4.05 (1H, m, 
CH2), 4.64 (1H, br.s. NH), 6.60-6.63 (2H, m, ArH), 7.34 (1H, t, J = 8.0 Hz, ArH), 7.39-
7.47 (5H, m, ArH), 7.60 (2H, d, J = 7.6Hz, ArH), 7.68 (1H, br.s, NH), 7.70-7.74 (2H, 
m, ArH).  13CNMR (CDCl3, 101 MHz) δ 31.8 (CH3), 32.6, 40.1, 46.4 (CH2), 49.6 (CH), 
112.1, 119.9 (ArCH), 123.9, 126.7, 128.5, 128.7, 129.0, 129.8 (ArCH), 135.5, 138.2, 
149.4 (ArC), 165.0, 170.4 (CO).  HRMS: Calcd for C25H25N3O2 (M+H)
+ 400.2020, 
found (M+Na)+ 400.2017. 
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2,4-Dichloro-N-(3-nitro-phenyl)-benzamide, 191, C13H8Cl2N2O3, MW 311.12, 
H
N
O
Cl
Cl
NO2
 
To a stirred solution of 2-nitroaniline (200 mg, 1.45 mmol) and K2CO3 (600 mg, 4.35 
mmol) in DCM (10 mL) was added 2,4-dichlorobenzoyl chloride (0.41 mL, 1.9 mmol).  
This was stirred at reflux for 5 h.  DMAP (cat.) was added and the solution was stirred 
at reflux for a further 2 days.  The reaction was quenched with NaHCO3 and extracted 
with DCM and the organic layers were washed with HCl (1 M) and brine.  These were 
dried (MgSO4) and evaporated in vacuo to afford the desired product as an off white 
solid, 330 mg, 73 % yield.  R.f. 0.55 (DCM), m.p. 138-140 °C (from hexane), LCMS tr= 
4.81 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z 
M+H 309.32, HPLC tr= 5.31 min (90 % acetonitrile in water at 0.5 mL/min), 89 %, 
1HNMR (CDCl3, 270 MHz) δ 7.23-7.30 (3H, m, ArH), 7.66-7.76 (2H, m, ArH), 8.26 
(1H, dd, J = 1.76, 8.67 Hz, ArH), 8.91 (1H, dd, J = 1.24, 8.67, ArH), 10.89 (1H, s, NH). 
 
N-(3-Nitro-phenyl)-benzamide, 192, C13H10N2O3, MW 242.23, 
H
N
O
NO2
 
To a stirred solution of 2-nitroaniline (0.2 g, 1.45 mmol) and TEA (0.35 mL) in DCM 
(10 mL) at 0°C, was added benzoyl chloride (0.34 mL, 2.9 mmol).  This was allowed to 
warm to r.t. and was stirred for 5 h.  DMAP (cat.) was added and the solution was 
stirred at reflux for 18 h.  The reaction was quenched with NaHCO3 and extracted with 
DCM.  The organic layers were washed with HCl (1 M) and brine.  They were then 
dried (MgSO4) and evaporated in-vacuo.  The crude product was purified by flash 
chromatography (0-100% DCM in hexane) to afford the desired product, 348 mg, 99 % 
yield.  R.f. 0.63 (DCM), m.p.87-90 °C (lit. 95-96 °C),152 LCMS tr= 7.48 min (50% to 
95% MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 243.37, 
HPLC tr= 12.23 min (70 % acetonitrile in 30 % H2O at 0.4 mL/min), 77 %,  
1HNMR 
(CDCl3, 270 MHz) δ 7.19-7.26 (1H, m, ArH), 7.49-7.66 (3H, m, ArH and NH), 7.67-
7.74 (1H, m, ArH), 7.97-8.01 (2H, m, ArH), 8.14-8.17 (1H, m, ArH), 8.28 (1H, dd, 
J=1.5, 8.4 Hz, ArH), 9.01 (1H, dd, J=1.2, 8.4 Hz, ArH). 
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N-(2-Amino-phenyl)-2,4-dichloro-benzamide, 193, C13H10Cl2N2O, MW 281.14, 
H
N
O
Cl
Cl
NH2
 
To a stirred mixture of iron powder (150 mg, 2.64 mmol) and NH4Cl (18 mg, 0.33 
mmol) in EtOH (5 mL) and water (0.5 mL) at reflux, was added 2,4-dichloro-N-(3-
nitro-phenyl)-benzamide (150 mg, 0.48 mmol). The mixture was stirred at reflux for 1 h 
and then allowed to cool and the solvent was removed in vacuo.  The residue was re-
dissolved in DCM (40 mL) and washed with sat. NaHCO3 (40 mL).  The organic layers 
were combined, dried (MgSO4), filtered and evaporated in vacuo to afford the desired 
product as an off white solid, 118 mg, 83 % yield.  R.f. 0.38 (DCM), m.p. 177-179 °C, 
LCMS tr= 1.04 min (95 % MeOH in water at 1.0 mL/min), m/z M+H 282.35, HPLC tr= 
3.99 min (90 % acetonitrile in water at 0.5 mL/min), 98 %, 1HNMR (CDCl3, 270 MHz) 
δ 3.87 (2H, s, NH2), 6.82-6.89 (2H, m, ArH), 7.08-7.14 (1H, m, ArH), 7.35-7.40 (2H, 
m, ArH), 7.48 (1H, d, J = 1.97 Hz, ArH), 7.78 (1H, d, J = 8.4 Hz, ArH), 7.82 (1H, s, 
NH). 
 
N-(2-Amino-phenyl)-benzamide, 194, C13H12N2O, MW 212.25, 
H
N
O
NH2
 
To a stirred mixture of iron powder (0.19 g, 3.41 mmol) and NH4Cl (0.023 g, 0.43 
mmol) in EtOH (5 mL) and water (0.5 mL) at reflux, was added N-(3-nitro-phenyl)-
benzamide (150 mg, 0.62 mmol).  The mixture was stirred at reflux for 1.5 h allowed to 
cool and the solvent was removed in vacuo.  The residue was re-dissolved in DCM (40 
mL) and washed with sat. NaHCO3 (40 mL).  The organic layers were combined, dried 
(MgSO4), filtered and evaporated in vacuo to afford the desired product as a yellow 
waxy solid, 98 mg, 75 % yield.  R.f. 0.33 (DCM), LCMS tr = 3.05 min (50 % to 95 % 
MeOH in water at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 213.23, HPLC tr = 
6.56 min (70 % acetonitrile in water at 0.5 mL/min), 97 %, 1HNMR (CDCl3, 270 MHz) 
δ 3.87 (2H, s, NH2), 6.82-6.87 (2H, m, ArH), 7.07-7.13 (1H, m, ArH), 7.31-7.34 (1H, 
m, ArH), 7.42-7.59 (3H, m, ArH), 7.82 (1H, s, NH), 7.90 (2h, d, J = 6.9 Hz, ArH).  This 
compound was previously synthesised using a different method, by Kettlera et al.117 
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N-[2-(1-Acetyl-piperidin-4-ylamino)-phenyl]-2,4-dichloro-benzamide, 195, 
C20H21Cl2N3O2, MW 406.31, 
Cl
Cl
H
N
O
HN
N
O
 
To a solution of N-(2-amino-phenyl)-2, 4-dichloro-benzamide (100 mg, 0.36 mmol) and 
1-acetyl-4-piperidone (0.1 mL, 0.72 mmol) in toluene (2 mL), was added sodium 
triacetoxyborohydride (190 mg, 0.9 mmol) and AcOH (0.08 mL, 1.08 mmol).  The 
solution was heated using a CEM microwave at 140 °C for 10 min.85  NaHCO3 was 
added and the mixture was repeatedly extracted with EtOAc.  The organic layers were 
combined and dried (MgSO4).  The crude mixture was purified using flash 
chromatography (0-10 % MeOH in DCM) to afford an off-white oil, 61mg, 42 % yield.  
Rf: 0.3 (EtOAc), m.p. 107-109 °C, LCMS tr = 4.04 min (50 % to 95 % MeOH in water 
at 0.5 mL/min to 1.0 mL/min over 5 min), m/z M+H 407.42, HPLC tr = 3.80 min (90 % 
acetonitrile in water at 1.0 mL/min), >99 %, 1HNMR (CDCl3, 400 MHz) (a mixture of 
conformational isomers was obtained, the major isomer is reported here), δ 2.05 (3H, s, 
CH3), 2.14 (1H, d, J = 11.2Hz, ½CH2), 2.29-2.36 (1H, m, ½CH2), 2.41-2.52 (1H, m, 
½CH2), 2.87-2.94 (1H, m, ½CH2), 3.15-3.22 (1H, m, ½CH2), 3.48-3.54 (1H, m, ½CH2), 
3.72-3.77 (1H, m, ½CH2), 3.86-4.11 (2H, m, NH and CH), 4.30- 4.35 (1H, m, ½CH2), 
6.78-6.81 (1H, m, ArH), 7.14-7.18 (1H, m, ArH), 7.27-7.31 (1H, m, ArH), 7.34 (1H, dd, 
J = 2.0, 8.0Hz, ArH), 7.39-7.42 (1H, m, ArH), 7.45 (1H, d, J = 2.0Hz, ArH), 7.67 (1H, 
d, J =8.4Hz, ArH), 8.12 (1H, br.s, NHCO).  13CNMR (CDCl3, 101 MHz) (a mixture of 
conformational isomers was obtained, the major isomer is reported here), δ 21.4 (CH3), 
31.9, 32.5, 40.0, 44.8 (CH2), 49.9 (CH), 111.9, 113.9, 118.5 (ArCH), 120.1, 122.5, 
123.9 (ArC), 125.9, 127.7, 130.0, 131.4 (ArCH), 137.1, 140.8 (ArC), 168.9, 168.8 
(CO). HRMS: Calcd for C20H21Cl2N3O2 (M-H)
+ 405.1084, found (M-H)+ 405.1085. 
 
1-[4-(2-Phenyl-benzoimidazol-1-yl)-piperidin-1-yl]-ethanone, 196, C20H21N3O, MW 
319.40, 
N
N
N
O  
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To a solution of N-(2-amino-phenyl)-benzamide (98 mg, 0.46 mmol), 1-acetyl-4-
piperidone (0.114 mL, 0.92 mmol) in toluene (2 mL) was added sodium 
triacetoxyborohydride (0.25g, 1.15 mmol) and AcOH (0.08 mL, 1.4 mmol).  The 
solution was heated using a CEM microwave at 140 °C for 10 min and then stirred at r.t. 
for 2 days.85  NaHCO3 was added and the mixture was extracted with EtOAc and dried 
(MgSO4).  The crude mixture was purified using flash chromatography (0-100 % 
EtOAc in hexane) to afford a white solid, 112 mg, 72 % yield.  mp. 207-209 °C, Rf: 0.6 
(DCM), LCMS tr= 3.63 min (50 % to 95 % MeOH in water at 0.5 mL/min to 1.0 
mL/min over 5 min), m/z M+H 320.53, HPLC tr= 3.39 min (90 % acetonitrile in water 
at 1.0 mL/min), 95 %.  1H NMR (CDCl3, 400 MHz) δ 1.95-2.09 (2H, m, CH2), 2.18 
(3H, m, CH3), 2.45-2.57 (3H, m, ½CH2 and CH2), 3.06-3.14 (1H, m, ½CH2), 3.96-400 
(1H, m, ½CH2), 4.53-4.62 (1H, m, CH), 4.87 (1H, d, J = 8.8 Hz, ½CH2), 7.26-7.29 (2H, 
m, ArH), 7.50-7.56 (4H, m, ArH), 7.60-7.63 (2H, m, ArH), 7.81-7.83 (1H, m, ArH).  
13C NMR (CDCl3, 101 MHz) δ 21.5 (CH3), 30.1, 30.9, 41.1, 45.8 (CH2), 54.9 (CH), 
112.1, 120.5, 122.4, 122.7, 128.9, 129.4, 129.9 (ArCH), 130.6, 133.5, 143.6, 153.6 
(ArC), 168.9 (CO).  HRMS: Calcd for C20H21N3O (M+H)
+ 320.1757, found (M+Na)+ 
320.1758. 
 
4-(2-Phenyl-benzoimidazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester, 197, 
C23H27N3O2, MW 377.48, 
N
N
N
OO  
To a solution of N-(2-amino-phenyl)-benzamide (145 mg, 0.68 mmol) and 1-Boc-4-
piperidine (272 mg, 1.4 mmol) in DCE (3 mL) was added NaBH(OAc)3 (360 mg, 1.7 
mmol) and AcOH (0.24 mL, 2 mmol).  The resulting mixture was then subjected to 
microwave heating at 140 °C for 10 min.  The reaction was quenched with sat. 
NaHCO3, extracted with DCM and dried (MgSO4).
85  The crude product was purified 
by flash chromatography (0-95 % EtOAc in hexane) to yield the desired product as a 
yellow oil, 147 mg, 57 % yield.  R.f. 0.55 (EtOAc), LCMS: tr = 1.9 min (95 % MeOH in 
water), m/z M+H 375.15, HPLC: tr = 2.3 min (90 % acetonitrile in water), 98 %, 
1H 
NMR (CDCl3, 400 MHz,): δ 1.51 (9H, s, (CH3)3), 1.89-1.92 (2H, m, CH2), 2.52-2.57 
(2H, m, CH2), 2.73 (2H, br.s CH2), 3.82 (1H, br.s, ½CH2), 4.30 (1H, br.s, ½CH2), 4.46-
4.54 (1H, m, CH), 7.24-7.31 (2H, m, ArH), 7.53-7.64 (6H, m, ArH), 7.82 (1H, dd, J = 
2.4, 6.8Hz, ArH).  13C NMR (CDCl3, 68 MHz): 28.4 ((CH3)3), 30.3, 34.1 (CH2), 55.1 
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(CH), 67.7, 80.1 (CH2), 112.2, 120.4, 122.3, 122.5, 128.8, 129.4, 129.9 (ArCH), 130.7, 
133.6, 143.6, 153.6 (ArC), 154.6 (CO).  HRMS: Calcd for C23H27N3O2 (M+H)
+ 
378.2176, found (M+H)+ 378.2189. 
 
2-Phenyl-1-piperidin-4-yl-1H-benzoimidazole, 198, C18H19N3, MW 277.36, 
N
N
N
H  
A solution of 4-(2-phenyl-benzoimidazol-1-yl)-piperidine-1-carboxylic acid tert-butyl 
ester (130 mg, 0.35 mmol) in DCM (5 mL) was cooled to 0 °C and to this was added 
TFA (1 mL) and the resulting solution was stirred at r.t. for 30 min.  The reaction 
solution was poured onto solid K2CO3, extracted with DCM, dried (MgSO4) and 
evaporated in vacuo to yield the desired product as an oil, 83 mg, 87 % yield.  R.f. 0.1 
(EtOAc), m.p. 185-188 °C (from hexane/DCM), LCMS: tr = 1.34 min (95 % MeOH in 
water), m/z M+H 278.09, HPLC: tr = 6.42 min (90 % acetonitrile in water), 87 %, (note: 
contained 10 % SM), 1H NMR (CDCl3, 270 MHz,): δ 1.90 (2H, d, J = 12.4Hz, CH2), 
2.55-2.70 (5H, m, 2CH2), 3.26 (2H, d, J = 9.9Hz, CH2), 4.40-4.46 (1H, m, CH), 7.22-
7.28 (2H, m, ArH), 7.51-7.53 (3H, m, ArH), 7.59-7.62 (2H, m, ArH), 7.73-7.82 (2H, m, 
ArH). 
 
1-4-[4-(2-Phenyl-benzoimidazol-1-yl)-piperidine-1-carbonyl]-piperidin-1-yl-
ethanone, 199, C26H30N4O2, MW 430.54, 
N
N
N
O
N O
 
A solution of 2-phenyl-1-piperidin-4-yl-1H-benzoimidazole, (83 mg, 0.3 mmol) was 
dissolved in DCM (5 mL) and cooled to 0 °C, to this was added TEA (0.2 mL, 0.9 
mmol) and 1-acetyl-4-carbonyl chloride (171 mg, 0.9 mmol).  The resulting solution 
was stirred at r.t. for 4 h and was then quenched with sat. NaHCO3, extracted with DCM 
and dried (MgSO4).  The crude material was then purified by flash chromatography (0-
 306 
10 % MeOH in EtOAc) to yield the desired product, 12 mg, 9 % yield.  R.f. 0.35 
(EtOAc with TEA), LCMS: tr = 1.27 min (80 % MeOH in water), m/z M+H 431.15, 
HPLC: tr = 1.86 min (70 % acetonitrile in water), 98 %, 
1H NMR (CDCl3, 400 MHz,): δ 
1.68-1.80 (4H, m, CH2), 1.99-2.07 (2H, m, CH2), 2.11 (3H, s, CH3), 2.49-2.68 (4H, m, 
CH2), 2.75-2.81 (1H, m, CH), 3.06-3.14 (2H, m, CH2), 3.24-3.39 (1H, m, ½CH2), 3.87-
3.94 (1H, m, ½CH2), 4.08 (1H, d, J = 15.2Hz, ½CH2), 4.57-4.69 (1H, m, CH), 4.85-4.86 
(1H, m, ½CH2), 7.26-7.36 (2H, m, ArH), 7.47-7.51 (1H, m, ArH), 7.53-7.56 (3H, m, 
ArH), 7.60-7.63 (2H, m, ArH), 7.82-7.84 (1H, m, ArH).  13C NMR (CDCl3, 101 MHz): 
21.5 (CH3), 28.3, 28.6, 28.7, 29.0, 29.7, 30.3, 31.2, 34.5 (CH2), 38.3, 38.5 (CH), 40.3, 
41.0, 41.6, 42.0, 44.9, 45.8, 45.9 (CH2), 55.0 (CH), 112.0, 120.6, 122.5, 122.7 (ArCH), 
128.2, 128.7 (ArC), 129.0, 129.4, 130.1 (ArCH), 133.4, 143.6 (ArC), 172.6, 168.9 
(CO).  HRMS: Calcd for C26H30N4O2 (M+H)
+ 431.2442, found (M+H)+ 431.2422. 
 
Experimental Details: Chapter 10: Synthesis of Compounds with an Benzophenone 
Linked Hydrophobic Headgroup 
 
1-Acetyl-piperidine-4-carboxylic acid (2-benzoyl-phenyl)-amide, 200, C21H22N2O3, 
MW 350.41, 
O HN
O
N
O
 
The above compound was synthesised using a method reported by Kettler et al.117  1-
Acetylpiperidine-4-carbonyl chloride (173 mg, 0.91 mmol) was dissolved in toluene (5 
mL) and this was added to a solution of 2-aminobenzophenone (150 mg, 0.76 mmol) 
and pyridine (0.38 mL, 4.6 mmol) in toluene (15 mL).  The resulting mixture was 
heated at reflux for 6 h.  The toluene was removed in-vacuo and aqueous HCl solution 
(1 M) was added.  The mixture was then extracted with DCM, dried (MgSO4) and 
evaporated to dryness.  The crude product was purified by flash chromatography (0-10 
% MeOH in DCM), to yield the desired product as a white solid, 129 mg, 48 % yield.  
R.f. 0.44 (10 % MeOH in EtOAc), m.p. 191-193 °C, LCMS: tr = 0.94 min (95 % MeOH 
in water), m/z M-H 349.14, HPLC: tr = 1.68 min (90 % acetonitrile in water),>99 %, 
1H 
NMR (CDCl3, 270 MHz,): δ 1.67-1.87 (2H, m, CH2), 2.01-2.09 (2H, m, CH2), 2.09 (3H, 
s, CH3), 2.50-2.61 (1H, m, CH), 2.60-2.75 (1H, m, ½CH2), 3.08-3.17 (1H, m, ½CH2), 
3.89 (1H, d, J = 13.9 Hz, ½CH2), 4.64 (1H, d, J = 13.4 Hz, ½CH2), 7.09 (1H, td, J = 
0.97, 7.4 Hz, ArH), 7.46-7.51 (2H, m, ArH), 7.55-7.63 (3H, m, ArH), 7.67-7.69 (2H, m, 
ArH), 8.63-8.66 (1H, m, ArH), 11.10 (1H, s, NH).  13C NMR (CDCl3, 68 MHz): 21.6 
(CH3), 28.5, 28.9, 41.1 (CH2), 44.7 (CH), 45.9 (CH2), 121.5, 122.4 (ArCH), 123.1 
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(ArC), 128.5, 129.9, 132.7, 134.0, 134.7 (ArCH), 138.7, 140.7 (ArC), 167.5, 169.0, 
173.2 (CO).  Anal. Calcd for C21H22N2O3: C 71.98, H 6.33, N 7.99 %. Found: C 71.6, H 
6.29, N 8.00 %.  HRMS: Calcd for C21H22N2O3 (M+Na)
+ 373.1526, found (M+Na)+ 
373.1523. 
 
1-Acetyl-piperidine-4-carboxylic acid [4-chloro-2-(2-fluoro-benzoyl)-phenyl]-
amide, 201, C21H20ClFN2O3, MW 402.85, 
F
O
Cl
HN
O
N
O
 
The above compound was synthesised using a method reported by Kettler et al.117  1-
Acetylpiperidine-4-carbonyl chloride (136 mg, 0.72 mmol) was dissolved in toluene (5 
mL) and this was added to a solution of 2-amino-5-chloro-2’-fluorobenzophenone (150 
mg, 0.6 mmol) in toluene (15 mL).  The reaction was heated at reflux for 2 h.  The 
toluene was removed in vacuo and 1 M HCl was added, the crude residue was then 
extracted with DCM, dried (MgSO4) and evaporated to dryness.  The crude product was 
purified by flash chromatography (0-10 % MeOH in DCM) to yield the desired product 
as an off-white solid, 112 mg, 46 % yield.  R.f. 0.35 (EtOAc), m.p. 202-204 °C, LCMS: 
tr = 1.07 min (95 % MeOH in water), m/z M-H 401.10, HPLC: tr = 1.79 min (90 % 
acetonitrile in water), >99 %, 1H NMR (CDCl3, 270 MHz,): δ 1.65-1.90 (2H, m, CH2), 
2.02-2.08 (5H, m, CH2 and CH3), 2.51-2.75 (2H, m, ½CH2 and CH), 3.08-3.18 (1H, m, 
½CH2), 3.89 (1H, d, J = 13.3 Hz, ½CH2), 4.63 (1H, d, J = 13.3 Hz, ½CH2), 7.15-7.31 
(2H, m, ArH), 7.41-7.61 (4H, m, ArH), 8.71 (1H, d, J = 8.9 Hz, ArH), 11.35 (1H, br.s, 
NH).  13C NMR (CDCl3, 68 MHz): 21.5 (CH3), 28.5, 28.9, 41.0 (CH2), 44.7 (CH), 45.8 
(CH2), 116.6, 122.5 (ArCH), 123.7 (ArC), 130.3, 133.4, 133.8, 133.9, 135.4 (ArCH), 
139.7, 157.7, 161.5 (ArC), 169.0, 173.3, 196.3 (CO).  Anal. Calcd for C21H20ClFN2O3:C 
62.61, H 5.00, N 6.95 %. Found: C 62.78, H 5.01, N 6.87 %.  HRMS: Calcd for 
C21H20ClFN2O3 (M+H)
+ 403.1219, found (M+H)+ 403.1218. 
 
1-[4-(2-Benzoyl-phenylamino)-piperidin-1-yl]-ethanone, 202, C20H22N2O2, MW 
322.40, 
O HN
N
O  
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To a solution of 2-aminobenzophenone (197 mg, 1 mmol) and 1-acetyl-4-piperidine 
(282 mg, 2 mmol) in DCE (3 mL) was added NaBH(OAc)3 (530 mg, 2.5 mmol) and 
AcOH (0.18 mL).  The resulting solution was stirred at r.t. for 36 h.  NaHCO3 was 
added and the mixture was extracted with DCM.  The crude product was purified by 
flash chromatography (0-10 % MeOH in EtOAc) to yield the desired product as a 
yellow oil, 116 mg, 36 % yield.  R.f. 0.58 (10 % MeOH in EtOAc), LCMS: tr = 4.39 
min (50 % to 95 % MeOH in water), m/z M+H 323.14, HPLC: tr = 2.03 min (90 % 
acetonitrile in water), 95 %, 1H NMR (CDCl3, 270 MHz,): δ 1.48-1.68 (2H, m, CH2), 
2.00-2.10 (5H, m, CH3 and CH2), 3.10-3.34 (2H, m, CH2), 3.67-3.82 (2H, m, CH2), 
4.19-4.28 (1H, m, CH2), 6.50-6.56 (1H, m, ArH), 6.78 (1H, d, J = 8.4 Hz, ArH), 7.33-
7.59 (7H, m, 6ArH and NH), 8.78 (1H, d, J = 7.2 Hz, ArH).  13C NMR (CDCl3, 68 
MHz): 21.6 (CH3), 31.4, 32.2, 39.8, 44.7 (CH2), 48.4 (CH), 111.8, 114.1, 128.2, 129.1, 
130.9, 135.1, 136.0 (ArCH), 150.6, 169.0 (CO).  HRMS: Calcd for C20H22N2O2 
(M+H+Na)+ 345.1573, found (M+H+Na)+ 345.1565. 
 
General Procedure for the Friedländer Cyclisation 
The desired benzophenone (1 mmol) and ketone (2 mmol) were dissolved in AcOH (2 
mL).  The resulting solution was subjected to microwave heating for 5 min at 160 °C:  
Saturated NaHCO3 was then added and the mixture was extracted with DCM, dried 
(MgSO4) and purified by flash chromatography to yield the desired quinoline product as 
detailed below. 
 
1-(10-Phenyl-3,4-dihydro-1H-benzo[b][1,6]naphthyridin-2-yl)-ethanone, 203, 
C20H18N2O, MW 302.37, 
N
N
O  
Following the general procedure for the Friedländer Cyclisation and flash 
chromatography it was found that the product was still contaminated with the 1-acetyl-
4-piperidone starting material.  This was removed by use of PS-TsNHNH2.  The crude 
material was dissolved in DCM (~10 mL/g) and the resin was added (3 eq, 2.8 mmol/g), 
this was then stirred at r.t. for 1 h.  The resin was removed by filtration and flash 
chromatography isolated the desired product as a white solid, 206 mg, 68 % yield.  R.f. 
0.33 (10 % MeOH in DCM), m.p. 163-165 °C (from hexane), (lit. ref. 166-167 °C153), 
LCMS: tr = 0.95 min (95 % MeOH in water), m/z M+H 303.09, HPLC: tr = 1.83 min (90 
% acetonitrile in water), 99 %, 1H NMR (CDCl3, 270 MHz,): δ 1.95, 2.16 (3H, CH3), 
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3.29-3.32 (2H, m, CH2), 3.83-3.99 (2H, m, CH2), 4.43, 4.60 (2H, CH2), 7.23-7.28 (2H, 
m, ArH), 7.38-7.39 (2H, m, ArH), 7.47-7.59 (3H, m, ArH), 7.62-7.70 (1H, m, ArH), 
8.04 (1H, t, J = 6.6 Hz, ArH).  13C NMR (CDCl3, 101 MHz): 21.4, 21.9 (CH3), 32.8, 
33.9, 39.8, 42.6, 43.8, 46.5 (CH2), 124.0, 124.6 (ArC), 125.9, 126.0, 126.2, 126.3 
(ArCH), 126.4, 126.8 (ArC), 128.4, 128.5, 128.6, 128.7, 128.9, 129.0, 129.1, 129.3, 
129.5 (ArCH), 135.1, 135.2, 145.1, 146.1, 146.6, 146.9, 155.3, 156.3 (ArC), 169.3, 
169.4 (CO).  Anal. Calcd for C20H18N2O (+ ½mole AcOH): C 75.9, H 6.1, N 8.4 %. 
Found: C 76.1, H 6.2, N 9.0 %.  HRMS: Calcd for C20H18N2O (M+H)
+ 303.1492, found 
(M+H)+ 303.1491.  IR: 2800 (m), 1650 (s), 1300 (m), 1030 (m).  X-Ray crystallography 
was used to identify structure, see Appendix III.  This compound was previously 
synthesised, via a different method by Khaldeeva et al.153 
 
9-Phenyl-1,2,3,4-tetrahydro-acridine, 204, C19H17N, MW 259.34, 
N
 
Following the general procedure for the Friedländer Cyclisation the desired product was 
isolated, 246 mg, 94 % yield.  R.f. 0.7 (10 % MeOH in DCM), m.p. 137-139 °C, (lit. 
139-141 °C154), LCMS: tr = 4.19 min (50 % to 95 % MeOH in water at 0.5 mL/min to 
1.0 mL/min over 5 min), m/z M+H 400.50, 1H NMR (CDCl3, 270 MHz,): δ 1.7-1.79 
(2H, m, CH2), 1.90-2.01 (2H, m, CH2), 2.59 (2H, t, J = 6.5 Hz, CH2), 3.19 (2H, J = 6.4 
Hz, CH2), 7.20-7.31 (4H, m, ArH), 7.4-7.65 (4H, m, ArH), 8.00 (1H, d, J = 8.2 Hz, 
ArH).  13C NMR (CDCl3, 68 MHz): 23.0, 23.1, 28.2, 34.4 (CH2), 125.5, 125.9 (ArCH), 
127.0 (ArC), 127.8, 128.4, 128.7, 129.2 (ArCH), 137.2, 147.0, 159.2 (ArC).  This 
compound has been previously synthesised using a different method, by Shaabani et 
al.154 
 
12-Phenyl-6,7,8,9,10,11-hexahydro-cycloocta[b]quinoline, 205, C21H21N, MW 
287.40,155 
N
 
Following the general procedure for the Friedländer Cyclisation the desired product was 
isolated as an off-white solid, 267 mg, 93 % yield.  R.f. 0.3 (DCM), m.p. 120-122 °C, 
LCMS: tr = 1.78 min (95 % MeOH in water), m/z M+H 288.10, HPLC: tr = 4.9 min (90 
% acetonitrile in water), 98 %, 1H NMR (CDCl3, 270 MHz,): δ 1.30-1.51 (6H, m, CH2), 
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1.90-1.98 (2H, m, CH2), 2.76 (2H, t, J = 5.7 Hz, CH2), 3.22 (3H, t, J = 6.2 Hz, CH2), 
7.18-7.32 (4H, m, ArH), 7.45-7.51 (3H, m, ArH), 7.55-7.52 (1H, m, ArH), 8.05 (1H, d, 
J = 7.9 Hz, ArH).  13C NMR (CDCl3, 68 MHz): 25.9, 26.8, 28.2, 31.2, 31.4, 36.5 (CH2), 
125.5, 126.2 (ArCH), 127.3 (ArC), 127.7, 128.3, 128.4, 128.6, 129.4 (ArCH), 131.9, 
137.7, 146.5, 163.6 (ArC).  HRMS: Calcd for C21H21N (M+H)
+ 288.1747, found 
(M+H)+ 288.1756.  Anal. Calcd for C21H21N ,C 87.76, H 7.36, N 4.87 %. Found: C 
87.40, H 7.32, N 4.87 %.  This compound has been previously synthesised using a 
different method, by Bose et al.155 
 
9-Phenyl-2,3-dihydro-1H-cyclopenta[b]quinoline, 206, C18H15N, MW 245.32, 
N
 
Following the general procedure for the Friedländer Cyclisation the desired product was 
isolated as an off-white solid, 243 mg, 99 % yield.  R.f. 0.32 (DCM), m.p. 132-134 °C, 
(lit. 131-132 °C154), LCMS: tr = 1.5 min (95 % MeOH in water), m/z M+H 245.90,  
HPLC: tr = 3.2 min (90 % acetonitrile in water), >99 %, 
1H NMR (CDCl3, 270 MHz,): δ 
2.10-2.20 (2H, m, CH2), 2.89 (2H, t, J = 7.4 Hz, CH2), 3.23 (2H, t, J = 7.7 Hz, CH2), 
7.32-7.65 (8H, m, ArH), 8.06-8.08 (1H, m, ArH).  13C NMR (CDCl3, 68 MHz): 23.6, 
30.4, 35.2 (CH2), 126.6, 125.7 (ArCH), 126.3 (ArC), 128.1, 128.4, 128.6, 128.7, 129.4 
(ArCH), 133.8, 136.8, 143.0, 147.9, 167.5 (ArC).  HRMS: Calcd for C18H15N (M+H)
+ 
246.1277, found (M+H)+ 246.1250.  Anal. Calcd for C18H15N ,C 88.13, H 6.16, N 5.71 
%. Found: C 87.90, H 6.13, N 5.76 %.  This compound has been previously synthesised 
using a different method, by Shaabani et al.154 
 
2-Butyl-4-phenyl-quinoline, 207, C19H19N, MW 261.36 and 2-methyl-4-phenyl-3-
propyl-quinoline, 208, C19H19N, MW 261.36,  
N N
207 208
 
Following the general procedure for the Friedländer Cyclisation the desired products 
were synthesised and isolated.  Overall yield 171 mg, 66 %, selectivity 1:1.9 (A:B). 
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207: 2-Butyl-4-phenyl-quinoline was isolated as an off-white oil, 59 mg, 23 % yield.  
R.f. 0.38 (DCM), LCMS: tr = 1.54 min (95 % MeOH in water), m/z M+H 261.96, 
HPLC: tr = 4.75 min (90 % acetonitrile in water), 93 %, 
1H NMR (CDCl3, 270 MHz,): 
0.96 (3H, t, J = 7.2 Hz, CH3), 1.39-1.52 (2H, m, CH2), 1.79-1.86 (2H, m, CH2), 2.99 
(2H, t, J = 7.9 Hz, CH2), 7.39-7.59 (7H, m, ArH), 7.62-7.71 (1H, m, ArH), 8.08-8.11 
(1H, m, ArH).  13C NMR (CDCl3, 68 MHz): 15.0 (CH3), 22.9, 32.4, 39.3 (CH2), 121.7 
(ArCH), 125.3 (ArC), 125.7, 125.8, 128.4, 128.6, 129.3, 129.3, 129.6 (ArCH), 138.4, 
148.5, 148.6, 148.6, 167.8 (ArC).  HRMS: Calcd for C19H19N (M+H)
+ 262.1590, found 
(M+H)+ 262.1598.  This compound has been previously synthesised via a different route 
by Kobayashi et al.156 
 
208: 2-Methyl-4-phenyl-3-propyl-quinoline was isolated as a white solid, 112 mg, 43 
% yield.  R.f. 0.24 (DCM), m.p.= 114-116 °C, LCMS: tr = 1.41 min (95 % MeOH in 
water), m/z M+H 261.96, HPLC: tr = 3.87 min (90 % acetonitrile in water), >99 %, 
1H 
NMR (CDCl3, 270 MHz,): δ 0.81 (3H, t, J = 7.4 Hz, CH3CH2), 1.40-1.49 (2H, m, CH2), 
2.48-2.54 (2H, m, CH2), 2.80 (3H, s, CH3Ar), 7.20-7.32 (3H, m, ArH), 7.44-7.51 (4H, 
m, ArH), 7.54-7.61 (1H, m, ArH), 8.03 (1H, dd, J = 0.5, 8.4 Hz, ArH).  13C NMR 
(CDCl3, 68 MHz): 14.5 (CH3), 23.6 (CH2), 23.9 (CH3), 32.5 (CH3), 125.4, 126.2 
(ArCH), 127.1 (ArC), 127.6, 128.2, 128.3, 128.4, 129.3 (ArCH), 132.1, 137.4, 145.9, 
146.5, 158.6 (ArC).  Anal. Calcd for C19H19N: C 87.31, H 7.33, N 5.36 %. Found: C 
86.9, H 7.48, N 5.26 %.  HRMS: Calcd for C19H19N (M+H)
+ 262.1590, found (M+H)+ 
262.1591. 
 
10-Phenyl-3,4-dihydro-1H-pyrano[4,3-b]quinoline, 209, C18H15NO, MW 261.32, 
N
O
 
Following the general procedure for the Friedländer Cyclisation the desired product was 
isolated as a yellow solid, 260 mg, 99 % yield.  R.f. 0.65 (10 % MeOH in DCM), m.p.= 
146-148 °C, (lit. 130°C157), LCMS: tr = 1.35 min (95 % MeOH in water), m/z M-H 
262.09, HPLC: tr = 2.41 min (90 % acetonitrile in water), >99 %, 
1H NMR (CDCl3, 270 
MHz,): δ 1.93 (2H, s, CH2), 2.24 (2H, s, CH2), 4.80 (2H, s, CH2), 7.02-7.12 (2H, m, 
ArH), 7.21-7.30 (4H, m, ArH), 8.20 (1H, dd, J = 7.7 Hz, ArH)., 9.89 (1H, s, NHCO).  
13C NMR (CDCl3, 68 MHz): 22.1, 24.6 (CH2), 49.8 (CH2), 118.1, 120.7, 122.1, 123.0, 
124.0 (ArCH), 125.0 (ArC), 129.2 (ArCH), 129.8 (ArC), 130.1, 130.2, 131.5 (ArCH), 
137.7, 153.2, 153.8 (ArC), 169.5, 172.7 (CO).  HRMS: Calcd for C18H15NO 3 (M+H)
+ 
262.1226, found (M+H)+ 262.1223.  Anal. Calcd for C18H15NO, C 82.73, H 5.79, N 
 312 
5.36 %. Found: C 82.30, H 5.74, N 5.38 %.  This compound was previously 
synthesised, using a different route, by Kempter et al.157 
 
9-Methyl-acridine, 210, C14H11N, MW 193.24, 
N
 
Following the general procedure for the Friedländer Cyclisation the desired product was 
isolated as a yellow oil, 180 mg, 91 % yield.  R.f. 0.14 (DCM), LCMS: tr = 1.32 min (95 
% MeOH in water), m/z M+H 197.71, HPLC: tr = 4.8 min (90 % acetonitrile in water), 
>99 %, 1H NMR (CDCl3, 270 MHz,): δ 1.88-1.92 (4H, m, 2CH2), 2.52 (3H, s, CH3), 
2.86 (2H, br.s, CH2), 3.10-3.12 (2H, m, CH2), 7.41-7.47 (1H, m, ArH), 7.59 (1H, td, J = 
1.4, 6.9 Hz, ArH), 7.93 (1H, dd, J = 0.81, 8.5 Hz, ArH), 8.00 (1H, d, J = 8.5 Hz, ArH).  
13C NMR (CDCl3, 68 MHz): 13.8 (CH3), 22.7, 23.2, 27.2, 33.9 (CH2), 123.4, 125.5 
(ArCH), 126.9 (ArC), 128.3, 128.5 (ArCH), 128.6, 128.9, 142.1, 145.3, 158.5, 171.0 
(ArC).  HRMS: Calcd for C14H11N (M+H)
+ 198.1277, found (M+H)+ 198.1271.  This 
compound was previously synthesised, using a different route, by Wang et al.158 
 
1-[8-Chloro-10-(2-fluoro-phenyl)-3,4-dihydro-1H-benzo[b][1,6] naphthyridin-2-yl]-
ethanone, 211, C20H16ClFN2O, MW 354.81, 
N
N
O
F
Cl
 
Following the general procedure for the Friedländer Cyclisation and flash 
chromatography it was found that the product was still contaminated with 1-acetyl-4-
piperidone.  This was removed by use of PS-TsNHNH2, the crude material was 
dissolved in DCM (~10mL/g) and the resin was added (3eq, 2.8mmol/g), this was 
stirred at r.t. for 1h.  The resin was removed by filtration and flash chromatography 
isolated the desired product as a white solid, 248 mg, 70 % yield.  R.f. 0.30 (EtOAc), 
m.p. 196-199 °C, LCMS: tr = 1.03 min (95 % MeOH in water), m/z M+H 355.19, 
HPLC: tr = 2.07 min (90 % acetonitrile in water), 98 %, 
1H NMR (CDCl3, 270 MHz,): δ 
2.18 (3H, s, CH3), 3.27-3.33 (2H, m, CH2), 3.81-4.00 (2H, m, CH2), 4.37-4.45 (1H, m, 
½CH2), 4.75, 4.82 (1H, ½CH2), 7.19-7.39 (4H, m, ArH), 7.50-7.64 (2H, m, ArH), 7.96-
8.02 (1H, m, ArH).  13C NMR (CDCl3, 101 MHz): 21.7, 21.8 (CH3), 32.9, 34.0, 39.7, 
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42.4, 43.7, 46.4 (CH2), 116.7 (d, J=21.8Hz, ArCH), 122.0 (ArC), 124.3 (ArCH), 125.1 
(d, J=3.7Hz, ArCH), 126.8 (ArC), 130.5, 130.6, 131.0, 131.5 (ArCH), 132.5, 139.0, 
155.7, 157.6, 161.3 (ArC), 169.2, 169.4 (CO).  Anal. Calcd for C20H16ClFN2O: C 67.70, 
H 4.55, N 7.90%. Found: C 67.8, H 4.57, N 7.84%.  HRMS: Calcd for C20H16ClFN2O 
(M+Na)+ 377.0817, found (M+Na)+ 377.0827. 
 
10-Phenyl-1,2,3,4-tetrahydro-benzo[b][1,6]naphthyridine, 212, C18H16N2, MW 
260.33, 
N
HN
 
Following the general procedure for the Friedländer Cyclisation using 2-
aminobenzophenone (197 mg) and 1-Boc-4-piperidone (300 mg) and subsequent 
purification (0-10 % MeOH in EtOAc, with 5 % TEA) the desired product was isolated 
as a yellow oil, 170 mg, 65 % yield.  R.f. 0.12 (10 % MeOH in EtOAc), LCMS: tr = 
1.70 min (95 % MeOH in water), m/z M+H 261.08, HPLC: tr = 3.20 min (90 % 
acetonitrile in water), 96 %, 1H NMR (CDCl3, 270 MHz,): δ 2.05 (1H, br.s, NH), 3.21-
3.30 (4H, m, 2CH2), 3.84 (2H, s, CH2), 7.20-7.25 (3H, m, ArH), 7.31-7.33 (2H, m, 
ArH), 7.45-7.53 (2H, m, ArH), 7.57-7.63 (1H, m, ArH), 8.01 (1H, dd, J = 0.8, 9.1 Hz, 
ArH).  13C NMR (CDCl3, 68 MHz): 34.3, 44.1, 47.5 (CH2), 125.8, 125.9 (ArCH), 126.6, 
127.0 (ArC), 128.2, 128.5, 128.8, 129.0 (ArCH), 136.0, 144.9, 146.8, 156.6 (ArC). 
 
1-[4-(10-Phenyl-3,4-dihydro-1H-benzo[b][1,6]naphthyridine-2-carbonyl) -
cyclohexyl]-ethanone, 213, C27H28N2O2, MW 413.41, 
N
N
O
N
O
 
A solution of 10-phenyl-1,2,3,4-tetrahydro-benzo[b][1,6]naphthyridine (195 mg, 0.38 
mmol) in DCM (10 mL) was cooled in an ice bath and to this was added 1-acetyl-
piperidine-4-carbonyl chloride (282 mg, 0.76 mmol) and TEA (0.46 mL).  The resulting 
solution was stirred at r.t. for 2 days.  NaHCO3 was added and the mixture was 
extracted with DCM.  The organic portions were washed with 1M HCl, dried (MgSO4) 
and purified using flash chromatography (0-10 % MeOH in EtOAc) to afford the title 
compound as a cream oil, 66 mg, 21 % yield.  R.f. 0.65 (EtOAc), LCMS: tr = 0.93 min 
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(95 % MeOH in water), m/z M+H 414.20, HPLC: tr = 1.65 min (90 % acetonitrile in 
water), 99 %, 1H NMR (CDCl3, 400 MHz,): δ (Multiple signals observed due to 
restricted rotation and therefore the presence of rotamers) 1.62-1.79 (3H, m, CH2 and 
½CH2), 1.98 (1.3H, s, CH3), 2.02 (1.7H, s, CH3), 2.25-2.32 (1H, m, ½CH2), 2.66 (1H, t, 
J=12.0Hz, ½CH2), 2.75-2.84 (1H, m, ½CH2), 3.04-3.11 (1H, m, ½CH2), 3.23-3.31 (2H, 
m, CH2), 3.67-3.93 (3H, m, CH2 and CH), 4.38-4.63 (3H, m, CH2 and ½CH2), 7.20 (2H, 
t, J = 9.6 Hz, ArH), 7.30-7.40 (2H, m, ArH), 7.42-7.51 (3H, m, ArH), 7.60-7.65 (1H, m, 
ArH), 7.99 (1H, t, J = 11.2 Hz, ArH).  13C NMR (CDCl3, 101 MHz): 21.4 (CH3), 28.1, 
28.3, 28.4, 28.7, 32.5, 34.2 (CH2), 38.4, 39.0 (CH), 40.5, 40.8, 42.9, 43.1, 45.4, 45.5, 
45.7, 45.8 (CH2), 124.2, 124.4 (ArC), 126.0, 126.3, 126.4, 126.7, 128.3, 128.5, 128.7, 
128.8, 128.9, 129.0, 129.1, 129.4, 129.6 (ArCH), 135.0, 135.2, 144.7, 146.2, 147.1, 
154.8, 156.3, 168.9 (ArC), 172.5, 173.0 (CO).  HRMS: Calcd for C27H28N2O2 (M+H)
+ 
414.2176, found (M+H)+ 414.2192. 
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Appendix I: X-ray Crystallography Data 
 
X-ray crystallography data for 184 
 
 
Cl
O
HN
H
N
O
 
 
Identification Code k07farm3  
Empirical Formula C24 H23 Cl N2 O2  
Formula Weight 406.89  
Temperature 150(2) K  
Wavelength 0.71073 Å  
Crystal System Orthorhombic  
Space Group P212121  
Unit cell dimensions a = 8.9500(0)Å α = 90o  
 b = 10.4450(0)Å β = 90o  
 c = 22.6800(2)Å γ = 90o  
Crystal Size 0.35 x 0.25 x 0.25 mm 
 
Notes: 
 
H1A and H2 (attached to N1 and N2, respectively) were located and refined at a 
distance of 0.9Å from the parent nitrogen atoms.  Hydrogen bonded polymers in the 
gross structure: 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
N1-H1A 0.906     
N2-H2 0.898 1.921 177.51 2.818 
O2  
[ x+1/2, -y+3/2, -z+2 ] 
 
For supplementary data, cf. enclosed CD (file name ‘suppl. 184). 
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X-ray crystallography data for 184 
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X-ray crystallography data for 196 
 
 
N
N
N
O
 
 
Identification Code k05bp1 
Empirical Formula C20 H21 N3 O1 
Formula Weight 321.65 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal System Monoclinic 
Space Group P21/n 
Unit cell dimensions a = 13.5250(10Å α = 90o 
 b = 16.4220(2)Å β = 104.561(1)o 
 c = 15.6910(2)Å γ = 90o 
Crystal Size 0.40 x 0.30 x 0.07 mm 
 
Notes: 
 
Asymmetric unit consists of 2 molecules, which differ in the relative torsions of the 
phenyl substituents, and a partial water molecule (O(3)) at 0.25 occupancy. The 
hydrogen atoms on this water fragment could not be reliably located and hence were 
omitted from the refinement. Based on N…O and O…O distances, it is highly likely 
that there is H-bonding associated with this solvent moiety. 
 
For supplementary data, cf. enclosed CD (file name ‘suppl. 196). 
 333 
X-ray crystallography data for 196 
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X-ray crystallography data for 203 
 
 
N
N
O  
 
Identification Code h06farm3 
Empirical Formula C20 H20 N2 O2 
Formula Weight 320.38 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal System Orthorhombic 
Space Group Pbca 
Unit cell dimensions a = 13.3600(2)Å α = 90o 
 b = 15.2190(3)Å β = 90o 
 c = 15.6200(3)Å γ = 90o 
Crystal Size 0.60 x 0.50 x 0.35 mm 
 
Notes: 
 
Water hydrogens located and refined at a distance of 0.89 Å from O2. Both of these 
hydrogen atoms are implicated in hydrogen-bonding. 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Å and  <DHA > 110 deg. 
 
D-H d(D-H) d(H..A) <DHA d(D..A) A 
O2-H19 0.890 2.073 172.34 2.958 
N2 
[ -x+2, y+1/2, -z+1/2 ] 
O2-H20 0.890 1.958 174.03 2.845 O1 
 
For supplementary data, cf. enclosed CD (file name ‘suppl. 203). 
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X-ray crystallography data for 203 
 
 
 
 
Appendix III: Compound 184 
 
Table 1.  Crystal data and structure refinement for 184.  
   
 Identification code c:\x-ray\kappa\k07farm3\maxus\k07farm3  
 Empirical formula C24 H23 Cl N2 O2  
 Formula weight 406.89  
 Temperature 150(2) K  
 Wavelength 0.71073 Å  
 Crystal system Orthorhombic  
 Space group P212121  
 Unit cell dimensions a = 8.9500(0)Å  = 90o  
       b = 10.4450(0)Å  = 90o  
       c = 22.6800(2)Å  = 90o  
 Volume 2120.19(4) Å3  
 Z 4  
 Density (calculated) 1.275 Mg/m3  
 Absorption coefficient 0.202 mm-1  
 F(000) 856  
 Crystal size 0.35 x 0.25 x 0.25 mm  
 Theta range for data collection 3.53 to 30.04o  
 Index ranges -12<=h<=12; -14<=k<=14; -31<=l<=30  
 Reflections collected 42345  
 Independent reflections 6200 [R(int) = 0.0403]  
 Reflections observed (>2 ) 5626  
 Data Completeness 0.996  
 Absorption correction None  
 Refinement method Full-matrix least-squares on F2  
 Data / restraints / parameters 6200 / 2 / 269  
 Goodness-of-fit on F2 1.038  
 Final R indices [I>2 (I)] R1 = 0.0330   wR2 = 0.0767  
 R indices (all data) R1 = 0.0388  wR2 = 0.0799  
 Absolute structure parameter -0.01(4)  
 Largest diff. peak and hole 0.196 and -0.212 eÅ-3  
  
 
Notes: H1A and H2 (attached to N1 and N2, respectively) were located and refined at a 
distance of 0.9Å from the parent nitrogen atoms. 
 
 Hydrogen bonded polymers in the gross structure: 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1A         0.906 
 N2-H2          0.898    1.921   177.51    2.818    O2 [ x+1/2, -y+3/2, -z+2 ] 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) 
for 184.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
   
   
  Atom   x   y   z  U(eq)  
       
Cl(1) 13383(1) 5597(1) 6077(1) 41(1)  
O(1) 7750(1) 4512(1) 7316(1) 31(1)  
O(2) 7183(1) 7843(1) 10380(1) 34(1)  
N(1) 8652(1) 4860(1) 8465(1) 26(1)  
N(2) 9269(1) 6827(1) 10066(1) 25(1)  
C(1) 9448(1) 5227(1) 9001(1) 24(1)  
C(2) 10980(1) 4564(1) 8993(1) 28(1)  
C(3) 11963(1) 4983(1) 8495(1) 32(1)  
C(4) 12551(2) 4214(2) 8099(1) 46(1)  
C(5) 8615(1) 4829(1) 9556(1) 26(1)  
C(6) 7902(2) 3645(1) 9574(1) 38(1)  
C(7) 7205(2) 3208(1) 10081(1) 44(1)  
C(8) 7246(2) 3947(1) 10589(1) 38(1)  
C(9) 7942(1) 5124(1) 10583(1) 30(1)  
C(10) 8615(1) 5580(1) 10067(1) 25(1)  
C(11) 8502(1) 7886(1) 10220(1) 25(1)  
C(12) 9338(1) 9136(1) 10187(1) 29(1)  
C(13) 7475(1) 5594(1) 8248(1) 25(1)  
C(14) 6683(2) 6478(1) 8588(1) 29(1)  
C(15) 5513(2) 7186(1) 8344(1) 35(1)  
C(16) 5100(2) 7018(1) 7760(1) 40(1)  
C(17) 5869(2) 6132(1) 7417(1) 36(1)  
C(18) 7029(1) 5444(1) 7660(1) 27(1)  
C(19) 9075(1) 4849(1) 7042(1) 26(1)  
C(20) 9785(2) 6019(1) 7115(1) 28(1)  
C(21) 11124(2) 6256(1) 6818(1) 30(1)  
C(22) 11713(2) 5321(1) 6456(1) 31(1)  
C(23) 11008(2) 4154(1) 6383(1) 34(1)  
C(24) 9683(2) 3914(1) 6680(1) 33(1)  
  
 
Table 3. Bond lengths [Å] and angles [o] for 184.  
   
Cl(1)-C(22) 1.7476(13)  
O(1)-C(19) 1.3848(15)  
O(1)-C(18) 1.4035(15)  
O(2)-C(11) 1.2362(15)  
N(1)-C(13) 1.3922(15)  
N(1)-C(1) 1.4616(15)  
N(2)-C(11) 1.3475(15)  
N(2)-C(10) 1.4285(15)  
C(1)-C(5) 1.5195(16)  
C(1)-C(2) 1.5361(17)  
C(2)-C(3) 1.4980(18)  
C(3)-C(4) 1.315(2)  
C(5)-C(6) 1.3922(18)  
C(5)-C(10) 1.4007(16)  
C(6)-C(7) 1.3853(19)  
C(7)-C(8) 1.389(2)  
C(8)-C(9) 1.3781(19)  
C(9)-C(10) 1.3989(16)  
C(11)-C(12) 1.5058(17)  
C(13)-C(14) 1.3963(17)  
C(13)-C(18) 1.4016(16)  
C(14)-C(15) 1.3953(19)  
C(15)-C(16) 1.387(2)  
C(16)-C(17) 1.391(2)  
C(17)-C(18) 1.3767(18)  
C(19)-C(24) 1.3866(17)  
C(19)-C(20) 1.3880(17)  
C(20)-C(21) 1.3969(18)  
C(21)-C(22) 1.3803(18)  
C(22)-C(23) 1.3828(19)  
C(23)-C(24) 1.387(2)  
    
C(19)-O(1)-C(18) 117.88(9)  
C(13)-N(1)-C(1) 121.22(10)  
C(11)-N(2)-C(10) 122.65(10)  
N(1)-C(1)-C(5) 112.21(10)  
N(1)-C(1)-C(2) 107.89(9)  
C(5)-C(1)-C(2) 108.93(10)  
C(3)-C(2)-C(1) 113.68(10)  
C(4)-C(3)-C(2) 124.94(13)  
C(6)-C(5)-C(10) 118.22(11)  
C(6)-C(5)-C(1) 119.48(11)  
C(10)-C(5)-C(1) 122.18(10)  
C(7)-C(6)-C(5) 121.54(12)  
C(6)-C(7)-C(8) 119.67(13)  
C(9)-C(8)-C(7) 119.91(13)  
C(8)-C(9)-C(10) 120.45(12)  
C(9)-C(10)-C(5) 120.16(11)  
C(9)-C(10)-N(2) 119.26(10)  
C(5)-C(10)-N(2) 120.56(10)  
O(2)-C(11)-N(2) 122.19(11)  
O(2)-C(11)-C(12) 121.33(11)  
N(2)-C(11)-C(12) 116.48(10)  
N(1)-C(13)-C(14) 123.63(11)  
N(1)-C(13)-C(18) 119.35(11)  
C(14)-C(13)-C(18) 117.02(11)  
C(15)-C(14)-C(13) 120.89(12)  
C(16)-C(15)-C(14) 120.71(13)  
C(15)-C(16)-C(17) 119.10(13)  
C(18)-C(17)-C(16) 119.82(13)  
C(17)-C(18)-C(13) 122.45(12)  
C(17)-C(18)-O(1) 119.16(11)  
C(13)-C(18)-O(1) 118.32(11)  
O(1)-C(19)-C(24) 115.05(11)  
O(1)-C(19)-C(20) 124.18(11)  
C(24)-C(19)-C(20) 120.76(12)  
C(19)-C(20)-C(21) 119.42(12)  
C(22)-C(21)-C(20) 119.27(12)  
C(21)-C(22)-C(23) 121.39(13)  
C(21)-C(22)-Cl(1) 120.13(11)  
C(23)-C(22)-Cl(1) 118.48(10)  
C(22)-C(23)-C(24) 119.44(12)  
C(19)-C(24)-C(23) 119.71(12)  
   
Symmetry transformations used to generate equivalent atoms:  
             
  
Table 4. Anisotropic displacement parameters (Å2 x 103) for 184. The anisotropic displacement 
factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U  
   
  Atom  U11  U22  U33  U23  U13  U12  
         
Cl(1) 33(1) 52(1) 38(1) 7(1) 5(1) 8(1)  
O(1) 37(1) 30(1) 27(1) -4(1) 2(1) -8(1)  
O(2) 21(1) 35(1) 48(1) -7(1) 1(1) 1(1)  
N(1) 29(1) 26(1) 22(1) -2(1) 1(1) 2(1)  
N(2) 21(1) 28(1) 26(1) -4(1) 1(1) 0(1)  
C(1) 31(1) 22(1) 20(1) 0(1) 1(1) -2(1)  
C(2) 31(1) 25(1) 27(1) 2(1) -2(1) 1(1)  
C(3) 29(1) 30(1) 36(1) 2(1) 2(1) 0(1)  
C(4) 46(1) 45(1) 48(1) -4(1) 16(1) 0(1)  
C(5) 33(1) 24(1) 22(1) 1(1) 2(1) -1(1)  
C(6) 60(1) 27(1) 27(1) -2(1) 9(1) -9(1)  
C(7) 69(1) 31(1) 33(1) 1(1) 14(1) -14(1)  
C(8) 53(1) 36(1) 26(1) 5(1) 10(1) -4(1)  
C(9) 33(1) 34(1) 23(1) -1(1) 1(1) 2(1)  
C(10) 24(1) 26(1) 24(1) 0(1) -1(1) 1(1)  
C(11) 23(1) 29(1) 24(1) -3(1) -4(1) 2(1)  
C(12) 27(1) 28(1) 32(1) -3(1) -1(1) 0(1)  
C(13) 25(1) 24(1) 26(1) 3(1) 2(1) -4(1)  
C(14) 29(1) 29(1) 30(1) 0(1) 6(1) -3(1)  
C(15) 29(1) 31(1) 46(1) 3(1) 8(1) 2(1)  
C(16) 27(1) 41(1) 53(1) 11(1) -3(1) 2(1)  
C(17) 33(1) 42(1) 35(1) 6(1) -7(1) -6(1)  
C(18) 28(1) 27(1) 27(1) 1(1) 1(1) -5(1)  
C(19) 31(1) 29(1) 19(1) 1(1) -3(1) 0(1)  
C(20) 34(1) 27(1) 24(1) -2(1) 0(1) 0(1)  
C(21) 34(1) 29(1) 28(1) 1(1) -1(1) -1(1)  
C(22) 29(1) 38(1) 26(1) 6(1) 0(1) 7(1)  
C(23) 41(1) 31(1) 30(1) -3(1) -1(1) 9(1)  
C(24) 42(1) 27(1) 29(1) -2(1) -4(1) 1(1)  
  
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 184.  
   
  Atom   x   y   z  U(eq)  
       
H(1) 9594 6176 9004 29  
H(2A) 11497 4742 9370 33  
H(2B) 10827 3628 8966 33  
H(3) 12178 5871 8462 38  
H(4A) 12361 3320 8116 55  
H(4B) 13165 4553 7795 55  
H(6) 7893 3125 9230 46  
H(7) 6703 2407 10080 53  
H(8) 6793 3642 10941 46  
H(9) 7966 5628 10931 36  
H(12A) 8788 9735 9935 43  
H(12B) 10333 8987 10020 43  
H(12C) 9435 9497 10584 43  
H(14) 6943 6600 8990 35  
H(15) 4993 7789 8582 43  
H(16) 4303 7501 7596 48  
H(17) 5595 6001 7017 44  
H(20) 9364 6654 7364 34  
H(21) 11625 7051 6865 36  
H(23) 11427 3521 6131 41  
H(24) 9194 3112 6636 39  
H(1A) 9244 4501 8186 38(4)  
H(2) 10206(8) 6913(15) 9931(7) 38(4)  
  
Appendix III: Compound 196 
 
Table 1.  Crystal data and structure refinement for 196. 
                                                        
 Identification code k05bp1 
 Empirical formula C20 H21.25 N3 O1.13 
 Formula weight 321.65 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 13.5250(10Å  = 90o 
       b = 16.4220(2)Å  = 104.561(1)o 
       c = 15.6910(2)Å  = 90o 
 Volume 3373.15(6) Å3 
 Z 8 
 Density (calculated) 1.267 Mg/m3 
 Absorption coefficient 0.080 mm-1 
 F(000) 1370 
 Crystal size 0.40 x 0.30 x 0.07 mm 
 Theta range for data collection 3.64 to 27.52o 
 Index ranges -17<=h<=17; -21<=k<=18; -20<=l<=20 
 Reflections collected 57457 
 Independent reflections 7735 [R(int) = 0.0571] 
 Reflections observed (>2 ) 6290 
 Data Completeness 0.995 
 Absorption correction none 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 7735 / 0 / 445 
 Goodness-of-fit on F2 1.079 
 Final R indices [I>2 (I)] R1 = 0.0504   wR2 = 0.0951 
 R indices (all data) R1 = 0.0678  wR2 = 0.1014 
 Largest diff. peak and hole 0.227 and -0.238 eÅ-3 
  
 
Notes: Asymmetric unit consists of 2 molecules, which differ in the relative torsions of the 
phenyl substituents, and a partial water molecule (O(3)) at 0.25 occupancy. The 
hydrogen atoms on this water fragment could not be reliably located and hence were 
omitted from the refinement. Based on N…O and O…O distances, it is highly likely 
that there is h-bonding associated with this solvent moiety. 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) 
for 196.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 
  Atom   x   y   z  U(eq) 
                                  
O(1) 8270(1) 2583(1) 614(1) 46(1) 
O(2) 5844(1) 3934(1) -1422(1) 45(1) 
N(1) 4032(1) 3656(1) 963(1) 27(1) 
N(2) 2387(1) 3816(1) 1006(1) 37(1) 
N(3) 7190(1) 3447(1) 1050(1) 30(1) 
N(4) 4032(1) -756(1) -1179(1) 26(1) 
N(5) 4575(1) 455(1) -1565(1) 22(1) 
N(6) 5822(1) 2707(1) -2075(1) 27(1) 
C(1) 3345(1) 3763(1) 1471(1) 30(1) 
C(2) 2438(1) 3732(1) 139(1) 35(1) 
C(3) 1644(1) 3728(1) -633(1) 44(1) 
C(4) 1893(1) 3634(1) -1427(1) 46(1) 
C(5) 2910(1) 3546(1) -1463(1) 40(1) 
C(6) 3709(1) 3537(1) -713(1) 33(1) 
C(7) 3454(1) 3632(1) 93(1) 30(1) 
C(8) 3626(1) 3799(1) 2442(1) 31(1) 
C(9) 3196(1) 4410(1) 2849(1) 38(1) 
C(10) 3382(1) 4444(1) 3756(1) 45(1) 
C(11) 3992(1) 3861(1) 4268(1) 44(1) 
C(12) 4421(1) 3249(1) 3875(1) 39(1) 
C(13) 4245(1) 3218(1) 2965(1) 34(1) 
C(14) 5156(1) 3639(1) 1276(1) 25(1) 
C(15) 5657(1) 4308(1) 855(1) 27(1) 
C(16) 6815(1) 4262(1) 1186(1) 30(1) 
C(17) 6742(1) 2795(1) 1464(1) 31(1) 
C(18) 5583(1) 2803(1) 1140(1) 28(1) 
C(19) 7917(1) 3276(1) 622(1) 36(1) 
C(20) 8270(1) 3956(1) 125(1) 49(1) 
C(21) 4757(1) -367(1) -1436(1) 23(1) 
C(22) 3316(1) -161(1) -1141(1) 24(1) 
C(23) 2382(1) -241(1) -924(1) 31(1) 
C(24) 1790(1) 449(1) -952(1) 33(1) 
C(25) 2120(1) 1206(1) -1182(1) 31(1) 
C(26) 3046(1) 1301(1) -1393(1) 28(1) 
C(27) 3638(1) 601(1) -1378(1) 23(1) 
C(28) 5659(1) -781(1) -1602(1) 24(1) 
C(29) 5871(1) -757(1) -2426(1) 32(1) 
C(30) 6679(1) -1204(1) -2575(1) 41(1) 
C(31) 7276(1) -1671(1) -1910(1) 42(1) 
C(32) 7078(1) -1691(1) -1091(1) 38(1) 
C(33) 6269(1) -1250(1) -937(1) 29(1) 
C(34) 5284(1) 1065(1) -1762(1) 23(1) 
C(35) 4815(1) 1492(1) -2632(1) 27(1) 
C(36) 5535(1) 2143(1) -2820(1) 29(1) 
C(37) 6334(1) 2307(1) -1248(1) 30(1) 
C(38) 5632(1) 1670(1) -1008(1) 27(1) 
C(39) 5589(1) 3508(1) -2088(1) 31(1) 
C(40) 5012(1) 3873(1) -2952(1) 44(1) 
O(3) 541(4) 4642(4) 842(3) 58(1) 
                                 
 Table 3.   Bond lengths [Å] and angles [o] for 196. 
  
O(1)-C(19) 1.2344(18) O(2)-C(39) 1.2324(18) 
N(1)-C(1) 1.3779(18) N(1)-C(7) 1.3928(17) 
N(1)-C(14) 1.4757(17) N(2)-C(1) 1.3206(18) 
N(2)-C(2) 1.386(2) N(3)-C(19) 1.3528(19) 
N(3)-C(17) 1.4613(18) N(3)-C(16) 1.4652(17) 
N(4)-C(21) 1.3165(16) N(4)-C(22) 1.3882(17) 
N(5)-C(21) 1.3778(16) N(5)-C(27) 1.3913(16) 
N(5)-C(34) 1.4719(16) N(6)-C(39) 1.3517(18) 
N(6)-C(37) 1.4632(17) N(6)-C(36) 1.4651(17) 
C(1)-C(8) 1.476(2) C(2)-C(3) 1.402(2) 
C(2)-C(7) 1.403(2) C(3)-C(4) 1.379(3) 
C(4)-C(5) 1.398(2) C(5)-C(6) 1.383(2) 
C(6)-C(7) 1.401(2) C(8)-C(9) 1.392(2) 
C(8)-C(13) 1.393(2) C(9)-C(10) 1.383(2) 
C(10)-C(11) 1.383(2) C(11)-C(12) 1.381(2) 
C(12)-C(13) 1.388(2) C(14)-C(15) 1.5260(18) 
C(14)-C(18) 1.5262(17) C(15)-C(16) 1.5235(19) 
C(17)-C(18) 1.5217(19) C(19)-C(20) 1.508(2) 
C(21)-C(28) 1.4763(18) C(22)-C(23) 1.3950(18) 
C(22)-C(27) 1.4043(18) C(23)-C(24) 1.382(2) 
C(24)-C(25) 1.399(2) C(25)-C(26) 1.384(2) 
C(26)-C(27) 1.3979(18) C(28)-C(33) 1.3886(19) 
C(28)-C(29) 1.3929(19) C(29)-C(30) 1.385(2) 
C(30)-C(31) 1.380(2) C(31)-C(32) 1.378(2) 
C(32)-C(33) 1.383(2) C(34)-C(35) 1.5247(18) 
C(34)-C(38) 1.5267(18) C(35)-C(36) 1.5228(18) 
C(37)-C(38) 1.5227(18) C(39)-C(40) 1.508(2) 
                                             
C(1)-N(1)-C(7) 106.04(11) C(1)-N(1)-C(14) 126.70(11) 
C(7)-N(1)-C(14) 127.07(11) C(1)-N(2)-C(2) 104.59(12) 
C(19)-N(3)-C(17) 120.18(12) C(19)-N(3)-C(16) 125.73(13) 
C(17)-N(3)-C(16) 114.01(11) C(21)-N(4)-C(22) 104.62(11) 
C(21)-N(5)-C(27) 106.03(10) C(21)-N(5)-C(34) 126.48(10) 
C(27)-N(5)-C(34) 127.16(10) C(39)-N(6)-C(37) 120.47(12) 
C(39)-N(6)-C(36) 126.10(12) C(37)-N(6)-C(36) 113.24(11) 
N(2)-C(1)-N(1) 113.52(13) N(2)-C(1)-C(8) 122.03(13) 
N(1)-C(1)-C(8) 124.43(12) N(2)-C(2)-C(3) 129.20(15) 
N(2)-C(2)-C(7) 110.64(12) C(3)-C(2)-C(7) 120.15(15) 
C(4)-C(3)-C(2) 118.23(16) C(3)-C(4)-C(5) 120.94(14) 
C(6)-C(5)-C(4) 122.19(16) C(5)-C(6)-C(7) 116.78(15) 
N(1)-C(7)-C(6) 133.10(13) N(1)-C(7)-C(2) 105.20(13) 
C(6)-C(7)-C(2) 121.70(13) C(9)-C(8)-C(13) 118.83(14) 
C(9)-C(8)-C(1) 118.22(13) C(13)-C(8)-C(1) 122.80(13) 
C(10)-C(9)-C(8) 120.77(15) C(11)-C(10)-C(9) 119.88(15) 
C(12)-C(11)-C(10) 120.08(15) C(11)-C(12)-C(13) 120.22(15) 
C(12)-C(13)-C(8) 120.23(14) N(1)-C(14)-C(15) 112.06(10) 
N(1)-C(14)-C(18) 111.39(10) C(15)-C(14)-C(18) 111.21(11) 
C(16)-C(15)-C(14) 110.31(11) N(3)-C(16)-C(15) 111.02(11) 
N(3)-C(17)-C(18) 110.63(11) C(17)-C(18)-C(14) 110.80(11) 
O(1)-C(19)-N(3) 121.84(15) O(1)-C(19)-C(20) 120.34(15) 
N(3)-C(19)-C(20) 117.80(14) N(4)-C(21)-N(5) 113.65(11) 
N(4)-C(21)-C(28) 122.85(11) N(5)-C(21)-C(28) 123.46(11) 
N(4)-C(22)-C(23) 128.94(12) N(4)-C(22)-C(27) 110.46(11) 
C(23)-C(22)-C(27) 120.58(12) C(24)-C(23)-C(22) 117.92(13) 
C(23)-C(24)-C(25) 121.14(13) C(26)-C(25)-C(24) 121.91(13) 
C(25)-C(26)-C(27) 116.90(12) N(5)-C(27)-C(26) 133.25(12) 
N(5)-C(27)-C(22) 105.22(11) C(26)-C(27)-C(22) 121.53(12) 
C(33)-C(28)-C(29) 119.43(13) C(33)-C(28)-C(21) 118.95(12) 
C(29)-C(28)-C(21) 121.48(12) C(30)-C(29)-C(28) 119.79(14) 
C(31)-C(30)-C(29) 120.19(14) C(32)-C(31)-C(30) 120.33(14) 
C(31)-C(32)-C(33) 119.87(15) C(32)-C(33)-C(28) 120.39(14) 
N(5)-C(34)-C(35) 110.83(10) N(5)-C(34)-C(38) 111.70(10) 
C(35)-C(34)-C(38) 111.85(11) C(36)-C(35)-C(34) 110.74(11) 
N(6)-C(36)-C(35) 110.13(11) N(6)-C(37)-C(38) 110.06(11) 
C(37)-C(38)-C(34) 110.22(11) O(2)-C(39)-N(6) 121.63(13) 
O(2)-C(39)-C(40) 120.59(13) N(6)-C(39)-C(40) 117.78(13) 
                                                        
Symmetry transformations used to generate equivalent atoms: 
                                                            
 
Table 4.   Anisotropic displacement parameters (Å2 x 103) for 196. The anisotropic displacement 
factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
O(1) 36(1) 53(1) 44(1) -16(1) 0(1) 14(1) 
O(2) 55(1) 32(1) 45(1) -7(1) 9(1) 2(1) 
N(1) 26(1) 23(1) 28(1) -2(1) 1(1) 3(1) 
N(2) 29(1) 33(1) 45(1) -2(1) 3(1) 6(1) 
N(3) 26(1) 28(1) 34(1) 0(1) 2(1) 4(1) 
N(4) 26(1) 23(1) 31(1) 0(1) 8(1) -2(1) 
N(5) 21(1) 21(1) 24(1) 2(1) 5(1) -1(1) 
N(6) 28(1) 23(1) 26(1) 2(1) 3(1) -5(1) 
C(1) 29(1) 23(1) 37(1) -2(1) 6(1) 4(1) 
C(2) 31(1) 26(1) 44(1) -2(1) -1(1) 4(1) 
C(3) 33(1) 36(1) 53(1) -2(1) -9(1) 5(1) 
C(4) 46(1) 34(1) 42(1) -3(1) -17(1) 2(1) 
C(5) 53(1) 27(1) 32(1) -3(1) -4(1) 0(1) 
C(6) 40(1) 22(1) 32(1) -2(1) 0(1) 2(1) 
C(7) 32(1) 20(1) 31(1) -1(1) -4(1) 2(1) 
C(8) 27(1) 29(1) 36(1) -3(1) 9(1) -4(1) 
C(9) 38(1) 35(1) 45(1) -3(1) 15(1) 3(1) 
C(10) 47(1) 44(1) 49(1) -10(1) 25(1) -4(1) 
C(11) 43(1) 57(1) 35(1) -5(1) 18(1) -11(1) 
C(12) 35(1) 46(1) 38(1) 6(1) 9(1) -4(1) 
C(13) 32(1) 31(1) 39(1) 0(1) 11(1) -1(1) 
C(14) 25(1) 22(1) 24(1) -1(1) 0(1) 3(1) 
C(15) 30(1) 21(1) 28(1) 1(1) 3(1) 4(1) 
C(16) 32(1) 23(1) 33(1) 0(1) 4(1) 1(1) 
C(17) 31(1) 22(1) 35(1) 0(1) 0(1) 5(1) 
C(18) 29(1) 21(1) 30(1) -2(1) 1(1) 2(1) 
C(19) 26(1) 49(1) 26(1) -7(1) -5(1) 4(1) 
C(20) 40(1) 72(1) 34(1) 5(1) 9(1) 7(1) 
C(21) 24(1) 20(1) 22(1) -1(1) 3(1) -1(1) 
C(22) 23(1) 24(1) 24(1) -1(1) 4(1) -1(1) 
C(23) 27(1) 32(1) 34(1) 0(1) 9(1) -4(1) 
C(24) 22(1) 42(1) 35(1) -2(1) 8(1) 1(1) 
C(25) 27(1) 33(1) 31(1) -2(1) 3(1) 8(1) 
C(26) 27(1) 25(1) 27(1) 1(1) 2(1) 3(1) 
C(27) 22(1) 25(1) 21(1) 0(1) 2(1) -1(1) 
C(28) 24(1) 18(1) 30(1) -4(1) 6(1) -3(1) 
C(29) 37(1) 29(1) 31(1) -3(1) 11(1) -6(1) 
C(30) 47(1) 38(1) 46(1) -14(1) 28(1) -11(1) 
C(31) 32(1) 32(1) 67(1) -14(1) 22(1) 0(1) 
C(32) 29(1) 29(1) 53(1) -2(1) 6(1) 4(1) 
C(33) 29(1) 25(1) 33(1) -2(1) 6(1) 0(1) 
C(34) 23(1) 21(1) 24(1) 1(1) 5(1) -3(1) 
C(35) 31(1) 26(1) 22(1) 0(1) 3(1) -5(1) 
C(36) 34(1) 28(1) 25(1) 2(1) 7(1) -4(1) 
C(37) 29(1) 28(1) 27(1) 2(1) -3(1) -6(1) 
C(38) 31(1) 26(1) 22(1) 2(1) -1(1) -3(1) 
C(39) 27(1) 28(1) 37(1) 2(1) 9(1) -1(1) 
C(40) 44(1) 33(1) 49(1) 10(1) 1(1) 4(1) 
O(3) 42(3) 90(4) 44(3) 8(3) 14(2) 11(3) 
  
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 196. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(3) 953 3787 -610 53 
H(4) 1367 3630 -1958 55 
H(5) 3058 3489 -2021 48 
H(6) 4397 3471 -743 39 
H(9) 2769 4808 2499 46 
H(10) 3090 4867 4027 54 
H(11) 4117 3881 4891 52 
H(12) 4838 2847 4229 47 
H(13) 4547 2798 2698 40 
H(14) 5332 3745 1924 30 
H(15A) 5459 4245 206 33 
H(15B) 5416 4847 1000 33 
H(16A) 7132 4668 870 36 
H(16B) 7017 4396 1822 36 
H(17A) 6941 2866 2112 37 
H(17B) 7008 2263 1325 37 
H(18A) 5290 2388 1464 34 
H(18B) 5382 2661 506 34 
H(20A) 8791 3751 -155 73 
H(20B) 8559 4396 534 73 
H(20C) 7688 4165 -328 73 
H(23) 2160 -754 -762 37 
H(24) 1147 408 -812 40 
H(25) 1695 1669 -1193 37 
H(26) 3270 1818 -1542 33 
H(29) 5463 -434 -2884 38 
H(30) 6823 -1190 -3137 49 
H(31) 7826 -1980 -2017 50 
H(32) 7496 -2007 -632 45 
H(33) 6129 -1268 -374 35 
H(34) 5904 767 -1832 28 
H(35A) 4673 1088 -3116 32 
H(35B) 4160 1747 -2607 32 
H(36A) 6155 1882 -2921 35 
H(36B) 5195 2447 -3359 35 
H(37A) 6518 2718 -773 36 
H(37B) 6970 2044 -1312 36 
H(38A) 5029 1940 -883 33 
H(38B) 5999 1377 -470 33 
H(40A) 4819 4434 -2857 66 
H(40B) 4395 3551 -3195 66 
H(40C) 5446 3869 -3367 66 
 
Appendix III: Compound 203 
 
Table 1.  Crystal data and structure refinement for 203. 
 
Identification code h06farm3 
 Empirical formula C20 H20 N2 O2 
 Formula weight 320.38 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Orthorhombic 
 Space group Pbca 
 Unit cell dimensions a = 13.3600(2)Å  = 90o 
       b = 15.2190(3)Å  = 90o 
       c = 15.6200(3)Å  = 90o 
 Volume 3175.95(10) Å3 
 Z 8 
 Density (calculated) 1.340 Mg/m3 
 Absorption coefficient 0.087 mm-1 
 F(000) 1360 
 Crystal size 0.60 x 0.50 x 0.35 mm 
 Theta range for data collection 4.01 to 27.50o 
 Index ranges -17<=h<=17; -19<=k<=19; -20<=l<=20 
 Reflections collected 52442 
 Independent reflections 3638 [R(int) = 0.0784] 
 Reflections observed (>2 ) 2467 
 Data Completeness 0.996 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.97 and 0.92 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3638 / 2 / 227 
 Goodness-of-fit on F2 1.050 
 Final R indices [I>2 (I)] R1 = 0.0430   wR2 = 0.1009 
 R indices (all data) R1 = 0.0783  wR2 = 0.1144 
 Largest diff. peak and hole 0.265 and -0.225 eÅ-3 
  
 
Notes: Water hydrogens located and refined at a distance of 0.89 Å from O2. Both of these 
hydrogen atoms are implicated in hydrogen-bonding. 
 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O2-H19         0.890    2.073   172.34    2.958    N2 [ -x+2, y+1/2, -z+1/2 ] 
 
 O2-H20         0.890    1.958   174.03    2.845    O1  
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) 
for 203.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
O(1) 12094(1) 3224(1) 1942(1) 36(1) 
O(2) 10227(1) 4114(1) 1812(1) 53(1) 
N(1) 12254(1) 1786(1) 1611(1) 26(1) 
N(2) 9867(1) 123(1) 1572(1) 23(1) 
C(1) 12504(1) 871(1) 1799(1) 27(1) 
C(2) 11563(1) 362(1) 2020(1) 26(1) 
C(3) 10681(1) 598(1) 1458(1) 22(1) 
C(4) 10736(1) 1310(1) 868(1) 22(1) 
C(5) 11672(1) 1872(1) 825(1) 27(1) 
C(6) 9920(1) 1481(1) 353(1) 21(1) 
C(7) 9048(1) 953(1) 434(1) 22(1) 
C(8) 9045(1) 291(1) 1072(1) 21(1) 
C(9) 8162(1) -202(1) 1219(1) 26(1) 
C(10) 7323(1) -45(1) 745(1) 28(1) 
C(11) 7329(1) 598(1) 94(1) 29(1) 
C(12) 8167(1) 1083(1) -59(1) 26(1) 
C(13) 9927(1) 2237(1) -259(1) 22(1) 
C(14) 9726(1) 3080(1) 38(1) 27(1) 
C(15) 9720(1) 3782(1) -527(1) 30(1) 
C(16) 9909(1) 3651(1) -1388(1) 31(1) 
C(17) 10111(1) 2818(1) -1686(1) 32(1) 
C(18) 10115(1) 2109(1) -1127(1) 28(1) 
C(19) 12382(1) 2479(1) 2137(1) 28(1) 
C(20) 12890(1) 2326(1) 2987(1) 39(1) 
                                     
 
 Table 3.   Bond lengths [Å] and angles [o] for 203. 
  
O(1)-C(19) 1.2364(18) N(1)-C(19) 1.3473(19) 
N(1)-C(5) 1.4587(18) N(1)-C(1) 1.4618(19) 
N(2)-C(3) 1.3179(18) N(2)-C(8) 1.3713(18) 
C(1)-C(2) 1.517(2) C(2)-C(3) 1.5123(19) 
C(3)-C(4) 1.425(2) C(4)-C(6) 1.379(2) 
C(4)-C(5) 1.517(2) C(6)-C(7) 1.421(2) 
C(6)-C(13) 1.495(2) C(7)-C(8) 1.4175(19) 
C(7)-C(12) 1.419(2) C(8)-C(9) 1.4168(19) 
C(9)-C(10) 1.364(2) C(10)-C(11) 1.410(2) 
C(11)-C(12) 1.362(2) C(13)-C(14) 1.391(2) 
C(13)-C(18) 1.393(2) C(14)-C(15) 1.386(2) 
C(15)-C(16) 1.383(2) C(16)-C(17) 1.377(2) 
C(17)-C(18) 1.388(2) C(19)-C(20) 1.509(2) 
                                            
C(19)-N(1)-C(5) 120.72(12) C(19)-N(1)-C(1) 126.40(12) 
C(5)-N(1)-C(1) 112.11(12) C(3)-N(2)-C(8) 118.83(12) 
N(1)-C(1)-C(2) 110.09(12) C(3)-C(2)-C(1) 113.08(12) 
N(2)-C(3)-C(4) 123.11(12) N(2)-C(3)-C(2) 115.76(12) 
C(4)-C(3)-C(2) 121.10(12) C(6)-C(4)-C(3) 118.73(13) 
C(6)-C(4)-C(5) 121.29(12) C(3)-C(4)-C(5) 119.97(12) 
N(1)-C(5)-C(4) 110.60(11) C(4)-C(6)-C(7) 119.28(13) 
C(4)-C(6)-C(13) 120.89(13) C(7)-C(6)-C(13) 119.76(12) 
C(8)-C(7)-C(12) 118.52(13) C(8)-C(7)-C(6) 117.83(12) 
C(12)-C(7)-C(6) 123.58(13) N(2)-C(8)-C(9) 118.44(12) 
N(2)-C(8)-C(7) 122.05(12) C(9)-C(8)-C(7) 119.50(12) 
C(10)-C(9)-C(8) 120.23(13) C(9)-C(10)-C(11) 120.53(14) 
C(12)-C(11)-C(10) 120.42(13) C(11)-C(12)-C(7) 120.75(14) 
C(14)-C(13)-C(18) 119.24(13) C(14)-C(13)-C(6) 119.72(12) 
C(18)-C(13)-C(6) 121.03(13) C(15)-C(14)-C(13) 119.98(13) 
C(16)-C(15)-C(14) 120.54(14) C(17)-C(16)-C(15) 119.73(14) 
C(16)-C(17)-C(18) 120.31(14) C(17)-C(18)-C(13) 120.20(14) 
O(1)-C(19)-N(1) 121.81(14) O(1)-C(19)-C(20) 119.91(14) 
N(1)-C(19)-C(20) 118.28(14)   
  
Symmetry transformations used to generate equivalent atoms: 
                                                            
  
 
Table 4.   Anisotropic displacement parameters (Å2 x 103) for 203.  The anisotropic displacement 
factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
O(1) 42(1) 29(1) 37(1) 1(1) -2(1) 2(1) 
O(2) 70(1) 52(1) 36(1) -15(1) -13(1) 21(1) 
N(1) 24(1) 28(1) 26(1) 2(1) -5(1) -1(1) 
N(2) 24(1) 23(1) 21(1) -1(1) 1(1) 0(1) 
C(1) 24(1) 29(1) 29(1) 1(1) -1(1) 3(1) 
C(2) 26(1) 27(1) 23(1) 3(1) -2(1) 2(1) 
C(3) 24(1) 23(1) 19(1) -2(1) 1(1) 2(1) 
C(4) 23(1) 23(1) 19(1) -2(1) 1(1) 0(1) 
C(5) 28(1) 31(1) 23(1) 4(1) -3(1) -3(1) 
C(6) 26(1) 22(1) 17(1) -2(1) 2(1) 2(1) 
C(7) 24(1) 22(1) 18(1) -4(1) 1(1) 3(1) 
C(8) 24(1) 21(1) 19(1) -4(1) 2(1) 2(1) 
C(9) 30(1) 24(1) 24(1) -1(1) 3(1) -1(1) 
C(10) 25(1) 29(1) 31(1) -3(1) 2(1) -4(1) 
C(11) 24(1) 35(1) 29(1) -2(1) -3(1) 2(1) 
C(12) 28(1) 27(1) 22(1) -1(1) -1(1) 3(1) 
C(13) 20(1) 23(1) 23(1) 1(1) -1(1) 0(1) 
C(14) 29(1) 28(1) 25(1) -2(1) -1(1) 0(1) 
C(15) 25(1) 23(1) 43(1) -1(1) -1(1) 1(1) 
C(16) 21(1) 33(1) 39(1) 16(1) 2(1) 2(1) 
C(17) 31(1) 40(1) 25(1) 8(1) 5(1) 6(1) 
C(18) 31(1) 28(1) 25(1) 0(1) 2(1) 4(1) 
C(19) 25(1) 31(1) 28(1) 0(1) 2(1) -2(1) 
C(20) 41(1) 43(1) 31(1) -4(1) -8(1) -1(1) 
  
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 203. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(1A) 12978 847 2286 33 
H(1B) 12833 602 1295 33 
H(2A) 11701 -275 1962 31 
H(2B) 11386 477 2625 31 
H(5A) 12085 1688 331 33 
H(5B) 11482 2495 741 33 
H(9) 8154 -644 1648 31 
H(10) 6730 -371 854 34 
H(11) 6745 693 -239 35 
H(12) 8163 1512 -500 31 
H(14) 9594 3175 629 32 
H(15) 9584 4357 -322 36 
H(16) 9900 4134 -1773 37 
H(17) 10248 2728 -2276 38 
H(18) 10247 1535 -1337 33 
H(20A) 12986 2890 3279 58 
H(20B) 13542 2048 2893 58 
H(20C) 12472 1942 3342 58 
H(19) 10160(17) 4379(14) 2317(7) 88(8) 
H(20) 10796(10) 3809(15) 1824(18) 103(10) 
 
